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 Novel antibiotic chemotherapies are in high demand for the treatment of drug-
resistant and hypervirulent bacterial infections. Clostridium difficile has been identified as 
the costliest bacterial pathogen – both in terms of financial burden and human mortality.  
Furthermore, the current treatments that exist for C. difficile infection (CDI) are inadequate 
and expensive. Therefore, an ongoing collaborative effort has focused on the design and 
development of novel antibacterial chemotherapeutics for the treatment of CDI. Sixty-two 
novel biarylpeptide derivatives were synthesized from 17 unique scaffolds and tested for 
antimicrobial efficacy against a wide range of pathogenic bacteria and fungi at multiple 
laboratories. An efficient, modular and scalable synthesis that utilized 11 key building block 
precursors was designed and employed in the realization of the novel biarylpeptide scaffolds. 
The modular approach allowed for facile diversification and derivatization of the target 
scaffolds. 
One or two peptidomimetic 1,2,3-triazole rings were installed into the peptide backbone of 
the biarylpeptide derivatives to achieve increased metabolic resistance. Subsequent 
derivatization of these scaffolds produced a wide array of compounds with structural 
variation in the following moieties: the hydrophobic aromatic core (biphenyl or binaphthyl), 
the cationic amino acid residues (lysine and/or arginine) and the hydrophobic termini (mainly 
aryl or alkyl substituents). All synthesized derivatives exhibited some level of antimicrobial 
activity – i.e. minimum inhibitory concentration (MIC) values ≤ 16 μg/mL against S. aureus. 
The bis-triazole dicationic compound 80b exhibited the best broad-spectrum antibacterial 
activity, displaying MIC values of 2 μg/mL against S. aureus, 4 μg/mL against MRSA, and 
8 μg/mL against both A. baumannii and P. aeruginosa.  
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The results of the antimicrobial assays were utilized to explore the structure-activity 
relationship trends of the compounds so as to aid in the identification of the pharmacophore 
elements required for C. difficile antibacterial selectivity and broad-spectrum antibacterial 
activity. The structural modifications that were introduced to the biarylpeptide scaffold led 
to an increase in compound solubility and a substantial increase in antibacterial efficacy 
against Gram-negative bacteria in the bis-triazole dicationic derivatives. The monocationic 
derivatives (e.g. compound 77c) were generally not as potent as their dicationic analogues, 
but they exhibited strong Gram-positive selectivity, which is beneficial for a CDI 
chemotherapeutic. The pursuit of novel antibacterial molecules from lead biarylpeptide 
compounds led to the development of two distinct structural scaffolds (i.e. 80b and 77c) that 
exhibited desirable traits for an antibacterial chemotherapeutic. Compound 77c exhibited an 
increase in selectivity for C. difficile and Gram-positive bacteria; the molecule was also 
structurally simple and easier to synthesize, therefore making an ideal candidate for a 
potential CDI chemotherapeutic. Additionally, compound 80b exhibited a notable increase 
in the overall Gram-negative antibacterial efficacy; this could allow the biarylpeptide 
derivatives to be investigated for use in the treatment of topical and skin-related Gram-
negative bacterial infections.  
A solubility assay was developed and utilized to allow for solubility comparisons between 
similar derivatives; this also allowed for correlations to be drawn between a compound’s 
solubility and its in vitro and in vivo antibacterial activities. Four compounds with varying 
solubilities were selected based upon their in vitro activities against C. difficile and 
subsequently tested in an in vivo CDI mouse model. The Gram-positive selective compound 
77c exhibited promising preliminary results and has been selected for testing in further in 
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vivo CDI mouse models. The expected lack of systemic bioavailability following oral 
administration of the biarylpeptides was proven via pharmacokinetics assay on the mouse 
blood and faeces. A cytotoxicity assay was also employed in conjunction with the in vitro 
antimicrobial testing; compound 80b exhibited some cytotoxicity (CC50 = 16.4 μg/mL) while 
compound 77c failed to exhibit any cytotoxic effects at the concentrations tested. Compound 
77c exhibited increased selectivity for C. difficile (and other Gram-positive bacteria), 
structural simplicity and reduced cytotoxicity; these traits make compound 77c a prime 
candidate for further biological studies (i.e. in vitro and in vivo assays) and optimization. 
Therefore, compound 77c has been selected for ongoing biological and chemical assays to 
ascertain its efficacy and potential as a novel CDI chemotherapeutic. 
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1.0 – Introduction 
1.1 – Antibiotic resistance 
Bacterial resistance to known antibiotic drugs is a serious threat to modern 
healthcare and global security.1-6 Infectious disease is the second leading killer globally 
(17 million deaths annually) and drug resistant bacterial infections are now considered an 
“emergent global disease” by the World Health Organization (WHO) and the US Centers 
for Disease Control and Prevention (CDC).6-7 The CDC estimates that antibiotic resistance 
is responsible for more than two million infections and 23,000 deaths each year in the 
USA.2 The WHO has initiated a “Global Action Plan” to reduce the prevalence of drug 
resistance and both organizations have published lists of drug resistant bacteria that are 
currently considered a major threat.1, 3, 8  Bacterial strains have emerged that exhibit 
resistance to our most valued antibiotics and the prevalence of hypervirulent strains only 
potentiates the problem.9-10 Thus, the need for novel antibacterial compounds with new 
modes of action is of utmost importance. The threat of these resistant and/or hypervirulent 
prokaryotes is a serious concern in today’s healthcare sector and this concern is the impetus 
behind the ongoing need for and development of new antibiotic medications. 
In the past eighty years, a plethora of natural and synthetic antibacterial compounds have 
been discovered and yet, resistant bacterial strains have been reported for virtually all 
antibiotics.9 Bacteria can develop resistance to antibiotics rapidly, due to their short 
regeneration time and their ability to spread resistance to other bacteria via horizontal gene 
transfer.5, 9 Bacterial resistance to anthropogenic antibiotics has been developing at an 
alarming rate since the introduction of penicillin in the 1930s; by the end of the 1950s, 
almost 85% of clinically isolated staphylococci were penicillin-resistant.9  
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Vancomycin was rapidly approved for use as an antibiotic because an effective treatment 
for penicillin-resistant bacteria was urgently needed.11 Methicillin, the first semi-synthetic 
penicillin, was developed in 1959 and it soon became the antibiotic of choice for penicillin-
resistant bacteria.11  The subsequent emergence of methicillin-resistant Staphylococcus 
aureus (MRSA) and its acquired resistance to most other common antibiotics led to 
vancomycin becoming the ‘gold standard’ for MRSA treatment.11 This lead to an increase 
in vancomycin use in the 1970s – not only for MRSA treatment but also to treat the growing 
number of severe Clostridium difficile infection (CDI) cases.11 Extensive oral vancomycin 
use for the treatment of CDI led to the emergence of vancomycin-resistant enterococci 
(VRE) in 1986,11 while vancomycin-resistant S. aureus (VRSA) also emerged in 2002. In 
the latter case, the VRSA acquired resistance via horizontal gene transfer from VRE in a 
human patient who had been intermittently treated with vancomycin.11 Furthermore, some 
bacteria have developed resistance against multiple drug classes – these multi-drug 
resistant (MDR) bacteria are a serious concern facing modern healthcare.4, 7, 12-13 Resistant 
bacterial isolates, colloquially known as “superbugs”, are extremely worrying and they 
have provided a strong impetus for the discovery of novel antibiotic molecules.  
Recent potential vancomycin replacements for treating VRSA, MRSA and other Gram-
positive bacterial infections include linezolid, quinupristin/dalfopristin, daptomycin and 
tigecycline.10-11 Both daptomycin and linezolid have been used extensively for treating 
Gram-positive, drug-resistant infections; as a result, resistance to both drugs has already 
been documented.11, 14 Gram-negative bacteria are inherently more resistant to antibiotics 
due to their impermeable outer membrane and their broad-substrate transmembrane efflux 
pumps (for transporting unwanted molecules out of the cell).13 Multi-drug resistance 
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amongst Gram-negative bacteria has been on the increase and there is an unmet need for 
novel antibiotics capable of treating such infections.13 Therefore, the research focus has 
now shifted towards developing new antibiotic molecules for treatment of MDR Gram-
negative bacterial infections.5, 13 The ESKAPE pathogens (i.e. Enterococcus faecium, 
Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas 
aeruginosa and Enterobacter spp.) are six antibiotic resistant bacterial species that have 
been identified by multiple agencies (including the Infectious Diseases Society of 
America) as key pathogens behind the majority of nosocomial infections.5 These bacteria 
have been identified due to their virulence, tenacity, propensity for resistance and 
pathogenicity.5 Notably, P. aeruginosa and A. baumannii exhibit a particularly strong 
ability to resist antibiotic molecules, likely due to their ability to withstand toxic 
environments.13 There are limited chemotherapeutic treatments for MDR bacterial 
infections and pan-drug resistant (PDR) Gram-negative strains have also been identified 
(i.e. resistant to all known antibiotic treatment options).13 The lack of viable treatment 
options for Gram-negative bacterial infections has even led to the reintroduction of 
polymyxin B and polymyxin E (colistin), despite known toxicity issues – polymyxins are 
large, cyclic cationic peptides with potent antibacterial activity.5, 13 
Unfortunately, bacterial resistance is inevitable for almost all antibiotic molecules; bacteria 
will eventually find a way to negate, destroy, pacify, eliminate or withstand the target 
antibiotic.5 Resistance becomes possible as soon as bacteria have been exposed to an 
antibacterial agent. By increasing the exposure to the antibiotic, there is an increased 
chance for a resistant bacterial strain to develop. Therefore, the increased use of antibiotics 
by the agriculture industry (for animal growth – which accounts for > 50% of antibiotics 
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consumed) and by modern medicine (i.e. misuse and overuse) only serves to exacerbate 
the problem of resistance by accelerating the process.7, 15 The overuse of antibiotics is such 
a big problem that the US White House instituted a 5-year plan in 2015 to reduce the 
unnecessary use of antibiotics in farm animal growth.7 Furthermore, the US White House 
has created the ‘National Action Plan for Combating Antibiotic-Resistant Bacteria’ – this 
plan aims to fund novel antibiotic drug discovery for treating MDR bacterial infections.7 
The antibiotic resistance problem has become so severe that the WHO now warns of a 
‘post-antibiotic era’ where common infections and minor injuries will prove lethal due to 
the lack of viable antibiotic therapies.16 Thus, novel antibacterial compounds with unique 
mechanisms of action are always needed to help combat the constantly evolving threat of 
bacterial resistance. 
1.2 – Clostridium difficile infection (CDI) 
C. difficile is a Gram-positive, anaerobic bacterium that causes mild to serious 
infections in the gastrointestinal (GI) tract due to the potent toxins and resilient endospores 
that are produced by the organism (Figure 1.1).17-18  
 
Figure 1.1 - Transmission electron micrograph of C. 
difficile forming an endospore (red).19 
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CDI occurs when the normal GI microbiota is compromised; this allows C. difficile to 
flourish in the GI tract due to the absence of the usual enteric microbiome.17-18 Most 
common oral antibiotics, including penicillins, can destroy the normal GI microflora – this 
unwanted side-effect allows C. difficile to infect up to 20% of hospital patients 
administered oral antibiotics.17 C. difficile produces robust endospores that are spread by 
the faecal-oral route; these spores are resistant to most antibiotics, alcohol-based hand 
sanitizers and heat.20 The hospital setting provides a prime ‘breeding ground’ for C. 
difficile spores, which can stay viable for months at a time.17-18  It is often considered a 
nosocomial infection; the disease is most prevalent in the hospital setting because the main 
risk factor for CDI is previous antibiotic therapy.18 Broad spectrum antibiotic therapy 
indiscriminately destroys the GI microflora, but fails to eradicate C. difficile spores.20 
Almost all broad-spectrum antibiotics can instigate CDI by eliminating the commensal GI 
microflora; however, antibiotics such as ampicillin/amoxicillin, cephalosporins, 
clindamycin and fluoroquinolones are most commonly associated with CDI.17 
GI infection from C. difficile can result in symptoms such as diarrhoea, abdominal pain 
and pseudomembranous colitis (PMC – a severe gastric disease). PMC is caused by colonic 
inflammation due to infection which leads to the appearance of white “pseudomembranes” 
that inhibit normal colonic function.17-18, 21 CDI-associated PMC can be so severe as to 
warrant colectomy (i.e. resection of the colon) for which there is a ~55% mortality rate for 
patients that undergo such surgery/procedures.21 Furthermore, toxic megacolon can also 
result from CDI, wherein the patient suffers from severe colonic inflammation and 
abdominal distension.20 CDI exhibits an overall mortality rate of up to 8%18 and infection 
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recurrence occurs in up to 20% of cases treated with first-line medications (i.e. vancomycin 
or metronidazole).22  
Once the infectious spores have reached the GI tract, the presence of bile salts initiates 
germination of the spores to produce the vegetative C. difficile cells.20 Disease caused by 
CDI is primarily the result of two virulence factors (Toxin A and Toxin B) that are excreted 
by the vegetative C. difficile cells; these toxins promote colonic inflammation and 
epithelial tissue damage which causes fluid loss (i.e. diarrhoea).20 A third toxin (known as 
CDT or binary toxin) is found in high levels in hypervirulent C. difficile strains, although 
the role of this toxin in disease has not yet been elucidated.20 
Recently, both the severity and incidence of CDI cases has increased due to epidemics of 
hypervirulent C. difficile strains, e.g. ribotype 027 – also known as strain B1/NAP1/027.17-
18 The hypervirulent ribotype 027 produces higher levels of toxins than normal C. difficile 
strains – these toxins are thought to be responsible for disease symptoms like diarrhoea and 
PMC.18 As a result, ribotype 027 exhibits a mortality rate that is three times higher than 
normal C. difficile isolates.17  
The prevalence of C. difficile infection results in a massive financial burden on the modern 
healthcare system (>$1 billion/year in the USA);17, 23 another estimate put CDI-related 
healthcare costs in 2008 at $4.8 billion.18 The CDC issued a report in 2013 entitled 
‘Antibiotic Resistance Threats’; C. difficile was listed as the number one bacterial threat 
facing the healthcare sector and humans in general.3 A recent update by the CDC reports 
that CDI is responsible for approximately 500,000 infections and 15,000 deaths annually 
in the USA – the highest of any of the bacterial threats listed by the CDC.23 Therefore, the 
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heightened concern over CDI is understandably justified and the alarm over impending 
resistance and hypervirulence only complicates the situation. Due to the high levels of 
infection, recurrence, mortality, cost, and the lack of adequate treatments for CDI, there 
exists a substantial incentive to pursue novel chemotherapeutics that effectively combat 
CDI. 
Antibacterial selectivity for C. difficile is an essential component for a fully effective CDI 
chemotherapeutic. The elimination of all GI bacteria by broad spectrum antibacterial 
activity provides an ideal habitat for C. difficile spores to grow; therefore, the maintenance 
and/or restoration of commensal GI microflora is essential for preventing CDI 
recurrence.17-18, 20  This explains why CDI is so difficult to eradicate with traditional 
antibiotics and why CDI recurs in 15-30% of patients treated with vancomycin.17 Faecal 
transplantation has thus become a viable method for treating cases of chronic/severe CDI, 
as it physically replaces the commensal GI microflora.17-18, 21 The classic chemotherapeutic 
treatments for CDI (i.e. vancomycin and metronidazole) suffer from efficacy issues, most 
notably CDI recurrence due to their lack of selectivity for C. difficile and inability to 
prevent sporulation.17-18 CDI recurrence is also linked with the inability to form a specific 
antibody response to the toxins released by C. difficile; healthy adults normally form an 
antibody against toxin A.17 Non-chemotherapeutic treatments (i.e. surgery) are available, 
but they are generally only used when classic chemotherapeutics fail. Surgical treatments 
are drastic and permanent – most involve subtotal colectomy in an attempt to physically 
remove the infection and diseased bowel.18 Current C. difficile treatment options are 
lacking in completely effective CDI medications. There exists a drastic need for more 
efficacious C. difficile chemotherapeutics for the treatment of CDI; a well-tolerated and 
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safe medication that could selectively target C. difficile (and its spores), while leaving the 
enteric microbiome intact, would prove invaluable in the treatment of severe and recurrent 
CDI.  
1.3 – Current chemotherapeutic treatments for CDI 
 There are currently only three medications that are widely-used and accepted as 
treatments for CDI; vancomycin, metronidazole and fidaxomicin.17, 20, 22, 24 Vancomycin 
was the only FDA-approved treatment for CDI until 2011 when fidaxomicin was approved. 
Metronidazole is widely used off-label as a first-line treatment for mild-to-moderate cases 
of CDI (despite not being FDA-approved for the aforementioned purpose), whereas oral 
vancomycin is commonly used for moderate-to-severe or recurrent cases of CDI.  
1.3.1 – Vancomycin 
 Vancomycin (Figure 1.2) is the prototypical glycopeptide antibiotic.9 The 
glycopeptides represent a complex class of molecular structures; the main cyclic scaffold 
is comprised of sugars and amino acids joined via peptide bonds. Vancomycin was 
discovered in 1959 by the Eli Lilly pharmaceutical company – the compound was isolated 
from a soil sample from the rainforests of Borneo and is now known to be produced by a 
microorganism named Amycolatopsis orientalis.9 Fermentation of A. orientalis yields a 
broth rich in vancomycin; this production method is economically more viable than 
synthesis because the drug’s structure is so complex.11 As a result, vancomycin is rather 





Figure 1.2 – The glycopeptide antibiotic vancomycin. 
Vancomycin is known to work by interfering with bacterial manufacture of the 
peptidoglycan cell wall by binding to the two terminal D-alanine residues of the 
peptidoglycan precursor that participates in enzymatic cross-linking. The binding of 
vancomycin to the terminal D-alanine residues prevents the transglycosylase enzyme from 
cross-linking the peptide as part of the cell wall manufacture.9 Vancomycin exhibits potent 
antibacterial activity against Gram-positive bacteria; minimum inhibitory concentration 
(MIC) values of ≤ 0.50 µg/mL were observed for 207 C. difficile strains that were tested.26  
Vancomycin exhibits many traits that make it ideal for severe CDI treatment such as a low 
oral bioavailability and a potent MIC value against C. difficile; unfortunately, it has several 
drawbacks such as production/cost, lack of selectivity for C. difficile, and recurrence of 
CDI following treatment.9, 11, 25 Vancomycin’s broad-spectrum antibacterial activity results 
in indiscriminate annihilation of the enteric microbiota; this allows the resilient C. difficile 
spores (which are resistant to most antibiotics) to recolonize the colon due to a lack of 
viable competition, resulting in infection recurrence. Most importantly, because 
vancomycin fills an important role in treating MRSA and other MDR bacteria, it will never 
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be given full license for treatment of mild or moderate CDI. The threat of widespread 
vancomycin resistance limits the compound’s use to only the more severe cases.9, 11 
1.3.2 – Metronidazole 
Metronidazole (Figure 1.3) is a nitroimidazole derivative that exhibits antimicrobial 
activity and has been in use for more than 45 years.27 The medication was originally used 
for the treatment of protozoal infections (e.g. Trichomonas vaginalis and giardiasis) and 
was eventually found to be effective against anaerobic bacteria (both Gram-positive and 
Gram-negative infections).27-28 
 
Figure 1.3 – Metronidazole (a nitroimidazole antibiotic). 
Metronidazole was renowned for having a very low resistance profile because during the 
first thirty years of use, there was very little resistance observed.28 The drug is very versatile 
because it can be administered intravenously, orally, topically and vaginally; it exhibits 
ideal pharmacokinetics for a systemic antibiotic.27-28 The chemical structure of 
metronidazole is very simple and this allows for cheap production of the drug on a large 
scale (cost = ~$0.86 USD/dose).25 
Metronidazole exhibits activity through a free radical mechanism whereby the nitro group 
is reduced in vivo to create an unstable ‘nitro radical anion’ which rapidly decomposes to 
give an imidazole radical and a nitrite ion.20, 28 The imidazole radical and nitrite ion cause 
oxidative damage to DNA strands, resulting in apoptosis. The intracellular reduction of 
metronidazole occurs via electron capture from a reduced ferredoxin oxidoreductase 
enzyme.28 Metronidazole has become a very common-place treatment for mild-to-
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moderate CDI, despite not being formally approved by the FDA for CDI treatment.25, 27-28 
Metronidazole has replaced vancomycin as the main treatment for milder cases of CDI as 
it is much cheaper to manufacture, has a similar efficacy profile in mild cases and its use 
does not contribute to vancomycin resistance.25 The majority of oral metronidazole is 
absorbed systemically which is not ideal for the treatment of a gastric bacterium like C. 
difficile.27-28 A low oral bioavailability is essential for any oral treatment of CDI as the drug 
must stay available in the gut and not be absorbed systemically. Metronidazole’s usage as 
a treatment for CDI will wane as newer and more efficacious CDI chemotherapeutics 
become available. 
1.3.3 – Fidaxomicin 
Fidaxomicin (Figure 1.4) is the prototypical macrocycle antibiotic and it was 
approved in 2011 by the FDA specifically for the treatment of CDI.25 Fidaxomicin is a 
relatively complex unsaturated macrolide with two sugar derivatives attached; the drug is 
isolated from the fermentation broth of Dactylosporangium aurantiacum.22 Fidaxomicin is 
very expensive (~$156 USD/dose) and the molecule is currently under patent.25 
 
Figure 1.4 – The macrolide antibiotic fidaxomicin. 
Importantly, fidaxomicin exhibits narrow-spectrum antibacterial activity; the drug 
selectively eliminates C. difficile and does not harm important commensal GI bacteria.20, 29 
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Fidaxomicin allows the commensal GI microbiome (i.e. Bacteroides spp.) to stay intact 
and it is also known to prevent spore formation.30 These two combined effects are thought 
to be responsible for fidaxomicin’s reduced recurrence rates.20, 29 Fidaxomicin exhibits 
approximately 50% less CDI recurrence when compared to treatment with vancomycin; a 
recurrence rate of 22.6% was observed for vancomycin versus 11.7% recurrence for 
fidaxomicin.30 
Fidaxomicin works by inhibiting bacterial RNA polymerase where it binds to a site distinct 
from the rifamycin-type antibiotics.29 Systemic absorption of fidaxomicin is negligible and 
therefore its notable cytotoxicity is not a problem.20 The drug is well-tolerated and it 
exhibited similar tolerability to a comparator medication (i.e. an accepted medication).29 
Fidaxomicin also exhibited an MIC value of 0.008 – 0.25 μg/mL for 90% of C. difficile 
isolates tested and it has given promising results in the treatment of CDI.22 Fidaxomicin 
inhibits virulent strains of C. difficile better than vancomycin.25 The lower CDI recurrence 
rate is likely a result of fidaxomicin’s greater ability to leave the intestinal microflora intact 
while simultaneously inhibiting C. difficile (when compared to vancomycin).25 
Fidaxomicin has been shown to lessen the spore load (i.e. the quantity of C. difficile spores 
in the intestine) of a patient following successful CDI treatment and it is thought that this 
plays a major role in eliminating CDI recurrence. 29 Following treatment cessation with 
fidaxomicin, there is an extended “post-antibiotic effect” relative to the other common CDI 
treatments – this period of “sterility” would also help to prevent recolonization by C. 
difficile spores.25 There are studies currently being conducted to ascertain whether 
fidaxomicin could function as a prophylactic for CDI or as a post-antibiotic ‘chaser’ to 
prevent antibiotic therapy-induced CDI.25    
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1.3.4 – Rifaximin 
 Rifaximin (Figure 1.5) is a semi-synthetic derivative of the rifamycin antibiotic 
family which includes such drugs as rifampicin. It has broad-spectrum activity and is 
extremely potent against C. difficile; rifaximin exhibited an MIC value of  ≤ 0.015 µg/mL 
for 110 toxigenic C. difficile strains.25, 31 Rifaximin has poor water solubility and as such, 
it maintains a high intestinal concentration following oral administration; so high, that 97% 
of a dose can be reclaimed as unchanged rifaximin in the faeces.32 The result is a systemic 
bioavailability of less than 0.4% – this is ideal for the treatment of C. difficile.32 
 
Figure 1.5 – Rifaximin. 
Recent studies have shown that rifaximin can be useful in the treatment of resistant CDI – 
as a “salvage therapy” when the multiple classic treatments have failed.25, 33 These studies 
have also shown that rifaximin is well-tolerated by the majority of patients and that it has 
had some success in treating resilient cases of CDI, including some strains belonging to 
the NAP1/BI/027 ribotype.33 Resistance to rifamycins by C. difficile is a developing issue 
with approximately 2% of current strains exhibiting rifaximin resistance; there is growing 
concern that this number could rise.33  
Rifaximin’s extreme potency against C. difficile and its usefulness in treating resilient cases 
of CDI will result in its continued use in the modern repertoire of CDI treatments – 
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although concern over rifamycin-resistant C. difficile will prevent the drug from becoming 
the new “standard treatment” for CDI – it will likely remain a useful alternative treatment 
to utilize when other drugs are ineffective. 
1.3.5 – C. difficile resistance to the current chemotherapeutics 
 C. difficile has been shown to exhibit reduced susceptibility to the common 
chemotherapeutics (vancomycin, metronidazole and fidaxomicin), but the resistance is not 
widespread. For example, C. difficile isolates with reduced susceptibility to metronidazole 
(MIC > 32 μg/mL) have been documented in recent years.34 The Anaerobe Research Unit 
in the UK found that four C. difficile isolates, out of 30 tested, showed reduced 
susceptibility to metronidazole.34 The reduced susceptibility to metronidazole exhibited by 
C. difficile is not long-lived as it is often lost after freeze-thawing or passaging of the 
bacteria.20 Reduced susceptibility to vancomycin and fidaxomicin (MIC values of 4 μg/mL 
and 16 μg/mL, respectively) has also been observed in C. difficile isolates. The reduced 
susceptibility to metronidazole has clinical significance because concentrations < 32 μg/g 
faeces are obtained following oral administration of metronidazole (due to the high 
systemic absorption).20 The implications of reduced susceptibility to vancomycin and 
fidaxomicin are less significant, because high concentrations ( > 1000 μg/g faeces) of the 
drugs are obtained in the GI tract due to their low systemic bioavailability following oral 
administration.20 The spread of C. difficile resistance is a growing concern and multiple 






1.4 – Potential CDI chemotherapeutics 
There exists a wide array of novel C. difficile inhibitors that are currently in various 
stages of development. Due to the recent high demand for novel CDI chemotherapeutics, 
a plethora of unique molecules are currently undergoing preclinical and clinical trials for 
potential application as CDI treatments.20, 22, 25 Some of the more promising antibiotic 
compounds will be discussed briefly in terms of their potential for CDI treatment. 
Surotomycin 
 Surotomycin (previously CB-183,315) (Figure 1.5) is a cyclic lipopeptide 
antibiotic that is structurally related to daptomycin and was developed for CDI treatment 
by Cubist Pharmaceuticals.20, 35 Daptomycin is manufactured via precursor-directed 
fermentation of S. roseosporus and surotomycin is manufactured through a similar 
process.35 
 
Figure 1.5 – Cyclic lipopeptide surotomycin (previously CB-183,315). 
Surotomycin exhibited an MIC value of 0.5 µg/mL against C. difficile and exhibited MIC 
values > 8192 µg/mL for other intestinal bacteria such as “the Bacteroides fragilis group, 
Prevotella spp., Gram-negative cocci (Veillonella spp. and Acidaminococcus spp.), E. coli, 
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Enterobacter spp. and Klebsiella spp.” – this strong preference for C. difficile over other 
commensal bacteria makes surotomycin a prime candidate for CDI treatment.36  
A phase II clinical trial evaluated the safety/efficacy of the medication as a CDI treatment; 
the study concluded that surotomycin was safe and well-tolerated at two doses of 125 mg 
or 250 mg per day and that the drug “sustained better cure rates” than vancomycin.37 
Surotomycin was then subjected to a similar phase III clinical trial, but the compound failed 
to meet noninferiority criteria relative to vancomycin.38 Surotomycin displayed efficacy 
and tolerability that was on par with vancomycin (clincal cure rates of 79 % and 83.6% for 
surotomycin and vancomycin, respectively).38 Overall, surotomycin exhibited potential as 
a novel CDI chemotherapeutic, but it failed to meet initial phase III criteria for progression 
into a marketable pharmaceutical.  
CRS3123 
 CRS3123 (Figure 1.6) is a novel diaryldiamine that is currently being developed 
by the National Institute for Allergy and Infectious Diseases (NIAID); the chemical is 
active against Gram-positive bacteria like C. difficile.22, 39 CRS3123 works by inhibiting 
bacterial methionyl-tRNA synthetase and as a result, the chemical exhibits activity against 
numerous clinically relevant bacteria (e.g. MRSA and Enterococcus faecium).39 
 
Figure 1.6 – CRS3123 (previously REP3123). 
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CRS3123 exhibited potent MIC values (1.0 µg/mL) against 108 C. difficile clinical 
isolates.39 Treatment of lethal CDI in a hamster model by CRS3123 resulted in a substantial 
increase in survival rate vs. vancomycin. All vancomycin-treated hamsters were dead by 
day 17, whereas 62% and 75% of the hamsters treated with CRS3123 (at dose rates of 0.5 
mg/kg and 5 mg/kg, respectively) were alive at day 35.22 CRS3123 has recently undergone 
phase I clinical trials assessing tolerability and safety with positive results.40 
LFF571 
 LFF571 (Figure 1.7) is a semi-synthetic thiopeptide that was recently developed as 
part of an investigation into the activity of 4-aminothiazolyl analogues of GE2270A (a 
known, natural product antibiotic – see Figure 1.7) for the identification of potential CDI 
chemotherapetuics.41  
         
Figure 1.7 – LFF571 (left) and GE2270A (right). 
GE2270A was discovered in 1991 by researchers at the Lepetit Research Institute – it was 
isolated from the fermentation broth of Planobispora rosea.41 The compound was found 
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to inhibit prokaryotic chaperone elongation factor Tu via inhibition of aa-tRNA binding; 
this translation inhibition mechanism imparts strong antibacterial activity against a broad 
spectrum of Gram-positive bacteria.41-43 This novel mechanism of action is important 
because it prevents the development of cross-resistance to “standard-of-care” antibiotics.43  
One study indicated that LFF571 exhibits an MIC value of ≤ 0.5 µg/mL for all C. difficile 
isolates tested (whereas vancomycin exhibits an MIC90 value ≤ 2.0 µg/mL).
42  In a hamster 
model of CDI, LFF571 was more effective than vancomycin (at a lower dose and with 
fewer recurrences of CDI); LFF571 substantially reduced the risk of death when compared 
to both saline and vancomycin.42 Novartis Pharmaceuticals has recently performed a phase 
II clinical trial of LFF571 as a possible treatment for CDI; results showed the drug to be 
comparable to vancomycin in efficacy and safety.44  
Nitazoxanide and derivatives  
 Nitazoxanide (Figure 1.8) is a nitrothiazolide derivative that is licensed by the FDA 
for use against intestinal parasites like giardiasis and cryptosporidiosis; the medication is 
now being explored for treatment of CDI.22, 25, 45  
 
Figure 1.8 – Nitazoxanide (left) and amixicile (right). 
Nitazoxanide is known to disrupt cellular metabolism via inhibition of the 
pyruvate:ferredoxin oxidoreductase system.22, 25 The drug competes with pyruvate for the 
thiamine pyrophosphate vitamin cofactor of the pyruvate:ferredoxin oxidoreductase 
complex; by acting upon and inhibiting the co-factor and not the enzyme itself, it is 
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theorized that nitazoxanide and its derivatives will not be susceptible to the same mutation-
based resistance that plagues other enzyme-targeting drugs.46 The pyruvate:ferredoxin 
oxidoreductase enzyme system is a semi-selective C. difficile target as many beneficial 
enteric microflora do not utilize pyruvate:ferredoxin oxidoreductase because they make 
use of pyruvate dehydrogenase.46 
Nitazoxanide has been shown to exhibit MIC values between 0.3-1.0 µg/mL against C. 
difficile isolates.22 When the chemical was first trialled against CDI, it was found to be at 
least as effective as metronidazole and effective in cases where metronidazole was not.45, 47 
Further small studies tested the efficacy of nitazoxanide compared with vancomycin in a 
double-blind study – the results indicated that nitazoxanide was equally effective against 
CDI when compared to vancomycin.47  
Nitazoxanide suffers from poor water solubility and this property makes it accumulate in 
the intestine following consumption.46 Amixicile (Figure 1.8) is a chemical derivative of 
nitazoxanide that was identified amongst 250+ nitazoxanide derivatives as a lead 
compound with increased solubility and thus increased pyruvate:ferredoxin oxidoreductase 
inhibitory activity.46 This new nitazoxanide derivative was tested in an optimized murine 
model of CDI and the chemical exhibited a greater survival rate (56%) than both 
vancomycin (15%) and nitazoxanide (22%).46 CDI recurrence was not observed in mice 
treated with amixicile and nitazoxanide while the other drugs tested (i.e. vancomycin, 
fidaxomicin, etc.) exhibited CDI recurrence.46 
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Thus, the nitrothiazolide derivatives represent a promising new class of potential CDI 
inhibitors. Further pharmacological study into these chemicals is required before they can 
be relied upon as safe, effective CDI treatments.  
NVB302 
 NVB302 (Figure 1.9) is a chemically modified derivative of the peptide 
deoxyactagardine B, which is isolated from Actinoplanes liguriae.48 The peptide works by 
inhibiting cell wall biosynthesis via lipid II binding (at a site distinct from that of 
vancomycin); the drug also exhibits selectivity for C. difficile over other intestinal 
bacteria.48  
 
Figure 1.9 – Antibacterial peptide NVB302. 
Furthermore, NVB302 has been shown to be stable in the environment of the gut, as up to 
60% of the unmetabolized drug is recoverable from the faeces of dosed rats.22 NVB302 
initially exhibited MIC values in the range of 0.5 µg/mL to 2.0 µg/mL against C. difficile; 
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further activity studies against 91 clinical isolates showed an average MIC value of 1.04 
µg/mL against C. difficile.22 Furthermore, NVB302 was shown to exhibit MIC values of 
>256 µg/mL for fusobacteria and Bacteroides fragilis – as well as reduced activity against 
other intestinal microflora (e.g. MIC value of 64 – 256 µg/mL for Prevotella spp.).22 In a 
comparative study of NVB302 versus vancomycin in a human gut model of CDI, NVB302 
was found to be non-inferior to vancomycin and it also exhibited less detrimental effects 
against intestinal microflora like the Bacteroides fragilis group.48 NVB302 has now 
completed phase I clinical trials with Novacta Biosystems;20 unfortunately, the drug has 
been found to be ineffective at eliminating C. difficile spores, much like vancomycin and 
other common CDI treatments.22  
Ridinilazole 
 Ridinilazole (previously known as SMT19969) (Figure 1.10) is a bis-
benzimidazole derivative that exhibits strong antibacterial selectivity for C. difficile over 
other bacteria (including S. aureus and intestinal microflora).49-50 Ridinilazole selectively 
targets specific Clostridia spp. without affecting the other commensal GI microflora (both 
Gram-positive and Gram-negative species); the drug generally shows MIC values of 0.125 
– 0.25 µg/mL against most C. difficile strains.50 
 
Figure 1.10 – Ridinilazole (formerly SMT19969). 
Summit Pharmaceuticals has completed phase I clinical trials with ridinilazole exhibiting 
good tolerability, low systemic absorption rates and selectivity for Clostridium spp.; 
furthermore, ridinilazole passed superiority criteria against vancomycin in a multicentre 
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phase II trial of 100 CDI patients.50 The antibacterial mechanism of action is not 
completely understood, but studies indicate that ridinilazole is implicated in the inhibition 
of cell division – the drug is also known to reduce toxin titre levels and spore loads.50 The 
company is currently pursuing phase III trials and further development.50 
Cadazolid 
 Cadazolid (Figure 1.11) is a oxazolidinone and quinolone antibiotic hybrid that 
exhibits strong potential as a novel CDI chemotherapeutic.51 The drug exhibits 
antibacterial efficacy via inhibition of protein synthesis without cross-resistance to the 
quinolone class or oxazolidinone class of antibiotics.51-52 Cadazolid also exhibits inhibition 
of toxin production and sporulation; furthermore, the drug has a low oral bioavailability 
and it exhibits respectable selectivity for C. difficile over intestinal microflora.51-52 
 
Figure 1.11 – Cadazolid (hybrid quinolone and oxazolidinone antibiotic). 
Cadazolid exhibits MIC values ranging from 0.125 – 0.50 µg/mL against C. difficile 
isolates.51-52 The compound passed initial phase I and II clinical trials, showing similar 
tolerability and efficacy relative to vancomycin. Recent global phase III clinical trials have 
been concluded with mixed results (currently unpublished); progression to further phase 





Other novel CDI treatments 
 A plethora of other potential CDI therapies are currently under investigation – these 
include chemotherapeutics (including small molecules, polymers and larger biological 
molecules) and non-invasive non-drug therapies (e.g. faecal transplant therapy).20, 22, 24  
For example, ramoplanin is a lipodepsipeptide antibiotic owned by Nanotherapeutics that 
is currently undergoing clinical trials for CDI treatment and relapse prevention.20 
Tigecycline is a known antibiotic drug that is also under investigation for potential use as 
a CDI chemotherapeutic.20, 25 Furthermore, various synthetic derivatives of purines,54 
macrolides,55 nitroheterocycles,56 glycopeptides,57 tetramic acids,58 antimicrobial 
peptidomimetics59, nylon-3 polymers60 and bis-indoles61 have been shown to exhibit 
significant antibacterial activity against C. difficile; these molecular classes are generally 
under explored and more investigation is certainly warranted as novel, efficacious CDI 
medications are currently in high demand.  
Immunotherapeutic approaches include vaccination and passive antibody therapy; so far, 
these therapies have all focused on the C. difficile toxins. There are three vaccines currently 
being independently investigated in clinical trials by Sanofi-Pasteur, Pfizer and Intercell.20 
In October 2016, bezlotoxumab (Merck’s monoclonal antibody targeting C. difficile toxin 
B) was given FDA approval as an adjunct therapy for patients who are currently 
undergoing antibiotic therapy for CDI treatment and are at high risk of recurrent 
infection.62  
1.5 – Antibacterial binaphthylpeptide derivatives  
 In our laboratory, there has been an ongoing project focused on the development of 
novel antibacterial compounds originally based upon a binaphthylpeptide scaffold.59, 63-69 
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The key structural moieties that confer antibacterial activity to this class of compounds are 
outlined on lead compound 1 (Figure 1.12) as a rudimentary pharmacophore. The essential 
structural features include a hydrophobic biaryl moiety with an alkyloxy substituent 
attached to one ring system and a peptide chain attached to the other aromatic ring. The 
peptide chain comprises one to three amino acid residues; importantly, at least one of the 
amino acid residues must contain a cationic (i.e. basic) side chain functionality. Lysine 
(Lys) and arginine (Arg) have been found to be key amino acids for establishing 
antibacterial activity amongst this class of compounds. A hydrophobic terminus is essential 
for ensuring potent antibacterial activity, although bifurcation of the terminus does not 
seem to be vital.59, 69 
 
Figure 1.12 – General pharmacophore for binaphthylpeptide compounds 
(shown on lead compound 1). 
These binaphthylpeptide derivatives generally exhibit broad-spectrum Gram-positive 
antibacterial activity, e.g. compound 1 exhibits an MIC = 2.0 µg/mL against VRSA and 
4.0 µg/mL against VRE.64 Notably, compound 1 also exhibited potent antibacterial activity 
against MRSA and S. aureus strains that were resistant to linezolid. The compound 
displayed reduced activity against Gram-negative bacteria, including E. coli and K. 
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pneumoniae with MIC values of 16.0 µg/mL and > 32.0 µg/mL, respectively. 64 Compound 
1 was licensed to Valevia Pharmaceuticals in 2010 and the company was pursuing topical 
use of the drug in catheter and wound related infections.70 
In vitro studies also indicated that resistance to the binaphthylpeptides develops extremely 
slowly compared to vancomycin; 18 generations of S. aureus were required for 
development of vancomycin resistance, whereas compound 1 required over 50 generations 
of S. aureus for the development of in vitro resistance.64 Bacteria that eventually developed 
reduced susceptibility to 1 did not exhibit cross-resistance to vancomycin.64 These data 
indicate that vancomycin and compound 1 do not share a common mechanism of action.  
Recent studies in our laboratory indicated potent antibacterial activity (MIC = 2.0 – 8.0 
µg/mL) against C. difficile by various oxazole and triazole derivatives of compound 1.59, 68 
Lead compound 2 was developed as a peptidomimetic derivative of compound 1 and it was 
found to exhibit notable in vitro antibacterial activities against both S. aureus and 
hypervirulent C. difficile (Figure 1.13).69  
Compound 2 was subsequently tested in an in vivo murine model of CDI with some 
promising initial results.71 Attempts are currently being made to increase antibacterial 
activity and introduce C. difficile selectivity. Notably, these biarylpeptide derivatives are 
non-drug like as the presence of many heteroatoms and its dicationic nature confers poor 
membrane permeability to the molecules. This property makes these compounds perfect 
candidates for a potential new CDI treatment as they are not absorbed systemically; this 
allows for a high gastrointestinal concentration of the drug to be maintained, which is 
essential for CDI treatment. Thus, a library of novel derivatives, based upon lead 
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compound 2, will be pursued in an attempt to develop a drug that can effectively and safely 
treat CDI.   
  
Figure 1.13 – Lead compound 2 with a table of antibacterial activities against S. aureus 
(ATCC 29213), MRSA (NCTC 10442), E. faecalis (ATCC 29212), S. pneumoniae (ATCC 
49619), C. difficile (ATCC 700057, C. difficile (RT027 – NSW132) and E. coli 
(ATCC25922). 
1.6 – Target design: concepts and synthetic strategy 
1.6.1 – Peptidomimetic bioisostere incorporation 
 The human GI tract is acidic and contains numerous peptidases (i.e. peptide-
cleaving enzymes) and other metabolic enzymes; these conditions cause peptide bond 
degradation via acidic hydrolysis or enzymatic cleavage.72 Peptide bond decomposition 
can be avoided by replacing an amide moiety (Figure 1.14a – blue circle) in the target 
molecule with a peptidomimetic bioisostere, such as a 1,4-disubstituted-1,2,3-triazole ring 
(Figure 1.14c – blue portion).  
Studies have shown that the 1,2,3-triazole ring exhibits a similar planarity, dipole (Figure 
1.14b and 1.14c) and spatial arrangement (for the 1,4-substituents) to that of a normal 
peptide moiety.73-74 Notably, 1,4-disubstituted-1,2,3-triazoles exhibit the same potential to 
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accept and donate hydrogen bonds as normal amides yet they are considered more resistant 
to enzymatic cleavage, hydrolysis and oxidation.74 
 
Figure 1.14 – a) Portion of lead compound 1 with targeted amide group (blue circle) 
b) Amide moiety (blue) and corresponding dipole moment (red) c) 1,2,3-Triazole 
moiety (blue) and corresponding dipole moment (red). 
Peptidomimetic replacement of the first amide (Figure 1.14a – blue circle) in the peptide 
chain of binaphthylpeptide 1, by a 1,2,3-triazole moiety, led to derivatives like compound 
2. These triazole moieties were most reliably installed via a Cu-catalyzed azide-alkyne [3 
+ 2]-cycloaddition (CuAAC), i.e. a ‘click’ reaction.73-75 The precursors necessary for the 
formation of the triazole moieties were an alkyne fragment (e.g. compound 4) and the 
requisite azido-substituted fragment (e.g. azide 5), as shown in Scheme 1.1. 
 
Scheme 1.1 – Retrosynthesis of the internal triazole moiety (compound 3 - blue 
portion) gives alkyne 4 and azide 5. 
Furthermore, previous research in our laboratory has also led to the development of 
compounds with terminal 1,2,3-triazole moieties substituted for the amide terminus, e.g. 




Figure 1.15 – Lead compound 6 with a table of antibacterial activities against S. aureus 
(ATCC 29213), MRSA (NCTC 10442), E. faecalis (ATCC 29212), S. pneumoniae (ATCC 
49619), C. difficile (ATCC 700057, C. difficile (RT027 – NSW132) and E. coli 
(ATCC25922). 
1.6.2 – Peptide chain orientation 
The synthesis of the internal triazole moiety via a ‘click’ reaction allows for two 
potential peptide chain orientations; the resulting orientation is governed by the placement 
of the azide precursor functionality on the amino acid starting material (see Scheme 1.2). 
The amino acid precursor (7) can be functionalized in two ways, giving rise to either a β-
azido-amine (i.e. compound 8 in Pathway A – Scheme 1.2) or an α-azido-acid (i.e. 
compound 9 in Pathway B – Scheme 1.2). Subsequent ‘click’ reactions with these azide 
derivatives gives either scaffold orientation A or scaffold orientation B.  Both peptide 
orientations have been utilized in previous research on the biarylpeptides and both 
orientations are known to produce active compounds.59, 69, 76 Therefore, it was decided that 
both scaffold orientations, A and B,  would be pursued and they would be classified into 





Scheme 1.2 – Effect of azide functionality placement on the resultant scaffold's peptide backbone 
orientation. Pathway A shows the potential β-azido-amine and the resulting scaffold orientation 
(A). Pathway B shows the potential α-azido-acid and the resulting scaffold orientation (B). 
1.6.3 – Aromatic core modification 
 A hydrophobic aromatic core (red circle in Figure 1.12) is essential for the 
antimicrobial activity of the binaphthylpeptide derivatives. Previous research has shown 
that the substitution of the binaphthalene moiety (10) with an analogous biphenyl core (11) 
(Scheme 1.3) produces compounds with similar antimicrobial efficacy.65-66  
 
Scheme 1.3 – Aromatic core replacement showing the change from 
a binaphthalene core (10) to a biphenyl core (11). 
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The solubility and structure of the binaphthylpeptide derivatives will be modified by the 
introduction of a biphenyl aromatic core, which will allow for more variation in the target 
compound library.  
1.6.4 – Target compounds: scaffold variation and derivatization 
 A large number of structurally different biarylpeptide analogues will be designed 
and synthesized based upon lead compounds 2 and 6. A range of unique scaffolds will be 
synthesized, and each scaffold will be derivatized into a small number of analogues. The 
following structural scaffold parameters will be varied to give different scaffolds: the 
number of peptidomimetic 1,2,3-triazoles (Section 1.6.1), the peptide bond orientation 
(Section 1.6.2), the aromatic core (Section 1.6.3) and amino acid residues (i.e. number, 
type and orientation). Permutation of these scaffold variations will give rise to a large 
number of potential scaffold configurations. There are too many possibilities to synthesize 
them all, so selected scaffold variations will be synthesized to allow for key structure-
activity relationship (SAR) comparisons between specific analogues. Examples of the 
targeted scaffold variations for Series A, B and C are displayed in Figures 1.16, 1.17 and 
1.18, respectively. Previous research has shown that monocationic derivatives can display 
useful antibacterial potency;59, 69 therefore, simple monocationic derivatives (i.e. scaffold 
types 12 and 15) will be targeted as well, because smaller and more synthetically-accessible 
molecules are always preferable. Each synthesized scaffold will be derivatized by variation 
of the hydrophobic terminus (R); peptide coupling or CuAAC reactions will be utilized for 








Figure 1.16 – Series A scaffold variations: note the variable structural elements (i.e. 






Figure 1.17 – Series B scaffold variations: note the variable structural elements (i.e. amino 







Figure 1.18 – Series C scaffold variations: note the variable hydrophobic terminus 
(R). 
Derivatization of the scaffold fragments allows for the synthesis of multiple analogues for 
each scaffold type, increasing the productivity of the synthetic approach – more molecules 
translates to an increased number of potential hit compounds. A small number of molecules 
without an internal triazole moiety (i.e. Series C) will also be synthesized purely for SAR 
data.  
1.6.5 – Modular approach to scaffold synthesis  
To allow for easy synthetic access to multiple scaffold variations, a modular 
approach to scaffold synthesis will be adopted. The variable structural components of the 
scaffolds in both Series A and B are primarily attached by peptide bonds and 1,2,3-triazole 
rings; therefore, peptide coupling and CuAAC reactions will allow for the facile and 
reliable construction of numerous scaffold configurations from a number of primary 
building blocks (Figure 1.19) that contain these key reactive functionalities: amines 
(-NH2), acids (-COOH), azides (-N3) and alkynes (-C≡CH). The alkyne building blocks 
can be combined with the requisite azide building blocks to construct the necessary 1,2,3-
triazole moieties. Furthermore, any acid building blocks can be joined to any primary 




Figure 1.19 – Precursor building blocks for the modular approach to scaffold 
synthesis: azide and alkyne functionalities (blue) can be readily linked together via 
CuAAC reactions while the amine and acid moieties (red) can also join together via 
peptide coupling methods. 
Dual functionalization of the amino acid residues with both an azide and a group capable 
of peptide coupling (i.e. an amine or carboxylic acid) allows for the combination of 
multiple precursor building blocks to build the scaffolds; for example, the more complex 
scaffold types can be constructed from just three modular buildings blocks (Scheme 1.4). 
Previous research69 has shown that CuAAC reactions do not work well with the 
unprotected β-azido-amines 22 and 25, so N-protected derivatives 23, 26, and 27 were 





Scheme 1.4 – Modular approach to scaffold synthesis: azide and alkyne 
functionalities (blue) are combined into a 1,2,3-triazole moiety while the 
amine and acid moieties (red) are coupled together via an amide bond. 
Note the dual functionalization of the amino acid derivatives that allows 
for the modular synthesis; the remaining terminal azide handle (green) 
allows for scaffold derivatization. 
1.6.6 – Synthesis: proposed pathway and considerations  
The aforementioned precursor building blocks (Figure 1.19) will be achieved 
through the utilization of known synthetic methodologies; these precursors will be 
combined through CuAAC and peptide coupling reactions to achieve the aforementioned 
scaffolds (Section 1.6.4). The various scaffolds will be subsequently derivatized by either 
CuAAC or peptide coupling reactions followed by side-chain N-deprotection and HCl 
salting; such iterative derivatization of the various scaffold types will allow for the creation 
of a small library of novel antibacterial compounds.   
Importantly, the proposed synthesis requires the use of four protecting groups, i.e. Boc, 





Figure 1.20 – Nitrogen protecting group structures and abbreviations. 
Three of the groups (Boc, Cbz, and Fmoc) form carbamates with free amines while the 
other group (Pbf) protects guanidino residues via arylsulfonimide formation. Previous 
syntheses64-65 have utilized the Boc and Pbf groups for protection of the lysine and arginine 
amino acid side-chains, respectively. Importantly, these two groups can be simultaneously 
cleaved by acidolysis as a final step, which allows the side chains to remain protected 
throughout the entire synthetic process. In peptide synthesis, the backbone (or α) nitrogen 
is most commonly protected by the base-labile Fmoc group.77 The “Boc/Fmoc” orthogonal 
deprotection strategy (i.e. acid for Boc/Pbf, base for Fmoc) has been employed in the 
synthesis of previous binaphthylpeptide antibacterials64-65 and a similar orthogonal 
protocol will be utilized for the realization of the targeted cationic biarylpeptides. Instead, 
the Cbz protecting group will be utilized for protection of the α-nitrogen on the amino acid 
precursors (when required), as this protecting group is stable to the pursuant azidation 
conditions.69 Furthermore, the Cbz protecting group is also ideal because it allows for 
selective deprotection, in the presence of a Boc group, via catalytic hydrogenolysis.78 The 
Fmoc group will only be utilized in known synthetic procedures for building the 
unprotected β-azido-amine precursors 22 and 25, because the N-protecting group is not 
required after azidation for these amine building blocks. 
 The proposed synthetic pathways (Schemes 1.5, 1.6 and 1.7) allow for the divergent 
synthesis of multiple scaffold types from simpler scaffold molecules. For example, the 
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larger scaffold types (e.g. 14) will be synthesized from the smaller scaffold precursors (e.g. 
amine scaffold 38 – see Scheme 1.5); this divergent synthetic approach allows for simple 
diversification of the scaffold types with minimal synthetic labour. This modular synthetic 
approach will allow for multiple scaffold variations to be synthesized from the same key 
precursor building blocks. This approach also allows for derivatization of each scaffold 
type, allowing for the facile synthesis of a large number of antibacterial compounds.  
 









Scheme 1.7 – Potential synthetic pathway to Series C scaffold types 18 and 19. Precursor 
compound 42 was gifted from previous researcher (S. Wales). Precursor compound 29 will be 
synthesized from Fmoc-(D)-Arg(Pbf)-OH via methyl esterification followed by N-Fmoc 
deprotection.  
 
1.7 – Project Aims 
 It is evident that there exists a strong, unmet need for novel antibacterial 
compounds to effectively treat CDI. Therefore, a joint research project (NHRMC Project 
Grant# APP1124032) to pursue the synthesis and development of effective CDI 
chemotherapeutics was established between the University of Wollongong (design and 
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synthesis), the University of Western Australia (microbiology) and Monash University 
(pharmacology). The aims of this project are: 
 To incorporate an increased number of peptidomimetic bioisosteres (i.e. a 1,2,3-
triazole moiety) into the peptide backbone of the lead binaphthylpeptides 2 and 6 
– in an attempt to increase gastrointestinal stability by replacing amide moieties 
with bioisosteres that exhibit increased resistance to enzymatic cleavage;73 
 To design and establish a viable, multi-gram synthesis of numerous novel triazole-
containing scaffolds;  
 To simplify the hydrophobic aromatic core in these scaffolds in an attempt to 
increase compound solubility;  
 To vary the number and orientation of cationic amino acid residues embedded in 
these novel scaffolds;  
 To synthesize a small library of novel antibacterial derivatives by installing 
various hydrophobic termini on the new scaffolds; 
 To ascertain the antimicrobial activity of the synthesized derivatives against a 
range of pathogenic Gram-negative bacteria, Gram-positive bacteria and fungi via 
MIC assays; 
 To ascertain the general toxicity of the synthesized compounds via cytotoxicity 
assay; 
 To explore the structure-activity relationship of the compounds by utilizing the 
obtained MIC data; 
 To incorporate the structure-activity relationship findings into the target design; 
40 
 
 To design and identify a novel hit compound that could be utilized in the effective 
treatment of CDI; 
 To ascertain the efficacy of the compound as a CDI chemotherapeutic via testing 
in an in vivo CDI mouse model; 
 To develop and utilize a comparative solubility assay for determining the relative 
solubilities of the synthesized compounds; 
and 
 To perform a rudimentary pharmacokinetics study on the biarylpeptides by testing 
the blood and faeces of mice from the in vivo CDI model. 
These goals represent a multi-faceted approach to designing and creating an effective CDI 
chemotherapeutic based upon the lead binaphthylpeptide scaffolds 2 and 6. The knowledge 




2.0 – Synthesis: results and discussion 
2.1 – Synthesis of precursor building blocks 
 This section describes the synthesis of the scaffold precursor building blocks from 
commercially available precursors. The known compounds are marked by a reference to the 
previous literature. All compounds were synthesized with modified literature procedures. 
Schemes detailing each reaction mechanism can be found in Appendix A – Section A1. 
2.1.1 – Synthesis of aromatic cores 
2.1.1.1 – Synthesis of alkyne 20 
The synthesis of alkyne 20 from precursor 45 was accomplished in two steps: 
O-alkylation followed by O-propargylation (Scheme 2.1). The base-promoted mono-O-
alkylation of (S)-BINOL63 (45) (500 mg, 1.75 mmol) with 1-bromo-3-methylbutane was 
achieved with K2CO3 in acetone at reflux (Scheme 2.1) and produced ether 46 in 81% yield. 
The reaction was also successfully conducted on larger scales with comparable yields – e.g. 
10.00 g (34.92 mmol) of (S)-BINOL gave a 78% yield of ether 46. 
 
Scheme 2.1 – Two-step synthesis of key alkyne 20: first, O-alkylation of compound 45 to 
give ether 46 and then O-propargylation of 46 to yield target alkyne 20. 
Target alkyne 20 was then realized in 98% yield via base-promoted O-propargylation of 
intermediate 4679 (1.50 g, 4.21 mmol) with propargyl bromide and K2CO3 in acetonitrile at 
reflux for 48 h. This reaction was also conducive to larger scale as 9.00 g (25.30 mmol) of 
starting material 46 was reacted to produce alkyne 20 in 95% yield. These compounds (46 
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and 20) exhibited spectroscopic data that were in agreement with those values reported 
previously.63, 69, 79 
2.1.1.2 – Synthesis of alkyne 21 
The synthesis of alkyne 21 from precursor 47 was accomplished in two steps: 
O-alkylation followed by O-propargylation (Scheme 2.2). The base-promoted mono-O-
alkylation of 2,2′-biphenol66 (47) (3.00 g, 16.11 mmol) with 1-bromo-3-methylbutane was 
achieved with K2CO3 in acetone at reflux (Scheme 2.2) and produced ether 48 in 89% yield. 
The reaction was also successfully conducted on larger scales with comparable yields – e.g. 
10.00 g (53.70 mmol) of 2,2′-biphenol gave an 81% yield of ether 48. 
 
Scheme 2.2 – Two-step synthesis of key alkyne 21: first, O-alkylation of compound 47 to 
give ether 48 and then O-propargylation of 48 to yield target alkyne 21. 
Target alkyne 21 was then realized in 99% yield via base-promoted O-propargylation of 
intermediate 48 (1.50 g, 5.85 mmol) with propargyl bromide and K2CO3 in acetonitrile at 
reflux for 48 h. This reaction was also amenable to larger scale as 7.80 g (30.43 mmol) of 
starting material 48 was reacted to produce alkyne 21 in 96% yield. Ether 48 exhibited 
spectroscopic data that were in agreement with those values reported previously.66  
The 1H NMR spectrum for alkyne 21 displayed a characteristic triplet resonance at δ 2.43 
that was absent in the 1H NMR spectrum of the starting ether 48 – this resonance exhibited a 
small coupling constant (J = 2.3 Hz) which is characteristic of long-range propargylic 
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coupling with the adjacent methylene protons. Therefore, the resonance at δ 2.43 was 
assigned to the alkyne proton (-CH2C≡C-H); this assignment was further confirmed by a 
corresponding gHSQC correlation with a 13C NMR carbon resonance at δ 75.2, which had 
been assigned as the alkyne methine carbon (-C≡C-H). The 13C NMR spectrum of compound 
21 displayed two unique resonances (δ 79.3 and 75.2) that were not present in the 13C NMR 
spectrum of the starting ether 48; these 13C NMR resonances were assigned to the quaternary 
(-C≡C-H) and methine (-C≡C-H) alkyne carbons, respectively.  The molecular structure was 
verified by the presence of a peak at m/z 295.1692 in the HRMS that was assigned to the 
protonated molecular ion [M + H]+ (calcd for C20H23O2 295.1698). 
2.1.2 – Synthesis of lysine derivatives 
2.1.2.1 – Synthesis of azide 23 
 The synthesis of the doubly N-protected azide 23 from commercially available H-(D)-
Lys(Boc)-OH (49) was completed in a three step reaction sequence: Cbz protection,80 
carboxylic acid reduction,81 and then a two-step, one-pot mesylation/azidation procedure82 
(Scheme 2.3). Installation of the Cbz protecting group on substrate 49 (4.00 g, 16.24 mmol) 
gave Cbz-Lys(Boc)-OH (50) in 95% yield by reaction with benzyl chloroformate and 
aqueous NaOH solution. This reaction required a substantially modified work-up procedure, 
due to the solubility of the sodium carboxylate product in organic solvents. A traditional 
acid/base work-up could not be employed; the product was extracted directly from the 
reaction mixture into EtOAc as the sodium carboxylate salt followed by back-extraction into 
distilled H2O. The intermediate acid 50 (804 mg, 2.11 mmol) was then subjected to a ‘mixed 
anhydride reduction’ technique: the acid was converted into a mixed carbonic-carboxylic 
anhydride by reaction with isobutyl chloroformate in the presence of N-methylmorpholine. 
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The resultant mixed anhydride was then reduced by an aqueous solution of NaBH4 to give 
the desired alcohol (51) in near quantitative yield (98%). This reaction was also implemented 
on larger scales – 6.81 g (17.90 mmol) of acid 50 produced a 96% yield of alcohol 51. This 
intermediate alcohol was then subsequently utilized in the two-step, one-pot synthesis of 
azide 23. 
 
Scheme 2.3 – Synthesis of key azide 23, from the lysine precursor 49, in three steps: N-Cbz 
protection to give compound 50, then reduction of the acid functionality to give alcohol 51, 
followed by consecutive mesylation/azidation to furnish the target azide 23. 
The alcohol substrate 51 (6.56 g, 17.90 mmol) was first converted in situ to a mesylate via 
MsCl/NEt3/CH2Cl2 followed by a biphasic, SN2-type azidation reaction with NaN3, toluene, 
H2O, and the phase transfer catalyst (Bu)4NBr;
83 azide 23 was thus isolated in 83% yield over 
the two steps. Compounds 50, 51 and 23 exhibited spectroscopic data that were in agreement 




2.1.2.2 – Synthesis of azide 22 
 The synthesis of azide 22 from commercially available Fmoc-(D)-Lys(Boc)-OH (52) 
was achieved by carboxylic acid reduction81 followed by mesylation and subsequent 
azidation/N-deprotection84 (Scheme 2.4). Reduction of the starting acid 52 (4.00 g, 8.54 
mmol) via a mixed anhydride reduction with isobutyl chloroformate, N-methylmorpholine 
and NaBH4 gave alcohol 53 in 92% yield.  
 
Scheme 2.4 – Synthesis of azide 22 from the lysine precursor 52: reduction of the 
carboxylic acid functionality to give alcohol 53, followed by mesylation and then 
sequential azidation/N-deprotection to furnish target azide 22. 
The intermediate alcohol 53 (100 mg, 0.22 mmol) was then subjected to mesylation with 
MsCl/NEt3/CH2Cl2 followed by azidation and N-Fmoc deprotection
84 with NaN3 in DMF at 
50 °C to give the target azide 22 in 46% yield over two steps. It was assumed that the 
azidation of the mesylate intermediate occured rapidly followed by N-Fmoc deprotection 
with the excess NaN3 acting as a base to promote the deprotection step (see Appendix A, 
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Schemes A1.5 and A1.7 for related mechanisms).84 Compounds 53 and 22 exhibited 
spectroscopic data that were in agreement with those values reported previously.59, 85  
2.1.2.3 – Synthesis of azide 24 
 The synthesis of azide 24 from commercially available H-(D)-Lys(Boc)-OH (54) was 
achieved by copper-catalysed diazotransfer reaction86 with freshly prepared  imidazole-1-
sulfonyl azide87-88 (Scheme 2.5). The diazotransfer reagent (imidazole-1-sulfonyl azide) was 
prepared in an EtOAc solution as previously described.87 The EtOAc solution of imidazole-
1-sulfonyl azide was stirred with amino acid 54 (2.20 g, 8.93 mmol) in the presence of 
CuSO4·5H2O and K2CO3 in MeOH at rt; the product α-azido acid 24 was thus furnished in 
98% yield utilizing a modified work-up procedure.87 The purification procedure was 
modified to eliminate flash chromatography in favour of an acid/base extraction purification 
with Et2O. This modification allowed for a faster purification and isolation with less chemical 
waste. Compound 24 exhibited spectroscopic data that were in agreement with those values 
reported previously.89-90 
 






2.1.3 – Synthesis of arginine derivatives 
2.1.3.1 – Synthesis of azide 26 
 The synthesis of the doubly N-protected azide 26 from commercially available Cbz-
(D)-Arg(Pbf)-OH (55) was achieved by carboxylic acid reduction81 followed by a two-step, 
one-pot mesylation/azidation procedure82 (Scheme 2.6).  
 
Scheme 2.6 – Synthesis of azide 26 from the arginine precursor 55: reduction of the 
carboxylic acid functionality to give alcohol 56 followed by mesylation and then 
azidation to furnish target azide 26. 
The acid 55 (5.00 g, 8.92 mmol) was converted into a mixed carbonic-carboxylic anhydride 
by reaction with isobutyl chloroformate in the presence of N-methylmorpholine followed by 
reduction with aqueous NaBH4 to give the desired alcohol (56) in 78% yield. 
Evidence of the carbonyl reduction was seen in the 1H NMR spectrum of compound 56 as a 
new multiplet resonance centred at δ 3.60. This multiplet integrated to three protons and it 
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was not present in the starting material 55. Therefore, the multiplet was assigned to the newly 
installed methylene protons (-CH2OH) in conjunction with the adjacent methine proton 
(-CHNHCbz). The methine assignment was confirmed by gCOSY correlation to the 
resonance at δ 5.62 (assigned as the carbamate proton (-NHCbz)). 
Furthermore, this multiplet resonance displayed gHSQC correlations with two resonances 
(δ 64.8 and 52.8) in the 13C NMR spectrum of compound 56 – these resonances were assigned 
to the corresponding methylene carbon (-CH2OH) and methine (-CHNHCbz) carbon, 
respectively. The molecular structure of compound 56 was verified by the presence of a peak 
at m/z 547.2589 in HRMS that was assigned to the protonated molecular ion [M + H]+ 
(calculated for C27H39N4O6S 547.2590). This intermediate alcohol was then subsequently 
utilized in the two-step, one-pot synthesis of azide 26.  
The alcohol substrate 56 (3.79 g, 6.94 mmol) was first converted in situ to a mesylate via 
MsCl/NEt3/CH2Cl2 followed by a biphasic, SN2-type azidation reaction with NaN3, toluene, 
H2O, and a phase transfer catalyst;
83 azide 26 was thus isolated in 71% yield over the two 
steps. The 1H NMR spectrum of azide 26 displayed a 2H multiplet resonance at δ 3.31 which 
was assigned to the methylene protons (-CH2N3) adjacent to the azide moiety; this assignment 
was confirmed by a gHSQC correlation with a 13C NMR resonance at δ 54.9 (assigned as the 
corresponding methylene carbon) and by gCOSY correlation with a 1H NMR resonance at δ 
3.73 (assigned to the adjacent methine proton (-CHNHCbz)). 
Additionally, the multiplet resonance at δ 3.60 in the 1H NMR spectrum of the starting 
alcohol 56 (assigned to the corresponding methylene protons (-CH2OH)) was no longer 
visible in the 1H NMR spectrum of the product azide 26. The resonance at δ 3.31 (assigned 
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to the methylene protons in the 1H NMR spectrum of the azide) was shifted upfield (i.e. more 
shielded) relative to the signal at δ 3.60 (assigned to the corresponding methylene protons 
(-CH2OH)) in the 
1H NMR spectrum of the starting alcohol 56 – this upfield shift is to be 
expected, given the greater deshielding effect of the alcohol group relative to the azide 
moiety. Analysis of the IR spectrum of azide 26 revealed a characteristic band at 2098 cm-1 
that was assigned to the newly installed azide moiety. The molecular structure of compound 
26 was verified by the presence of a peak at m/z 572.2677 in HRMS that was assigned to the 
protonated molecular ion [M + H]+ (calcd for C27H38N7O5S 572.2655). 
2.1.3.2 – Synthesis of azide 25 
 The synthesis of β-azido-amine 25 from commercially available Fmoc-(D)-Arg(Pbf)-
OH (57) was achieved by carboxylic acid reduction, iodination and subsequent azidation/N-
deprotection (Scheme 2.7) as previously described.59 Reduction of the starting acid 57 (4.00 
g, 6.17 mmol) via a mixed anhydride reduction with isobutyl chloroformate, 
N-methylmorpholine and NaBH4 gave alcohol 58 in 80% yield. The intermediate alcohol 58 
(3.10 g, 4.88 mmol) was then subjected to iodination with I2/PPh3/imidazole in CH2Cl2 at rt 
followed by azidation and N-Fmoc deprotection84 with NaN3 in DMF to give the target azide 
25 in 80% yield over two steps.  
A modified procedure was developed to enhance the yield and reduce the labour required: 
the azidation and N-Fmoc deprotection were carried out independently by allowing the 
azidation to proceed at rt first before allowing the N-Fmoc deprotection reaction to occur by 
heating the reaction to 50 °C. This modification was introduced to prevent the observed 
oxazolidinone by-product from forming via SN2 displacement of the iodide leaving group 
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with the carbamic anion produced during N-Fmoc removal (see Scheme A1.6 in Appendix 
A). 
 
Scheme 2.7 – Synthesis of azide 25 from the arginine precursor 57: reduction of the 
carboxylic acid functionality to give alcohol 58, followed by iodination and then 
azidation/N-deprotection to furnish target azide 26. 
Furthermore, a traditional acid/base work-up procedure was utilized to purify the β-azido-
amine product instead of flash chromatography. These modifications led to a substantially 
increased yield over the literature method (61%59 to 80%) and significantly easier isolation 
procedure. Compounds 58 and 25 exhibited spectroscopic data that were in agreement with 





2.1.3.3 – Synthesis of azide 27 
 The synthesis of azide 27 was achieved by a traditional N-Boc protection of β-azido-
amine (26).91 The substrate amine 25 (100 mg, 0.23 mmol) was reacted with Boc2O in CH2Cl2 
at rt for 2 h to give the target N-Boc amine 27 in 98% yield (Scheme 2.8).  
The 1H NMR spectrum of compound 27 displayed a prominent singlet resonance at δ 1.43 
that was not found in the 1H NMR spectrum of the starting material 25; this 9H singlet was 
assigned to the newly introduced t-butyl protons (-C(CH3)3). 
 
Scheme 2.8 – Synthesis of azide 27 from β-azido-amine 25 via N-Boc protection. 
The installation of the N-Boc protecting group was further confirmed by the appearance of a 
new 13C NMR resonance at δ 156.1 which was assigned as the new carbamate carbon (C=O). 
The presence of the N-Boc protecting group was further confirmed by the new 1H NMR 
resonance at δ 4.89 (assigned as the -NHBoc proton) – this broad doublet resonance was not 
present in the starting β-azido-amine 25 and this resonance displayed coupling by gCOSY 
correlation with the resonance at δ 3.69 (which was assigned to the adjacent methine proton). 
The molecular structure of compound 27 was verified by the presence of a peak at m/z 
538.2811 in the HRMS that was assigned to the protonated molecular ion [M + H]+ (calcd 





2.1.3.4 – Synthesis of azide 28  
 The synthesis of azide 28 from commercially available H-(D)-Arg(Pbf)-OH (60) was 
achieved by copper-catalysed diazotransfer reaction86 with imidazole-1-sulfonyl azide87-88 
(Scheme 2.9). The EtOAc solution of imidazole-1-sulfonyl azide was then stirred with 
precursor 60 (2.00 g, 4.69 mmol) in the presence of CuSO4·5H2O and K2CO3 in MeOH at rt; 
the product α-azido-acid 28 was thus furnished in 83% yield.87 The purification procedure 
was modified to eliminate flash chromatography in favour of an acid/base isolation work-up 
with Et2O. Compound 28 exhibited spectroscopic data that were in agreement with those 
values reported previously.92 
 
Scheme 2.9 – Synthesis of α-azido-acid 28 from the arginine precursor 60 via 
diazotransfer reaction. 
2.1.3.5 – Synthesis of amine 29  
 The synthesis of amine 29 from commercially available Fmoc-(D)-Arg(Pbf)-OH (61) 
was achieved by esterification followed by base-promoted N-Fmoc deprotection (Scheme 
2.10).59, 79, 91 The starting compound 61 (1.00 g, 1.54 mmol) in MeOH was treated with SOCl2 
to afford an intermediate methyl ester (i.e. Fmoc-(D)-Arg(Pbf)-OMe) – this ester was then 
stirred with piperidine in MeOH at rt to furnish the target amine 29 in 80% yield over two 





Scheme 2.10 – Synthesis of amine 29 from the arginine precursor 
61: esterification followed by base-promoted N-Fmoc deprotection. 
 
2.2 – Series A synthesis: scaffolds and derivatives 
2.2.1 – Synthesis of monocationic derivatives (Series A1) 
2.2.1.1 – Synthesis of Series A1 scaffolds via CuAAC and N-deprotection 
2.2.1.1.1 – 1,2,3-Triazole formation via a ‘click reaction’ 
 The synthesis and incorporation of 1,4-disubstituted-1,2,3-triazole rings in novel 
pharmaceuticals has become an extremely widespread practice and the common ‘click 
reaction’ (i.e. a Cu-catalysed azide-alkyne cycloaddition (CuAAC)) has become the most 
reliable methodology for the formation of these moieties.73-75, 93-94 Therefore, formation of 
the key scaffold intermediates 62a-d (Scheme 2.11) was realized via CuAAC reactions.  
For example, scaffold 62a was achieved by following General Procedure A (Section 6.2), 
wherein azide 23 (1.50 g, 3.83 mmol) and alkyne 21 (2.0 eq) were treated with 
Cu(II)/ascorbate in t-BuOH/H2O
59, 75 for 48 h at rt to give a 75% yield of compound 62a after 
purification by flash chromatography. Furthermore, this reaction methodology was effective 
on a larger scale, as an 88% yield of 62a was obtained from 2.64 g (6.74 mmol) of precursor 




Scheme 2.11 - Cu-catalysed [3 + 2] cycloaddition reactions between an alkyne building block (20 
or 21 - blue triple bond) and an azide precursor (23, 26 or 27 - blue portion) to give the key scaffold 
intermediates 62a-d for Series A1. 
The 1H NMR spectrum of compound 62a displayed resonances that corresponded to 
fragments from both starting materials (alkyne 21 and azide 23) – see Appendix C (Figures 
C1.1 and C1.2) for the NMR spectra. The most noteworthy and diagnostic difference was the 
disappearance of the 1H NMR singlet resonance at δ 2.43 (-CC-H) that was seen in the 1H 
NMR spectrum of alkyne 21 and the appearance of a significantly more downfield resonance 
at δ 7.17 (triazole CH) in the 1H NMR spectrum of 62a. This significant difference in 
chemical shift was indicative of triazole formation; the terminal alkyne proton in compound 
21 had now become the lone proton on the newly formed aromatic triazole ring – this results 
in a strong deshielding of the proton (relative to the alkyne proton) and results in a large 
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downfield chemical shift. Two unique aromatic 13C NMR resonances at δ 145.2 and 123.3 
were present in the 13C NMR spectrum of compound 62a and they were assigned to the 
methine and quaternary triazole carbons, respectively. The resonance at δ 145.2 was 
extremely diagnostic because few other aromatic carbon resonances appear in that region 
(i.e. δ 141-150). As expected, the 13C NMR resonance at δ 123.3 (triazole CH) displayed a 
correlation in the gHSQC spectrum with the 1H NMR resonance at δ 7.17 (triazole CH). 
Furthermore, the appearance of these two unique 13C NMR resonances coincided with the 
disappearance of the two alkyne (-CC-) 13C NMR resonances at δ 79.3 and 75.2 that are 
evident in the 13C NMR spectrum of starting alkyne 21. These two alkyne carbons (-CC-) 
had now become the aromatic triazole carbons – this explains the associated large downfield 
chemical shifts. HRMS analysis confirmed the molecular identity, as a peak was observed at 
m/z 708.3755 that was assigned to the sodiated molecular ion, [M + Na]+ (calcd for 
C39H51N5O6Na 708.3737).  
Scaffold intermediates 62a-d (Scheme 2.11) were obtained by implementation of the 
aforementioned General Procedure A. Evidence for the regioselective outcome of the 1,2,3-
triazole formation (i.e. solely the 1,4-isomer and not the 1,5-isomer) was established for the 
scaffold amine (i.e. the Nα-deprotected derivative) of 62a (i.e. compound 63a) via analysis 
of the relevant gHMBC spectrum; this evidence is discussed in Section 4.2.  
The CuAAC reaction requires the presence of a catalytic quantity of Cu(I); this catalyst can 
be added directly or prepared in situ by reduction of a Cu(II) salt with an excess of an 
antioxidant75 (e.g. single electron transfer by sodium ascorbate – Scheme 2.12). The latter 
method is generally preferred, as the presence of an excess amount of reducing agent (relative 
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to the catalyst) prevents the disproportionation or oxidation of the active catalytic species 
(i.e. Cu(I)) to the inactive Cu(II) species.75, 93-94 Most importantly, this allows the reaction to 
be successfully conducted under open-air conditions without the need for an inert 
atmosphere.  
The regioselective construction of the 1,4-disubstituted-1,2,3-triazole is controlled by the 
relative binding orientation of the alkyne and azide precursors to the active Cu(I) catalyst 
complex (Scheme 2.12). The coordination of the primary azide nitrogen to the terminal Cu-
acetylide complex restricts the orientation of the resultant [3 + 2]-cycloaddition (Scheme 2.12 
– transition state) so that only the 1,4-regioisomer is produced.75, 93-94 This regioselectivity 
occurs because the two substituents are forcibly oriented in opposite directions during the 
catalysed cycloaddition. 
The proposed mechanism in Scheme 2.12 represents the currently accepted CuAAC catalysis 
model, based upon multiple CuAAC studies such as kinetic analysis and DFT 
calculations.75, 93-96 Kinetic analysis has found that the reaction is 2nd order with respect to 
the concentration of Cu(I); this implicates the likely role of a di-nuclear acetylide-bridged 
Cu(I) complex as the active catalytic species,93-94 as illustrated in the transition state complex 
in Scheme 2.12. Furthermore, experimental evidence for the involvement of alkynyl 
dicopper(I) complexes in the CuAAC reaction has been published.93, 97 Importantly, the mild 
catalytic conditions required for the CuAAC reaction allowed for reliable, clean and high-




Scheme 2.12 – Proposed catalytic cycle for the CuACC reaction:75, 93, 95-96 
[Cu] represents a Cu(I) complex that is coordinated to the requisite number 
of ancillary ligands. The mechanism allows for control over the 
regioselectivity of the cycloaddition by restricting the relative orientation of 
the 1,4-substituents. 
2.2.1.1.2 – N-deprotection: Cbz or Boc removal 
Removal of the N-Cbz protecting group can be achieved through a variety of reaction 
conditions; the most common methodologies are catalytic hydrogenolysis (e.g. Pd/C and H2 
gas) and acid-promoted nucleophilic cleavage (e.g. HBr/AcOH).78, 80 To avoid deprotection 
of the acid-labile Boc group, scaffold intermediate 62a (1.90 g, 2.77 mmol) was subjected to 
catalytic hydrogenolysis, by reaction with 10% w/w palladium-on-carbon (Pd-C – 0.15 eq) 
in a mixture of MeOH/AcOH under an atmosphere of H2 gas (via a balloon attached to the 
reaction flask), furnishing a 99% yield of scaffold amine 63a (Scheme 2.13). 
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Scheme 2.13 – Removal of the N-protecting group from intermediates 62a-d to give scaffold 
amines 63a-d: N-Cbz removal by catalytic hydrogenolysis (A) or N-Boc removal by acidolytic 
cleavage (B). 
Analysis of the 1H NMR spectrum of amine 63a revealed the lack of key N-Cbz diagnostic 
resonances at δ 5.06 (-CH2Ph) and 7.21 – 7.38 (phenyl) that were present in the spectrum of 
scaffold intermediate 62a. The removal of the N-Cbz protecting group was further supported 
by the lack of the characteristic downfield resonance at δ 66.9 (-OCH2Ph) normally seen in 
the 13C NMR spectrum of starting compound 62a. Furthermore, the disappearance of an 
additional four aromatic 13C NMR resonances (i.e. the phenyl carbons) provided substantial 
evidence of N-Cbz removal. 
TLC analysis of the product compound (63a) revealed a more polar compound has been 
produced and a strong purple colour after staining with ninhydrin confirmed the presence of 
a free amine. The product identity was confirmed via HRMS analysis; a peak observed at m/z 
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552.3564 was assigned to the protonated molecular ion, [M + H]+ (calcd for C31H46N5O4 
552.3550).  
Scaffold amines 63b and 63c (Scheme 2.13) were also achieved by implementation of the 
aforementioned catalytic hydrogenolysis procedure. Attempts to isolate scaffold amine 63d 
through the same methodology (i.e. N-Cbz removal via catalytic hydrogenolysis) failed due 
to the occurrence of multiple amine by-products (as confirmed by TLC and NMR analysis). 
The most prevalent by-product exhibited a peak in the LRMS with an m/z value that was 28 
amu heavier than that of the protonated molecular ion for the desired product (63d). With 
longer reactions times (> 24 h), notably larger quantities of this by-product were observed – 
these impurities could not be separated by flash chromatography or by recrystallization. In 
an attempt to solve these issues, the N-Boc protecting group was utilized as it would likely 
allow acidolytic cleavage in the presence of a side-chain N-Pbf protecting group. The 
arginine side-chain protecting group (N-Pbf) requires a strong acid for deprotection (e.g. 
TFA) and hydrogen-bonding solvents like MeOH, EtOH and H2O are known to suppress the 
acidolytic N-Pbf deprotection reaction.98-99 Therefore, reaction conditions employing 1.0 M 
HCl in MeOH/Et2O were utilized to successfully remove the N-Boc group from compound 
62d (113 mg, 0.12 mmol) without cleaving the N-Pbf side chain protecting group; a 95% 
yield of scaffold amine 63d was realized after 18 h at rt. See Section 2.2.1.2 for more 
information regarding N-Boc deprotection (i.e. mechanism and reaction details). 
MeOH is one of the most effective and widely used solvents for catalytic hydrogenolysis of 
the N-Cbz protecting group and the addition of acetic acid is helpful for protonation of the 
resultant amine product; this prevents coordination of the free amine to the palladium which 
can cause inactivation of the catalyst.100-102 Ideally, the only by-products produced are 
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volatile (i.e. CO2 and toluene) which makes for an extremely clean reaction and work-up. 
Benzyl carbamates (i.e. N-Cbz groups) are readily cleaved via Pd-catalysed hydrogenolysis 
due to their highly activated benzylic position and their ability to coordinate to the Pd catalyst 
through either aryl or oxygen coordination.101 The mechanism for catalytic hydrogenolysis 
of benzyl carbamates has not been completely elucidated, but certain key steps are 
understood.100 The most important and least understood step in the mechanism is the 
heterolysis of the benzylic C–O bond (Scheme 2.14– red bond scission); this essential step is 
thought to occur in a manner similar to the deprotection of O-benzyl or N-benzyl 
substituents,100 i.e. through coordination of the Cbz functionality to the Pd surface, followed 
by hydrogenolytic cleavage of the C–O bond which generates the unstable carbamic acid 
derivative and toluene (Scheme 2.14).  
 
Scheme 2.14 – Known aspects of the Pd-catalysed hydrogenolysis 
of benzyl carbamates (black arrows) with the theoretical 
heterolysis mechanism (blue arrows). 
Following proton transfer, the carbamic acid derivative readily decomposes to give CO2 and 
the desired free amine.78 One proposed mechanism for the heterolysis step involves PdII-π 
aryl electron coordination followed by formation of a η3-PdII-benzyl cation complex with 
concomitant displacement of the carbamate anion (Scheme 2.14 – blue pathway).  
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2.2.1.2 – Synthesis of Series A1 derivatives via amide coupling and N-deprotection 
 The derivatization of mono-amino acid scaffolds required a two-step transformation: 
installation of the terminal amide moieties followed by side-chain N-deprotection to yield the 
target amines as hydrochloride salts. Previous syntheses of the binaphthylpeptides have 
utilized the common EDCI/HOBt† peptide coupling reagent system to form the necessary 
peptide bonds while N-Boc and/or N-Pbf deprotection was previously achieved with 
TFA/CH2Cl2.
59, 64-66, 68-69 
The formation of amide bonds from carboxylic acids and amines (e.g. amino acid derivatives) 
via peptide coupling was an extremely crucial component in the synthesis of the target 
biarylpeptide derivatives. Therefore, a general amide coupling procedure (General 
Procedure B – Section 6.2) with literature precedent59 was developed and utilized in all 
subsequent amide coupling reactions.  
The acidolytic cleavage of the N-Boc and/or N-Pbf protecting groups is easily achieved with 
a variety of acids – with trifluoroacetic acid (TFA) being used most often.77, 103 The ability 
of these two protecting groups to be cleaved independently or simultaneously by relatively 
mild acidic conditions was an essential feature to this general reaction. As such, a general N-
deprotection reaction procedure (General Procedure C – Section 6.2) was developed by 
modifying the previously published procedure59, 66 and employed for the final deprotection 
of most N-Boc and N-Pbf protected side chain residues. The mono-lysine derivatives, from 
both Series A and B, exhibited increased solubility relative to the arginine derivatives and a 
                                                 




modified work-up procedure for the N-deprotection reaction (i.e. General Procedure D, 
Section 6.2) was required to enable precipitation of the final hydrochloride salts. 
Therefore, for Series A1 derivatives, General Procedure B was utilized to install the 
terminal amide moiety (see Reaction (i) in Schemes 2.15 – 2.17); the resultant N-protected 
amide derivatives were then immediately subjected to acidolytic N-Boc or N-Pbf cleavage 
followed by work-up with ethereal HCl (General Procedure C or D: Reaction (ii) in 
Schemes 2.15 – 2.17) to achieve the target amine salts (64a-b, 65a-b and 66a-b).  
 
Scheme 2.15 – Derivatization of scaffold 63a: installation of the terminal amide moiety 
(R) followed by removal of the N-Boc side chain protecting group to give scaffold 
derivatives 64a-b as hydrochloride salts. The synthetic pathway to realize compound 64c 
from N-Cbz protected scaffold precursor 62a is also displayed. 
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Target amines 64c, 65c and 66c were realized directly from scaffold intermediates 62a, 62b 
and the N-Cbz analogue of 62d (respectively) via N-Boc or N-Pbf deprotection following 
General Procedure C or General Procedure D. 
Importantly, yields of the final derivatives were undertaken over a two-step process. Reaction 
completion and product purity of the intermediate N-protected amides were monitored by 
TLC and/or MS analysis prior to subsequent N-deprotection. This methodology reduced the 
number of novel compounds that required extensive characterization, which allowed for 
facile and efficient derivatization of the scaffolds.  
For example, the synthesis of derivative 64a  (Scheme 2.15) was realized in 96% yield over 
two steps from scaffold amine 63a (50 mg, 0.09 mmol) by reaction with phenylacetic acid 
(1.2 eq), EDCI and HOBt in acetonitrile at rt for 24 h to give the corresponding amide which 
was immediately subjected to N-Boc deprotection with TFA in CH2Cl2 at rt for 18 h followed 
by work-up with ethereal HCl.  
The 1H NMR spectrum of derivative 64a displayed a new singlet resonance at δ 3.38 
(-CH2Ph) and a broad multiplet resonance at δ 7.36 – 7.10 (phenyl). These new 
1H NMR 
resonances support the installation of the terminal benzyl amide in compound 64a. The 
presence of the new amide moiety was further confirmed by the following 13C NMR 
resonances assignments: δ 174.3 (amide C=O), four resonances in the aromatic region 
(phenyl carbons) and δ 44.1 (-CH2Ph) – these resonances were not seen in the 
13C NMR 
spectrum of the starting amine 63a. Evidence of N-Boc deprotection was clearly seen by the 
lack of the 9H singlet resonance at δ 1.44 in the 1H NMR spectrum of amine salt 64a – 
whereas this N-Boc resonance was present in the protected starting amine 63a. Additionally, 
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the lack of key N-Boc resonances at δ 156.0 (Boc C=O), 79.2 (-C(CH3)3) and 28.5 (-C(CH3)3) 
in the 13C NMR spectrum of compound 64a provided further evidence that the N-Boc 
protecting group had been successfully removed. The molecular structure of the product was 
verified by the appearance of a peak at m/z 570.3451 in the HRMS that was assigned to the 
protonated molecular ion, [M + H]+ (calcd for C34H44N5O3 570.3444).  
 
Scheme 2.16 – Derivatization of scaffold 63b: installation of the terminal amide moiety (R) 
followed by removal of the N-Pbf side chain protecting group to give scaffold derivatives 
65a-b as hydrochloride salts. The synthetic pathway to realize compound 65c from the N-
Cbz protected scaffold precursor 62b is also displayed. 
In another example, the synthesis of derivative 65a  (Scheme 2.16) was realized in 84% yield 
over two steps from scaffold amine 62b (50 mg, 0.09 mmol) by a coupling reaction with 
phenylacetic acid (1.2 eq), EDCI and HOBt in acetonitrile at rt for 24 h to give the 
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corresponding amide which was immediately subjected to N-Pbf deprotection with TFA and 
H2O in CH2Cl2 at rt for 18 h followed by work-up with ethereal HCl. 
 
Scheme 2.17 – Derivatization of scaffold 63d: installation of the terminal amide moiety (R) 
followed by removal of the N-Pbf side chain protecting group to give scaffold derivatives 66a-b as 
hydrochloride salts. The synthetic pathway to realize compound 66c from the N-Cbz protected 
scaffold precursor 62d is also displayed. 
The 1H NMR spectrum of the final derivative 65a displayed resonances that were 
characteristic of the new terminal amide moiety (i.e. δ 3.33 (-CH2Ph) and 7.35 – 7.08 
(phenyl)). Evidence of N-Pbf deprotection was clearly seen by the lack of the five 
characteristic singlet resonances (δ 2.92, 2.56, 2.47, 2.06 and 1.43) in the 1H NMR spectrum 
of compound 65a – these resonances were present in the 1H NMR spectrum of starting amine 
63b and were assigned to the protons of the N-Pbf protecting group.  Additionally, the lack 
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of six distinct quaternary aromatic resonances in the 13C NMR spectrum of compound 65a 
provided further evidence for the removal of the N-Pbf protecting group. Six key non-
aromatic N-Pbf resonances at δ 86.5 (-C(CH3)3), 43.4 (ArCH2-), 28.7 (-C(CH3)2) and 19.4, 
18.1 and 12.6 (3 x ArCH3) in the 
13C NMR spectrum of starting amine 63b were also missing 
from the 13C NMR spectrum of final compound 65a, further proving the successful removal 
of the N-Pbf protecting group. The molecular structure of the product was verified by the 
appearance of a peak at m/z 598.3510 in the HRMS that was assigned to the protonated 
molecular ion, [M + H]+ (calcd for C34H44N7O3 598.3506).  
Modifications to the previous published procedure66 included reporting the synthetic yield 
over two steps for facile and efficient derivatization and the incorporation of a more recent 
published extractive aqueous work-up59 followed by flash chromatography (only when 
required) for the peptide coupling reaction. This vastly improved derivatization and 
purification procedure allowed for the rapid turn-over of multiple derivatives simultaneously, 
obviating the need for extensive flash chromatography for the majority of derivatization 
reactions. 
The most important modification to the N-deprotection procedure was the incorporation of 
20 equivalents of water to all N-Pbf deprotection reactions. This modification was introduced 
after large quantities of N-sulfonation by-products were observed (by NMR and HPLC – See 
Figures A2.2 and A2.3 in Appendix A) during synthetic scale-up for in vivo murine models. 
During small scale (≤ 0.10 mmol) synthesis, enough H2O/moisture was present in the TFA 
and on the flask walls to adequately scavenge the SO3 by-product produced during N-Pbf 
deprotection (see Scheme 2.19). During larger scale (> 1.00 mmol) synthesis, there was 
insufficient water present and N-sulfonation of the desired deprotected product would 
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occur.104 Therefore, it was theorized that a small volume but sufficient molar excess (20.0 
eq) of H2O would prevent N-sulfonation by reacting with the SO3 to produce H2SO4; the 
overall volume percentage of H2O was kept down to prevent inhibition of the N-Pbf 
deprotection reaction.98 Thioanisole is traditionally used to scavenge the SO3
104
 and promote 
deprotection,105 but H2O was found to be a cost-effective, clean and safe alternative for these 
reactions conditions. 
The N-Boc protecting group is extremely susceptible 
to acidic conditions; TFA has been observed to fully 
deprotect the N-Boc side chain residue in less than 10 
min. Deprotection of the N-Boc carbamate gives rise 
to the amine product (as the TFA salt) and two volatile 
by-products: CO2 and isobutene (Scheme 2.18).
78 The 
acidolytic cleavage mechanism proceeds via 
protonation of the carbamate oxygen followed by 
heterolytic cleavage of the O–C(CH3)3 bond to 
release the carbamic acid intermediate and the stable 
t-butyl carbocation (Scheme 2.18); it is the stability 
of the resultant carbocation that makes the Boc carbamate susceptible to acidolysis. Proton 
transfer allows for spontaneous decomposition of the deprotonated carbamic acid derivative 
to give CO2 and the free amine product (which rapidly protonates upon reaction with excess 
TFA); the t-butyl carbocation undergoes proton abstraction to give isobutene as a by-
product.78  
Scheme 2.18 – Mechanism of t-butyl 
carbamate acidolysis by TFA to give 




The N-Pbf protecting group is more resistant to acidolytic cleavage than the N-Boc group 
and less amenable to synthesis because it requires notably longer reaction times and side 
reactions are possible, if a SO3 scavenger is not utilized.
105 The mechanism for acidolysis 
(Scheme 2.19) proceeds via protonation of the guanidino residue followed by heterolytic 
cleavage of the N–S bond to give the product guanidine (as its TFA salt) and an arylsulphonyl 
cation.103, 105-106  
 
Scheme 2.19 – Mechanism for the acidolysis of an N-Pbf group to give the product guanidine 
(blue) and by-products (green). N-Sulfonation of the product guanidine (side reaction - red arrow) 
and scavenging of the SO3 (green arrow) are also shown. 
The ability of the N-Pbf group to undergo acidolysis relies on the ability of the arylsulphonyl 
group to stabilize the resulting cation.105-106 The arylsulphonyl cation then combines with the 
trifluoroacetate anion to generate an intermediate – subsequent protonation and H2O attack 
causes decomposition to give 2,2,4,6,7-pentamethyldihydrobenzo[b]furan, TFA, and SO3. 
The resultant SO3 by-product is electrophilic and will combine with the free guanidine 
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product to give sulfamic acid derivative by-products,104  hence the need for a scavenger (i.e. 
H2O or thioanisole).  
The simple acidolytic conditions required for both N-Boc and N-Pbf deprotection allowed 
for the isolation of the crude TFA-amine salt by simple solvent removal. Solvent-aided anion-
exchange with anhydrous HCl in ether then allowed for the simple isolation of the final 
compounds as the hydrochloride salts by precipitation from Et2O. The general procedure that 
was developed allowed for 18 h reaction time to ensure complete deprotection of the N-Pbf 
group, as shorter reaction periods have been observed to give incomplete acidolysis. Due to 
the volatility of the N-Boc deprotection by-products, no resultant impurities were ever 
observed for N-Boc protected derivatives. For N-Pbf protected derivatives, the final salt 
required repeated precipitation and trituration of the final hydrochloride salt to remove the 
benzofuran by-product. The relative ease, speed and resultant product purity of the acidolytic 
deprotection and HCl salting allowed for the fast turn-over of multiple derivatives. 
2.2.2 – Synthesis of dicationic derivatives (Series A2) 
2.2.2.1 – Synthesis of Series A2 scaffolds via amide coupling 
  Traditional peptide coupling107-108 allowed for the construction of amide bonds from 
carboxylic acids and amines (e.g. amino acid derivatives) and provided a simple and reliable 
methodology for the synthesis of dual-amino acid (i.e. Series A2) scaffolds.59, 68-69 The 
scaffolds for Series A2 (67a-c) were constructed by the formation of a key amide bond 
between a mono-amino acid scaffold (i.e. Series A1) and a precursor amino acid derivative 
(Scheme 2.20); this transformation was accomplished by EDCI/HOBt in acetonitrile59 
utilizing the aforementioned General Procedure B (Section 6.2).  
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This procedure was utilized for the formation of all amide bonds (i.e. for both scaffold 
formation and derivatization). For example, the synthesis of scaffold azide 67a was realized 
in 89% yield by reaction of scaffold amine 63a (300 mg, 0.54 mmol) with precursor α-azido-
acid 28 (1.2 eq), EDCI and HOBt in acetonitrile at rt for 48 h followed by purification by 
flash chromatography.  
 
Scheme 2.20 – Synthesis of scaffolds 67a-c: amide coupling between amine scaffolds 63a-c and 
an α-azido-acid precursor (24 or 28) to give the scaffold azides 67a-c for Series A2. 
Analysis of the 1H NMR spectrum of compound 67a confirmed the presence of resonances 
that were assigned to functionalities from both precursors 63a and 28. The broad resonance 
at δ 3.02 –3.10 (-CHNH2) in the 
1H NMR spectrum of starting amine 63a was no longer 
observed in the spectrum of 67a; there was however, a new more deshielded resonance at 
δ 4.35 that was assigned to the lysine α-methine proton. This evidence indicated that the 
methine proton, adjacent to the primary amine in precursor 63a, experienced a downfield 
chemical shift due to the newly installed amide bond. Furthermore, a gHMBC correlation 
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was observed between the 1H NMR resonance at δ 4.35 (assigned to the α-lysine methine 
proton) and the 13C NMR resonance at δ 170.9 (assigned to the new amide carbonyl). The 
molecular structure of the product was further verified by the appearance of a peak at m/z 
986.5325 in HRMS, that was assigned to the protonated molecular ion, [M + H]+ (calcd for 
C50H72N11O8S 986.5286). 
The reliable and mild conditions afforded by the amide coupling reagents EDCI and HOBt 
were essential for the synthesis and derivatization of these multi-functionalized molecules. 
An uncatalysed reaction between the carboxylic acid and amine components generates an 
ammonium carboxylate salt; subsequent amide condensation requires intense heat, which 
would be incompatible with highly functionalized molecules.108 Therefore, peptide coupling 
reagents (or ‘activators’) are utilized to increase the electrophilicity of the acyl moiety; these 
reagents allow amide bond formation via aminolysis of an activated acyl species under much 
milder conditions.107-110  
Carbodiimides (e.g. 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI)) 
are employed to generate an active O-acylisourea intermediate (Scheme 2.21) by reaction 
with the carboxylate anion. This intermediate can undergo aminolysis by the precursor amine 
to give the desired product amide.107-108 In a possible side reaction, the highly activated 
O-acylisourea intermediate can undergo intramolecular acyl transfer to give an inactive 
N-acylurea by-product (Scheme 2.21 – red pathway),107-108, 110 thus consuming the precursor 




Scheme 2.21 – Mechanism of EDCI/HOBt promoted amide coupling: both the 
product pathway (blue) and the undesired side reaction (red) are displayed. 
To avoid this deleterious side reaction and the possibility of racemization, nucleophilic 
additives such as HOBt (1-hydroxy-1H-benzotriazole) are added to the reaction.107-110 HOBt 
reacts with the active O-acylisourea intermediate to generate an activated HOBt ester with 
the key acyl moiety (Scheme 2.21 – blue pathway). Crucially, this reaction occurs faster than 
the intramolecular acyl transfer, thus preventing the side reaction but still generating an 
activated acid derivative for subsequent aminolysis to the product amide. 107-108 Epimerization 
of the stereogenic α-carbon on the O-acylisourea intermediate is another possible side 
reaction and it can occur through two mechanisms – simple enolate formation by 
deprotonation of the α-hydrogen (resulting in epimerization at the stereogenic centre) or via 
formation of the planar 5(4H)-oxazolone intermediate, in which the α-hydrogen is readily 
deprotonated due the resonance stabilization of the resulting carbanion. HOBt helps to 
prevent epimerization as the intermediate HOBt ester that is preferentially formed is less 
activated than the O-acylisourea, i.e. the -OBt functionality is less electron-withdrawing than 
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the corresponding isourea substituent and therefore the adjacent α-hydrogen is less prone to 
enolization.107, 110 The lack of epimerization observed during the performed amide coupling 
reactions was likely a result of the HOBt. Epimerization would result in the formation of 
diastereomeric products that could be detected by 1H NMR and/or TLC analysis. Based on 
such analyses, the isolated amide products were obtained as single diastereomers. 
2.2.2.2 – Synthesis of Series A2 derivatives via CuAAC and N-deprotection 
  The derivatization of the dual-amino acid scaffolds for Series A2 required a two-step 
transformation: installation of the terminal triazole moieties by CuAAC followed by side-
chain N-deprotection to yield the target amines as dihydrochloride salts. The derivatization 
of scaffold azides to achieve terminal triazole biarylpeptides has been accomplished 
previously via CuACC reaction59 while subsequent N-Boc and N-Pbf deprotection was 
previously achieved with TFA/CH2Cl2.
59, 69 
Therefore, CuAAC reactions (General Procedure A) were employed to derivatize scaffolds 
67a-c and to install the terminal triazole moieties (Reaction (i) in Schemes 2.22 – 2.24);  the 
resultant N-protected triazole derivatives were then immediately subjected to acidolytic 
N-Boc and N-Pbf cleavage followed by work-up with ethereal HCl (General Procedure C: 
Reaction (ii) in Schemes 2.22 – 2.24) to afford the target amines as their dihydrochloride 
salts (68a-d, 69a-d and 70a-b). Much like Series A1, the derivatization of scaffolds 67a-c 
for Series A2 was conducted in two consecutive steps; CuAAC reaction completion and 
product purity was monitored by TLC and/or MS analysis prior to subsequent 
N-deprotection. 
For example, the synthesis of compound 68a  (Scheme 2.22) was realized in 86% yield over 
two steps from scaffold azide 67a (50 mg, 0.05 mmol) by reaction with 3-phenyl-1-propyne 
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(3.0 eq), Cu(OAc)2·H2O, and sodium ascorbate in t-BuOH/H2O at rt for 20 h to give the 
intermediate N-protected triazole derivative, which was then subjected to N-Boc/N-Pbf 
deprotection with TFA and H2O in CH2Cl2 at rt for 18 h followed by treatment with ethereal 
HCl and purification by precipitation. Scaffold azide 67b (50 mg, 0.05 mmol) was also 
directly deprotected with TFA and H2O in CH2Cl2 at rt for 18 h followed by treatment with 
ethereal HCl and purification by precipitation to give final compound 69d in 97% yield 
(Scheme 2.23). 
 
Scheme 2.22 – Derivatization of scaffold 67a: installation of the terminal triazole moiety 
(with R substituent) followed by removal of the side chain N-protecting groups to give 
scaffold derivatives 68a-d as dihydrochloride salts. 
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The 1H NMR spectrum of the final derivative 68a displayed characteristic resonances that 
were assigned to the terminal benzyl moiety (i.e. a singlet resonance at δ 4.07 (-CH2Ph) and 
a broad multiplet resonance at δ 7.34 – 7.10 (phenyl)).  
 
Scheme 2.23 – Derivatization of scaffold 67b: installation of the terminal triazole moiety 
(with R substituent) followed by removal of the side chain N-protecting groups to give 
scaffold derivatives 69a-c as dihydrochloride salts. The direct N-deprotection of scaffold 67b 
to give compound 69d is also displayed. 
Importantly, a new degenerate resonance at δ 7.86 (2H) in the 1H NMR spectrum of 
compound 68a was observed and assigned to the protons on both triazole rings. The presence 
of the new triazole moiety was further confirmed by the 13C NMR resonance assignments: 
δ 148.4 (quaternary triazole carbon – only observed by gHMBC), four resonances in the 
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aromatic region (phenyl carbons), δ 124.5 (triazole CH – only observed by gHSQC/gHMBC) 
and 32.4 (-CH2Ph) – these resonances were not seen in the 
13C NMR spectrum of the starting 
azide 67a. Evidence for successful N-Boc deprotection was clearly seen by the lack of the 
9H singlet resonance at δ 1.44 (assigned as the t-butyl protons (-C(CH3)3)) in the 
1H NMR 
spectrum of amine salt 68a. Additionally, the lack of key resonances at δ 156.3 (Boc C=O), 
79.2 (-C(CH3)3) and 28.5 (-C(CH3)3) in the 
13C NMR spectrum of compound 68a provided 
further evidence that the N-Boc protecting group had been successfully removed.  
 
Scheme 2.24 – Derivatization of scaffold 67c: installation of the terminal triazole moiety (with 
R substituent) followed by removal of the side chain N-protecting groups to give scaffold 
derivatives 70a-b as dihydrochloride salts.  
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Conclusive evidence for N-Pbf deprotection was clearly seen by the lack of the five 
characteristic Pbf singlet resonances (δ 2.95, 2.58, 2.51, 2.09 and 1.46) in the 1H NMR 
spectrum of compound 68a and the lack of corresponding N-Pbf resonances in the 13C NMR 
spectrum. The molecular structure of the product was verified by the appearance of a peak at 
m/z 750.4587 in HRMS that was assigned to the protonated molecular ion, [M + H]+ (calcd 
for C41H56N11O3 750.4568).  
For more information on both the CuAAC and the N-deprotection reactions (e.g. reaction 
mechanism and details), see Section 2.2.1.1. 
2.2.2.3 –Series A2 exceptions 
  The synthesis of dicationic derivatives with terminal amide moieties for Series A2 
was attempted via an analogous pathway to those procedures utilized for Series A1 and A2 
derivatives. Unfortunately, realization of the required scaffold amine 71 proved difficult. 
Initial attempts utilized the N-Cbz protecting group for the arginine residue; repeated 
attempts to remove this protecting group via catalytic hydrogenolysis resulted in a complex 
mixture of amine products consisting of the target amine along with at least four other 
compounds (observed by TLC and MS analysis). MS analysis revealed the major side-
product to be 14 amu heavier than the target amine 71. The target product could not be 
adequately separated from these side-products, so the N-Cbz route was abandoned. Instead, 
the N-Fmoc protecting group was utilized; classic N-Fmoc deprotection with piperidine was 
attempted but a mixture of amine products was also obtained – MS analysis revealed the 
major side-product to be 40 amu heavier than the target amine 71. Catalytic hydrogenolysis 
was then attempted to remove the N-Fmoc group,111 but this methodology also gave a 
complex mixture of amine products. After extensive trial reactions, the amine scaffold 71 
78 
 
was isolated and was deemed of sufficient purity (> 90%) for further derivatization (but not 
characterization). Ultimately, amine 71 was synthesized from scaffold amine 63a (400 mg, 
0.73 mmol) in 58% yield over two steps by reaction with Fmoc-(D)-Arg(Pbf)-OH (1.2 eq), 
EDCI and HOBt in acetonitrile at rt followed by base-promoted N-Fmoc deprotection with 
tris-(2-aminoethyl)amine (TAEA)112 in acetonitrile (Scheme 2.25). 
 
Scheme 2.25 – Synthesis of scaffold 71: addition of the arginine residue by amide coupling 
followed by base-promoted removal of the N-Fmoc group. 
The impure amine 71 (53 mg, 0.06 mmol) was then derivatized in the same manner as Series 
A1 scaffolds: amide coupling (General Procedure B: Reaction (i) in Scheme 2.26) to install 
the terminal benzyl amide moiety followed by N-Boc/N-Pbf side chain deprotection 
(General Procedure C: Reaction (ii) in Scheme 2.26) to give final compound 73 as a 
dihydrochloride salt in 61% yield over two steps. Reaction success for derivatization (i.e. 
amidation and subsequent N-deprotection) was verified in the same manner as Series A1 
derivatives; NMR spectral analysis confirmed the installation of the benzyl amide and the 
removal of the N-Boc/N-Pbf protecting groups (see Section 2.2.1.2 for specific details). 
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Furthermore, the molecular identity was confirmed by the appearance of a peak at m/z 
748.4288 in the HRMS, which was assigned to the sodiated molecular ion [M + Na]+. The 
derivatization procedures eliminated the side-product impurity that was present in the starting 
amine 71; the precipitation and trituration of the final HCl salt helped to remove most 
impurities that may have been present from previous reactions. Recrystallization of the final 
HCl salts can also be achieved by slow evaporation of a MeOH/CH2Cl2 solvent mixture (see 
Figure A2.4 in Appendix A). 
 
Scheme 2.26 – Derivatization of scaffold 71: installation of the terminal amide group (R) via amide 
coupling followed by side chain N-deprotection to give compound 73 as a dihydrochloride salt. 
The synthetic pathway to realize to compound 74 by side chain N-deprotection of the N-Fmoc 
scaffold 72 is also displayed. 
Additionally, General Procedure C was utilized to realize compound 74 in 95% yield by 






2.3 – Series B synthesis: scaffolds and derivatives 
2.3.1 – Synthesis of monocationic derivatives (Series B1) 
2.3.1.1 – Synthesis of Series B1 scaffolds via CuAAC 
The traditional click reaction (i.e. CuAAC)75 allowed for the construction of 1,4-
disubstituted-1,2,3-triazoles from alkyne and azide precursor components; this provided a 
simple and reliable methodology for the synthesis of mono-amino acid (i.e. Series B1) 
scaffolds.59, 69 The scaffolds for Series B1 (75a-d) were constructed from a biaryl alkyne and 
an α-azido acid precursor by the CuAAC reaction (Scheme 2.27); this transformation was 
accomplished by utilizing the aforementioned General Procedure A (Section 6.2).  
 
Scheme 2.27 – Cu-catalysed [3 + 2] cycloaddition reaction between an alkyne building 
block (20 or 21 - blue triple bond) and an azide precursor (24 or 28 - blue portion) to 
give the key scaffold acids 75a-d for Series B1. 
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For example, scaffold acid 75a was achieved in 85% yield by reaction of α-azido acid 24 
(400 mg, 1.47 mmol) with alkyne 21 (2.0 eq), Cu(OAc)2·H2O and sodium ascorbate in 
t-BuOH/H2O at rt for 26 h followed by purification by flash chromatography (Scheme 2.27). 
Interestingly, the 1H and 13C NMR spectra of scaffold acids 75a-d in CD3OD were lacking 
some key resonances; the spectra had to be collected in DMSO-d6 to ensure all resonances 
were observed. Despite using DMSO-d6, the binaphthyl scaffold acids 75c and 75d failed to 
display 13C NMR resonances for the carboxyl carbon (C=O) or the adjacent α-methine carbon 
(-CHC=O). Furthermore, the resonances assigned to the α-methine proton in the 1H NMR 
spectra of compounds 75c or 75d exhibited significant broadening. These NMR anomalies 
are explored in more detail in Section 4.6. 
The 1H NMR spectrum of compound 75a displayed resonances that corresponded to 
fragments from both starting materials (alkyne 21 and azide 24). The most diagnostic 
difference was the disappearance of the 1H NMR singlet resonance at δ 2.43 (-CC-H) that 
was seen in the 1H NMR spectrum of alkyne 21 and the appearance of the significantly 
downfield resonance at δ 7.89 (triazole CH) in the 1H NMR spectrum of 75a. The terminal 
alkyne proton in compound 21 had now become the lone proton on the newly formed triazole 
ring in scaffold 75a – this results in a strong deshielding of the proton (relative to the alkyne 
proton) and a large downfield chemical shift. Two unique aromatic 13C NMR resonances at 
δ 142.9 and 123.3 were present in the 13C NMR spectrum of scaffold acid 75a – these 
resonances were assigned to the methine and quaternary triazole carbons, respectively. The 
resonance at δ 142.9 was extremely diagnostic because few other aromatic carbon resonances 
appear in that region (i.e. δ 141-150). As expected, the 13C NMR resonance at δ 123.3 
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(triazole CH) displayed a correlation in the gHSQC spectrum with the 1H NMR resonance at 
δ 7.89 (triazole CH). Furthermore, the appearance of these two unique 13C NMR resonances 
coincided with the disappearance of the two alkyne (-CC-) 13C NMR resonances at δ 79.3 
and 75.2 that are evident in the 13C NMR spectrum of starting alkyne 21. These two alkyne 
carbons (-CC-) had now become the aromatic triazole carbons – this explains the associated 
large downfield chemical shift. Additionally, the methine proton (adjacent to the acid moiety) 
was assigned to a downfield resonance at δ 5.19 in the 1H NMR spectrum of compound 75a 
– this proton was originally assigned to a resonance at δ 3.95 in the 1H NMR spectrum of 
starting α-azido acid 24. This large downfield shift occured due to the formation of the new 
adjacent triazole ring, which strongly deshielded the nearby methine proton. The molecular 
identity was confirmed as HRMS analysis displayed a peak at m/z 589.2993 that was assigned 
to the sodiated molecular ion, [M + Na]+ (calcd for C31H42N4O6Na 589.3002).  
2.3.1.1 – Synthesis of Series B1 derivatives via amide coupling and N-deprotection 
The derivatization of the mono-amino acid scaffolds for Series B1 required a two-
step transformation: installation of the terminal amide moieties followed by side-chain 
N-deprotection to yield the target amines as hydrochloride salts. Previous syntheses of 
binaphthylpeptides have utilized the common EDCI/HOBt peptide coupling reagent system 
to form the necessary peptide bonds while N-Boc and/or N-Pbf deprotection was previously 
achieved with TFA/CH2Cl2.
59, 64-66, 68-69 The derivatization for Series B1 was achieved using 
the same methodology as Series A1 (see Section 2.2.1.2). 
Therefore, for Series B1 derivatives, General Procedure B was utilized to install the 
terminal amide moiety (see Reaction (i) in Schemes 2.28 – 2.30);  the resultant N-protected 
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amide derivatives were then immediately subjected to acidolytic N-Boc or N-Pbf cleavage 
followed by work-up with ethereal HCl (General Procedure C or D: Reaction (ii) in 
Schemes 2.28 – 2.30) to achieve the target amine salts (76a-f, 77a-l and 78a-b) in high 
purities.  
 
Scheme 2.28 - Derivatization of scaffold 75a: installation of the terminal amide 
moiety (R) followed by removal of the N-Boc side chain protecting group to give 
scaffold derivatives 76a-f as hydrochloride salts. 
For example, the synthesis of derivative 76a (Scheme 2.28) was realized in 95% yield over 
two steps from scaffold amine 75a (50 mg, 0.09 mmol) by reaction with benzylamine (1.2 
eq), EDCI and HOBt in acetonitrile at rt for 24 h to give the corresponding amide which was 
immediately subjected to N-Boc deprotection with TFA in CH2Cl2 at rt for 18 h followed by 
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treatment with ethereal HCl and purification by precipitation. Much like Series A, the 
derivatization of scaffolds 75a-b and 75d for Series B1 was conducted in two consecutive 
steps; reaction completion and product purity for the amide coupling reactions was monitored 
by TLC and/or MS analysis prior to subsequent N-deprotection. 
The 1H NMR spectrum of the final compound 76a displayed resonances that were assigned 
to the benzyl amide substituent (i.e. δ 4.37 (-CH2Ph) and δ 7.34 – 7.10 (phenyl)). The 
presence of the new amide moiety was further confirmed by the following 13C NMR 
resonances: δ 169.8 (amide C=O), four resonances in the aromatic region (phenyl carbons) 
and δ 44.6 (-CH2Ph), which were not seen in the 
13C NMR spectrum of the starting acid 75a. 
Evidence of N-Boc deprotection was seen by the lack of the diagnostic 1H NMR singlet 
resonance at δ 1.44 (-C(CH3)3) and the lack of key 
13C NMR resonances at δ 155.5 (Boc 
C=O), 77.3 (-C(CH3)3) and 28.2 (-C(CH3)3) in the spectra of compound 76a. The molecular 
structure of the product was verified by the appearance of a peak at m/z 556.3302 in HRMS 
that was assigned to the protonated molecular ion, [M + H]+ (calcd for C33H42N5O3 
556.3288). 
In another example, the synthesis of derivative 77a (Scheme 2.29) was realized in 94% yield 
over two steps from scaffold acid 75b (50 mg, 0.07 mmol) by reaction with benzylamine (1.2 
eq), EDCI and HOBt in acetonitrile at rt for 22 h to give the intermediate amide which was 
immediately subjected to N-Pbf deprotection with TFA and H2O in CH2Cl2 at rt for 18 h 
followed by treatment with ethereal HCl and purification by precipitation. NMR spectral 
analysis confirmed the installation of the benzyl amide and the removal of the N-Pbf 
protecting group as per previous examples (see Section 2.2.1.2). The molecular structure of 
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the product was verified by the appearance of a peak at m/z 584.3373 in HRMS that was 
assigned to the protonated molecular ion, [M + H]+ (calcd for C33H42N7O3 584.3349).  
 
Scheme 2.29 – Derivatization of scaffold 75b: installation of the terminal amide moiety 
(R) followed by removal of the N-Pbf side chain protecting group to give scaffold 






Scheme 2.30 – Derivatization of scaffold 75d: installation of the terminal amide moiety (R) 
followed by removal of the N-Pbf side chain protecting group to give scaffold derivatives 78a-b 
as hydrochloride salts. 
2.3.2 – Synthesis of dicationic derivatives (Series B2) 
2.3.2.1 – Synthesis of Series B2 scaffolds via amide coupling  
 The synthesis of dual-amino acid scaffolds for Series B2 was conducted in a manner 
analogous to the synthesis of Series A2 scaffolds (Section 2.2.2.1). A second amino acid 
residue was attached to a scaffold from Series B1 via the reliable amide coupling 
methodology (General Procedure B) to generate scaffolds 79a-d (Scheme 2.31). 
For example, scaffold azide 79a was isolated in 82% yield from starting acid 75a (176 mg, 
0.31 mmol) by treatment with amine 25 (1.2 eq), EDCI and HOBt in acetonitrile at rt for 48 h 





Scheme 2.31 – Synthesis of scaffolds 79a-d: amide coupling between scaffold acids 75a-d and 
a β-azido-amine precursor (22 or 25) to give the scaffold azides 79a-d for Series B2. 
Analysis of the 1H NMR spectrum of scaffold azide 79a confirmed the presence of 
resonances that were assigned to functionalities from both precursors 75a and 25. The singlet 
resonance at δ 2.81 (-CHNH2) in the 
1H NMR spectrum of starting acid 75a was no longer 
observed in the spectrum of 79a; however, a new resonance at δ 3.96 (1H) was observed and 
it was assigned to the arginine α-methine proton. The methine proton, adjacent to the primary 
amine in precursor amine 25, had experienced a downfield chemical shift due to the newly 
installed amide bond. The 13C NMR spectrum of scaffold azide 79a did not display a 
resonance at δ 156.6 (assigned to the carboxylic acid carbon, C=O); instead, the spectrum 
exhibited a new resonance at δ 168.5 that was assigned to the new amide carbonyl (C=O). 
Furthermore, a gHMBC correlation was observed between the 1H NMR resonance at δ 3.96 
(assigned to the arginine methine proton) and the 13C NMR resonance at δ 168.5 (assigned 
88 
 
to the new amide carbonyl) – providing further evidence of successful amide bond formation. 
The molecular structure was verified by the appearance of a peak at m/z 986.5335 in HRMS, 
that was assigned to the protonated molecular ion, [M + H]+ (calcd for C50H72N11O8S 
986.5286). 
2.3.2.2 – Synthesis of Series B2 derivatives via CuAAC and N-deprotection 
 The derivatization of the dual-amino acid scaffolds 79a-d (for Series B2) was 
accomplished via utilization of the same two-step methodology that was employed for the 
derivatization of Series A2 scaffolds (see Section 2.2.2.2); the terminal triazole moieties were 
installed via CuAAC reactions (General Procedure A: Reaction (i) in Schemes 2.32 – 2.35) 
followed by acidolytic N-Boc/N-Pbf deprotection and HCl salting (General Procedure C: 
Reaction (ii) in Schemes 2.32 – 2.35) to give the target compounds (80a-d, 81a-d, 82a-b and 
83a-b) as their dihydrochloride salts. As per Series A2, the derivatization of scaffolds 79a-d 
for Series B2 was conducted in two consecutive steps; CuAAC reaction completion and 
product purity was monitored by TLC and/or MS analysis prior to subsequent N-
deprotection. 
For example, derivative 80a was afforded in 95% yield over two steps from scaffold azide 
79a (50 mg, 0.05 mmol) by reaction with 3-phenyl-1-propyne (3.0 eq), Cu(OAc)2·H2O and 
sodium ascorbate in t-BuOH/H2O at rt for 24 h followed by N-Boc/N-Pbf deprotection with 
TFA and H2O in CH2Cl2 at rt for 18 h followed by treatment with ethereal HCl and 





Scheme 2.32 – Derivatization of scaffold 79a: installation of the terminal triazole moiety 
(with R substituent) followed by removal of the side chain N-protecting groups to give 
scaffold derivatives 80a-d as dihydrochloride salts. 
The 1H NMR spectrum of the final derivative 80a displayed 1H NMR resonances that were 
assigned to the new benzyl substituent (i.e. δ 4.08 (-CH2Ph) and δ 7.36 – 7.09 (phenyl)). 
Furthermore, a new downfield singlet resonance at δ 7.92 (1H) in the 1H NMR spectrum of 
compound 80a was observed and assigned to the proton on the newly installed triazole ring. 
The presence of the new triazole moiety was confirmed by assignment of the 13C NMR 
resonances: δ 148.3 (quaternary triazole carbon – only observed by gHMBC), four 
resonances in the aromatic region (phenyl carbons), δ 125.7 (triazole CH) and 32.4 (-CH2Ph), 
which were not seen in the 13C NMR spectrum of the starting azide 79a. 
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NMR spectral analysis of compound 80a confirmed the removal of the N-Boc/N-Pbf 
protecting groups as per previous examples (see Section 2.2.2.2). The molecular structure of 
the product was verified by the appearance of a peak at m/z 750.4570 in HRMS that was 
assigned to the protonated molecular ion, [M + H]+ (calcd for C41H56N11O3 750.4568). 
 
Scheme 2.33 – Derivatization of scaffold 79b: installation of the terminal triazole moiety 
(with R substituent) followed by removal of the side chain N-protecting groups to give 











Scheme 2.34 – Derivatization of scaffold 79c: installation of the terminal triazole moiety (with 
R substituent) followed by removal of the side chain N-protecting groups to give scaffold 





Scheme 2.35 – Derivatization of scaffold 79d: installation of the terminal triazole moiety 
(with R substituent) followed by removal of the side chain N-protecting groups to give 
scaffold derivatives 83a-b as dihydrochloride salts. 
2.3.2.2 –Series B2 exceptions: terminal amide derivatives 
 The synthesis of dicationic derivatives with terminal amide moieties for Series B was 
accomplished via the construction of scaffold acid 84 by amide coupling the arginine 
derivative 29  onto scaffold 75c69 followed by base-promoted hydrolysis of the methyl ester 
group (Scheme 2.36). Scaffold acid 84 was then derivatized to afford compounds 85a-c as 
dihydrochloride salts via the same two-step methodology employed for Series B1: amide 
coupling (General Procedure B: Reaction (i) in Scheme 2.37) to install the terminal amide 
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moiety followed by side chain N-deprotection and HCl salting (General Procedure C: 
Reaction (ii) in Scheme 2.37). 
 
Scheme 2.36 – Synthesis of scaffold 84: amide coupling between scaffold acid 75c and amine 29 
followed by base-promoted removal of the methyl ester protecting group to give scaffold acid 84. 
Scaffold acid 84 was achieved in 86% yield over steps from scaffold 75c (150 mg, 0.23 
mmol) by reaction with amine 29 (1.2 eq), EDCI and HOBt in acetonitrile at rt for 18 h 
followed by hydrolysis with LiOH·H2O in THF/H2O at rt for 24 h and subsequent 
acidification with 1.0 M aqueous HCl (Scheme 2.36). Initial examination of the 1H and 13C 
NMR spectra of scaffold acid 84 suggested the presence of impurities with doubling up of 
many 1H and 13C NMR resonances (see Figures C1.11 – C1.13 in Appendix C). The 
compound appeared pure by TLC analysis (one spot) and product identity was confirmed by 
HRMS analysis (one peak at m/z 1073.5156 – assigned as the deprotonated molecular ion, 
[M − H]− (calcd for C58H73N8O10S 1073.5170)). The extra resonances in the NMR spectra of 
scaffold acid 84 were found to be a result of syn- and anti-carbamate and amide rotamers – 




Scheme 2.37 - Derivatization of scaffold 84: installation of the terminal amide moiety 
(with R substituent) followed by removal of the side chain N-protecting groups to give 
scaffold derivatives 85a-c as dihydrochloride salts. 
In one example of derivatization, compound 85a was afforded in 79% yield over two steps 
from scaffold acid 84 (50 mg, 0.05 mmol) by reaction with benzylamine (1.2 eq), EDCI and 
HOBt in acetonitrile at rt for 24 h followed by side chain N-deprotection with TFA and H2O 
in CH2Cl2 at rt for 18 h – subsequent HCl salting with HCl/Et2O and purification by 
precipitation gave the product as a dihydrochloride salt (Scheme 2.37). The derivatization of 
scaffold 84 was conducted in two consecutive steps without full spectroscopic 
characterization of the N-Boc/N-Pbf protected intermediates. Amide coupling reaction 
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completion and product purity was monitored by TLC and/or MS analysis prior to subsequent 
N-deprotection. 
Reaction success for derivatization (i.e. amidation and subsequent N-deprotection) was 
verified in the same manner as Series B1 derivatives; NMR spectral analysis confirmed the 
installation of the benzyl amide and the removal of the N-Boc/N-Pbf protecting groups (see 
Section 2.2.1.2 for specific details). Furthermore, the molecular identity was confirmed by 
the appearance of a peak at m/z 812.4604 in the HRMS, which was assigned to the protonated 
molecular ion, [M + H]+ (calcd for C47H58N9O4 812.4612).  
2.4 – Series C synthesis: scaffolds and derivatives 
2.4.1 – Synthesis of monocationic derivatives (Series C) 
 Series C constitutes two biarylpeptide scaffolds (and their derivatives) that did not 
contain an internal triazole linker in the peptide backbone; one series with no triazoles (Series 
C1) and one series with terminal triazoles moieties only (Series C2). 
2.4.1.1 – Synthesis of Series C1 
The scaffold acid 86 for Series C1 was realized in 82% over two steps from aromatic acid 
42† (246 mg, 0.59 mmol) from the reaction with amine 29 (1.2 eq), EDCI and HOBt in 
acetonitrile at rt for 21 h followed by hydrolysis with LiOH·H2O in THF/H2O at rt for 18 h 
and subsequent acidification with 1.0 M aqueous HCl (Scheme 2.38).  
The 1H NMR spectrum of acid 86 displayed resonances that were assigned to both the 
binaphthyl and arginine precursor fragments. Evidence of the newly installed amide bond 
                                                 
† Compound gifted from previous researcher (S. Wales). 
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was seen by the appearance of a broad resonance at δ 7.75 (1H) in the 1H NMR spectrum of 
scaffold 86, assigned as the amide proton (N-H). 
 
Scheme 2.38 – Synthesis of scaffold 86: amide coupling of aromatic acid 42 and 
arginine residue 29 followed by base-promoted removal of the methyl ester 
protecting group to give scaffold acid 86. 
Notably, the 13C NMR spectrum of compound 86 (in CD3OD) was missing six N-Pbf 
resonances that were observable only through gHMBC correlations with the protons of the 
attached -CH3 groups. The guanidine carbon (C=N) could not be assigned to a resonance in 
the 13C NMR spectrum but was shown to be present in subsequent derivatives (87a-c). It has 
been observed that carboxylic acid containing derivatives can exhibit weak aromatic N-Pbf 
13C NMR resonances.  
The derivatization of scaffold 86 was conducted in two consecutive steps; amide coupling 
reaction completion and product purity were monitored by TLC and/or MS analysis prior to 
subsequent N-deprotection. For example, derivative 87a was isolated in 97% yield over two 
steps from scaffold acid 86 by reaction with benzylamine (1.2 eq), EDCI, HOBt in 
acetonitrile at rt for 22 h followed by N-Pbf deprotection with TFA and H2O in CH2Cl2 at rt 




Scheme 2.39 - Derivatization of scaffold 86: installation of the terminal amide moiety 
(with R substituent) followed by removal of the side chain N-Pbf group to give scaffold 
derivatives 87a-c (Series C1) as hydrochloride salts. 
The 1H NMR spectrum of the final derivative 87a displayed resonances that were 
characteristic of the benzyl amide substituent (i.e. δ 4.25 (-CH2Ph) and δ 7.39 – 7.15 (phenyl); 
As seen in previous examples, the lack of key N-Pbf resonances in the NMR spectra of 
compound 87a provided further evidence for the removal of the N-Pbf protecting group. The 
molecular structure of the product was verified by the appearance of a peak at m/z 660.3553 
in HRMS that was assigned to the protonated molecular ion, [M + H]+ (calcd for C40H46N5O4 
660.3550). 
2.4.1.2 – Synthesis of Series C2 (terminal triazoles) 
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The scaffold azide 88 for Series C2 was realized in 94% from acid 42 (207 mg, 0.50 
mmol) by reaction with amine 22 (1.2 eq), EDCI and HOBt in acetonitrile at rt for 24 h 
(Scheme 2.40) followed by purification by flash chromatography.  
 
Scheme 2.40 – Synthesis of scaffold azide 88: amide coupling between aromatic 
acid 42 and β-azido-amine 22. 
The 1H NMR spectrum of azide 88 displayed resonances that were assigned to both the 
binaphthyl and lysine precursor fragments. Evidence of the newly installed amide bond was 
seen by the appearance of a new resonance at δ 5.60 (1H) in the 1H NMR spectrum of scaffold 
88 – this broad singlet resonance was assigned as the new amide proton (N-H). Furthermore, 
the broad singlet at δ 2.89 (-CHNH-) in the 1H NMR spectrum of starting amine 22 was no 
longer present in the spectrum of scaffold azide 88 – the α-methine proton was assigned to a 
new downfield resonance at δ 3.75 in the 1H NMR spectrum of target azide 88 and was a 
direct result of the newly installed amide bond. Additionally, the resonance at δ 167.9 in the 
13C NMR spectrum was assigned to the amide carbonyl (C=O) and was confirmed by a 
heteronuclear gHMBC correlation with the 1H NMR resonance at δ 3.75 (-CHNH-). Analysis 
of the IR spectrum of azide 88 revealed a strong characteristic band at 2101 cm-1 that was 
assigned to the azide moiety. 
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The derivatization of scaffold 88 to realize compounds 89a-c (Scheme 2.41) was conducted 
in two consecutive steps; CuAAC reaction completion and product purity was monitored by 
TLC and/or MS analysis prior to subsequent N-deprotection. 
 
Scheme 2.41 – Derivatization of scaffold 88: installation of the terminal triazole 
moiety (with R substituent) followed by removal of the side chain N-Boc group to 
give scaffold derivatives 89a-c (Series C2) as hydrochloride salts. 
For example, derivative 89a was isolated in 50% yield over two steps from scaffold azide 88 
by reaction with 3-phenyl-1-propyne (3.0 eq), Cu(OAc)2·H2O and sodium ascorbate in 
t-BuOH/H2O at rt for 20 h followed by N-Boc deprotection with TFA in CH2Cl2 at rt for 18 




The 1H NMR spectrum of the final derivative 89a displayed resonances that were assigned 
to the terminal benzyl moiety (i.e. δ 3.95 (-CH2Ph) and δ 7.22 – 7.08 (phenyl)). The presence 
of the triazole moiety was confirmed by assignment of the following 13C NMR resonances: 
δ 148.2 (quaternary triazole carbon), 124.3 (methine triazole carbon), four resonances in the 
aromatic region (phenyl carbons) and δ 32.0 (-CH2Ph), which were not seen in the 
13C NMR 
spectrum of the starting azide 88. The resonance at δ 7.20 (triazole CH) in the 1H NMR 
spectrum of derivative 89a displayed a gHMBC correlation and a gHSQC correlation with 
the resonances at δ 148.2 and 124.3 (triazole carbons), respectively. As per previous 
examples, evidence of N-Boc deprotection was seen by the lack the characteristic 1H and 13C 
NMR resonances typical of the N-Boc protecting group. The molecular structure of the 
product was verified by the appearance of a peak at m/z 692.3611 in HRMS that was assigned 





3.0 – Biological and pharmacological assays: results and discussion 
3.1 – Background information 
This chapter reports the results of the in vitro, in vivo and pharmacological assays 
performed on the library of synthesized biarylpeptide derivatives. All final derivatives were 
subjected to a multi-phase testing procedure, as outlined in Figure 3.1.  
 
Figure 3.1 – Overview of the three-phase biological testing procedure 
utilized to determine the antimicrobial activity of the synthesized compounds.  
Primary in vitro MIC screening (against Gram-positive bacteria including C. difficile – see 
Table 3.1) was performed at the University of Western Australia by project collaborators.† 
Secondary in vitro MIC screening (against Gram-negative bacteria/fungi – see Table 3.1) and 
                                                 
† Prof. Thomas V. Riley, Dr. Katherine A. Hammer and Dr. Dan Knight. 
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a cytotoxicity assay was performed by CO-ADD.‡ Compounds that exhibited significant MIC 
values in the primary and secondary screening phases were then sent to collaborators§ at 
Monash University for a third round of in vitro MIC testing against the hypervirulent C. 
difficile strain (RT027–M7404); compounds that performed well in vitro against the virulent 
C. difficile strain at Monash University were then selected for testing in an in vivo murine 
model of CDI. The in vivo murine model of CDI was developed and performed by 
collaborators§ at Monash University; this assay was used to ascertain the viability and 
efficacy of identified hit compounds as potential CDI chemotherapeutics.  
In conjunction with the in vivo CDI mouse models, a comparative solubility assay was 
developed and utilized to gauge and compare compound solubilities. Furthermore, a 
rudimentary pharmacokinetic analysis via low resolution ESI-MS was performed at the 
University of Wollongong on the blood and faeces of the mice from the in vivo studies to 
ensure that the compounds were not being absorbed systemically after oral administration.  
3.2 –  In vitro assays: MIC and cytotoxicity 
MIC assays provide a quantitative measurement (in μg/mL) of a compound’s ability 
to inhibit bacterial or fungal growth. The MIC assays were conducted against a range of 
various pathogenic microbes, including four Gram-positive and four Gram-negative bacterial 
species (Table 3.1) in total. Furthermore, compounds were also tested against two pathogenic 
fungal species. The compounds were tested against this wide set of pathogenic bacteria and 
                                                 
‡ Community for Open Antimicrobial Drug Discovery (www.co-add.org) – funded by the Wellcome Trust 
(UK) and The University of Queensland 




fungi to gauge their broad-spectrum activity (i.e. activity against a range of species including 
five of the six ESKAPE pathogens5) and their activity against the various C. difficile strains 
(to identify potential CDI chemotherapeutics or lead compounds).  
 Testing Facility 
Gram +ve Bacterial Species UWA CO-ADD Monash 
Staphylococcus aureus 
ATCC 29213 
ATCC 43300 (MRSA) - NCTC 10442 
(MRSA) 
Clostridium difficile 
ATCC 700057 - 
M7404 (RT027) 
NSW132 (RT027) - 
Enterococcus faecalis ATCC 29212 - - 
Streptococcus pneumoniae ATCC 49619 - - 
Gram −ve Bacterial Species    
Escherichia coli ATCC 25922 ATCC 25922 - 
Klebsiella pneumoniae - ATCC 700603 (MDR) - 
Acinetobacter baumannii - ATCC 19606 - 
Pseudomonas aeruginosa - ATCC 27853 - 
Fungal Species 
   
Candida albicans - ATCC 90028 - 
Cryptococcus neoformans - ATCC 208821 - 
Table 3.1 – Bacterial and fungal species that were tested against in the various in vitro MIC assays. 
3.2.1 – General methodology for MIC and cytotoxicity assays 
The MIC assays were performed in multi-well micro-titre plates and the wells were 
filled with inoculated growth medium and varying, incremental concentrations of the 
compounds to be tested. The plates were then cultured and the resulting bacterial growth 
inhibition was observed. Compound concentrations ranging from 0.125 μg/mL to 128 μg/mL 
were typically employed and vancomycin, colistin and fluconazole were utilized as positive 
controls for Gram-positive bacteria, Gram-negative bacteria and fungi, respectively. For 
CO-ADD screening, a single point concentration (32 μg/mL) of each compound was first 
tested to confirm antibacterial activity; compounds that displayed activity at this 
concentration were then subjected to a comprehensive MIC assay. Compound cytotoxicity 
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was measured at CO-ADD against human embryonic kidney cells (HEK-293 – ATCC CRL-
1573) with tamoxifen as a control and the data is reported as the concentration required to 
inhibit cell growth by 50% (CC50). The experimental methodologies for the different MIC 
assays and cytotoxicity assay are reported in Section 6.4.1 
3.2.2 – MIC assay results: overview and lead compound identification 
The synthesized compounds exhibited antibacterial activities that ranged from 
inactive (> 128 μg/mL) to potent (2 μg/mL). The results show that some level of antibacterial 
activity was exhibited by every compound synthesized – see Tables 3.2 – 3.6 for the primary 
and secondary MIC screening data. For a set of the MIC data with the corresponding 
compound structures, please see Tables B1.1 – B2.9 in Appendix B. 
 Most of the compounds exhibited a decreased propensity to inhibit Gram-negative bacteria 
relative to the Gram-positive bacteria that were tested. These Gram-negative bacteria 
required concentrations of drug that were approximately two to four times higher than the 
corresponding Gram-positive MIC values; for example, compound 64a exhibits an MIC = 
8 μg/mL against S. aureus but an MIC = 32 μg/mL against E. coli (as seen in Table 3.2). The 
extra membrane inherent to Gram-negative bacteria is known to impede the absorption and 
therefore the action of various antibiotics.13 Klebsiella pneumoniae was the least susceptible 
species to the majority of tested compounds and no compound displayed an MIC below 16 
μg/mL for this bacterial species. The compounds generally did not exhibit MIC values below 
8 μg/mL for the Gram-negative bacteria that were tested (Tables 3.4 – 3.6), whereas activities 
around 2 – 4 μg/mL were common for the Gram-positive bacterial species (Tables 3.2 and 
3.3). Furthermore, C. difficile proved to be the most resilient of the Gram-positive bacteria 
that were tested; the hypervirulent C. difficile strain (RT027) also displayed decreased 
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susceptibility to the tested compounds, when compared with the normal C. difficile strain 
(Tables 3.2 and 3.3). 
Out of the 62 antibiotics synthesized and tested, eight structures were identified as potential 
broad-spectrum lead antibacterial compounds. These novel biphenyl-triazole peptidomimetic 
compounds (i.e. 68a-d, 69b, 80b and 81c-d) were found to exhibit broad-spectrum activity 
against both Gram-positive and Gram-negative bacteria; these compounds displayed active 
MIC values (≤ 16 μg/mL) against all tested bacterial species. Compound 80b from Series B 
was the best broad-spectrum lead compound, as it was the only compound to display an MIC 
value of 8 μg/mL against both P. aeruginosa and A. baumannii (Figure 3.2 and Table 3.6).  
Furthermore, four compounds (i.e. 68c-d, 77c and 87a) were identified as potential CDI 
chemotherapeutics due to their in vitro activities against C. difficile (MIC ≤ 8 μg/mL) and 
solubility profiles; these compounds were then synthesized on larger scale (approximately 




Table 3.2 – Primary antimicrobial screening data for all synthesized compounds reported as 
the MIC values (μg/mL). 
























64a 8 8 8 8 32 32 32 
64b 8 4 8 8 16 8 16 
64c 16 16 16 32 32 8 32 
65a 16 16 16 16 64 64 16 
65b 16 16 16 32 64 128 16 
65c 4 4 8 16 32 32 32 
66a 4 4 8 8 32 64 64 
66b 4 4 8 8 >128 16 16 
66c 4 4 8 8 >128 32 32 
68a 8 8 16 4 64 16 16 
68b 4 4 8 8 64 8 8 
68c 8 4 8 4 64 4 8 
68d 4 4 4 4 32 4 4 
69a 4 4 8 4 32 64 64 
69b 4 4 8 4 32 16 16 
69c 4 4 8 4 32 32 32 
69d 16 16 16 8 64 64 32 
70a 4 4 4 4 16 16 16 
70b 4 4 4 4 16 8 16 
73 8 8 8 8 32 16 16 
74 4 4 4 4 64 32 32 
76a 8 16 16 8 32 32 32 
76b 8 8 8 8 16 32 32 
76c 8 16 16 8 32 16 32 
76d 8 8 8 8 16 16 32 
76e 4 4 4 8 16 32 32 
76f 4 8 8 8 16 32 64 
77a 4 8 8 4 32 32 64 
77b 2 2 4 4 16 8 32 
77c 4 4 4 4 16 8 16 
77d 4 4 8 8 32 32 64 
Vancomycin 1 1 4 1 >16 0.5 0.5 
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Table 3.3 – Primary antimicrobial screening data for all synthesized compounds reported as 
the MIC values (μg/mL). † MIC = 2 μg/mL against C. diff. (RT027 – M7404).
























77e 16 16 16 32 64 128 128 
77f 4 4 4 4 32 64 64 
77g 8 8 8 16 32 32 32 
77h 4 8 8 8 32 32 64 
77i 2 2 2 2 16 16 32 
77j 4 4 4 4 32 32 32 
77k 16 32 32 8 64 64 128 
77l 4 4 4 2 32 16 16 
78a 4 8 2 8 >128 16 16 
78b 8 8 4 16 >128 16 64 
80a 4 4 8 4 32 8 16 
80b 4 4 8 8 16 16 16 
80c 16 16 16 32 64 64 128 
80d 4 4 4 8 32 16 16 
81a 8 8 8 4 32 32 16 
81b 4 8 8 2 16 16 16 
81c 8 8 8 2 16 8 16 
81d 4 4 4 2 16 8 16 
82a 4 4 4 4 16 16 16 
82b 4 4 4 4 16 16 16 
83a 4 4 4 2 8 16 16 
83b 4 4 4 2 8 8 8 
85a 8 8 8 8 32 16 16 
85b 8 8 4 8 32 16 32 
85c 8 8 8 8 16 16 32 
 87a† 2 2 2 2 >128 8 8 
87b 2 2 4 2 >128 32 32 
87c >128 >128 >128 >128 >128 >128 64 
89a 4 8 4 32 >128 16 16 
89b 4 4 4 32 >128 8 8 
89c 8 8 4 32 128 16 16 







Table 3.4 – MIC or CC50 values for the various control inhibitors utilized in the secondary antimicrobial screening – reported in μg/mL.




































Vancomycin 1 >32 >32 >32 >32 - - - 
Colistin >32 0.25 0.25 0.25 0.125 - - - 
Fluconazole - - - - - 0.125 8 - 
Tamoxifen - - - - - - - 13.06 
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Table 3.5 – Secondary antimicrobial screening data for all synthesized compounds 
reported as the MIC or CC50 values (μg/mL). * Cryptococcus neoformans data was not 
consistent with initial screening data – compounds need to be rescreened. 
















64a 16 32 >32 32 >32 32 32 14.2 
64b 16 32 32 >32 32 >32 16 4.8 
64c 16 32 >32 32 32 16 32 4.7 
65a 16 >32 >32 >32 >32 >32 32 29.0 
65b 16 >32 >32 >32 >32 >32 32 >32 
65c 8 >32 >32 >32 >32 8 16 >32 
66a 4 >32 >32 >32 >32 32 8 16.5 
66b 4 >32 >32 >32 >32 32 8 15.9 
66c 4 >32 >32 >32 >32 16 4 13.8 
68a 4 16 16 8 16 32 32 21.9 
68b 2 8 16 16 8 32 4 >32 
68c 4 8 16 16 8 32 4 14.2 
68d 2 16 16 8 4 >32 4 >32 
69a 4 16 32 16 8 32 4 17.8 
69b 2 8 16 16 4 32 2 17.4 
69c 4 8 32 8 8 32 2 15.3 
69d 8 32 32 16 16 >32 4 >32 
70a 4 32 >32 32 >32 8 2 >32 
70b 2 32 >32 16 32 4 2 >32 
73 4 32 32 32 16 32 2 28.7 
74 4 >32 >32 >32 >32 >32 8 16.5 
76a 16 32 >32 32 >32 >32 >32* >32 
76b 8 >32 >32 32 >32 >32 >32* >32 
76c 8 32 >32 32 >32 32 32* >32 
76d 8 >32 >32 32 >32 32 16* 5.6 
76e 8 >32 >32 32 >32 >32 32* >32 
76f 8 >32 >32 16 >32 >32 12* 5.5 
77a 8 >32 >32 32 >32 16 16 16.8 
77b 8 >32 >32 32 >32 16 32 17.9 
77c 4 >32 >32 32 >32 16 16 19.7 
77d 4 >32 >32 >32 >32 32 32 16.9 
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Table 3.6 – Secondary antimicrobial screening data for all synthesized compounds 
reported as the MIC or CC50 values (μg/mL). * Cryptococcus neoformans data was not 
consistent with initial screening data – compounds need to be rescreened. 
 
















77e 16 >32 >32 >32 >32 >32 32 >32 
77f 16 >32 >32 >32 >32 >32 32 19.1 
77g 16 >32 >32 >32 >32 >32 >32 22.9 
77h 4 >32 >32 >32 >32 >32 4 >32 
77i 8 >32 >32 >32 >32 >32 32 21.6 
77j 8 >32 >32 >32 >32 >32 >32 12.2 
77k 32 >32 >32 >32 >32 >32 >32 20.0 
77l 8 >32 >32 >32 >32 32 32 19.7 
78a 8 >32 >32 >32 >32 16 8 16.5 
78b 8 >32 >32 >32 >32 32 16 >32 
80a 4 16 32 16 8 32 4 17.1 
80b 2 8 16 8 8 32 4 16.4 
80c 4 16 16 8 8 32 4 19.8 
80d 2 32 16 8 8 16 4 19.1 
81a 8 16 32 32 >32 32 4* >32 
81b 4 16 16 32 16 32 2* >32 
81c 4 8 16 16 16 32 2* >32 
81d 8 16 16 16 16 32 2* >32 
82a 2 16 >32 8 >32 4 2 >32 
82b 2 32 >32 8 >32 4 1 16.6 
83a 4 32 >32 32 >32 32 1* >32 
83b 32 32 >32 32 >32 32 1* >32 
85a 4 32 32 32 >32 16 4 17.4 
85b 2 32 16 8 >32 16 2 15.2 
85c 2 16 16 8 32 16 4 16.8 
87a 4 >32 >32 >32 >32 >32 16* >32 
87b 4 >32 >32 >32 >32 32 16* >32 




Figure 3.2 – Structures, MIC and CC50 values for lead compounds 68d and 80b. See Table 3.1 for 
the specific bacterial strains that were tested. 
The broad-spectrum lead compound 80b displayed the best antibacterial activity against 
Gram-negative bacteria of any compound tested; despite this, it did not display the best 
activity against Gram-positive bacteria (Figure 3.2). Many other compounds displayed better 
Gram-positive activities, especially against the target species C. difficile; therefore, 
compound 80b was not chosen for subsequent in vivo assay. However, compound 68d 
displayed a similar Gram-negative activity profile to compound 80b while maintaining an 
excellent Gram-positive activity profile (MIC values ≤ 4 μg/mL – Figure 3.2) with no 
observable cytotoxicity (unlike compound 80b). Notably, this compound compared quite 
favourably with vancomycin, which exhibited MIC values between 1 - 4 μg/mL for the same 
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Gram-positive bacteria. Thus, both compound 68d and a similar derivative, 68c, where 
chosen for testing in the in vivo CDI model.  
The other two compounds selected for the in vivo CDI mouse model study were compounds 
77c and 87a (Figure 3.3); both compounds exhibited strong activity against most Gram-
positive bacteria (MIC values ≤ 4 μg/mL) with an MIC value of 8 μg/mL against C. difficile 
in preliminary testing. Follow-up testing against the hypervirulent C. difficile strain (M7404 
– RT027) at the Monash University laboratory revealed an MIC value of 2 μg/mL for 
compound 87a.  
 
Figure 3.3 – Structures, MIC values and CC50 values for selected compounds 77c and 87a. 
† Compound 87a exhibited MIC = 2 μg/mL against C. difficile (M7404 - RT027) when tested at 




3.2.3 – MIC assay results: structure-activity relationship (SAR) trends 
Sixty-two antibacterial compounds were synthesized from 17 unique scaffolds; this 
allowed for a large diversity in compound structure and orientation. There was no observable 
major difference in the antibacterial activities of the two peptide bonding orientations (blue 
arrow in Figure 3.4) that were investigated (i.e. Series A vs. Series B) as both series produced 
highly active derivatives (e.g. 68d and 80b) that exhibited broad spectrum activity against 
both Gram-positive and Gram-negative bacteria (see Figure 3.2). The dicationic derivatives 
were notably more active than the monocationic compounds and these findings were 
consistent with previous research.69 The dicationic derivatives generally exhibited slightly 
increased antibacterial potency (2 – 4 times more active) against Gram-positive bacterial 
species – e.g. the activity of dicationic compound 80a against S. aureus (MIC = 4 μg/mL) 
was notably stronger than the activity of the similar monocationic derivative 76a (MIC =  8 
– 16 μg/mL) – see Tables 3.2 and 3.3. Furthermore, many of the dicationic derivatives (Series 
A2 and B2) now exhibited significant activity against Gram-negative bacteria, whereas the 
mono-cationic derivatives (Series A1 and B1) were virtually inactive against Gram-negative 
bacteria – e.g. the monocationic compounds 65a-c and the dicationic derivatives 68a-d in 
Table 3.5. The introduction of a second cationic amino acid residue conferred a large increase 
in antimicrobial potency with broad-spectrum activity against both Gram-positive and Gram-
negative bacteria. For example, compound 64b did not exhibit Gram-negative antibacterial 
activity, but the dicationic analogue (compound 68b) exhibited activity against all Gram-
negative bacteria; it also displayed an MIC = 2 μg/mL against S. aureus, whereas the mono-
cationic derivative (64b) exhibited an MIC = 16 μg/mL (see Tables 3.2 and 3.5). The addition 
of a second cationic side-chain residue likely allows for strong binding to the outer anionic 
bacterial membrane. It has been shown previously69 that arginine residues are slightly more 
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potent than their corresponding lysine analogues; the current SAR data confirms this finding 
(e.g. arginine derivative 77a was generally more potent than the lysine analogue 76a – see 
Table 3.2). 
While previous dicationic binaphthylpeptide derivatives have been known to exhibit potent 
antibacterial activity against Gram-positive bacteria, they were not as successful against 
Gram-negative bacteria. The more soluble biphenyl aromatic core was substituted for the 
traditional binaphthyl aromatic core (red arrow in Figure 3.4) in an attempt to increase 
compound solubility without compromising activity; this increase in solubility led to a 
notable increase in compound activity against Gram-negative bacteria. For example, both 
binaphthyl dicationic derivatives 70a and 70b were effectively inactive against Gram-
negative bacteria (Table 3.5); substitution of the biphenyl aromatic core to generate 
analogues 68b and 68d led to observed antibacterial activity against Gram-negative species 
(MIC values = 4 – 16 μg/mL, see Table 3.5). Interestingly, the biphenyl core did not lead to 
an increase in Gram-positive antibacterial potency relative to the binaphthyl aromatic core 
(i.e. the binaphthyl derivative 78a was more potent against Gram-positive bacteria (e.g. C. 
difficile MIC = 16 μg/mL) than its biphenyl analogue 77a (C. difficile MIC = 32 – 64 μg/mL) 
– see Tables 3.2 and 3.3. The substitution of a biphenyl aromatic core increased the solubility 
of the compound (relative to the binaphthyl aromatic core – see Section 3.4.1); this increase 
in solubility was likely responsible for the increase in antimicrobial efficacy against Gram-
negative bacteria. The resilient Gram-negative species are notably impermeable to antibiotics 
due to their secondary membrane layer; this increase in compound solubility and smaller 
molecular size may allow for better diffusion into the bacterial cell membrane, hence the 




Figure 3.4 – Diagram showing the structural modifications that were 
investigated: biphenyl core substitution (red), peptide bond orientation 
(blue), peptidomimetic 1,2,3-triazole incorporation (green), amino 
acid residue variation (black) and hydrophobic termini variation 
(magenta). 
The addition of a second triazole moiety (green arrow in Figure 3.4) was also key for 
conferring Gram-negative activity; a biphenyl analogue of lead compound 2 (i.e. compound 
73) was not active against four of the five Gram-negative bacteria tested but the addition of 
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a second terminal triazole moiety gave a compound (i.e. 68a) that was active against all the 
Gram-negative bacteria tested (Tables 3.5 and 3.6). 
Interestingly, derivatives 85a-c did not contain a terminal triazole moiety nor a biphenyl 
aromatic core, yet these derivatives still exhibited some Gram-negative activity with MIC 
values ranging from 8 μg/mL to > 32 μg/mL – see Table 3.6.   
Compounds that contained the more flexible termini (e.g. phenethyl compared to benzyl 
derivatives) exhibited slightly better antibacterial activity; for example, compound 68b 
(phenethyl derivative) was approximately 2 – 4 times more active than its corresponding 
benzyl analogue (compound 68a – Tables 3.2 and 3.5) against most of the bacteria tested. 
The same was true for the cyclohexyl (Cy) and cyclohexylmethyl (CH2Cy) derivatives; the 
more flexible CH2Cy termini generally gave more active derivatives (e.g. compare 
compounds 80c and 80d in Tables 3.3 and 3.6). This increase in activity is likely due to the 
flexible termini’s ability to adopt more conformations and therefore, there is an increased 
chance for a more active conformation to be achieved.  
The relative positioning of the arginine and lysine amino acid residues in the peptide 
backbone was found to have a notable influence over the antibacterial efficacy of the 
molecules. For example, when the order of the two cationic amino acids was switched in 
compounds 68a-c to give compounds 69a-c, there was a loss of antibacterial activity against 
C. difficile (e.g. MIC = 4 μg/mL to 32 μg/mL – see Table 3.2). In the Series B analogues, the 
same alteration in amino acid order led to an increase in antibacterial efficacy against C. 
difficile for some derivatives (see compounds 80c-d and 81c-d – Table 3.3). It was concluded 
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that the relative orientation of the cationic amino acid residues was important but predicting 
the result from such structural changes was not possible. 
3.2.4 – Mechanism of action  
Minimum bactericidal concentration (MBC) values were also recorded for the 
bacterial species tested at UWA. The MBC data was not included because most compounds 
exhibited MBC values that were more or less congruent with the observed MIC values; this 
is indicative of a bactericidal mechanism, as there is little variation between inhibition of cell 
growth and cell death. Various studies113-116 have previously implicated membrane 
depolarization as a likely mechanism for the antibacterial activity of many cationic peptide 
derivatives. Lysis of the cellular membrane is thought to be achieved by aggregation of the 
amphipathic compounds on and in the membrane which results in pore formation.113, 116 The 
electrochemical gradient that drives cellular biological processes becomes disrupted and this 
results in cell death.113 Such a mechanism of action for the biarylpeptide derivatives would 
explain the lack of disparity between the observed MIC and MBC values. A membrane 
depolarization mechanism would also explain the increased activity seen with compounds 
having two cationic amino acid side chains compared to a single cationic side chain, because 
these moieties are necessary for electrostatic attraction to the anionic bacterial membrane and 
for amphipathic pore formation via molecular aggregation.115 While the data supports a 
membrane-based mechanism, it does not rule out the possibility of an intracellular target. 
Further biological testing (e.g. a membrane depolarization assay) is necessary before any 





3.2.5 – Cytotoxicity assay results 
The synthesized compounds were screened for any partial cytotoxicity by testing at 
the same concentration range that was used for MIC analysis at CO-ADD (≤ 32 μg/mL). 
Compounds are normally tested for cytotoxicity at much higher concentrations; this low-
concentration testing allows for the identification of a CC50 value (i.e. the concentration 
which is cytotoxic to 50% of cells) through curve-fitting and extrapolation of the low-
concentration cytotoxicity data. Some compounds did not exhibit significant cytotoxicity at 
these low concentrations and therefore curve fitting was not possible; a CC50 value could not 
be extrapolated from the data – these compounds have CC50 values listed as > 32 μg/mL as 
they do not exhibit significant cytotoxicity at the tested concentrations. Cytotoxicity assays 
were completed in duplicate and the lower CC50 values are reported in Tables 3.5 and 3.6 
(see Tables B2.1 – B2.9 in Appendix B for a set of the cytotoxicity assay data with 
corresponding structures). 
No definitive observable correlations could be drawn between a compound’s measured 
cytotoxicity and its antibacterial efficacy from the data set. The majority of compounds 
displayed some level of cytotoxicity; only four scaffold types had no cytotoxic derivatives 
(compounds 70a-b, 81a-d, 83a-b and 85a-c). Most notably, the mono-cationic derivatives 
(Series A1 and B1) seemed to exhibit the most significant cytotoxicity; compound 64c had 
the strongest observed cytotoxicity with a CC50 value of 4.7 μg/mL. Unfortunately, many of 
the identified lead compounds exhibited some level of cytotoxicity, for example compound 
80b had an observed CC50 value of 16.4 μg/mL. Importantly, some of the identified lead 
compounds (e.g. compound 68d) failed to exhibit any cytotoxicity at concentrations up to 32 
μg/mL (i.e. well above the compound’s observed MIC value of 4 μg/mL against C. difficile). 
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Although cytotoxicity is not as important for topical or gastrointestinal (i.e. non-systemic) 
antibiotic formulations, compounds that exhibited limited or no cytotoxicity were certainly 
preferred. Previous research69  has shown a positive correlation between cytotoxicity (as 
measured by haemolysis) and antibacterial efficacy in the binaphthyltriazole derivatives; 
compounds with reduced antibacterial efficacy exhibited reduced haemolysis. Such a 
correlation could be explained if the binaphthylpeptide derivatives exhibit their activity 
through a membrane depolarization mechanism, like other antimicrobial peptides.114, 116 In 
this study, both highly active and less active antibacterial derivatives were found to exhibit 
CC50 values across the range of measured concentrations. While tentative positive 
correlations were seen when comparing a few individual compounds, there was no 
consistency amongst the wider set of recorded data. Furthermore, different derivatives of a 
single scaffold were found to vary in their cytotoxicities; for example, compound set 68a-d 
(Series A2) had two derivatives that were non-cytotoxic and two derivatives that exhibited 
cytotoxic CC50 values (≤ 32 μg/mL). A compound’s cytotoxicity could not be gauged by the 
nature of its termini; a particular terminus might cause cytotoxicity in one scaffold, but be 
non-cytotoxic in another scaffold (e.g. the phenethyl terminus occurs in the cytotoxic 
compound 69b and in the non-cytotoxic compound 68b – Table 3.5). 
3.3 –  In vivo assay: murine model of CDI 
3.3.1 – General methodology 
 The murine model of C. difficile infection involved pretreating cohorts of five mice 
with an antibiotic cocktail prior to infection via oral gavage with hypervirulent M7404 C. 
difficile spores; this helped to eliminate the commensal GI microbiota and allowed the C. 
difficile infection to flourish. The infection was allowed to incubate for 12 h before the trial 
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drugs were administered every 12 h for five days. The mice received a compound dose of 2.5 
mg (i.e. 100 mg/kg for an average 25 g mouse) administered in a solvent mixture of 
DMSO/H2O (1:9) at each 12 h dosing interval. The mice were weighed daily: if a mouse lost 
≥ 10% of its body weight in the first 24 h (or ≥ 15% thereafter), then the infection was 
obviously proliferating and the mouse was removed from the trial and culled for ethical 
reasons. The overall survival rate for each drug cohort was used as a measure of drug’s 
effectiveness. The latest murine trial also incorporated the use of physiological parameter 
scores (like faecal consistency scores and cage appearance scores) as other measures of the 
drug’s efficacy. The full experimental methodology and relevant data for the in vivo CDI 
model can be found in Section 6.4. 
3.3.2 – Preliminary trials  
 Lead compound 2 had been previously synthesized on larger scale69 (~700 mg) and 
subjected to an in vivo mouse model of CDI at Monash University (with four other 
binaphthylpeptide derivatives, including lead compound 1).71 This initial trial attempted to 
administer the compounds via the drinking water; unfortunately, the mice refused to drink 
the adulterated water, which ruined the trial results (as the mice were not consuming enough 
drug and they also became dehydrated and lost weight).  
Two compounds were selected (including lead compound 2) and then subjected to a second 
CDI mouse model trial wherein oral gavage was utilized for compound administration (via a 
10% v/v DMSO/H2O vehicle). These preliminary trials saw a 60% survival rate (three out of 
five mice) for lead compound 2 compared with a 100% survival rate for the control drug 
(vancomycin).71 These results were promising but a new problem was observed; the other 
tested compound was quite difficult to administer by oral gavage, as it precipitated and 
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flocculated out of solution almost immediately upon dilution of the compound/DMSO stock 
solution with water. Despite the initial promising results, it was decided to revisit the CDI 
murine model after addressing this poor solubility issue (see Section 3.4.1).  
3.3.3 – Secondary trial  
Four of the synthesized compounds (68c-d, 77c and 87a – Figure 3.5) were selected 
for a CDI mouse model trial due to their promising antibacterial activities against C. difficile 
and their varying solubility profiles (see Section 3.4.1).  
 
Figure 3.5 – Structures of the four compounds selected for testing in the murine model of 
CDI. Their MIC values against C. difficile and their solubilities (relative to prototypical 
compound 1) are displayed. 
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Due to solubility issues and administration difficulties during previous trials, Andrew Tague 
attended Monash University to ensure the complete solubilization, proper dilution and 
administration of the drugs during the CDI murine model.  
Unfortunately, none of the compounds fully protected the mice and all mice in the secondary 
trial had to be culled by 42 h due to disease weight loss (see Figure 3.6). Twenty-four hours 
after infection with C. difficile spores, only one of the four tested compounds (i.e. compound 
77c) displayed signs that it was protecting the mice from disease. The mice that were given 
compound 77c lost the least amount of weight by 24 h (Figure 3.7) and they also had the least 
diarrhoea (as shown by the faecal consistency and cage appearance scores – see Figures 3.8 
and 3.9). Furthermore, these mice looked physically healthier than the other three cohorts (as 
shown by physiological appearance scores – see Figure 3.10). The mice that were given drug 
77c (red line in Figure 3.6) exhibited an 80% (four out of five) survival rate until 42 h, 
compared with a 40% survival rate in the DMSO control cage group (blue line) until 42 h. 
Despite being the most active derivative against C. difficile in vitro, compound 87a appeared 
to make the disease worse; these mice had to be culled by 24 h due to weight loss and disease 




Figure 3.6 – Kaplan-Meier survival curve for the in vivo CDI mouse trial. Compound 90 
















Figure 3.8 – Faecal consistency scores for the various 
compound cohorts in the in vivo CDI mouse model. 
 
 
Score Faecal Consistency 
0 
Normal stool: solid stool that is firm when subjected to pressure with forceps. 
Mouse has no sign of soiling around the anus and passes the stool quickly and 
easily. 
1 
Mildly soft stool: formed stools that appear moist on the outside and have a 
slightly sticky consistency. Stools will easily submit to pressure applied with 
forceps. Mouse has no sign of soiling around the anus, but passes faeces quickly 
and easily. 
2 
Moderately soft stool: irregularly formed stools that do not hold a normal shape. 
Stool appears very moist and is difficult to pick up with forceps. Mouse has some 
signs of soiling around anus and takes a longer than normal time to pass the stool.  
3 
Diarrhoea: stool has no form and/or has a mucous-like liquid appearance with 
minimal solid present. Considerable soiling around the anus and the fur around 
tail. Mouse takes a long time to pass stool if at all.  
 








Figure 3.9 – Cage condition scores for the various 






Score Cage Condition (Diarrhoea) 
0 Normal cage 
1 
Faeces stuck to the side of cage, but clean 
nest and sawdust. 
2 Mildly soiled nest. 
3 Moderately soiled nest. 
4 Severely soiled nest 
 







Figure 3.10 – Physiological appearance scores for the 






Score Physiological Appearance 
0 Normal activity, alertness, breathing and movement/gait. 
1 
Mouse shows signs of reduced grooming with coat starting to appear 
rough/scruffy with slight piloerection. 
2 
Mouse appears slightly hunched with mildly scruffy coat, but moves 
when the cage is disturbed.  Possible diminished alertness, squinted 
eyes or lethargy. 
3 
Mouse has isolated itself from cage mates, displays hunched posture 
and unkempt coat. Mouse does not move when cage is disrupted and 
has little response to external environment or handling. Possible 
laboured breathing or eye discharge. 
 
Table 3.9 – Physiological appearance scoring system. 
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Compound 77c displayed some promising activity, despite not completely protecting the 
mice from disease as per the control drug (e.g. vancomycin exhibits a 100% survival rate 
until trial completion). The compound (77c) obviously delayed the onset and severity of the 
C. difficile infection, as measured by multiple physiological parameters. As predicted by their 
measured solubility parameters, compounds 77c and 87a exhibited the least solubility during 
the in vivo CDI mouse trial, rapidly precipitating out of solution after dilution of the DMSO 
stock solution with water. The insoluble nature of compound 77c meant that the mice were 
not receiving the full target dosage (i.e. 100 mg/kg); therefore, compound 77c will likely be 
re-trialed with a different drug administration method (possibly in food). By administering 
the drug in food to each mouse separately, we can ensure the mice will receive a full dose of 
the drug. 
3.4 –  Pharmacology experiments 
3.4.1 – Comparative solubility assay 
 Some of the previous binaphthylpeptide derivatives were mostly insoluble in the 10% 
DMSO/H2O mixture used in the mouse model of CDI; therefore, a comparative solubility 
assay was developed to ascertain the relative solubilities of the synthesized compounds. 
Knowledge of their solubilities was helpful for selecting compounds that would work well in 
the mouse model of CDI. 
Lead compound 1 was used as the prototype molecule and all other compounds were 
compared to this compound. The compound of interest (5.0 mg) was fully dissolved in 
DMSO (50 μL) and then H2O aliquots (5 μL) were added with adequate manual agitation in 
between additions. Addition of H2O was continued until a persistent turbidity and cloudiness 
was apparent that did not fade after agitation. Compound 1 precipitated after the addition of 
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15 μL H2O; compounds that required twice as much water (i.e. 30 μL) than compound 1 to 
precipitate from solution are effectively two times more soluble than compound 1 (i.e. 
solubility ratio = 2). This comparative solubility ratio was utilized to measure a compound’s 
relative solubility and it thus allowed for comparison between multiple similar compounds. 
The solubility assay was performed on a varied sample of the synthesized compounds to 
ascertain which structural elements are beneficial for solubility (Table 3.10).  
Solubility Assay Data 
Compound 






1 15 1 7.47 
2 45 3 5.76 
64a >300 (NP) >20 (NP) 4.97 
65c 65 4.33 4.26 
66c 20 1.33 6.61 
68b 35 2.33 3.89 
68c 60 4 4.07 
68d 45 3 4.6 
69c 30 2 4.07 
70a 30 2 6.24 
73 15 1 3.02 
76d >200 (NP) >13.3 (NP) 5.81 
77c 30 2 3.77 
80c 30 2 4.07 
81d 55 3.67 4.60 
83b 15 1 6.94 
87a 15 1 5.82 
Table 3.10 – Comparative solubility assay data and CLogP values for selected 
compounds. NP = No precipitation observed. 
See Tables B3.1 – B3.6 in Appendix B for a set of the solubility assay data with the 
corresponding compound structures. The CLogP values for the tested compounds are also 
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included in the solubility tables; unfortunately, no correlation between a compound’s CLogP 
value and its measured solubility was observed. 
As expected, the biphenyl derivatives were much more soluble than their corresponding 
binaphthyl analogues – for example, the Series A1 biphenyl derivative 65c is over three times 
more soluble than its binaphthyl analogue 66c (Table 3.10).  This effect is further exemplified 
by the binaphthyl derivative 83b from Series B2 – the corresponding biphenyl analogue 81d 
is almost four times more soluble (Table 3.10). Compounds that contained a single lysine 
amino acid side-chain were found to be substantially more soluble than the corresponding 
arginine containing analogues. Both of the single lysine derivatives (compounds 64a and 
76d) tested in the solubility assay were so soluble that they failed to precipitate during the 
experiment. They were shown to be at least five to ten times more soluble than similar mono-
arginine derivatives (e.g. compounds 65c and 77c). Furthermore, changing the order of the 
amino acid residues for dicationic derivatives did have an impact on solubility; for example, 
compound 68c (Series A2 – Lys-Arg orientation) was two times more soluble than the 
corresponding Arg-Lys isomer 69c – see Table 3.10. When this same swap in amino acid 
order was performed in Series B2, the opposite result occurred; swapping a Lys-Arg 
orientation for an Arg-Lys pattern resulted in an increase in solubility (see Table B3.5 in 
Appendix B). Therefore, no one particular orientation of amino acid residues was always 
found to give rise to more soluble compounds than another; this is likely because the 
solubility was reliant on multiple complex factors (e.g. scaffold shape, internal hydrogen 
bonding, solvent effects and conformation).  
Additionally, the more flexible hydrocarbon termini (i.e. Cy and CH2Cy) were generally 
found to be more soluble than the aromatic termini (Bn and PhEt) – as seen in Table 3.10; 
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the more flexible hydrocarbon derivatives may be able to adopt more soluble conformations 
than the aromatic derivatives. There was no observable difference in solubility between the 
Series A and Series B peptide orientations. Both Series A and B derivatives were found to 
exhibit a range of various solubilities; neither series was generally more soluble than the 
other.  
The solubility ratio data allowed for the selection of compounds for the in vivo mouse model 
of CDI with varying solubilities; compounds with a range of solubilities (Figure 3.5 in 
Section 3.3.3 and Table 3.11) were chosen so that the effect of solubility on the drug’s 
administration, efficacy and pharmacokinetic parameters could be observed. There was a 
direct correlation between a compound’s solubility ratio and the compound’s propensity to 
precipitate during dilution with H2O (Table 3.11).  
Compound Solubility Ratio 
(Compound / Compound 1) 
Solubility in DMSO/H2O 
(9:1) 
1 1 - 
87a 1 Precipitated 
77c 2 Precipitated 
68d 3 Homogenous suspension 
68c 4 Homogenous solution 
Table 3.11 – The selected compounds for the in vivo CDI mouse model are displayed 
with their corresponding solubility ratio and observed solubility in 10% DMSO/H2O. 
The compound with the worst solubility ratio (i.e. 87a) was also the compound that exhibited 
the most precipitation and flocculation (making administration by oral gavage difficult); the 
compound produced a thick precipitate that stuck to the sides of the vial after dilution with 
H2O. Compound 68c (which had the largest solubility ratio) remained as a homogenous, 
lightly opaque suspension for the entire 30 min prior to dosing. Compounds required a 
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solubility ratio of three or greater to prevent immediate precipitation and flocculation of the 
compound after dilution of the DMSO stock solution with H2O (Table 3.11). 
There did not appear to be a correlation between solubility and compound efficacy in the in 
vivo model; compound 77c was the second least soluble derivative but it displayed the best 
efficacy of the compounds tested in the recent in vivo model. Mouse blood and faeces from 
the recent in vivo CDI mouse model will be analyzed for the presence of drug (study yet to 
be performed); by comparing this data to the solubility data, the optimum solubility to avoid 
systemic absorption may be identified. 
3.4.2 – Pharmacokinetics assay 
 Since CDI chemotherapeutics are required to stay in the GI tract to treat the infection, 
systemic absorption of the antibiotic is not desirable. Therefore, pharmacokinetic analysis 
was performed on the blood and faeces of mice that were infected with C. difficile and treated 
with lead compound 2 in the preliminary CDI mouse model trials (see Section 3.3.2). 
To ascertain the presence of compound 2 in the blood and faeces, an extraction/analysis 
procedure employing LRMS was developed and utilized (see Section 6.4.3 for the 
experimental methodology). The mouse blood was diluted with PBS and then extracted with 
CH2Cl2 (× 2); the faeces was extracted with CH2Cl2 (× 1). Concentration of the extracts and 
LRMS analysis of the residues revealed the presence of the drug (i.e. the doubly-protonated 
molecular ion, m/2 = 421 = [M + 2H]2+) in the faeces; whereas no drug could be found in the 
blood. To ensure the procedure was viable, mouse blood from an untreated cohort was doped 
to achieve a final concentration of compound 2 equivalent to an average 25 g mouse 
absorbing 1% of the total dose into its bloodstream – the drug was readily detected in the 
doped mouse blood, verifying the validity of the extraction protocol. 
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These findings confirm that compound 2 was not absorbed systemically into the bloodstream 
by the mice; following oral administration, the drug clearly stayed in the GI tract (i.e. faeces), 
as was intended.  
3.4.3 – HPLC purity assay 
 To ensure high sample purity for the in vivo CDI murine model, selected compounds 
68c-d, 77c and 87a (Figure 3.5, Section 3.3.3) were subjected to reverse-phase HPLC 
analysis with H2O and acetonitrile (both with 0.1% v/v TFA) as the polar and non-polar 
solvents, respectively. A gradient elution from 0:100  100:0 (acetonitrile/H2O) over 30 min 
was employed and compounds typically eluted between 20 – 25 min. The resultant purities 
for the four compounds are displayed in Table 3.12; all compounds were shown to be > 95% 
pure by HPLC (detected at 215 nm). The HPLC traces for compounds 68c-d, 77c and 87a 
can be found in Section B4 of Appendix B. 






Table 3.12 – Purity of the compounds selected for the 





4.0 – NMR spectroscopy analysis: regioselectivity, rotamers and 
anomalies 
4.1 – Background information 
This chapter contains elaboration on the 1-D and 2-D NMR experiments that were 
conducted to verify the molecular structures of the synthesized compounds through NMR 
assignments and [1H – 1H] and [1H – 13C] correlations. During the characterization process, 
numerous unexpected NMR spectroscopy results (i.e. anomalies) were observed. Due to the 
volume of spectroscopic data and analysis required for NMR assignment, only the 
challenging and novel aspects of complete 1H and 13C NMR assignment confirmation and 
the associated spectroscopic anomalies will be discussed. Protons and carbons will be notated 
using the same assignment numbers that are given in the Experimental section (Section 6.0). 
In particular, this chapter explores the 1,4-disubstitution regioselectivity of the 1,2,3-triazole 
formation via CuAAC and the following anomalous NMR spectroscopy findings:  syn-
rotamers of amides/carbamates/guanidines, guanidine tautomerization, missing 13C NMR 
resonances (especially in the case of the 1,2,3-triazole-acid systems) and anomalous 
resonances in the 13C and 2-D NMR spectra of alkynes 20 and 21.  
4.2 - Triazole orientation: proof of 1,4-regioselectivity 
 The regiochemistry of the installed 
1,2,3-triazole moieties were unambiguously 
established via analysis of the gHMBC spectrum of 
compound 63a (Figure C1.3 in Appendix C). The 
key observed [1H – 13C] correlations are depicted in 
Figure 4.1. Importantly, the 1H NMR resonances 
      
Figure 4.1 – Relevant portion of 
compound 63a: significant gHMBC 
correlations are shown that prove the 




assigned to H6A and H6B displayed 3-bond gHMBC correlations with the 
13C NMR 
resonance assigned to C5  (Figure 4.1 – blue arrow) but not with the resonance assigned to 
C4. This indicated the orientation of the C(4)=C(5) double bond, relative to the H6 proton 
pair; the 1,4-regioisomer had been selectively formed. If the 1,5-regioisomer had been 
produced, a correlation between the H6 diastereotopic proton pair and the quaternary triazole 
carbon (C4) would have been observed. These findings were congruent with the gHMBC 
correlations observed between the 1H NMR resonance at δ 5.17 (-OCH2-C4′)) and the 
13C 
NMR resonances assigned to both triazole carbons (C4′ and C5′). This evidence conclusively 
established the expected 1,4-regiochemistry of the 1,2,3-triazole ring.  
4.3 – Rotamers 
  Single C–N bonds that are attached to an adjacent carbon–heteroatom double bond 
(e.g. C=O or C=N) are known to exhibit partial double bond characteristic due to the 
delocalization of the nitrogen’s lone pair of electrons; this leads to restricted rotation of the 
C–N bond. If the energy barrier to rotation is high, two distinct rotameric conformations will 
be generated (i.e. anti- and syn-rotamers – Figure 4.2), with the anti-rotamer generally being 
preferred in secondary amides, carbamates, and guanidines due to steric considerations.78, 117 
 
Figure 4.2 – a) Generic anti- and syn-rotamers b) anti- and syn-rotamers of the Boc-
carbamate on the lysine side chain 
The existence of amide, carbamate and guanidine rotamers (i.e. anti and syn) was evident by 
the presence of smaller, additional resonances in the 1H and 13C NMR spectra of various N-
protected scaffolds and derivatives. These resonances were observed as additional resonance 
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“shoulders” or small satellite resonances. For example, compound 64c displayed some 
anomalous 1H NMR resonance shouldering and 13C NMR resonance splitting (Figures C1.4 
and C1.5 – Appendix C) due to the presence of anti and syn N-Cbz carbamate rotamers. 
While an accurate rotamer ratio could not be inferred from this example, one rotamer was 
most definitely dominant over the other (observed ratio ca. 9:1 – presumably anti : syn).  
 
Figure 4.3 – Rotameric forms of compounds 64c (rotameric carbamate) and 76d 
(rotameric amide): carbons assigned to 13C NMR resonances that exhibited splitting or 
shouldering are marked with red dots (·) on the syn-rotamers. 
The presence of syn-rotamers in compound 64c (Figure 4.3) was confirmed by utilizing 
DMSO-d6 (known to disrupt hydrogen bonding
117) and variable temperature (VT) NMR 
experiments (to increase the rate of bond rotation); compound 64c was dissolved in DMSO-
d6 and subjected to 
1H and 13C NMR spectroscopic analysis at both rt and 90 °C. The 
rotameric shoulder resonances present in the 13C NMR spectrum of compound 64c (when 
obtained in CD3OD – Figure 4.4 – top blue spectrum) were notably reduced when the 
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spectrum was recorded in DMSO-d6 at rt (Figure 4.4, middle green spectrum) – the minor 
syn-rotamer resonances became smaller, less apparent and they began to coalesce with the 
major anti-rotamer resonances. When the temperature was raised to 90 °C, the syn-rotamer 
resonances became virtually non-existent (Figure 4.4, bottom red spectrum). 
 
Figure 4.4 – 13C/DEPT Q NMR spectra of compound 64c recorded in CD3OD at rt (blue), DMSO-
d6 at rt (green) and DMSO-d6 at 90 °C (red). Visible rotameric shoulder peaks are marked with a 
red asterisk (*). 
Reduction of the syn-rotamer resonances in the 13C NMR spectra of compound 64c is further 
exemplified by Figure C1.6 in Appendix C; the use of DMSO-d6 and VT-NMR can be seen 
to decrease and almost eliminate the resonances attributed to the syn-rotamer. The use of 
hydrogen bond disruption by DMSO and increased temperature allowed for the positive 
identification of rotameric entities in the spectra of compound 64c and various other 
biarylpeptide derivatives. In another example, compound 76d was found to exhibit 
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shouldering and splitting of resonances in the 1H and 13C NMR spectra due to anti- and syn-
amide rotamers (Figures C1.7 and C1.8, Appendix C). The three carbons comprising and 
adjacent to the terminal amide moiety (see Figure 4.3 – red dots) were assigned to resonances 
at 170.1 (C=O), 65.0 (-CH-C=O) and 47.2 (-CH2Cy); these resonances all exhibited a 
rotameric partner (i.e. the resonance was split into two resonances) due to the presence of a 
stable syn-rotamer (Figure C1.8 in Appendix C). 
In a few of the dicationic compounds, the appearance of rotameric resonances in the 1H and 
13C NMR spectra was exacerbated by the presence of multiple moieties (e.g. amides, 
carbamates, guanidines and carboxylic acids) capable of forming or stabilizing rotameric 
forms. For example, 1H NMR spectrum of scaffold acid 84 showed resonances for multiple 
rotamers due to the stabilizing influence of a terminal carboxylic acid group117 – this moiety 
served to stabilize the syn-rotamer forms of the various rotamer-capable functionalities that 
were present in the molecule (i.e. amides, carbamates and guanidines). At least two different 
forms of rotameric splitting were observed; resonances at δ 8.71 (amide NH) and 7.49 
(triazole CH) in the 1H NMR spectra of compound 84 exhibited splitting due to anti- and syn-
rotamers at a molar ratio of 54:46 (determined by 1H NMR integration) as seen in Figure 
C1.9, Appendix C. This splitting pattern (primary rotameric splitting) was also observed in 
the five resonances assigned to the N-Pbf protons (found between δ 3.00 – 1.40); they 
appeared as apparent doublets in the 1H NMR spectrum of compound 84 (Figure C1.10 in 
Appendix C). A secondary rotameric splitting of the resonances assigned to the N-Pbf protons 
was also observed in the 1H NMR spectrum of compound 84; a molar ratio of 86:14 was 
determined by 1H NMR integration for this secondary rotamer pattern. Interestingly, the 
small secondary rotameric resonances also exhibited the primary splitting at the molar ratio 
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of 54:46 (e.g. the secondary rotameric N-Pbf resonances appeared as small apparent doublets 
– see Figure C1.10 in Appendix C).  Furthermore, the 13C NMR spectrum of scaffold acid 84 
displayed primary rotameric splitting for the majority of resonances observed with some 
secondary rotameric splitting evident as well (Figures C1.11 and C1.12 in Appendix C). 
DMSO-d6 and VT-NMR were utilized to disrupt the rotamer stabilization but the rotameric 
resonances failed to disappear completely – resonances began to coalesce and move closer 
together with DMSO-d6 and increased temperature, but rotamer-free 
1H or 13C NMR spectra 
were not obtained due the strong stabilizing effect of the carboxylic acid moiety. The 
rotameric nature of compound 84 was proven by the resolution of split resonances in the 13C 
NMR spectrum by the application of higher temperature; when compound 84 was placed in 
DMSO-d6 and then heated to 90 °C, split resonances at approximately δ 157.5 (Pbf CAr), 
153.5 (CAr2), and 18.5 (Pbf ArCH3) were found to coalesce into three individual resonances 
(Figures C1.13 and C1.14 in Appendix C). Additionally, some of the secondary rotameric 
resonances in the 13C NMR spectrum of compound 84 were found to resolve and even 
disappear after the utilization of DMSO-d6 and VT-NMR (Figure C1.13 in Appendix C). 
Futhermore, the split resonance at δ 7.5 (triazole CH) in the 1H NMR spectrum of compound 
84 was also found to change splitting pattern with the application of DMSO-d6 and VT-NMR 
(Figure C1.15 in Appendix C). These spectroscopic experiments were able to show the 
solvent and temperature dependence of the various 1H and 13C NMR resonances assigned to 
the rotameric syn-conformers in the spectra of the biarylpeptide derivatives.  
The stabilization of syn-amide and syn-carbamate rotamers by carboxylic acids is a well 
understood phenomenon.117 Rotamer stabilization can occur through either inter- or 
intra-molecular hydrogen bonding to any dual hydrogen bond donor-acceptor (e.g. a 
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carboxylic acid, carbamate or guanidine – see Figure 4.5); the biarylpeptide derivatives 
exhibit a predilection for such rotameric stabilization due to their flexible scaffold and 
numerous heteroatoms capable of accepting and donating hydrogen bonds. The ability of a 
molecule to simultaneously accept and donate hydrogen bonds has been shown to aid 
stabilization of the normally non-existent syn-rotamer in carbamates.117-118  Therefore, the 
possible hydrogen bonding arrangements (Figure 4.5) were studied and found to exhibit the 
correct potential orientation for rotamer stabilization.  
 
Figure 4.5 – Potential inter- or intra-molecular hydrogen 
bonding arrangements between the different rotamers 
(anti or syn) of the carbamate and guanidine groups. 
In summary, the presence of syn-rotamers were evident in both the 1H and 13C NMR spectra 
of various biarylpeptide derivatives. These anomalies were investigated by extensive NMR 
experiments utilizing DMSO-d6 and VT-NMR. The results of these experiments indicated 






4.4 – Guanidine tautomerization 
 In the previous published 1H NMR assignments for N-Pbf protected 
binaphthylpeptides,63-67 the three guanidino protons were always assigned to a single broad 
resonance around δ 6.50. Analysis of the 1H NMR spectra of N-Pbf protected biarylpeptide 
derivatives found that although a single broad resonance for the guanidine protons (3H) was 
sometimes observed, it often contained a ‘shoulder’ adjacent to the main peak. Furthermore, 
depending on compound concentration (which affects the chemical shifts of exchangeable 
nitrogen protons119) and/or the utilized NMR solvent, the ‘shoulder’ would resolve 
completely, resulting in two distinct resonances (i.e. a 1H and 2H resonance – see Figure 
C1.16 in Appendix C). Reports on the tautomerization of guanidine compounds revealed that 
guanidine moieties are subject to different tautomeric forms depending on the attached 
substituents.120  In the presence of a strongly electron-withdrawing substituent (e.g. a N-Pbf 
group), disubstituted guanidines will tautomerize such that the double-bond is located on the 
nitrogen to which the electron-withdrawing group is attached (Figure 4.6 – structure A).120  
 
Figure 4.6 – (Left) Tautomerization of disubstituted guanidines: if R = electron withdrawing 
group, then tautomer A is preferred.120  (Right) Potential E and Z isomers of the guanidine 
double bond. 
The electronic preference for structure A (Figure 4.6 – left) readily explains the observed 2:1 
split seen in the resonances assigned to the guanidino protons. The two resonances are often 
degenerate, hence the previous published assignments as a single resonance. Additionally, 
the presence of the N-Pbf imine allowed for the possibility of two isomers (E or Z) as seen in 
Figure 4.6 (right); it is currently unknown whether the compound exists as one isomer or a 
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mixture. Steric considerations dictate that the E-isomer would be energetically favoured, but 
there is yet no experimental evidence to support this statement.  
4.5 – Missing 13C NMR resonances  
4.5.1 – Resonances assigned to the 1,2,3 triazole carbons 
 Previous research59, 69 has shown that the final mono- or dihydrochloride salt products 
do not give adequate NMR spectra (i.e. broad resonances are observed) when CDCl3 is used 
as the solvent; therefore, the final hydrochloride salts were dissolved in CD3OD for NMR 
spectroscopic analysis. Unfortunately, a large number of the synthesized biaryltriazole 
derivatives exhibited anomalous or missing 13C NMR resonances for the 1,2,3-triazole 
carbons. Many quaternary triazole carbons were not observed in the 13C NMR spectrum and 
their presence could only be ascertained by positive gHMBC correlations. The methine 
triazole carbons were also occasionally afflicted, exhibiting a weak, broad resonance or no 
observable resonance at all; gHSQC and gHMBC correlations were utilized to detect the 
presence of the methine triazole carbons. 
For example, bis-triazole 68a failed to display resonances in the 13C NMR spectrum that 
could be assigned to any of the four triazole carbons (both quaternary and methine) – see 
Figure C1.17 in Appendix C. A resonance at δ 7.86 (2H) was assigned as the two degenerate 
triazole proton resonances (H5′ and Hα in Figure 4.8); this resonance exhibited gHSQC 
correlations with two missing 13C NMR resonances at δ 126.4 (C5′) and 124.5 (Cα) – these 
correlations allowed for assignment of the triazole methine carbons (Figure C1.18 in 
Appendix C). 1H NMR resonances at δ 5.11 (-OCH2-C4') and 4.07 (-CH2Ph) were assigned 
to the two pairs of methylene protons directly attached to the quaternary triazole carbons. 
gHMBC correlations were observed between these methylene resonances at δ 5.11 and 4.07 
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and the other two missing 13C NMR resonances at δ 145.7 (C4′) and 148.4 (Cβ), respectively; 
these correlations allowed for the positive identification of the quaternary triazole carbons 
(Figure C1.19 in Appendix C). The different gHMBC correlations that allowed for the 
identification and assignment of the missing 13C NMR triazole resonances are displayed on 
compounds 68a and 68b in Figure 4.8. 
 
Figure 4.8 - Structures of compounds 68a, 68b and 64c: carbons that could not be assigned 
to a visible 13C NMR resonance are marked with red dots (·). The key gHMBC correlations 
that allowed for assignment are displayed with blue arrows. 2-D NMR spectroscopy could 
not be utilized to assign the triazole carbons in compound 64c and DMSO-d6 was ultimately 
required. 
In another example, bis-triazole compound 68b failed to display any resonances in the 13C 
NMR spectrum that could be assigned to the two quaternary triazole carbons. Resonances at 
δ 7.94 and 7.88 in the 1H NMR spectrum of compound 68b were assigned to the two triazole 
protons (H5′ and Hα); these resonances displayed gHMBC correlations (Figure C1.20 in 
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Appendix C) with the two missing 13C NMR resonances at δ 147.2 (Cβ) and 145.6 (C4′) – 
this evidence allowed for the positive assignment of the two quaternary triazole carbons, 
despite the lack of visible resonances in the 13C NMR spectrum. Notably, the two methine 
triazole carbons were positively assigned to two weak, broadened resonances at δ 126.3 (C5′) 
and 125.0 (Cα) in the 13C NMR spectrum; these assignments were confirmed by gHSQC 
correlations with the appropriate 1H NMR resonances (Figure C1.21 in Appendix C).  
In some derivatives lacking the appropriate 13C NMR triazole resonances, prolonged 
gHMBC experiments (> 1 h) were not sufficient to detect the desired heterocorrelations. For 
example, N-Cbz analogue 64c failed to exhibit 13C NMR resonances that could be assigned 
to either of the triazole carbons (Figure 4.8). Furthermore, no gHMBC or gHSQC 
correlations could be observed that allowed for the assignment of these triazole carbons; the 
resonances for these carbons could not be observed when the spectrum was acquired in 
CD3OD. When compound 64c was subjected to 
13C NMR experiments in DMSO-d6, the 
triazole carbons were easily assigned to resonances that appeared in the expected regions. 
Figure C1.22 in Appendix C shows how the two distinct 13C NMR resonances assigned to 
the triazole carbons were not present in the spectrum acquired in CD3OD, but they can be 
clearly seen in the spectrum acquired in DMSO-d6. The use of DMSO-d6 as an NMR solvent 
obviated the need for extensive 2-D NMR experiments to determine triazole carbon 
assignments. Compounds 64c, 65c and 66a all required the use of DMSO-d6 as a solvent for 
complete 13C NMR characterization due to missing resonances in other solvents.  
It is proposed that hydrogen bonding between the triazole moieties and other capable 
functionalities was the primary cause of the observed lack of key NMR resonances; for more 
information regarding this phenomenon, see Section 4.6. 
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4.5.2 – Trifluoromethyl (CF3) derivatives 
 Two final Series B1 derivatives (compounds 76e and 77e) contained a terminal 
4-CF3-benzylamide moiety; in both molecules, the strong JCF coupling (caused by the -CF3 
substituent) obscured the 13C NMR resonances attributed to the ipso aromatic carbon and 
the -CF3 carbon itself. In the 
13C NMR spectrum of compound 76e, the two expected quartet 
resonances (assigned as the carbons closest to the fluorine atoms, i.e. -CF3 and C-CF3) were 
each missing one of the outer quartet peaks. The strong JCF coupling spread the weak 
quaternary 13C NMR resonances over multiple lines (as quartets); thus, the resonance became 
even weaker and buried amongst the background noise. Furthermore, quaternary carbons do 
not experience the large Overhauser enhancement by proton decoupling that is experienced 
by protonated carbons, so they exhibit a notably weaker 13C NMR resonance.119  
Furthermore, the related and expected 13C NMR quartet resonances (assigned to the -CF3 and 
C-CF3 carbons) in the spectrum of compound 77e could not be observed at all; the already 
weak quaternary carbon resonances were distributed across a quartet resonance by the strong 
JCF coupling – this created extremely weak resonances that were buried amongst the 
background noise. The presence of these two carbons could not be inferred from relevant 2-D 
NMR correlations because the quartet splitting and lack of Overhauser enhancement by 
proton decoupling resulted in correlations that were diffuse and non-observable. The 
presence of the attached trifluoromethyl moiety was clear from MS analysis and was inferred 
from the other observed aromatic resonances which displayed distinct JCF coupling constants, 




4.6 – Weak and non-observable NMR resonances in the 1,2,3-triazole-acid 
system  
 The triazole acid scaffolds synthesized for Series B1 (i.e. compounds 75a-d) 
exhibited a lack of expected NMR resonances normally assigned to the triazole ring and the 
adjacent methine and carboxylic acid functionalities (Figure 4.9). The 1H and 13C NMR 
resonances associated with these moieties were observed as broad, weak resonances or not 
observed when the spectra were acquired in CDCl3 or CD3OD. The effect was most 
prominent in the 13C NMR spectra, although some molecules exhibited anomalous 
resonances in the 1H NMR spectra as well. 
 
Figure 4.9 – General structure of scaffolds that 
exhibited weak or non-observable NMR 
resonances: the affected carbons and protons are 
marked with red (· or H). 
For example, compound 75a failed to exhibit 13C NMR resonances that could be assigned to 
the affected carbons (red dots in Figure 4.9) when the spectrum was acquired in CD3OD. The 
utilization of DMSO-d6 and/or 2-D NMR was required for observation of these carbon 
resonances; when DMSO-d6 was employed, three resonances appeared in the 
13C NMR 
spectrum of compound 75a that were assigned to both triazole carbons (C4′ and C5′) and the 
carboxyl carbon (C1) (Figure C1.23 in Appendix C). The methine carbon (C2) could not be 
assigned to a resonance in the 13C NMR spectrum of compound 75a; however, the gHSQC 
spectrum (acquired in DMSO-d6) displayed a correlation with a broad 
1H NMR resonance 
assigned as the methine proton (H2) – this allowed for assignment of the methine carbon 
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(C2). Interestingly, the downfield resonances assigned to the triazole proton (H5′) and 
methine proton (H2) were substantially broad when the spectrum was acquired in CD3OD; 
swapping the solvent to DMSO-d6 resulted in a sharper resonance that was assigned to the 
triazole proton (Figure C1.24 in Appendix C). 
Additionally, compounds 75b-d exhibited a similar lack of characteristic NMR resonances 
for the same moieties as compound 75a (Figure 4.10); a combination of DMSO-d6 and 2-D 
NMR spectroscopy was required for assignment of the missing carbon resonances in these 
compounds.  
 
Figure 4.10 – Weak and non-observable NMR resonance assignments for compounds 75a-d. 
Carbons that are marked with red (·) could not be assigned to a 13C or 2-D NMR resonance. 
Carbons that are marked with blue (·) required DMSO-d6 and/or 2-D NMR for assignment. 
Protons that are marked with blue (H) exhibited significant NMR resonance broadening. 
For the binaphthyl analogues (75b and 75d), the carboxyl (C1) and methine (C2) carbons 
could not be assigned to any resonances in the 13C NMR spectra of these compounds, despite 
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the use of DMSO-d6. Furthermore, these carbons could not be assigned via 2-D NMR 
correlations either. 
The weak and non-observable NMR resonances assigned to the triazole-acid systems display 
parallels with the missing triazole 13C NMR resonances (Section 4.5.1); both anomalies 
occurred most prominently in the hydrogen bonding solvent CD3OD and the use of DMSO-
d6 ameliorated or eliminated any observed NMR deactivation phenomena. Therefore, it is 
proposed that the NMR effects were a result of hydrogen bonding involving the triazole 
moieties. In the case of missing resonances in simple 1,2,3-triazole systems (i.e. Section 
4.5.1), it is likely that the triazole rings were hydrogen bonding to the solvent (or inter-/intra-
molecularly with other hydrogen bonding moieties, e.g. amines or guanidines); this bonding 
resulted in electronic disturbances that influenced the magnetic spin relaxation of the triazole 
carbons (resulting in weak or non-observable resonances). In the case of the triazole-acid 
scaffolds 75a-d, it is theorized that the carboxylic acid was intra-molecularly hydrogen 
bonding with the triazole moiety (Figure 4.11); this cyclic bonding would also likely result 
in electronic disturbances that could affect the NMR resonances of the triazole carbons (C4′ 
and C5′) and the adjacent carbons (C1 and C2). This proposed intramolecular hydrogen 
bonding could explain the weak and non-observable NMR resonances for scaffolds 75a-d. 
The increase in weak/non-observable NMR resonances observed for the binaphthyl 
analogues 75c and 75d could be due to the binaphthyl group having a more extreme 
electronic effect on the triazole ring than the biphenyl ring system; this could allow for 
increased hydrogen bonding between the triazole and the carboxylic acid moieties – allowing 
for the observed increase in weak/non-observable NMR resonances (relative to the biphenyl 




Figure 4.11 – Potential intramolecular hydrogen 
bonding (----) between the 1,2,3-triazole and the 
adjacent carboxylic acid moiety. 
4.7 – Anomalous gHSQC correlations for alkynes 
 Precursor alkynes 20 and 21 both displayed anomalous DEPT Q resonances and 
gHSQC correlations that were assigned to the two alkyne carbons. For alkyne 21, the DEPT 
Q 13C NMR resonance and the gHSQC correlation assigned to the methine carbon (-C≡C-H) 
both exhibited polarities that corresponded to a methylene (CH2) or quaternary carbon 
(Figure C1.25 in Appendix C). This unexpected anomalous occurrence was a result of the 
defined DEPT Q one-bond [1H – 13C] coupling constant frequency (usually set at 145 Hz).119 
Since the methine alkyne carbon exhibited a non-traditional one-bond [1H – 13C] coupling 
constant (approximately 250 Hz),119 the parameter values utilized for determining carbon 
saturation (i.e. the number of C–H bonds) did not apply in this unique case. Furthermore, 
quaternary alkyne carbons (-C≡C-H) exhibit a two-bond [1H – 13C] coupling constant 
frequency around 50 Hz; this was sufficiently large to show as a weak correlation in the 
gHSQC spectrum (Figure C1.25 in Appendix C) but substantially different from the 145 Hz 






5.0 – Conclusions and future directions 
 A diverse set of 62 novel antibacterial biaryl-peptidomimetic derivatives were 
designed and synthesized as part of an ongoing project into the development of novel 
antibiotic drugs and C. difficile chemotherapeutics. This array of compounds was realized 
through derivatization of 17 novel scaffolds via the installation of various hydrophobic 
termini. The scaffolds were achieved through implementation of a novel, modular multi-step 
synthesis that utilized 11 key building block precursors. The modular approach allowed for 
easy diversification and manipulation of the target scaffolds based upon the resultant SAR 
data. 
The targeted compounds were designed to incorporate additional peptidomimetic 1,2,3-
triazole moieties into the peptide backbone of the lead binaphthylpeptide compounds 2 and 
6; this potentially allowed for increased metabolic resistance to the peptidases and acidic 
conditions found in the GI tract, which is ideal for a CDI chemotherapeutic. Additionally, the 
binaphthyl aromatic core was replaced with a biphenyl core to attain increased solubility and 
antibacterial activity. Following synthesis and spectroscopic characterization, the compounds 
were subjected to antimicrobial and toxicity assays to screen for potential lead or hit 
compounds. The results of these assays were used to explore the SAR trends of the 
compounds and thus, to identify pharmacophore elements or other vital structural 
components necessary for both C. difficile antibacterial activity as well as broad-spectrum 
antibacterial activity.  
All of the synthesized compounds exhibited some level of antibacterial activity; the least 
potent MIC value observed against S. aureus was 16 μg/mL, with the majority of compounds 
having MIC values ranging from 2 – 8 μg/mL. There was a general reduction in the 
150 
 
antibacterial efficacy (2 – 4 times less active) that was observed amongst the monocationic 
derivatives, relative to the dicationic compounds; this result was in agreement with previous 
findings.59, 69 Despite this finding, the simple monocationic compound 77c (Figure 5.1) was 
identified as having strong Gram-positive antibacterial potency, especially against C. 
difficile. Interestingly, the biphenyl bis-triazole derivatives (e.g. compound 80b) were the 
only compounds that exhibited substantial broad-spectrum antibacterial activity against both 
Gram-positive and Gram-negative bacteria.  
 
Figure 5.1 – Development of potential hit compounds 80b and 77c from lead compound 2. 
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The biphenyl bis-triazole compound 80b exhibited the strongest broad-spectrum antibacterial 
efficacy, but it did not exhibit strong activity against C. difficile – these two spectrums of 
action were not mutually inclusive. The addition of a biphenyl aromatic moiety led to 
increased compound solubility which often translated to a decrease in Gram-positive 
antibacterial activity, but an increase in antibacterial efficacy against Gram-negative bacteria. 
This increase in solubility and decrease in molecular size may allow the drugs to permeate 
the extra external membrane exhibited by Gram-negative bacteria.  
As seen in Figure 5.1, the pursuit of novel antibacterial molecules from compound 2 led to 
the development of two distinct structural scaffolds (i.e. 80b and 77c) that both exhibited an 
increase in desirable traits for an antibacterial chemotherapeutic. Compound 80b exhibited a 
notable increase in the overall Gram-negative antibacterial efficacy; this could allow the 
biarylpeptides to be investigated for use in the treatment of Gram-negative bacterial 
infections. Furthermore, compound 77c exhibited an increase in selectivity for C. difficile; 
the molecule was also structurally simple and therefore, easier to synthesize. 
Four compounds (68b, 68d, 77c and 87a) were selected as potential hit compounds based 
upon their in vitro activities against C. difficile; they were synthesized on larger scale and 
used in an in vivo CDI mouse model at Monash University. Compound 77c was identified as 
the best performer in the in vivo CDI mouse model; both mouse weight loss and disease 
progression were significantly slowed by compound 77c during the administration of the 
trial. Compound 77c has been selected for testing in a further in vivo CDI mouse model. 
Compound 77c exhibited selectivity for Gram-positive bacteria – it was inactive against all 
of the Gram-negative bacteria that were tested. This selectivity could be reason for the drug’s 
positive performance in the CDI mouse model; by not eliminating the commensal, Gram-
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negative Bacteroides spp. and E. coli, compound 77c was likely quite effective at selectively 
killing C. difficile without destroying the entire enteric microflora. The monocationic 
compound 77c is a structurally simple molecule; large scale synthesis would be very cost 
effective, relative to the more complex CDI treatments available (e.g. vancomycin or 
fidaxomicin). If successful in further trials, the potential hit compound 77c will be studied 
and possibly developed as a potential CDI chemotherapeutic. Larger cohort (i.e. sample) 
sizes are needed to confirm the observed in vivo CDI model results; a cohort size of five mice 
is indicative, but not conclusive. Larger sample sizes are needed to be statistically confident 
in the in vivo CDI model results; unfortunately, the administration of large in vivo CDI model 
is extremely labour intensive and costly, so more preliminary in vivo work needs to be done 
before such a trial could be conducted.  
Furthermore, associated pharmacokinetic studies were performed as part of the in vivo CDI 
mouse model; the results confirmed the lack of systemic drug absorption by the mice, as was 
intended. A solubility assay was also developed and performed on selected compounds to 
ascertain the role of solubility in the efficacy and administration of the biarylpeptide 
derivatives. Future pharmacokinetic analysis will be performed on the recently tested 
derivatives (68c-d, 77c, and 87a) – i.e. blood and faeces analysis; the relationship between a 
compound’s solubility and its systemic absorption will be investigated.  
Numerous anomalies were observed during the analysis of the 1H and 13C NMR spectra of 
the various biarylpeptide derivatives (e.g. rotamers and some unique NMR properties); these 
anomalies were investigated in depth so as to ensure the correct characterization (and 
therefore structures and purities) of the compounds being synthesized. HPLC analysis was 
also utilized to further ensure compound purity and the lack of any diastereomer formation.  
153 
 
Further experiments are planned that will determine the mechanism of action for the 
biarylpeptide antibiotics; membrane depolarization assays utilizing permeable and non-
permeable fluorescent dyes will be conducted at Monash University to ascertain whether the 
molecules exhibit bacterial membrane disruption as their mode of action. Determination of 
the mechanism of the action will allow for a more complete understanding of the antibiotic 
properties of the biarylpeptides; such knowledge could allow for mechanism-based 
molecular design. The lack of a formal target is a current limitation in regard to the molecular 
design. Future drug design and development will likely involve two target streams. One 
stream will focus on optimizing compound 77c and other compounds that exhibit selectivity 
for Gram-positive bacteria, in hopes of achieving a novel CDI chemotherapeutic. The other 
research stream will likely focus on increasing compound solubility and Gram-negative 
antibacterial efficacy – this avenue will be pursued because there is a large, unmet medical 
need for novel medications that work against drug-resistant Gram-negative bacteria.5, 13 
In summation, a total of 62 novel antibacterial compounds were synthesized and fully 
characterized as part of this project. The synthesis of these derivatives involved the synthesis 
of 104 compounds in total, i.e. 88 novel compounds and 16 known compounds A modular 
synthetic route to various novel biarylpeptide scaffolds was realized and the resultant 
synthetic derivatives represent a potential new direction for developing novel antibiotics for 
the treatment of CDI and other bacterial infections. The compounds synthesized and 
identified in this project are the subject of ongoing studies into the development of a novel 
CDI treatment. Therefore, the current and future chemical and biological research focused 




6.0 – Experimental 
6.1 – General information 
Synthesis 
Unless stated otherwise, all solvents and chemicals were laboratory or reagent grade 
and were purchased from commercial sources. All chemicals were used as received. Water 
was purified via Millipore filtration prior to use. HOBt and propargyl bromide were 
purchased with added stabilizers (10% w/w H2O and 20% w/w toluene, respectively); 
therefore, the quantities required for reactions were adjusted accordingly and are reflected in 
the reagent masses reported in the experimental (whereas the reported mmol quantities reflect 
the true quantity of chemical). All reactions were conducted under normal atmosphere and 
cold reaction temperatures were obtained by an ice bath (0 ºC) or ice/salt bath (–10 ºC). 
Heating of reactions was performed with a paraffin oil bath. Small quantities of liquid 
reagents were measured and added to reactions via syringe or autopipette. Unless otherwise 
noted, all filtrations were conducted as vacuum filtration through a sintered glass funnel 
(medium porosity). Vacuum filtration was achieved with the aid of a water aspirator. Solvent 
removal via concentration was performed on a rotary evaporator under reduced pressure. All 
solvent mixtures are expressed in terms of volume ratio (i.e. v/v). Thin layer chromatography 
(TLC) was performed on aluminium-backed SiO2 gel plates (F254 grade - 0.20 mm thickness). 
Visualization was achieved with UV light, ninhydrin stain or cerium ammonium molybdate 
stain. Flash chromatography was performed on SiO2 gel 60 with a positive air pressure. All 
synthesized compounds were dried under high vacuum (< 1 mbar) before determination of 




Characterization and analysis 
All novel precursors, scaffold intermediates and scaffolds were subjected to full 
spectroscopic characterization and assignment. All final derivatives were subjected to full 
spectroscopic characterization, but due to the sheer number of final scaffold derivatives, only 
one example derivative from each scaffold type was fully assigned. 1H NMR spectra were 
recorded on a Bruker Avance 400 (400 MHz), a Varian VNMRS PS54 500 (500 MHz), a 
Varian Inova 500 (500 MHz) or a Varian Mercury 300 (300 MHz) NMR spectrometer. 
Chemical shifts are reported in ppm and were measured relative to the internal standard. 
Samples were dissolved in CDCl3 (with TMS as the internal standard – 0.00 ppm), CD3OD 
(solvent resonance as internal standard – 3.31 ppm) or DMSO-d6 (solvent resonance as 
internal standard – 2.50 ppm). The 1H NMR data is reported as follows: chemical shift, 
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, dt = doublet of triplets, m = 
multiplet, br = broad), coupling constants (Hz) and integration. 13C NMR spectra were 
recorded on a Bruker Avance 400 (101 MHz), a Varian VNMRS PS54 500 (126 MHz), a 
Varian Inova 500 (126 MHz) or a Varian Mercury 300 (75 MHz) NMR spectrometer with 
complete 1H decoupling. Chemical shifts are reported in ppm and were measured relative to 
the internal standard. Samples were dissolved in CDCl3 (solvent resonance as the internal 
standard – 77.16 ppm), CD3OD (solvent resonance as the internal standard – 49.20 ppm) or 
DMSO-d6 (solvent resonance as internal standard – 39.50 ppm). Variable temperature NMR 
experiments were performed at 90 C on the Bruker Avance 400 NMR spectrometer. 1H and 
13C NMR signal assignments were confirmed by analysis of NMR experiments: APT, 
gCOSY, gHSQC, gHMBC, zTOCSY, NOESY and/or gHSQC-TOCSY. The abbreviations 
section defines all NMR experiment acronyms. Ambiguous degenerate carbon resonances 
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are marked with a single asterisk * (representing two carbons) or a double asterisk ** 
(representing three or more carbons) for clarity. Carbon resonances that required 2-D NMR 
analysis for assignment (i.e. not observed via 1-D 13C NMR analysis) are marked with the 
label “observed by gHMBC” or “observed by gHSQC”. Compounds that exhibited non-
observable carbon resonances in both 1-D and 2-D NMR analysis are denoted and explained 
with footnotes. Unassigned aromatic hydrogens are labelled as “ArH”, whereas 
specific/assigned aromatic hydrogens are labelled with the normal nomenclature (i.e. HAr3 
= hydrogen atom attached to aromatic carbon #3). NMR spectra were processed, analysed 
and prepared with MestReNova (version 6.0) NMR software. Low resolution mass spectra 
(LRMS) were obtained via electrospray ionization (ESI) on a Shimadzu LC-2010 mass 
spectrometer. LRMS data was recorded as the ion mass/charge ratio (m/z) with the 
corresponding relative abundance as a percentage. High resolution mass spectrometry 
(HRMS) was performed on a Waters Quadrupole-Time of Flight (QTOF) Xevo spectrometer 
via ESI and with Leucine-Enkephalin as an internal standard. All mass spectrometry samples 
were dissolved in high performance liquid chromatography (HPLC) grade MeOH 
(containing <1% formic acid for ionization). Optical rotations were measured on a Jasco 
P-2000 polarimeter with a 10 cm path length; rotation values (α) are expressed in units of 
“deg cm3 g-1 dm-1” with concentration (c) expressed in units of “g/100 mL”. Solid-state 
infrared spectroscopy was performed on a Shimadzu IRAffinity-1 FTIR spectrometer in 
combination with a MIRacle 10 Single Reflection Attenuated Total Reflectance accessory 
outfitted with a 1.5 mm round diamond crystal. IR peaks are reported as the wavenumber 
(ν̄max in cm




Notes and other considerations 
All known compounds are marked with a reference after the compound title; all 
compounds without a reference are novel. Unless otherwise noted, all rotameric NMR data 
was expressed with relevant footnotes for clarity. Synthesized compounds that contain the 
(S)-isopentyloxybinaphthalene fragment and some chiral compounds that contain the 
isopentyloxybiphenyl fragment exhibit a pair of diastereotopic methyl (-CH3) groups on the 
terminus of the isopentyl substituent; these carbons are consistently referred to as C4 and 
C5. Importantly, these two carbons (and associated protons) will sometimes exhibit distinct 
chemical shifts due to the chiral environment imposed by the amino acid residue(s) (for all 
derivatives) and/or the adjacent (S)-BINOL moiety (for binaphthyl derivatives only). 
6.2 – General synthetic procedures 
General Procedure A: Copper catalyzed azide-alkyne cycloaddition  
 To a reaction vessel charged with the azide (1.0 eq), alkyne (2.0 – 3.0 eq), 
Cu(OAc)2∙H2O (0.2 eq), and sodium ascorbate (0.4 eq) was added t-BuOH (20 mL/mmol 
azide) and H2O (5 mL/mmol azide). The mixture was initially sonicated for < 1 min followed 
by vigorous stirring at rt (unless noted otherwise) for the specified time. The reaction mixture 
was diluted with EtOAc (20 mL for reactions that contained ≤ 1.0 mmol azide or 20 
mL/mmol azide for larger scale reactions) and washed with an equivalent volume of saturated 
aqueous NH4Cl solution (e.g. 20 mL). The organic phase was dried (MgSO4), filtered, 
concentrated and the residue was subjected to flash chromatography over SiO2 gel to afford 





General Procedure B: Amide coupling 
The amine (1.0 eq), carboxylic acid (1.0 eq), EDCI (1.2 eq) and HOBt (1.1 eq) were 
combined in an acetonitrile solution (10 mL/mmol amine) and stirred at rt for the specified 
time. The solvent was removed (not required for ≤ 5.0 mL acetonitrile) and the residue was 
dissolved in EtOAc (25 mL for reactions that contained ≤ 1.0 mmol amine or 25 mL/mmol 
amine for larger scale reactions). The organic solution was washed successively with aqueous 
HCl (1.0 M – 2 × 25 mL), saturated aqueous NaHCO3 (3 × 25 mL) and brine (1 × 25 mL). 
The EtOAc solution was dried (MgSO4), filtered and concentrated. If necessary, the residue 
was subjected to further purification via flash chromatography over SiO2 gel to furnish the 
targeted amide product. 
General Procedure C: Amine deprotection (N-Boc and/or N-Pbf removal) 
The N-protected amine (1.0 eq) was dissolved in a CH2Cl2 (30 mL/mmol substrate) 
with magnetic stirring. If the substrate molecule contained an N-Pbf moiety then H2O (20.0 
eq) was also added to the solution. TFA (30.0 mL/mmol substrate) was then added and the 
reaction mixture was stirred at rt overnight (> 16 h) followed by removal of the solvent. The 
residue was dissolved in CH2Cl2 (30 mL/mmol substrate), an excess amount of anhydrous 
HCl (2.0 M in Et2O, 15 mL/mmol substrate, 30.0 eq) was added and the solvent was then 
removed. The resulting residue was dissolved in a minimal volume of CH2Cl2 (or MeOH) 
and excess Et2O (25 mL for ≤ 0.1 mmol substrate) was added to precipitate the hydrochloride 
salt of the amine. The solvent was removed by filtration and the product (both in the filter 
funnel and in the flask) was triturated with Et2O (3 × 20 mL). The product was collected by 
dissolution in MeOH; concentration followed by drying in vacuo gave the final mono- or 
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di-hydrochloride salt as a thin, translucent film that was routinely scratched with a spatula 
into a fine hygroscopic powder or amorphous gum.  
General Procedure D: Modified amine deprotection (N-Boc removal) 
 For the monocationic lysine derivatives, General Procedure C was followed with 
the following modifications: Et2O (instead of CH2Cl2 or MeOH) was utilized to dissolve the 
residue for final precipitation and petroleum spirits (P.S. – instead of Et2O) was utilized as 
the antisolvent for precipitation.  
6.3 – Synthesis 
6.3.1 – Precursor Building Blocks 
Aromatic Cores 
(S)-2-(Isopentyloxy)-[1,1-binaphthalen]-2-ol (46)63  
1-Bromo-3-methylbutane (264 mg, 1.75 mmol) was added 
dropwise to a stirred solution of (S)-[1,1-binaphthalene]-2,2-
diol (45) (500 mg, 1.75 mmol) and K2CO3 (1.00 g, 7.27 mmol) 
in acetone (10 mL). The reaction mixture was heated at reflux for 24 h, cooled to rt and 
filtered. The solid residue was rinsed with acetone (2 × 20 mL), the combined filtrates were 
concentrated and the resultant residue was subjected to flash chromatography over SiO2 gel 
(EtOAc/P.S. – 10:90) to give compound 46 (508 mg, 81%) as a translucent, yellow oil. The 
spectroscopic data was found to be in agreement with those previously reported.63 TLC 
(EtOAc/P.S. – 10:90): Rf  = 0.34; 
1H NMR (300 MHz, CDCl3) δ 7.80 – 8.01 (m, 4H, H4, H4, 
H5, and H5), 7.01 – 7.44 (m, 8H, H3, H3, H6, H6, H7, H7, H8, and H8), 4.96 (br s, 
1H, -OH), 3.92 – 4.05 (m, 2H, H1), 1.21 – 1.37 (m, 3H, H2 and H3), 0.65 (d, J = 5.6 Hz, 
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3H, H4 or H5), 0.61 (d, J = 5.6 Hz, 3H, H5 or H4); 13C NMR (75 MHz, CDCl3) δ 155.8 
(C2), 151.5 (C2), 134.3 (C8a), 134.0 (C8a), 131.0 (C4), 129.8 (C4), 129.7 (C4a), 129.3 
(C4a), 128.3 (C5), 128.2 (C5), 127.4 (C7), 126.4 (C7), 125.3 (C8), 125.2 (C8), 124.4 (C6), 
123.4 (C6), 117.6 (C3), 116.5 (C1), 115.8 (C3′), 115.4 (C1), 68.4 (C1), 38.1 (C2), 24.9 
(C3), 22.54 (C4 or C5), 22.48 (C5 or C4); MS (ESI +ve) m/z 413 ([M + HCOOH + 
H]+, 100%), 357 ([M+H]+, 58%).  
 
(S)-2-(Isopentyloxy)-2-(propargyloxy)-1,1-binaphthalene (20) 
Propargyl bromide (80% w/w in toluene – 750 mg, 6.31 mmol) 
was added dropwise to a stirred solution of 46 (1.50 g, 4.21 
mmol) and K2CO3 (1.17 g, 8.40 mmol) in acetonitrile (30 mL). 
The mixture was heated at reflux for 40 h, cooled to rt and 
filtered. The solid residue was washed with acetonitrile (2 × 50 mL), the filtrate was 
concentrated and the resulting residue was subjected to flash chromatography over SiO2 gel 
(EtOAc/P.S. – 10:90) to give alkyne 20 (1.65 g, 99%) as a translucent, yellow oil. TLC 




 –25.7 (c 3.06, MeOH); 1H NMR (500 MHz, CDCl3) 
δ 7.91 – 7.98 (m, 2H, H4 and H4), 7.83 – 7.88 (m, 2H, H5 and H5),  7.56 (d, J = 9.0 Hz, 
1H, H3), 7.42 (d, J = 9.0 Hz, 1H, H3), 7.28 – 7.35 (m, 2H, H6 and H6), 7.17 – 7.23 (m, 2H, 
H7 and H7), 7.15 (d, J = 8.5 Hz, 1H, H8), 7.12 (d, J = 8.5 Hz, 1H, H8), 4.54 and 4.58 (ABq, 
2H, J = 8.5 Hz, -CHAHB-CC-), 4.01 (dt, J = 9.4, 6.1 Hz, 1H, H1A or H1′′B), 3.91 (dt, J = 
9.4, 6.1 Hz, 1H, H1B or H1A), 2.37 (s, 1H, -CCH), 1.22 – 1.36 (m, 3H, H2 and H3), 
0.63 (d, J = 5.7 Hz, 3H, H4 or H5), 0.58 (d, J = 5.7 Hz, 3H, H5 or H4); 13C NMR (126 
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MHz; CDCl3) δ 154.8 (C2), 153.4 (C2), 134.3 (C8a), 134.2 (C8a), 130.0 (C4a), 129.6 (C4), 
129.4 (C4a), 129.2 (C4), 128.1 (C5), 128.0 (C5), 126.4 (C7), 126.3 (C7), 125.8 (C8), 125.7 
(C8), 124.1 (C6), 123.8 (C6), 121.5 (C1), 120.1 (C1), 116.3 (C3), 116.0 (C3), 79.6 
(-CCH), 75.3 (-CCH), 68.4 (C1), 57.4 (-CH2-CCH), 38.3 (C2), 24.8 (C3), 22.6 (C4 
or C5), 22.4 (C5 or C4); IR (neat) ν̄max 3288, 3058, 2954, 2868, 2363, 1620, 1590, 1507, 
1460, 1429, 1355, 1329, 1270, 1243, 1217, 1146, 1133, 1084, 1050, 1017, 934, 804, 746, 
668 cm-1; MS (ESI +ve) m/z 417 ([M + Na]+, 100%), 395 ([M + H]+, 40%); HRMS (ESI +ve 




1-Bromo-3-methylbutane (2.43 g, 16.11 mmol) was added dropwise to a 
stirred solution of 2,2-biphenol (47) (3.00 g, 16.11 mmol) and K2CO3 
(9.24 g, 66.86 mmol) in acetone (97 mL). The mixture was heated at 
reflux for 24 h, cooled to rt and filtered. The solid residue was extracted 
with acetone (2 × 50 mL), the combined filtrates were concentrated and the resulting residue 
was subjected to flash chromatography over SiO2 gel (Et2O/hexanes – 10:90) to give the 
product ether 48 (3.68 g, 89%) as a translucent, viscous oil that eventually crystallized into a 
white solid. The spectroscopic data was found to be in agreement with those previously 
reported.66 TLC (Et2O/hexanes – 10:90): Rf = 0.50, (EtOAc/P.S. – 5:95): Rf  = 0.34; 
1H NMR 
(300 MHz, CDCl3) δ 7.41 – 7.23 (m, 4H, ArH), 7.16 – 6.96 (m, 4H, ArH), 6.62 (s, 1H, -OH), 
4.09 (t, J = 6.6 Hz, 2H, H1''), 1.78 – 1.58 (m, 3H, H2'' and H3''), 0.88 (d, J = 6.2 Hz, 6H, H4'' 
and H5''); 
13C NMR (101 MHz, CDCl3) δ 155.0 (C2'), 154.0 (C2), 132.7 (C6'), 131.4 (C6), 
129.2 (C4 and C4'), 128.1 (C1'), 126.7 (C1), 122.5 (C5'), 121.0 (C5), 117.8 (C3), 113.4 (C3'), 
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68.5 (C1''), 37.9 (C2''), 25.1 (C3''), 22.6 (C4'' and C5''); MS (ESI +ve) m/z 279 ([M + Na]+, 
100%), 257 ([M + H]+, 16%).  
 
2-(Isopentyloxy)-2'-(prop-2-yn-1-yloxy)-1,1'-biphenyl (21) 
Propargyl bromide (80% w/w in toluene – 1.31 g, 8.78 mmol) was added 
dropwise to a stirred solution of the ether 48 (1.50 g, 5.85 mmol) and 
K2CO3 (1.62 g, 11.70 mmol) in acetonitrile (41 mL). The mixture was 
then heated at reflux for 48 h, cooled to rt and filtered. The solid residue 
was washed with acetonitrile (2 × 50 mL), the combined filtrates were concentrated and the 
resulting residue was subjected to flash chromatography over SiO2 gel (EtOAc/P.S. – 5:95) 
to give alkyne 21 (1.70 g, 99%) as a translucent, yellow oil. TLC (EtOAc/P.S. – 5:95): Rf  = 
0.46; 1H NMR (400 MHz, CDCl3) δ 7.37 – 7.21 (m, 4H, ArH), 7.10 (d, J = 8.1 Hz, 1H, ArH), 
7.07 – 6.91 (m, 3H, ArH), 4.60 (d, J = 2.3 Hz, 2H, -CH2C≡C-), 3.95 (t, J = 6.7 Hz, 2H, H1''), 
2.43 (t, J = 2.3 Hz, 1H, -C≡CH), 1.71 – 1.44 (m, 3H, H2'' and H3''), 0.83 (d, J = 6.5 Hz, 6H, 
H4'' and H5''); 13C NMR (101 MHz, CDCl3) δ 156.7 (C2), 155.3 (C2'), 131.9 (C6 or C6'), 
131.7 (C6 or C6'), 128.9 (C1'), 128.7 (C4 or C4'), 128.4 (C4 or C4'), 128.0 (C1), 121.3 (C5'), 
120.3 (C5), 113.0 (C3'), 112.4 (C3), 79.3 (-C≡CH), 75.2 (-C≡CH), 67.1 (C1''), 56.4 
(-CH2C≡C-), 38.1 (C2''), 25.1 (C3''), 22.7 (C4'' and C5''); IR (neat) ν̄max 3292, 2955, 2870, 
2362, 2328, 1594, 1502, 1473, 1441, 1384, 1367, 1251, 1212, 1162, 1123, 1110, 1054, 909, 
749, 731, 668 cm-1; MS (ESI +ve) m/z 317 ([M + Na]+, 100%), 295 ([M + H]+, 22%); HRMS 






Lysine Building Blocks 
(R)-N2-(Benzyloxycarbonyl)-N6-(tert-butoxycarbonyl)-2,6-diaminohexanoic acid (50)69  
H-(D)-Lys(Boc)-OH (49) (4.00 g, 16.24 mmol) was dissolved 
in 4.0 M NaOH (4.06 mL, 16.24 mmol) and the solution was 
cooled to 0 ºC in an ice bath. With vigorous stirring at 0 ºC, 
benzyl chloroformate (2.84 g, 16.65 mmol) and 4.0 M NaOH 
(4.06 mL, 16.24 mmol) were added portion-wise and 
alternately over a 15 min period. The mixture was then removed from the ice bath and stirred 
at rt for 90 min. The reaction mixture was diluted with H2O (5 mL) and extracted with EtOAc 
(3 × 20 mL). The combined organic layers were extracted with H2O (3 × 30 mL); the 
combined aqueous extracts were then acidified to pH 2-3 with concentrated aqueous HCl 
(36% w/w) followed by extraction with Et2O (3 × 40 mL). The combined ethereal extracts 
were dried (MgSO4), filtered and concentrated to give the acid 50 (5.86 g, 95%) as a light 
yellow, viscous oil. The spectroscopic data was found to be in agreement those previously 
reported.69 TLC (MeOH/CH2Cl2 - 10:90): Rf = 0.43; 
1H NMR (500 MHz, CDCl3) δ 7.27 – 
7.38 (m, 5H, ArH), 5.68 (s, 1H, N2-H), 5.01 – 5.20 (m, 2H, -CH2Ph), 4.86 (br s, 1H, -OH), 
4.70 (s, 1H, N6-H), 4.34 (s, 1H, H2), 3.08 (br s, 2H, H6), 1.62 – 1.95 (m, 2H, H3), 1.21 – 
1.56 (m, 13H, H4, H5 and -C(CH3)3); 
13C NMR (126 MHz; CDCl3) δ 175.8 (C1), 156.6 (Cα), 
156.5 (Cβ), 136.5 (CAr1), 128.7 (CAr3 and CAr5), 128.34 (CAr2 and CAr6), 128.27 (CAr4), 
79.7 (-C(CH3)3), 67.2 (-CH2Ph), 54.1 (C2), 40.2 (C6), 32.0 (C3), 29.7 (C5), 28.6 (-C(CH3)3), 





Benzyl ((R)-N6-(tert-butoxycarbonyl)-6-amino-1-hydroxyhexan-2-yl)carbamate (51)82 
To a stirred solution of the acid 50 (804 mg, 2.11 mmol) in THF 
(4.3 mL) at −10 ºC was added dropwise N-methylmorpholine 
(243 mg, 2.11 mmol) followed by isobutyl chloroformate (288 
mg, 2.11 mmol). The mixture was stirred at –10 ºC for 30 min 
and then filtered. To the cold filtrate (ice/salt bath) was added a 
solution of NaBH4 (120 mg, 3.16 mmol) in H2O (1.1 mL) and then the reaction mixture was 
manually agitated for 15 s followed by quenching of the reaction with excess H2O (~65 mL). 
The reaction mixture was then extracted with EtOAc (3 × 30 mL) and the combined extracts 
were then washed with H2O (3 × 30 mL). The organic phase was dried (Na2SO4), filtered and 
concentrated to give alcohol 51 (762 mg, 98%) as a clear, viscous oil. The spectroscopic data 
was found to be in agreement with those previously reported.82 TLC (MeOH/CH2Cl2 – 
10:90): Rf = 0.41; 
1H NMR (500 MHz, CDCl3) δ 7.29 – 7.41 (m, 5H, ArH), 5.11 (br s, 
3H, -CH2Ph and N
2-H), 4.61 (s, 1H, N6-H), 3.54 – 3.73 (m, 3H, H1 and H2), 2.98 – 3.23 (m, 
2H, H6), 2.64 (br s, 1H, -OH), 1.75 (br s, 1H, H3A or H3B), 1.60 (br s, 1H, H3B or H3A), 1.20 
– 1.55 (m, 13H, -C(CH3)3, H4 and H5); 
13C NMR (126 MHz, CDCl3) δ 156.9 (Cα), 156.5 
(Cβ), 136.7 (CAr1), 128.7 (CAr3 and CAr5), 128.31 (CAr2 and CAr6), 128.29 (CAr4), 79.5 
(-C(CH3)3), 67.0 (-CH2Ph), 65.2 (C1), 53.3 (C2), 40.0 (C6), 30.8 (C3), 30.2 (C5), 28.6 
(-C(CH3)3), 22.9 (C4); MS (ESI +ve) m/z 389 ([M + Na]







Benzyl ((R)-N6-(tert-butoxycarbonyl)-6-amino-1-azidohexan-2-yl)carbamate (23)82 
To a stirred solution of the alcohol 51 (6.56 g, 17.90 mmol) in 
CH2Cl2 (54 mL) at 0 ºC was added dropwise triethylamine (2.36 
g, 23.27 mmol) followed by the slow, dropwise addition of 
methanesulfonyl chloride (2.67 g, 23.27 mmol). The reaction 
mixture was allowed to warm to rt and then stirring was 
continued for 1 h. Toluene (58 mL) was added and the reaction 
mixture was concentrated under vacuum (600 mbar) to selectively remove the CH2Cl2. To 
the resulting solution was added sodium azide (5.82 g, 89.50 mmol), tetrabutylammonium 
bromide (693 mg, 2.15 mmol) and H2O (5.8 mL) and the mixture was heated at 70 ºC for 18 
h with vigorous stirring. A further portion of H2O (4.0 mL) was added and stirring was 
continued at 70 ºC for 6 h before the mixture was cooled to rt and partitioned between Et2O 
(150 mL) and H2O (150 mL). The aqueous phase was separated and re-extracted with fresh 
Et2O (2 × 75 mL). The combined ethereal extracts were washed with brine (2 × 75 mL), dried 
(MgSO4), filtered and concentrated. The residue was subjected to flash chromatography over 
SiO2 gel (EtOAc/P.S. - 5:95  20:80) which gave the azide 23 (5.80 g, 83%) as a clear, 
viscous oil. The spectroscopic data was found to be in agreement with those previously 
reported.82 TLC (EtOAc/P.S. - 40:60): Rf  = 0.61; 
1H NMR (500 MHz, CDCl3) δ 7.28 – 7.40 
(m, 5H, ArH), 5.03 – 5.18 (m, 2H, -CH2Ph), 4.94 (br s, 1H, N
2-H), 4.57 (br s, 1H, N6-H), 
3.77 (br s, 1H, H2), 3.32 – 3.49 (m, 2H, H1), 3.10 (br s, 2H, H6), 1.29 – 1.59 (m, 15H, H3, 
H4, H5 and -C(CH3)3); 
13C NMR (126 MHz; CDCl3) δ 156.1 (Cα), 156.0 (Cβ), 136.3 (CAr1), 
128.5 (CAr3 and CAr5), 128.14 (CAr2 and CAr6), 128.06 (CAr4), 79.1 (-C(CH3)3), 66.8 
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(-CH2Ph), 54.7 (C1), 50.8 (C2), 40.0 (C6), 31.6 (C3), 29.7 (C5), 28.4 (-C(CH3)3), 22.8 (C4); 




Fmoc-(D)-Lys(Boc)-OH (52) (4.00 g, 8.54 mmol) was 
dissolved in THF (17.1 mL) with magnetic stirring. The 
solution was brought to −10 °C (ice/salt bath) followed by 
sequential dropwise addition of isobutyl chloroformate (1.12 
g, 8.54 mmol) and then N-methylmorpholine (983 mg, 8.54 
mmol). The mixture was stirred at −10 °C for 30 min and 
filtered through a small pad of Celite – the Celite pad was rinsed with fresh, cold THF (5 × 
5 mL) and the combined filtrates were kept cold (ice bath). The cold filtrate was added 
dropwise to a cold aqueous solution of NaBH4 (647 mg, 17.07 mmol in 12.8 mL H2O) with 
vigorous stirring. The mixture was stirred for 5 min before being added directly to H2O (213 
mL) with vigorous stirring. The reaction was stirred for 10 min and then the aqueous mixture 
was extracted with EtOAc (3 × 150 mL). The combined organic extracts were washed with 
H2O (2 × 200 mL) and brine (1 × 200 mL). The organic phase was dried (MgSO4), filtered, 
concentrated and subjected to flash chromatography over SiO2 gel (EtOAc/P.S. – 50:50) to 
afford the alcohol 53 (3.57 g, 92%) as a white, amorphous solid. The spectroscopic data was 
found to be in agreement with those previously reported.121 TLC (EtOAc/P.S. – 50:50): Rf  = 
0.35; 1H NMR (400 MHz, CDCl3) δ 7.76 (d, J = 7.5 Hz, 2H, HAr5), 7.59 (d, J = 7.4 Hz, 2H, 
HAr2), 7.39 (t, J = 7.4 Hz, 2H, HAr3), 7.31 (t, J = 7.4 Hz, 2H, HAr4), 5.12 (br s, 1H, N2-H), 
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4.61 (br s, 1H, N6-H), 4.41 (d, J = 6.5 Hz, 2H, H1'), 4.20 (t, J = 6.7 Hz, 1H, H2'), 3.73 – 3.50 
(m, 3H, H1 and H2), 3.24 – 2.97 (m, 2H, H6), 1.68 – 1.19 (m, 15H, H3, H4, H5 
and -C(CH3)3); 
13C NMR (101 MHz, CDCl3) δ 156.8 (Cα), 156.5 (Cβ), 144.1 (CAr1), 141.5 
(CAr6), 127.8 (CAr4), 127.2 (CAr3), 125.2 (CAr2), 120.1 (CAr5), 79.4 (-C(CH3)3), 66.7 
(C1'), 64.8 (C1), 53.1 (C2), 47.4 (C2'), 39.8 (C6), 30.6 (C3), 30.1 (C5), 28.6 (-C(CH3)3), 22.7 
(C4); MS (ESI +ve) m/z 477 ([M + Na]+, 100%).  
 
Tert-butyl (R)-(5-amino-6-azidohexyl)carbamate (22)59 
A stirred solution of the alcohol 53 (100 mg, 0.22 mmol) in anhydrous 
CH2Cl2 (2.2 mL) was brought to 0 °C (ice bath). Triethylamine (33 mg, 
0.33 mmol) was added followed by the dropwise addition of 
methanesulfonyl chloride (38 mg, 0.33 mmol). The solution was 
stirred at 0 °C for 15 min followed by stirring at rt for 60 min. The 
mixture was diluted with CH2Cl2 (30 mL) and washed successively with 1.0 M aqueous citric 
acid solution (2 × 20 mL) and brine (1 × 20 mL). The organic phase was dried (MgSO4), 
filtered and concentrated to give the intermediate mesylate as a yellow, translucent gum. The 
mesylate was dissolved in DMF (1.1 mL) with magnetic stirring. NaN3 (72 mg, 1.10 mmol) 
was added and the reaction mixture was stirred vigorously and heated at 45-50 °C for 18 h. 
After the reaction was complete (as verified by MS/TLC analysis), the DMF was removed 
from the reaction mixture via a rotary evaporator by utilizing the DMF-toluene azeotrope. 
The residue was subjected to flash chromatography over SiO2 gel (EtOAc  MeOH/CH2Cl2 
– 10:90) which afforded the target amine 22 (26 mg, 46%) as a yellow, translucent oil. The 
spectroscopic data was found to be in agreement with those previously reported.59 TLC 
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(MeOH/CH2Cl2 – 10:90): Rf  = 0.13, (NEt3/MeOH/CH2Cl2 – 2:10:88): Rf  = 0.41; 
1H NMR 
(400 MHz, CDCl3) δ 4.85 (br s, 1H, N
1-H), 3.35 (dd, J = 9.3, 4.7 Hz, 1H, H6A or H6B), 3.18 
– 3.04 (m, 3H, H6B or H6A and H1), 2.89 (br s, 1H, H5), 1.64 – 1.23 (m, 17H, H2, H3, 
H4, -C(CH3)3 and -NH2); 
13C NMR (101 MHz, CDCl3) δ 156.0 (C=O), 78.9 (-C(CH3)3), 58.2 
(C6), 50.9 (C5), 40.2 (C1), 34.5 (C4), 30.0 (C2), 28.3 (-C(CH3)3), 23.1 (C3); MS (ESI +ve) 
m/z 258 ([M + H]+, 100%), 280 ([M + Na]+, 10%).  
 
(R)-2-Azido-6-((tert-butoxycarbonyl)amino)hexanoic acid (24)90 
The methyl triflate salt of sulfuryl-diimidazole87-88 (4.85g, 13.40 mmol) 
was added to cold (≤ 5 °C) H2O (16 mL) and the mixture was 
magnetically stirred over an ice bath until the salt fully dissolved. 
EtOAc (16 mL) was added to the solution, followed by NaN3 (1.16 g, 
17.86 mmol); the mixture was stirred vigorously at 0 °C for 60 min. The 
EtOAc layer was separated, dried (Na2SO4), filtered and the Na2SO4 solids were rinsed with 
minimal fresh EtOAc. The combined EtOAc filtrate (containing the newly formed 
diazotransfer reagent) was then added to a reaction vessel containing a solution of H-(D)-
Lys(Boc)-OH (54) (2.20 g, 8.93 mmol) in MeOH (36 mL), CuSO4∙5H2O (22 mg, 0.09 mmol) 
and K2CO3 (1.85 g, 13.40 mmol). The reaction was stirred vigorously at rt for 24 h, at which 
point the reaction was shown to be complete by MS analysis. The mixture was diluted with 
H2O (50 mL) and a few drops of aqueous NaOH solution (10% w/w) were added to ensure 
an alkaline mixture (pH > 10). The volatile solvents (EtOAc and MeOH) were removed under 
reduced pressure at 40 °C. The aqueous reaction mixture was then washed with Et2O (2 × 50 
mL) and made acidic (pH < 3) with concentrated aqueous HCl (36% w/w). The aqueous 
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phase was extracted with Et2O (3 × 50 mL) and the combined ethereal extracts were washed 
with H2O (3 × 100 mL), brine (1 × 50 mL), dried (MgSO4), filtered and concentrated to afford 
a residue which was further purified by flash chromatography over SiO2 gel (EtOAc/P.S. – 
0:100  40:60) to yield the target α-azido-acid 24 (2.39g, 98%) as a translucent, viscous 
faint tan oil. The spectroscopic data was found to be in agreement with those previously 
reported.90 TLC (EtOAc/P.S. – 40:60): Rf  = 0.58; 
1H NMR (400 MHz, CD3OD) δ 4.00 – 3.89 
(m, 1H, H2), 3.04 (t, J = 6.6 Hz, 2H, H6), 1.90 – 1.79 (m, 1H, H3A or H3B), 1.79 – 1.67 (m, 
1H, H3B or H3A), 1.56 – 1.35 (m, 14H, H4, H5 and -C(CH3)3); 
13C NMR (101 MHz, CD3OD) 
δ 174.0 (C1), 158.7 (Cα), 80.1 (-C(CH3)3), 63.3 (C2), 41.2 (C6), 32.3 (C3), 30.6 (C5), 29.0 
(-C(CH3)3), 24.3 (C4); MS (ESI −ve) m/z 271 ([M − H]
−, 100%), (ESI +ve) m/z 295 ([M + 





Cbz-(D)-Arg(Pbf)-OH (55) (5.00 g, 8.92 mmol) was 
dissolved in THF (17.8 mL) with magnetic stirring. The 
solution was brought to −10 °C (ice/salt bath) followed by 
sequential dropwise addition of isobutyl chloroformate 
(1.22 g, 8.92 mmol) and N-methylmorpholine (1.03 g, 8.92 
mmol). The mixture was stirred at −10 °C for 30 min and then filtered through a small pad 
of Celite – the Celite pad was rinsed with fresh, cold THF (5 × 5 mL) and the combined 
filtrates were kept cold (ice bath). The cold filtrate was added dropwise to a cold aqueous 
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solution of NaBH4 (676 mg, 17.84 mmol in 13.4 mL H2O) with vigorous magnetic stirring. 
After the addition was complete, the reaction was allowed to react for 5 min and was added 
to excess H2O (223 mL) with vigorous stirring. The reaction was stirred for 10 min and the 
aqueous mixture was extracted with EtOAc (3 × 150 mL). The combined organic extracts 
were washed with H2O (2 × 200 mL), brine (1 × 200 mL), dried (MgSO4), filtered and 
concentrated. The residue was subjected to flash chromatography over SiO2 gel (EtOAc/P.S. 
– 80:20  100:0) to afford the alcohol 56 (3.82 g, 78%) as a white foam that collapsed into 




 –3.5 (c 0.77, MeOH); 1H 
NMR (400 MHz, CDCl3) δ 7.28 (br s, 5H, ArH), 6.10 – 6.32 (m, 3H, N
5-H/NH2), 5.62 (d, J 
= 8.5 Hz, 1H, N2-H), 5.03 (s, 2H, -CH2Ph), 3.50 – 3.69 (m, 3H, H1 and H2), 3.17 (br s, 2H, 
H5), 2.91 (s, 2H, ArCH2-), 2.53 (s, 3H, ArCH3), 2.46 (s, 3H, ArCH3), 2.06 (s, 3H, ArCH3), 
1.40 – 1.61 (m, 10H, H3, H4 and -C(CH3)2); 
13C NMR (101 MHz, CDCl3) δ 159.0 (Pbf CAr), 
157.1 (C=O), 156.5 (C=N), 138.5 (Pbf CAr), 136.6 (Cbz CAr), 132.7 (Pbf CAr), 132.4 (Pbf 
CAr), 128.6 (Cbz CAr)*, 128.2 (Cbz CAr), 128.0 (Cbz CAr)*, 124.8 (Pbf CAr), 117.7 (Pbf CAr), 
86.6 (-C(CH3)2), 66.9 (-CH2Ph), 64.8 (C1), 52.8 (C2), 43.3 (ArCH2-), 41.1 (C5), 28.7 
(-C(CH3)2), 28.7 (C3), 25.8 (C4), 19.4 (ArCH3), 18.1 (ArCH3), 12.6 (ArCH3); IR (neat) ν̄max 
3431, 3328, 2934, 1696, 1617, 1545, 1454, 1243, 1153, 1088, 1028, 903, 806, 781, 733, 658 
cm-1; MS (ESI +ve) m/z 569 ([M + Na]+, 100%), 547 ([M + H]+, 56%); HRMS (ESI +ve 









To a stirred solution of the alcohol 56 (3.79 g, 6.94 mmol) 
in CH2Cl2 (21 mL) at 0 ºC was added triethylamine (912 
mg, 9.02 mmol) followed by slow, dropwise addition of 
methanesulfonyl chloride (1.03 g, 9.02 mmol). The 
reaction was allowed to warm to rt and stirring was 
continued for 1 h. Toluene (22.5 mL) was added and the mixture was concentrated under 
vacuum (600 mbar) to selectively remove the CH2Cl2. Sodium azide (2.26 g, 34.68 mmol), 
tetrabutylammonium bromide (268 mg, 0.83 mmol) and H2O (4.9 mL) were added and the 
mixture was heated at 80 ºC for 36 h with vigorous stirring before being cooled to rt and 
partitioned between EtOAc (150 mL) and H2O (150 mL). The aqueous phase was separated 
and extracted with EtOAc (2 × 75 mL). The combined organic extracts were washed with 
H2O (1 × 100 mL), brine (1 × 100 mL), dried (MgSO4), filtered and concentrated. The residue 
was subjected to flash chromatography over SiO2 gel (EtOAc/P.S. – 20:80  60:40) which 
gave the target azide 26 (2.82 g, 71% over two steps) as an off-white foam that collapsed into 




 +4.5 (c 13.96, MeOH); 1H 
NMR (400 MHz, CDCl3) δ 7.31 (br s, 5H, ArH), 6.10 (br s, 3H, N
5-H/NH2), 5.29 (d, J = 9.0 
Hz, 1H, N2-H), 5.13 – 4.99 (m, 2H, -CH2Ph), 3.73 (br s, 1H, H2), 3.42 – 3.26 (m, 2H, H1), 
3.17 (br s, 2H, H5), 2.93 (s, 2H, ArCH2-), 2.55 (s, 3H, ArCH3), 2.48 (s, 3H, ArCH3), 2.08 (s, 
3H, ArCH3), 1.62 – 1.39 (m, 10H, H3, H4 and -C(CH3)2); 
13C NMR (101 MHz, CDCl3) 
δ 158.8 (Pbf CAr), 156.4 (C=O), 156.2 (C=N), 138.3 (Pbf CAr), 136.2 (Cbz CAr), 132.7 (Pbf 
CAr), 132.3 (Pbf CAr), 128.6 (Cbz CAr)*, 128.2 (Cbz CAr), 128.0 (Cbz CAr)*, 124.7  (Pbf CAr), 
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117.6 (Pbf CAr), 86.5 (-C(CH3)2), 67.0 (-CH2Ph), 54.9 (C1), 50.5 (C2), 43.2 (ArCH2-), 40.8 
(C5), 29.6 (C3), 28.6 (-C(CH3)2), 25.5 (C4), 19.3 (ArCH3), 17.9 (ArCH3), 12.5 (ArCH3); IR 
(neat) ν̄max 3431, 3332, 2930, 2098, 1700, 1616, 1540, 1456, 1242, 1153, 1088, 1028, 908, 
807, 781, 732, 658 cm-1; MS (ESI +ve) m/z 594 ([M + Na]+, 100%), 572 ([M + H]+, 52%); 





Fmoc-(D)-Arg(Pbf)-OH (57) (4.00 g, 6.17 mmol) was 
dissolved in THF (12.3 mL) with magnetic stirring. 
The solution was brought to −10 °C (ice/salt bath) 
followed by sequential dropwise addition of isobutyl 
chloroformate (842 mg, 6.17 mmol) and 
N-methylmorpholine (710 mg, 6.17 mmol). The mixture was stirred at −10 °C for 30 min 
and filtered through a small pad of Celite – the Celite pad was rinsed with fresh, cold THF 
(5 × 5 mL) and the combined filtrates were kept cold (ice bath). The cold filtrate was added 
dropwise to a cold aqueous solution of NaBH4 (467 mg, 12.33 mmol in 9.3 mL H2O) with 
vigorous magnetic stirring. After the addition was complete, the mixture was stirred for 5 
min and added to H2O (154 mL) with vigorous stirring. The reaction was stirred for 10 min 
and then the aqueous mixture was extracted with EtOAc (3 × 150 mL). The combined organic 
extracts were washed with H2O (2 × 200 mL), brine (1 × 200 mL), dried (MgSO4), filtered 
and concentrated. The residue was subjected to flash chromatography over SiO2 gel (EtOAc) 
to afford the alcohol 58 (3.12 g, 80%) as a translucent gum. The spectroscopic data was found 
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to be in agreement with those previously reported.121 TLC (EtOAc/P.S. – 60:40): Rf = 0.36; 
1H NMR (400 MHz, CDCl3) δ 7.69 (d, J = 7.5 Hz, 2H, HAr5), 7.52 (d, J = 7.4 Hz, 2H, HAr2), 
7.32 (t, J = 7.4 Hz, 2H, HAr3), 7.20 (t, J = 7.3 Hz, 2H, HAr4), 6.38 – 6.18 (m, 3H, N5-H/NH2), 
5.72 (d, J = 7.9 Hz, 1H, N2-H), 4.30 (d, J = 6.8 Hz, 2H, H1'), 4.09 (t, J = 6.7 Hz, 1H, H2'), 
3.67 – 3.48 (m, 3H, H1 and H2), 3.18 (s, 2H, H5), 2.86 (s, 2H, ArCH2-), 2.55 (s, 3H, ArCH3), 
2.47 (s, 3H, ArCH3), 2.04 (s, 3H, ArCH3), 1.63 – 1.41 (m, 4H, H3 and H4), 1.39 (s, 
6H, -C(CH3)2); 
13C NMR (101 MHz, CDCl3) δ 159.0 (Pbf CAr), 157.1 (C=N), 156.5 (C=O), 
144.0 (CAr1 or CAr1') 143.9 (CAr1' or CAr1), 141.3 (CAr6), 138.4 (Pbf CAr), 132.7 (Pbf 
CAr), 132.3 (Pbf CAr), 127.8 (C4), 127.2 (C3), 125.3 (C2), 124.9 (Pbf CAr), 120.0 (C5), 117.7 
(Pbf CAr), 86.6 (-C(CH3)2), 66.8 (C1'), 64.8 (C1), 52.8 (C2), 47.3 (C2'), 43.3 (ArCH2-), 41.1 
(C5), 28.7 (-C(CH3)2), 28.6 (C3), 25.8 (C4), 19.4 (ArCH3), 18.1 (ArCH3), 12.6 (ArCH3); MS 




A reaction vessel charged with triphenylphosphine (1.41 g, 5.37 
mmol), iodine (1.36 g, 5.37 mmol), imidazole (399 mg, 5.86 
mmol) and CH2Cl2 (7.0 mL) was stirred at rt for 10 min followed 
by the addition a solution of the alcohol 58 (3.10g, 4.88 mmol) in 
CH2Cl2 (3.0 mL). The reaction was stirred at rt for 20 h, diluted with CH2Cl2 (30 mL) and 
filtered to remove the white precipitate. The filtrate was concentrated and the residue was 
subjected to flash chromatography over SiO2 gel (EtOAc/Et2O – 50:50) to give a mixture of 
the intermediate iodide and triphenylphosphine oxide. The mixture was dissolved in DMF 
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(24.5 mL) and NaN3 (1.59g, 24.42 mmol) was added to the solution followed by vigorous 
stirring at rt for 4 h. After the azidation reaction was shown to be complete by TLC analysis 
(EtOAc/P.S. – 80:20), the reaction was heated to 50 °C (oil bath) overnight (18 h) to remove 
the N-Fmoc protecting group. The reaction mixture was cooled to rt and then partitioned 
between EtOAc (200 mL) and aqueous HCl (0.5 M – 200 mL) with magnetic stirring for 5 
min. The acidic aqueous phase was separated and washed with EtOAc (3 × 100 mL). The 
aqueous phase was made alkaline (pH > 10) with aqueous NaOH solution (10% w/w) and 
was extracted with EtOAc (3 × 100 mL). The organic extracts were combined and washed 
with H2O (1 × 150 mL), brine (1 × 100 mL), dried (Na2SO4), filtered and concentrated to 
afford the amine 25 (1.71 g, 80% over two steps) as an off-white foam that eventually 
collapsed into a translucent, pale yellow gum. The spectroscopic data was found to be in 
agreement with those previously reported.59 TLC (MeOH/CH2Cl2 – 10:90): Rf  = 0.21; 
1H NMR (400 MHz, CDCl3) δ 6.55 – 6.31 (m, 3H, N
5-H/NH2 (guanidine)), 3.27 (dd, J = 12.0, 
4.1 Hz, 1H, H1A or H1B ), 3.22 – 3.11 (m, 2H, H5), 3.07 (dd, J = 12.0, 7.4 Hz, 1H, H1B or 
H1A), 2.95 (s, 2H, ArCH2-), 2.86 – 2.76 (m, 1H, H2), 2.56 (s, 3H, ArCH3), 2.49 (s, 3H, 
ArCH3), 2.09 (s, 3H, ArCH3), 1.73 (s, 2H, -NH2), 1.61 – 1.34 (m, 9H, H3A or H3B, H4 
and -C(CH3)2), 1.31 – 1.19 (m, 1H, H3B or H3A); 
13C NMR (101 MHz, CDCl3) δ 158.8 (Pbf 
CAr), 156.4 (C=N), 138.2 (Pbf CAr), 132.9 (Pbf CAr), 132.1 (Pbf CAr), 124.7 (Pbf CAr), 117.6 
(Pbf CAr), 86.5 (-C(CH3)2), 58.3 (C1), 50.8 (C2), 43.3 (ArCH2-), 40.9 (C5), 31.7 (C3), 28.6 
(-C(CH3)2), 25.9 (C4), 19.3 (ArCH3), 18.0 (ArCH3), 12.5 (ArCH3); MS (ESI +ve) m/z 438 







To a stirred solution of amine 25 (100 mg, 0.23 mmol) in CH2Cl2 
(2.0 mL) was slowly added a solution of Boc2O (60 mg, 0.27 
mmol) in CH2Cl2 (0.5 mL) and the resulting mixture was stirred 
at rt for 2 h. The reaction was then diluted with EtOAc (100 mL) 
and washed successively with 1.0 M HCl (2 × 50 mL), saturated aqueous NaHCO3 (1 × 50 
mL), H2O (1 × 50 mL) and brine (1 × 50 mL). The organic phase was dried (MgSO4), filtered, 
concentrated and the resultant residue was subjected to flash chromatography over SiO2 gel 
(EtOAc/P.S. – 20:80  100:0) to afford the azide 27 (121 mg, 98%) as a light tan, translucent 




 –3.3 (c 0.70, MeOH); 
1H NMR (400 MHz, CDCl3) δ 6.22 (br s, 3H, N
5-H/NH2), 4.89 (d, J = 8.5 Hz, 1H, N
2-H), 
3.69 (br s, 1H, H2), 3.38 – 3.12 (m, 4H, H1 and H5), 2.96 (s, 2H, ArCH2-), 2.57 (s, 3H, 
ArCH3), 2.51 (s, 3H, ArCH3), 2.10 (s, 3H, ArCH3), 1.61 – 1.37 (m, 19H, H3, H4. -C(CH3)3 
and -C(CH3)2); 
13C NMR (101 MHz, CDCl3) δ 158.9 (Pbf CAr), 156.4 (C=N), 156.1 (C=O), 
138.5 (Pbf CAr), 133.0 (Pbf CAr), 132.4 (Pbf CAr), 124.8 (Pbf CAr), 117.7 (Pbf CAr), 86.6 
(-C(CH3)2), 80.1 (-C(CH3)3), 55.2 (C1), 50.0 (C2), 43.4 (ArCH2-), 41.1 (C5), 30.0 (C3), 28.7 
(-C(CH3)2), 28.5 (-C(CH3)3), 25.6 (C4), 19.4 (ArCH3), 18.1 (ArCH3), 12.6 (ArCH3); IR (neat) 
ν̄max 3452, 3333, 2975, 2934, 2098, 1684, 1617, 1545, 1456, 1367, 1248, 1163, 1089, 1028, 
901, 851, 808, 783, 660 cm-1; MS (ESI +ve) m/z 560 ([M + Na]+, 100%), 538 ([M + H]+, 






5-yl)sulfonyl)guanidino)pentanoic acid (28)89  
The methyl triflate salt of sulfuryl-diimidazole87-88 (2.55g, 7.03 
mmol) was added to cold (≤ 5 °C) H2O (8.5 mL) and was stirred 
over an ice bath until the salt fully dissolved. EtOAc (8.5 mL) was 
added to the solution, followed by NaN3 (549 mg, 8.44 mmol) and 
the mixture was then stirred vigorously at 0 °C for 60 min. The EtOAc layer was separated, 
dried (Na2SO4), filtered and the Na2SO4 solids were rinsed with minimal fresh EtOAc. The 
EtOAc filtrate (containing the newly formed diazotransfer reagent) was then added to 
reaction vessel charged with a solution of H-(D)-Arg(Pbf)-OH (60) (2.00 g, 4.69 mmol) in 
MeOH (12.7 mL), CuSO4∙5H2O (12 mg, 0.05 mmol) and K2CO3 (972 mg, 7.03 mmol). The 
mixture was stirred vigorously at rt for 24 h, at which point the reaction was shown to be 
complete by MS analysis; the reaction was diluted with H2O (50 mL) and a few drops of 
aqueous NaOH solution (10% w/w) were added to ensure an alkaline mixture (pH > 10). The 
volatile solvents (EtOAc and MeOH) were removed under reduced pressure at 40 °C. The 
aqueous reaction mixture was washed with Et2O (2 × 50 mL) and then made acidic (pH < 3) 
with concentrated aqueous HCl. The aqueous phase was extracted with Et2O (3 × 50 mL) 
and the combined ethereal extracts were washed with H2O (3 × 100 mL) and brine (1 × 50 
mL). The organic phase was dried (MgSO4), filtered and concentrated to afford the α-azido-
acid 28 (1.76 g, 83%) as a white foam that collapsed into a translucent gum. The 
spectroscopic data was found to be in agreement with those previously reported.89 TLC 
(EtOAc/P.S. – 80:20): Rf  = 0.44, (MeOH/CH2Cl2 – 10:90): Rf  = 0.37; 
1H NMR (400 MHz, 
CDCl3) δ 6.35 (br s, 4H, N
5-H/NH2 and -OH), 3.97 (t, J = 6.5 Hz, 1H, H2), 3.25 (s, 2H, H5), 
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2.95 (s, 2H, ArCH2-), 2.53 (s, 3H, ArCH3), 2.47 (s, 3H, ArCH3), 2.08 (s, 3H, ArCH3), 1.60 – 
1.98 (m, 4H, H3 and H4), 1.46 (s, 6H, -C(CH3)2); 
13C NMR (101 MHz, CD3OD) δ 173.7 
(C1), 160.0 (Pbf CAr), 158.1 (C=N), 139.5 (Pbf CAr), 134.4 (Pbf CAr), 133.6 (Pbf CAr), 126.2 
(Pbf CAr), 118.6 (Pbf CAr), 87.8 (-C(CH3)2), 63.0 (C2), 44.1 (ArCH2-), 41.4 (C5), 29.7 (C3), 
28.9 (-C(CH3)2), 27.1 (C4), 19.7 (ArCH3), 18.6 (ArCH3), 12.7 (ArCH3); MS (ESI −ve) m/z 




Fmoc-(D)-Arg(Pbf)-OH (61) (1.00 g, 1.54 mmol) was dissolved 
in MeOH (9.3 mL) and the solution was brought to 0 °C (ice bath) 
with magnetic stirring. Thionyl chloride (312 mg, 2.62 mmol) was 
added dropwise, the ice bath removed and the reaction solution 
stirred at rt for 24 h. The solvent was removed and the residue was dissolved in EtOAc (100 
mL); the organic phase was washed with aqueous NaHCO3 (5% w/w – 1 × 50 mL), brine (1 
× 50 mL), dried (MgSO4), filtered and concentrated to afford the intermediate methyl ester 
as a translucent gum. The ester was dissolved in MeOH (15.7 mL) with magnetic stirring and 
piperidine (668 mg, 7.85 mmol) was then added and the mixture was stirred at rt for 24 h. 
The reaction was diluted with MeOH (80 mL), washed with hexane (5 × 100 mL) and 
concentrated to afford the target amine 29 (551 mg, 80% over two steps) as a translucent, 
colourless gum. The spectroscopic data was found to be in agreement with those previously 
reported.59 TLC (MeOH/CH2Cl2 – 10:90): Rf  = 0.09, (NEt3/MeOH/CH2Cl2 – 2:10:88): Rf  = 
0.33; 1H NMR (400 MHz, CDCl3) δ 6.57 (br s, 1H, N
5-H), 6.47 (br s, 2H, -NH2 (guanidine)), 
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3.66 (s, 3H, -OCH3), 3.40 (br s, 1H, H2), 3.15 (br s, 2H, H5), 2.95 (s, 2H, ArCH2-), 2.55 (s, 
3H, ArCH3), 2.48 (s, 3H, ArCH3), 2.06 (s, 3H, ArCH3), 1.74 – 1.63 (m, 1H, H3A or H3B), 
1.61 – 1.39 (m, 9H, H3B or H3A, H4 and -C(CH3)2); 
13C NMR (101 MHz, CDCl3) δ 176.0 
(C1), 158.6 (Pbf CAr), 156.4 (C=N), 138.1 (Pbf CAr), 132.9 (Pbf CAr), 132.0 (Pbf CAr), 124.6 
(Pbf CAr), 117.4 (Pbf CAr), 86.3 (-C(CH3)2), 53.8 (C2), 51.9 (-OCH3), 43.1 (ArCH2-), 40.6 
(C5), 31.8 (C3), 28.5 (-C(CH3)2), 25.5 (C4), 19.2 (ArCH3), 17.9 (ArCH3), 12.4 (ArCH3); MS 
(ESI +ve) m/z 441 ([M + H]+, 100%), 463 ([M + Na]+, 95%).  
 
6.3.2 – Series A1  
Benzyl ((R)-N6-(tert-butoxycarbonyl)-6-amino-1-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-
2-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)hexan-2-yl)carbamate (62a) 
Following General Procedure A, azide 23 (1.50 g, 
3.83 mmol), alkyne 21 (2.26 g, 7.66 mmol), 
Cu(OAc)2∙H2O (153 mg, 0.77 mmol) and sodium 
ascorbate (304 mg, 1.53 mmol) were stirred in 
t-BuOH (77 mL) and H2O (19 mL) for 48 h to give 
the triazole 62a (1.97 g, 75%) as a white foam after flash chromatography over SiO2 gel 




 +31.3 (c 0.83, 
MeOH); 1H NMR (400 MHz, CDCl3) δ 7.38 – 7.21 (m, 9H, ArH), 7.17 (s, 1H, H5'), 7.07 – 
6.99 (m, 2H, ArH), 6.99 – 6.91 (m, 2H, ArH), 5.14 (s, 2H, -OCH2-C4'), 5.06 (s, 3H, -CH2Ph 
and N2-H), 4.55 (br s, 1H, N6-H), 4.39 (d, J = 5.1 Hz, 2H, H1), 3.92 (br s, 1H, H2), 3.88 (t, J 
= 6.6 Hz, 2H, H1''), 3.06 (br s, 2H, H6), 1.62 – 1.52 (m, 1H, H3''), 1.52 – 1.23 (m, 17H, H3, 
H4, H5, H2'' and -C(CH3)3), 0.79 (d, J = 6.6 Hz, 6H, H4'' and H5''); 
13C NMR (101 MHz, 
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CDCl3) δ 156.6 (CAr2'), 156.2 (Cβ), 155.9 (Cα), 155.8 (CAr2), 145.2 (C4'), 136.2 (Phenyl 
CAr), 131.7 (CAr6 or CAr6'), 131.5 (CAr6' or CAr6), 128.7 (CAr1), 128.54 (Phenyl CAr* and 
CAr4 or CAr4'), 128.46 (CAr4′ or CAr4), 128.2 (Phenyl CAr), 128.1 (Phenyl CAr* and CAr1'), 
123.3 (C5'), 121.1 (CAr5), 120.1 (CAr5'), 113.3 (CAr3), 112.3 (CAr3'), 79.2 (-C(CH3)3), 
67.0 (C1''), 66.9 (-CH2Ph), 63.4 (-OCH2-C4'), 53.1 (C1), 51.2 (C2), 39.8 (C6), 37.9 (C2''), 
31.0 (C3), 29.7 (C5), 28.4 (-C(CH3)3), 25.0 (C3''), 22.7 (C4), 22.5 (C4'' and C5''); IR (neat) 
ν̄max 3323, 2952, 2930, 2869, 2358, 2342, 1696, 1506, 1437, 1394, 1364, 1242, 1166, 1052, 
1011, 856, 750, 697 cm-1; MS (ESI +ve) m/z 708 ([M + Na]+, 100%), 686 ([M + H]+, 22%); 





To a reaction vessel charged with carbamate 62a (1.90 g, 
2.77 mmol), acetic acid (3.17 mL, 55.40 mmol) and 
palladium on charcoal (10% w/w – 442 mg, 0.42 mmol) 
was added MeOH (27.7 mL) under a flow of N2 gas. The 
reaction vessel was then sealed and degassed under high 
vacuum with magnetic stirring. N2 gas was allowed into the reaction vessel and the vessel 
was again degassed; this step was done twice. After the third degassing, the vacuum was 
maintained and a 2.0 L balloon of H2 gas was attached and allowed into the reaction vessel. 
The reaction mixture was then stirred vigorously at rt for 24 h under an atmosphere of H2 
gas. After the reaction was shown to be complete by TLC analysis (EtOAc/P.S. – 50:50), the 
H2 source was removed, the reaction vessel was purged with N2 gas and Celite was added to 
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the reaction mixture with vigorous magnetic stirring. The mixture was then vacuum filtered 
through a pad of fresh Celite atop a PTFE membrane, the solids were rinsed thoroughly with 
MeOH (5 × 20 mL) and the combined filtrates were concentrated until nearly dry. The residue 
was dissolved in EtOAc (200 mL) and washed successively with saturated aqueous NaHCO3 
(3 × 100 mL), H2O (1 × 100 mL) and finally brine (1 × 100 mL). The organic phase was 
dried (Na2SO4), filtered and concentrated to afford the amine 63a (1.52 g, 99%) as 




 +16.5 (c 
1.67, MeOH); 1H NMR (400 MHz, CDCl3) δ 7.34 – 7.22 (m, 5H, ArH and H5'), 7.08 – 6.92 
(m, 4H, ArH), 5.17 (d, J = 0.8 Hz, 2H, -OCH2-C4'), 4.57 (br s, 1H, N
1-H), 4.28 (dd, J = 13.6, 
4.2 Hz, 1H, H6A or H6B), 4.07 (dd, J = 13.6, 7.9 Hz, 1H, H6B or H6A), 3.90 (t, J = 6.6 Hz, 
2H, H1''), 3.21 – 3.02 (m, 3H, H1 and H5), 1.68 – 1.21 (m, 18H, H2, H3, H4, H2'', H3'' 
and -C(CH3)3), 0.80 (d, J = 6.6 Hz, 6H, H4'' and H5''); 
13C NMR (101 MHz, CDCl3) δ 156.6 
(CAr2'), 156.0 (C=O), 155.8 (CAr2), 145.2 (C4'), 131.62 (CAr6 or CAr6'), 131.56 (CAr6' or 
CAr6), 128.7 (CAr1), 128.50 (CAr4 or CAr4'), 128.49 (CAr4' or CAr4), 128.2 (CAr1'), 123.1 
(C5'), 121.1 (CAr5), 120.1(CAr5'), 113.2 (CAr3), 112.3 (CAr3'), 79.2 (-C(CH3)3), 67.1 (C1''), 
63.54 (-OCH2-C4'), 57.0 (C6), 51.5 (C5), 40.2 (C1), 38.0 (C2''), 34.5 (C4), 30.0 (C2), 28.5 
(-C(CH3)3), 25.0 (C3), 23.0 (C3''), 22.5 (C4'' and C5''); IR (neat) ̄νmax 3345, 2955, 2930, 2869, 
2362, 2327, 1700, 1506, 1437, 1388, 1364, 1241, 1166, 1125, 1051, 1002, 852, 750, 615 
cm-1; MS (ESI +ve) m/z 574 ([M + Na]+, 100%), 552 ([M + H]+, 80%); HRMS (ESI +ve 







triazol-1-yl)hexan-2-yl)-2-phenylacetamide hydrochloride (64a) 
Following General Procedure B, amine 63a (50 mg, 
0.09 mmol), phenylacetic acid (15 mg, 0.11 mmol), 
EDCI (21 mg, 0.11 mmol) and HOBt (15 mg, 0.10 
mmol) were stirred in acetonitrile (0.9 mL) for 24 h to 
give the intermediate amide as a translucent tan gum. Following General Procedure D, the 
amide was dissolved in CH2Cl2 (2.7 mL) and treated with CF3CO2H (2.7 mL) followed by 
work-up with ethereal HCl to give the amine salt 64a (53 mg, 96% over two steps) as a light 




 +22.7 (c 1.30, MeOH); 1H NMR 
(400 MHz, CD3OD) δ 7.50 (s, 1H, H5'), 7.36 – 7.10 (m, 10H, ArH), 7.06 – 6.91 (m, 3H, 
ArH), 5.02 (s, 2H, -OCH2-C4'), 4.51 (dd, J = 13.8, 4.3 Hz, 1H, H1A or H1B), 4.37 (dd, J = 
13.8, 8.0 Hz, 1H, H1B or H1A), 4.25 (br s, 1H, H2), 3.90 (t, J = 6.4 Hz, 2H, H1''), 3.38 (br s, 
2H, -CH2Ph), 2.92 – 2.77 (m, 2H, H6), 1.79 – 1.22 (m, 9H, H3, H4, H5, H2'' and H3''), 0.81 
(d, J = 6.6 Hz, 6H, H4'' and H5''); 13C NMR (101 MHz, CD3OD) δ 174.3 (C=O), 158.2 
(CAr2'), 157.4 (CAr2), 145.4 (C4'), 136.9 (Phenyl CAr), 133.0 (CAr6 or CAr6'), 132.6 (CAr6' 
or CAr6), 130.5 (CAr1), 130.3 (Phenyl CAr*), 129.9 (CAr4 or CAr4'), 129.77 (Phenyl CAr*), 
129.75 (CAr1' and CAr4' or CAr4), 128.2 (Phenyl CAr), 126.0 (C5'), 122.4 (CAr5), 121.5 
(CAr5'), 114.8 (CAr3), 113.9 (CAr3'), 68.2 (C1''), 63.6 (-OCH2-C4'), 54.6 (C1), 50.8 (C2), 
44.1 (-CH2Ph), 40.7 (C6), 39.4 (C2''), 32.3 (C3), 28.2 (C5), 26.2 (C3''), 23.9 (C4), 23.1 (C4'' 
and C5''); IR (neat) ν̄max 3242, 2955, 2873, 2363, 2337, 1653, 1559, 1539, 1506, 1437, 1261, 
1223, 1162, 1124, 1109, 1050, 1003, 876, 849 cm-1; MS (ESI +ve) m/z 570 ([M + H]+, 100%), 
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592 ([M + Na]+, 15%); HRMS (ESI +ve TOF)  calcd for C34H44N5O3 570.3444, found 
570.3451 ([M + H]+). 
 
(R)-N-(6-Amino-1-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2-yl)oxy)methyl)-1H-1,2,3-
triazol-1-yl)hexan-2-yl)-3-phenylpropanamide hydrochloride (64b) 
Following General Procedure B, amine 63a (50 
mg, 0.09 mmol), 3-phenylpropanoic acid (16 mg, 
0.11 mmol), EDCI (21 mg, 0.11 mmol) and HOBt 
(15 mg, 0.10 mmol) were stirred in acetonitrile (0.9 
mL) for 24 h to give the intermediate amide as a translucent tan gum. Following General 
Procedure D, the amide was dissolved in CH2Cl2 (2.7 mL) and treated with CF3CO2H (2.7 
mL) followed by work-up with ethereal HCl to give the amine salt 64b (52 mg, 93% over 




 +21.7 (c 1.37, 
MeOH); 1H NMR (400 MHz, CD3OD) δ 7.53 (s, 1H), 7.36 – 7.08 (m, 10H), 7.06 – 6.89 (m, 
3H), 5.09 (s, 2H), 4.45 (dd, J = 14.0, 4.4 Hz, 1H), 4.33 (dd, J = 13.8, 7.2 Hz, 1H), 4.20 (s, 
1H), 3.90 (t, J = 6.2 Hz, 2H), 3.00 – 2.75 (m, 4H), 2.50 – 2.29 (m, 2H), 1.80 – 1.18 (m, 9H), 
0.81 (d, J = 6.5 Hz, 6H);
 13C NMR (101 MHz, CD3OD) δ 175.3, 158.1, 157.4, 145.4, 142.2, 
133.0, 132.6, 130.5, 129.9, 129.72, 129.68*, 129.67*, 127.5, 126.1, 122.4, 121.5, 114.8, 
113.9, 68.2, 63.6, 54.8, 50.7, 40.7, 39.4, 38.8, 32.8, 32.1, 28.2, 26.2, 23.8, 23.1*; IR (neat) 
ν̄max 3242, 2954, 2869, 2358, 2329, 1653, 1559, 1539, 1506, 1437, 1387, 1261, 1225, 1161, 
1124, 1109, 1052, 1002, 847, 749, 699 cm-1; MS (ESI +ve) m/z 584 ([M + H]+, 100%), 606 
([M + Na]+, 11%); HRMS (ESI +ve TOF)  calcd for C35H46N5O3 584.3601, found 584.3609 




1,2,3-triazol-1-yl)hexan-2-yl)carbamate hydrochloride (64c) 
Following General Procedure D, carbamate 62a 
(50 mg, 0.07 mmol) was dissolved in CH2Cl2 (2.1 
mL) and treated with CF3CO2H (2.1 mL) followed 
by work-up with ethereal HCl to give the amine salt 





(c 1.20, MeOH); 1H NMR (400 MHz, DMSO) δ 7.83 (s, 1H), 7.39 – 7.18 (m, 8H), 7.18 – 
7.09 (m, 2H), 7.05 – 6.87 (m, 4H), 5.06 (s, 2H), 4.93 (s, 2H), 4.41 (dd, J = 13.7, 4.9 Hz, 1H), 
4.30 (dd, J = 13.6, 7.7 Hz, 1H), 3.94 – 3.77 (m, 3H), 2.78 – 2.66 (m, 2H), 1.60 – 1.24 (m, 
9H), 0.78 (d, J = 6.6 Hz, 6H); 13C NMR (101 MHz, DMSO) δ 156.0, 155.7, 155.6, 142.8, 
137.0, 131.3, 131.1, 128.5*, 128.4, 128.3*, 127.8, 127.7, 127.5, 127.4, 124.4, 120.4, 119.9, 
112.9, 112.3, 66.2, 65.2, 61.8, 52.7, 51.0, 38.4, 37.4, 30.9, 26.6, 24.4, 22.3, 22.2*; IR (neat) 
ν̄max 2956, 2926,  2873, 2357, 2337, 1700, 1680, 1559, 1539, 1506, 1437, 1339, 1261, 1204, 
1125, 1052, 1002, 833, 799, 750, 698 cm-1; MS (ESI +ve) m/z 608 ([M + Na]+, 100%), 586 
([M + H]+, 42%); HRMS (ESI +ve TOF)  calcd for C34H44N5O4 586.3393, found 586.3400 











Following General Procedure A, azide 26 (1.00 g, 
1.75 mmol), alkyne 21 (1.03 g, 3.50 mmol), 
Cu(OAc)2∙H2O (70 mg, 0.35 mmol) and sodium 
ascorbate (139 mg, 0.70 mmol) were stirred in 
t-BuOH (35 mL) and H2O (8.8 mL) for 20 h to give 
the product triazole 62b (1.24 g, 82%) as a white 
foam after flash chromatography over SiO2 gel 




 +18.3 (c 1.53, 
MeOH); 1H NMR (400 MHz, CDCl3) δ 7.32 – 7.15 (m, 10H, H5' and ArH), 7.04 – 6.96 (m, 
2H, ArH), 6.93 – 6.86 (m, 2H, ArH), 6.10 (br s, 2H, -NH2), 5.92 (br s, 1H, N
5-H), 5.81 (d, J 
= 8.2 Hz, 1H, N2-H), 5.04 (s, 2H, -OCH2-C4'), 4.99 (s, 2H, -CH2Ph), 4.30 (br s, 2H, H1), 
3.97 – 3.88 (m, 1H, H2), 3.84 (t, J = 6.6 Hz, 2H, H1''), 3.16 – 3.06 (m, 2H, H5), 2.90 (s, 2H, 
ArCH2-), 2.54 (s, 3H, ArCH3), 2.46 (s, 3H, ArCH3), 2.06 (s, 3H, ArCH3), 1.60 – 1.33 (m, 
13H, H3, H4, H2'', H3'' and -C(CH3)2), 0.77 (d, J = 6.6 Hz, 6H, H4'' and H5''); 
13C NMR (101 
MHz, CDCl3) δ 158.9 (Pbf CAr), 156.7 (CAr2'), 156.4 (C=O), 156.3 (C=N), 155.9 (CAr2), 
144.8 (C4'), 138.5 (Pbf CAr), 136.4 (Phenyl CAr), 132.9 (Pbf CAr), 132.4 (Pbf CAr), 131.9 
(CAr6 or CAr6'), 131.7 (CAr6 or CAr6'), 128.74 (CAr4 or CAr4'), 128.73 (CAr1), 128.66 
(Phenyl CAr)*, 128.6 (CAr1'), 128.3 (Phenyl CAr), 128.12 (CAr4 or CAr4'), 128.06 (Phenyl 
CAr)*, 124.8 (Pbf CAr), 124.1 (C5'), 121.33 (CAr5), 120.30 (CAr5'), 117.7 (Pbf CAr), 113.6 
(CAr3), 112.6 (CAr3'), 86.6 (-C(CH3)2), 67.2 (C1''), 66.9 (-CH2Ph), 63.3 (-OCH2-C4'), 53.2 
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(C1), 51.2 (C2), 43.3 (ArCH2-), 40.8 (C5), 38.0 (C2''), 28.9 (C3), 28.7 (-C(CH3)2), 25.5 (C4), 
25.1 (C3''), 22.6 (C4'' and C5''), 19.4 (ArCH3), 18.1 (ArCH3), 12.6 (ArCH3); IR (neat) ν̄max 
3336, 2955, 2927, 2873, 2312, 1715, 1700, 1617, 1559, 1540, 1507, 1457, 1340, 1241, 1154, 
1107, 1090, 1052, 1000, 902, 851, 806, 751, 734, 664, 642, 617 cm-1; MS (ESI +ve) m/z 888 
([M + Na]+, 100%), 866 ([M + H]+, 9%); HRMS (ESI +ve TOF) calcd for C47H59N7O7SNa 





To a reaction vessel charged with carbamate 62b (1.11 g, 
1.29 mmol), acetic acid (1.5 mL, 25.70 mmol) and 
palladium on charcoal (10% w/w – 205 mg, 0.19 mmol) 
was added MeOH (13.0 mL) under a flow of N2 gas. The 
reaction vessel was then sealed and degassed under high 
vacuum with magnetic stirring. N2 gas was allowed into the 
reaction vessel and the vessel was again degassed; this step was done twice. After the third 
degassing, the vacuum was maintained and a 2.0 L balloon of H2 gas was attached and 
allowed into reaction vessel. The reaction mixture was stirred vigorously at rt for 18 h under 
an atmosphere of H2 gas. After the reaction was shown to be complete by TLC analysis 
(EtOAc), the H2 source was removed, the reaction vessel was purged with N2 gas and Celite 
was added to the reaction mixture with vigorous magnetic stirring. The reaction mixture was 
vacuum filtered through a pad of fresh Celite atop a PTFE membrane, the solids were rinsed 
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thoroughly with MeOH (5 × 20 mL) and the combined filtrates were concentrated until nearly 
dry. The residue was dissolved in CH2Cl2 (100 mL) and washed successively with saturated 
aqueous NaHCO3 (3 × 50 mL), H2O (1 × 50 mL) and brine (1 × 50 mL). The organic phase 
was dried (Na2SO4), filtered and concentrated to afford the amine 63b (864 mg, 92%) as 





(c 4.27, MeOH); 1H NMR (400 MHz, CDCl3) δ 7.33 – 7.19 (m, 5H, H5' and ArH), 7.08 – 
6.97 (m, 2H, ArH), 6.96 – 6.89 (m, 2H, ArH), 6.29 – 6.13 (m, 3H, -NH/NH2 (guanidine)), 5.10 
(s, 2H, -OCH2-C4'), 4.22 (dd, J = 13.8, 4.2 Hz, 1H, H1A or H1B), 4.09 (dd, J = 13.8, 7.4 Hz, 
1H, H1B or H1A), 3.88 (t, J = 6.6 Hz, 2H, H1''), 3.14 (br s, 3H, H2 and H5), 2.92 (s, 2H, 
ArCH2-), 2.56 (s, 3H, ArCH3), 2.47 (s, 3H, ArCH3), 2.06 (s, 3H, ArCH3), 1.66 – 1.18 (m, 
13H, H3, H4, H2'', H3'' and -C(CH3)2), 0.78 (d, J = 6.6 Hz, 6H, H4'' and H5''); 
13C NMR (101 
MHz, CDCl3) δ 158.9 (Pbf CAr), 156.7 (CAr2'), 156.3 (C=N), 155.9 (CAr2), 145.0 (C4'), 
138.4 (Pbf CAr), 133.1 (Pbf CAr), 132.3 (Pbf CAr), 131.9 (CAr6 or CAr6'), 131.7 (CAr6' or 
CAr6), 128.8 (CAr1), 128.70 (CAr4 or CAr4'), 128.67 (CAr4' or CAr4), 128.2 (CAr1'), 124.8 
(Pbf CAr), 123.9 (C5'), 121.4 (CAr5), 120.3 (CAr5'), 117.6 (Pbf CAr), 113.5 (CAr3), 112.6 
(CAr3'), 86.5 (-C(CH3)2), 67.2 (C1''), 63.4 (-OCH2-C4'), 56.6 (C1), 51.3 (C2), 43.4 (ArCH2-
), 40.9 (C5), 38.1 (C2''), 31.4 (C3), 28.7 (-C(CH3)2), 25.6 (C4), 25.1 (C3'') 22.6 (C4'' and 
C5''), 19.4 (ArCH3), 18.1 (ArCH3), 12.6 (ArCH3); IR (neat) ν̄max 3337, 2956, 2870, 2358, 
2321, 1715, 1700, 1559, 1539, 1507, 1457, 1340, 1240, 1156, 1106, 1090, 1048, 906, 852, 
804, 783, 751, 734, 668, 639, 614 cm-1; MS (ESI +ve) m/z 754 ([M + Na]+, 100%), 732 ([M 






1,2,3-triazol-1-yl)pentan-2-yl)-2-phenylacetamide hydrochloride (65a) 
Following General Procedure B, amine 63b (50 mg, 
0.07 mmol), phenylacetic acid (11 mg, 0.08 mmol), 
EDCI (16 mg, 0.08 mmol) and HOBt (11 mg, 0.07 
mmol) were stirred in acetonitrile (0.7 mL) for 18 h to 
give the intermediate amide as a translucent tan gum. Following General Procedure C, the 
amide was dissolved in CH2Cl2 (2.0 mL) and treated with H2O (25 mg, 1.37 mmol) and 
CF3CO2H (2.0 mL) followed by work-up with ethereal HCl to give the amine salt 65a (36 





+28.2 (c 1.03, MeOH); 1H NMR (400 MHz, CD3OD) δ 7.48 (d, J = 8.0 Hz, 1H, H5'), 7.35 – 
7.08 (m, 10H, ArH), 7.05 – 6.86 (m, 3H, ArH), 5.01 (d, J = 4.0 Hz, 2H, -OCH2-C4'), 4.55 – 
4.14 (m, 3H, H1 and H2), 3.94 – 3.84 (m, 2H, H1''), 3.33 (s, 2H, -CH2Ph), 3.15 (br s, 2H, 
H6), 1.69 – 1.27 (m, 7H, H3, H4, H2'' and H3''), 0.80 (d, J = 6.6 Hz, 6H, H4'' and H5''); 13C 
NMR (101 MHz, CD3OD) δ 174.4 (C=O), 158.7 (C=N), 158.1 (CAr2'), 157.4 (CAr2), 144.1 
(C4' – observed by gHMBC), 136.8 (Phenyl CAr), 133.0 (CAr6 or CAr6'), 132.6 (CAr6 or 
CAr6'), 130.5 (CAr1), 130.3 (Phenyl CAr)*, 129.84 (CAr4 or CAr4'), 129.78 (Phenyl CAr)*, 
129.7 (CAr4 or CAr4' and CAr1'), 128.2 (Phenyl CAr), 125.9 (C5'), 122.4 (CAr5), 121.5 
(CAr5'), 114.7 (CAr3), 113.8 (CAr3'), 68.2 (C1''), 63.7 (-OCH2-C4'), 54.5 (C1), 50.7 (C2), 
44.1 (-CH2Ph), 42.1 (C5), 39.4 (C2''), 30.1 (C3), 26.4 (C4), 26.2 (C3''), 23.1 (C4'' and C5''); 
IR (neat) ν̄max 3336, 2957, 2873, 2362, 2327, 1715, 1700, 1653, 1559, 1540, 1507, 1457, 
1437, 1340, 1218, 1162, 1109, 1051, 1003, 914, 852, 751, 729, 668 cm-1; MS (ESI +ve) m/z 
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598 ([M + H]+, 100%), 620 ([M + Na]+, 21%); HRMS (ESI +ve TOF) calcd for C34H44N7O3 
598.3506, found 598.3510 ([M + H]+). 
 
(R)-N-(5-Guanidino-1-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2-yl)oxy)methyl)-1H-
1,2,3-triazol-1-yl)pentan-2-yl)-3-phenylpropanamide hydrochloride  (65b) 
Following General Procedure B, amine 63b (50 mg, 
0.07 mmol), 3-phenylpropanoic acid (12 mg, 0.08 
mmol), EDCI (16 mg, 0.08 mmol) and HOBt (11 mg, 
0.07 mmol) were stirred in acetonitrile (0.7 mL) for 
18 h to give the intermediate amide as a translucent tan gum. Following General Procedure 
C, the amide was dissolved in CH2Cl2 (2.0 mL) and treated with H2O (25 mg, 1.37 mmol) 
and CF3CO2H (2.0 mL) followed by work-up with ethereal HCl to give the amine salt 65b 





 +55.1 (c 0.53, MeOH); 1H NMR (400 MHz, CD3OD) δ 7.47 (d, J = 3.7 Hz, 1H), 7.34 – 
7.05 (m, 10H), 7.03 – 6.84 (m, 3H), 5.07 (d, J = 3.8 Hz, 2H), 4.45 – 4.08 (m, 3H), 3.93 – 
3.82 (m, 2H), 3.08 (br s, 2H), 2.84 – 2.74 (m, 2H), 2.44 – 2.28 (m, 2H), 1.63 – 1.22 (m, 7H), 
0.78 (d, J = 6.5 Hz, 6H); 13C NMR (101 MHz, CD3OD) δ 175.5, 158.7, 158.1, 157.5, 145.5, 
142.1, 133.0, 132.6, 130.5, 129.9, 129.74, 129.68*, 129.66**, 127.5, 125.9, 122.4, 121.5, 
114.7, 113.9, 113.8, 68.2, 63.7, 54.6, 50.5, 42.1, 39.4, 38.8, 32.8, 29.8, 26.3, 26.2, 23.1*; IR 
(neat) ν̄max 3330, 2955, 2873, 2331, 1684, 1653, 1559, 1539, 1507, 1457, 1219, 1162, 1109, 
1043, 1003, 913, 880, 852, 750, 698, 668 cm-1; MS (ESI +ve) m/z 612 ([M + H]+, 100%), 
634 ([M + Na]+, 14%); HRMS (ESI +ve TOF) calcd for C35H46N7O3 612.3662, found 




1,2,3-triazol-1-yl)pentan-2-yl)carbamate hydrochloride  (65c) 
Following General Procedure C, carbamate 62b 
(50 mg, 0.06 mmol) was dissolved in CH2Cl2 (1.9 
mL) and treated with H2O (18 mg, 1.00 mmol) and 
CF3CO2H (1.9 mL) followed by work-up with 
ethereal HCl to give the amine salt 65c (33 mg, 87%) as a light tan powder that rapidly 




 +82.0 (c 0.37, MeOH); 1H NMR (500 MHz, DMSO) δ 7.83 
(s, 1H), 7.53 (br s, 1H), 7.42 – 7.18 (m, 9H), 7.17 – 7.09 (m, 2H), 7.06 – 6.81 (m, 5H), 5.06 
(s, 2H), 4.95 (s, 2H), 4.41 (dd, J = 13.5, 4.3 Hz, 1H), 4.31 (dd, J = 13.5, 8.1 Hz, 1H), 3.92 – 
3.80 (m, 3H), 3.05 (br s, 2H), 1.61 – 1.21 (m, 7H), 0.78 (d, J = 6.6 Hz, 6H); 13C NMR (126 
MHz, DMSO) δ 156.6, 156.1, 155.8, 155.6, 142.9, 137.0, 131.3, 131.1, 128.5, 128.4, 128.3*, 
127.8, 127.5*, 127.4*, 124.4, 120.4, 119.9, 112.9, 112.3, 66.2, 65.2, 61.8, 52.6, 50.9, 40.4, 
37.5, 28.7, 25.0, 24.5, 22.4*; IR (neat) ν̄max 3337 3198, 2956, 2930, 2873, 2362, 2323, 1683, 
1653, 1559, 1539, 1507, 1457, 1340, 1212, 1162, 1109, 1040, 1003, 913, 852, 749, 697, 668 
cm-1; MS (ESI +ve) m/z 614 ([M + H]+, 100%), 636 ([M + Na]+, 8%); HRMS (ESI +ve TOF) 











Following General Procedure A, azide 27 (94 
mg, 0.17 mmol), alkyne 20 (138 mg, 0.35 mmol), 
Cu(OAc)2∙H2O (7 mg, 0.035 mmol) and sodium 
ascorbate (14 mg, 0.07 mmol) were stirred in 
t-BuOH (3.5 mL) and H2O (0.9 mL) at 45 °C for 
20 h to give the triazole 62d (153 mg, 94%) as a 
light tan gum after flash chromatography over 




 −6.5 (c 0.50, MeOH); 
1H NMR (400 MHz, CDCl3) δ 7.94 – 7.87 (m, 2H, ArH), 7.87 – 7.79 (m, 2H, ArH), 7.49 (d, 
J = 9.0 Hz, 1H, ArH), 7.39 (d, J = 9.0 Hz, 1H, ArH), 7.32 (t, J = 7.4 Hz, 1H, ArH), 7.29 – 
7.18 (m, 2H, ArH), 7.18 – 7.06 (m, 3H, ArH), 6.66 (s, 1H, H5'), 6.11 (br s, 2H, -NH2), 5.88 
(br s, 1H, N5-H), 5.16 (d, J = 8.5 Hz, 1H, N2-H), 5.08 (s, 2H, -OCH2-C4'), 4.23 – 4.06 (m, 
2H, H1), 4.01 – 3.92 (m, 1H, H1''A or H1''B), 3.90 – 3.82 (m, 1H, H1''B or H1''A), 3.77 (br s, 
1H, H2), 3.14 – 3.03 (m, 2H, H5), 2.91 (s, 2H, ArCH2-), 2.57 (s, 3H, ArCH3), 2.49 (s, 3H, 
ArCH3), 2.07 (s, 3H, ArCH3), 1.59 – 1.10 (m, 22H, H3, H4, H2'', H3'', -C(CH3)2 
and -C(CH3)3), 0.57 (d, J = 6.3 Hz, 3H, H4'' or H5''), 0.52 (d, J = 6.3 Hz, 3H, H5'' or H4''); 
13C NMR (101 MHz, CDCl3) δ 158.9 (Pbf CAr), 156.2 (C=N), 155.8 (C=O), 154.7 (CAr2'), 
153.9 (CAr2), 144.9 (C4'), 138.5 (Pbf CAr), 134.1 (CAr8a and CAr8a'), 133.1 (Pbf CAr), 132.4 
(Pbf CAr), 129.9 (CAr4a), 129.6 (CAr4), 129.5 (CAr4'), 129.3 (CAr4a'), 128.1 (CAr5), 128.0 
(CAr5'), 126.43 (CAr7), 126.39 (CAr7'), 125.7 (CAr8), 125.5 (CAr8'), 124.7 (Pbf CAr), 124.1 
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(CAr6), 124.0 (C5'), 123.7 (CAr6'), 121.5 (CAr1), 120.4 (CAr1'), 117.6 (Pbf CAr), 116.5 
(CAr3), 116.0 (CAr3'), 86.5 (-C(CH3)2), 80.0 (-C(CH3)3), 68.4 (C1''), 64.4 (-OCH2-C4'), 53.3 
(C1), 50.2 (C2), 43.4 (ArCH2-), 40.8 (C5), 38.2 (C2''), 29.1 (C3), 28.7 (-C(CH3)2), 28.4 
(-C(CH3)3), 25.4 (C4), 24.7 (C3''), 22.5 (C4'' or C5''), 22.2 (C5'' or C4''), 19.4 (ArCH3), 18.1 
(ArCH3), 12.6 (ArCH3); IR (neat) ν̄max 3345, 2967, 2930, 2873, 2537, 2331, 1700, 1683, 
1653, 1559, 1539, 1507, 1457, 1362, 1244, 1163, 1088, 1047, 1015, 904, 852, 807, 782, 748, 
668, 640, 618 cm-1; MS (ESI +ve) m/z 932 ([M + H]+, 100%), 954 ([M + Na]+, 90%); HRMS 






To a stirred solution of carbamate 62d (113 mg, 
0.12 mmol) in MeOH (1.2 mL) was added HCl (2.0 
M in Et2O – 1.2 mL, 2.40 mmol) and the resulting 
reaction mixture was stirred at room temperature 
for 18 h. The reaction mixture was concentrated, the 
residue was dissolved in CH2Cl2 (100 mL) and the 
organic solution was washed with saturated 
aqueous NaHCO3 (3 × 50 mL) and brine (1 × 50 mL). The organic phase was dried (Na2SO4), 
filtered and concentrated to afford the amine 63d (104 mg, 95%) as a light tan gum. TLC 




 +64.2 (c 0.37, MeOH); 1H NMR (400 MHz, 
CDCl3) δ 7.95 – 7.87 (m, 2H, ArH), 7.87 – 7.79 (m, 2H, ArH), 7.48 (d, J = 9.0 Hz, 1H, 
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HAr3), 7.39 (d, J = 9.0 Hz, 1H, HAr3'), 7.36 – 7.30 (m, 1H, ArH), 7.30 – 7.09 (m, 5H, ArH), 
6.58 (s, 1H, H5'), 6.24 (br s, 2H, -NH2), 6.18 (br s, 1H, N
5-H), 5.12 (s, 2H, -OCH2-C4'), 4.05 
– 3.82 (m, 4H, H1 and H1''), 3.10 (br s, 2H, H5), 2.94 (br s, 1H, H2), 2.89 (s, 2H, ArCH2-), 
2.57 (s, 3H, ArCH3), 2.48 (s, 3H, ArCH3), 2.07 (s, 3H, ArCH3), 1.61 – 1.46 (m, 2H, H3), 
1.41 (s, 6H, -C(CH3)2), 1.31 – 1.08 (m, 5H, H4, H2'' and H3''), 0.57 (d, J = 6.3 Hz, 3H, H4'' 
or H5''), 0.52 (d, J = 6.3 Hz, 3H, H5'' or H4''); 13C NMR (101 MHz, CDCl3) δ 158.9 (Pbf 
CAr), 156.3 (C=N), 154.8 (CAr2'), 153.9 (CAr2), 145.0 (C4'), 138.4 (Pbf CAr), 134.2 (CAr8a 
or CAr8a'), 134.1 (CAr8a' or CAr8a), 133.2 (Pbf CAr), 132.3 (Pbf CAr), 129.9 (CAr4a), 129.6 
(CAr4), 129.4 (CAr4'), 129.3 (CAr4a'), 128.0 (CAr5 and CAr5'), 126.4 (CAr7 and CAr7'), 
125.7 (CAr8), 125.5 (CAr8'), 124.8 (Pbf CAr), 124.1 (CAr6), 123.7 (CAr6' and C5'), 121.3 
(CAr1), 120.4 (CAr1'), 117.6 (Pbf CAr), 116.3 (CAr3), 116.0 (CAr3'), 86.5 (-C(CH3)2), 68.4 
(C1''), 64.5 (-OCH2-C4'), 56.5 (C1), 51.2 (C2), 43.3 (ArCH2-), 40.9 (C5), 38.2 (C2''), 31.3 
(C3), 28.7 (-C(CH3)2), 25.6 (C4), 24.7 (C3''), 22.5 (C4'' or C5''), 22.3 (C5'' or C4''), 19.4 
(ArCH3), 18.1 (ArCH3), 12.6 (ArCH3); IR (neat) ν̄max 3336, 2966, 2927, 2871, 2356, 2331, 
1700, 1653, 1617, 1559, 1539, 1507, 1457, 1340, 1261, 1243, 1146, 1087, 1046, 1016, 906, 
880, 852, 808, 783, 748, 668, 640 cm-1; MS (ESI +ve) m/z 854 ([M + Na]+, 100%), 832 ([M 










1H-1,2,3-triazol-1-yl)pentan-2-yl)-2-phenylacetamide hydrochloride (66a) 
Following General Procedure B, amine 63d 
(40 mg, 0.05 mmol), phenylacetic acid (8 mg, 
0.06 mmol), EDCI (11 mg, 0.06 mmol) and 
HOBt (8 mg, 0.06 mmol) were stirred in 
acetonitrile (1.0 mL) for 18 h to give the 
intermediate amide as a translucent tan gum. Following General Procedure C, the amide 
was dissolved in CH2Cl2 (1.5 mL) and treated with H2O (17 mg, 0.96 mmol) and CF3CO2H 
(1.5 mL) followed by work-up with ethereal HCl to give the amine salt 66a (30 mg, 86% 




 +38.0 (c 
0.77, MeOH); 1H NMR (400 MHz, DMSO) δ 8.11 (d, J = 8.4 Hz, 1H, N2-H), 8.07 – 7.99 (m, 
2H, ArH), 7.96 – 7.89 (m, 2H, ArH), 7.73 (d, J = 9.1 Hz, 1H, HAr3), 7.66 (t, J = 5.3 Hz, 1H, 
N5-H), 7.57 (d, J = 9.1 Hz, 1H, HAr3'), 7.41 (s, 1H, H5'), 7.36 – 7.27 (m, 2H, ArH), 7.24 – 
7.08 (m, 7H, ArH), 6.94 – 6.86 (m, 2H, ArH), 5.02 and 5.09 (ABq, 2H, J = 12.7 
Hz, -OCH2-C4'), 4.33 (dd, J = 13.8, 5.1 Hz, 1H, H1A or H1B), 4.24 (dd, J = 13.8, 7.5 Hz, 1H, 
H1B or H1A), 4.06 – 3.88 (m, 3H, H2 and H1''), 3.37 – 3.21 (m, 2H, -CH2Ph), 3.11 – 2.93 (m, 
2H, H5), 1.53 – 1.13 (m, 7H, H3, H4, H2'' and H3''), 0.57 (d, J = 6.3 Hz, 3H, H4'' or H5''), 
0.54 (d, J = 6.3 Hz, 3H, H5'' or H4''); 13C NMR (101 MHz, DMSO) δ 170.2 (C=O), 156.8 
(C=N), 154.2 (CAr2'), 153.7 (CAr2), 142.9 (C4'), 136.1 (Phenyl CAr), 133.42 (CAr8a or 
CAr8a'), 133.37 (CAr8a' or CAr8a), 129.3 (CAr4), 129.1 (CAr4'), 129.0 (CAr4a), 128.8 
(Phenyl CAr)*, 128.7 (CAr4a'), 128.1 (Phenyl CAr)*, 127.93 (CAr5 or CAr5'), 127.89 (CAr5' 
or CAr5), 126.24 (Phenyl CAr), 126.17 (CAr7 or CAr7'), 126.1 (CAr7' or CAr7), 124.7 
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(CAr8), 124.6 (CAr8'), 124.2 (C5'), 123.5 (CAr6), 123.3 (CAr6'), 119.8 (CAr1), 119.2 
(CAr1'), 116.2 (CAr3), 115.7 (CAr3'), 67.3 (C1''), 62.7 (-OCH2-C4'), 52.4 (C1), 48.6 (C2), 
42.3 (-CH2Ph), 40.1 (C5 – observed by gHMBC), 37.6 (C2''), 28.4 (C3), 24.9 (C4), 24.1 
(C3''), 22.2 (C4'' and C5''), 22.1 (C4'' and C5''); IR (neat) ν̄max 3172, 2954, 2873, 2363, 2331, 
1683, 1647, 1636, 1559, 1539, 1507, 1457, 1340, 1261, 1241, 1212, 1146, 1083, 1046, 1013, 
908, 865, 808, 746, 727, 694, 668, 625, 615, 609 cm-1; MS (ESI +ve) m/z 698 ([M + H]+, 
100%), 720 ([M + Na]+, 23%); HRMS (ESI +ve TOF) calcd for C42H48N7O3 698.3819, found 
698.3806 ([M + H]+). 
 
N-((R)-5-Guanidino-1-(4-((((S)-2'-(isopentyloxy)-[1,1'-binaphthalen]-2-yl)oxy)methyl)-
1H-1,2,3-triazol-1-yl)pentan-2-yl)-3-phenylpropanamide hydrochloride (66b) 
Following General Procedure B, amine 63d 
(40 mg, 0.05 mmol), 3-phenylpropanoic acid (9 
mg, 0.06 mmol), EDCI (11 mg, 0.06 mmol) and 
HOBt (8 mg, 0.06 mmol) were stirred in 
acetonitrile (1.0 mL) for 18 h to give the intermediate amide as a translucent tan gum. 
Following General Procedure C, the amide was dissolved in CH2Cl2 (1.5 mL) and treated 
with H2O (17 mg, 0.96 mmol) and CF3CO2H (1.5 mL) followed by work-up with ethereal 
HCl to give the amine salt 66b (32 mg, 89% over two steps) as a light tan powder that rapidly 




 +43.0 (c 0.67, MeOH); 1H NMR (400 MHz, CD3OD) 
δ 8.00 – 7.94 (m, 2H), 7.89 – 7.84 (m, 2H), 7.58 (d, J = 9.0 Hz, 1H), 7.48 (d, J = 9.0 Hz, 1H), 
7.33 – 7.25 (m, 2H), 7.21 – 7.06 (m, 7H), 7.03 (d, J = 8.5 Hz, 1H), 6.98 (d, J = 8.9 Hz, 1H), 
6.96 (s, 1H), 5.15 – 5.01 (m, 2H), 4.27 – 4.14 (m, 2H), 4.07 (br s, 1H), 4.03 – 3.96 (m, 1H), 
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3.93 – 3.85 (m, 1H), 3.11 – 2.97 (m, 2H), 2.77 (t, J = 7.5 Hz, 2H), 2.41 – 2.24 (m, 2H), 1.48 
– 1.11 (m, 7H), 0.56 (d, J = 6.4 Hz, 3H), 0.51 (d, J = 6.3 Hz, 3H); 13C NMR (101 MHz, 
CD3OD) δ 175.4, 158.7, 156.2, 155.5, 146.0 (observed by gHMBC), 142.1, 135.60, 135.58, 
131.5, 130.9, 130.8, 130.7, 129.7**, 129.3, 129.2, 127.5, 127.42, 127.39, 126.7, 126.4, 125.6, 
125.2, 124.8, 122.9, 121.5, 117.9, 117.0, 69.2, 64.9, 54.4, 50.4, 42.1, 39.5, 38.8, 32.8, 29.7, 
26.2, 25.8, 23.0, 22.7; IR (neat) ν̄max 3297, 2954, 2869, 2362, 2320, 1683, 1668, 1647, 1636, 
1559, 1539, 1507, 1457, 1340, 1269, 1213, 1150, 1084, 1044, 1016, 990, 953, 867, 807, 776, 
747, 703, 668 cm-1; MS (ESI +ve) m/z 712 ([M + H]+, 100%), 734 ([M + Na]+, 12%); HRMS 




yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)pentan-2-yl)carbamate hydrochloride (66c) 
Following General Procedure A, azide 26 
(310 mg, 0.54 mmol), alkyne 20 (428 mg, 1.08 
mmol), Cu(OAc)2∙H2O (22 mg, 0.11 mmol) and 
sodium ascorbate (43 mg, 0.22 mmol) were 
stirred in t-BuOH (10.8 mL) and H2O (2.7 mL) at 45 °C for 48 h to give the intermediate 
triazole (524 mg, 96%) as a light tan gum after flash chromatography over SiO2 gel 
(EtOAc/P.S. – 10:90  100:0). Following General Procedure C, the intermediate triazole 
(45 mg, 0.05 mmol) was dissolved in CH2Cl2 (1.4 mL) and treated with H2O (17 mg, 0.93 
mmol) and CF3CO2H (1.4 mL) followed by work-up with ethereal HCl to give the amine salt 





(c 0.70, MeOH); 1H NMR (400 MHz, CD3OD) δ 8.00 – 7.91 (m, 2H), 7.90 – 7.81 (m, 2H), 
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7.55 (d, J = 9.0 Hz, 1H), 7.45 (d, J = 9.0 Hz, 1H), 7.34 – 6.96 (m, 12H), 5.04 (s, 2H), 4.90 
(s, 2H), 4.31 (dd, J = 13.9, 4.9 Hz, 1H), 4.20 (dd, J = 13.9, 7.8 Hz, 1H), 4.03 – 3.92 (m, 1H), 
3.92 – 3.81 (m, 2H), 3.21 – 3.02 (m, 2H), 1.75 – 1.35 (m, 4H), 1.34 – 1.08 (m, 3H), 0.55 (d, 
J = 6.3 Hz, 3H), 0.51 (d, J = 6.3 Hz, 3H); 13C NMR (101 MHz, CD3OD) δ 158.7, 158.5, 
156.1, 155.4, 146.0 (observed by gHMBC) 138.3, 135.6, 135.5, 131.5, 130.9, 130.8, 130.7, 
129.7*, 129.3, 129.21, 129.17, 128.8*, 127.5, 127.4, 126.7, 126.4, 125.6, 125.2, 124.8, 122.9, 
121.5, 117.8, 117.0, 69.2, 67.6, 64.9, 54.8, 52.6, 42.1, 39.5, 30.1, 26.4, 25.8, 23.0, 22.7; IR 
(neat) ν̄max 3191, 2953, 2873, 2362, 2331, 1700, 1684, 1669, 1653, 1559, 1539, 1507, 1457, 
1340, 1260, 1212, 1146, 1083, 1044, 1016, 903, 860, 807, 774, 746, 697, 668 cm-1; MS (ESI 
+ve) m/z 714 ([M + H]+, 100%), 736 ([M + Na]+, 23%); HRMS (ESI +ve TOF) calcd for 
C42H48N7O4 714.3768, found 714.3799 ([M + H]
+). 
 




Following General Procedure B, amine 63a (300 
mg, 0.54 mmol), acid 28 (271 mg, 0.60 mmol), 
EDCI (125 mg, 0.65 mmol) and HOBt (88 mg, 0.60 
mmol) were stirred in acetonitrile (5.4 mL) for 48 h 
to give the amide 67a (479 mg, 89%) as a 
translucent tan gum after flash chromatography 
over SiO2 gel (EtOAc/P.S. – 30:70  80:20). TLC 
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(EtOAc/P.S. – 80:20): Rf  = 0.53; [α]
2
D
3 −14.7 (c 2.97, MeOH); 1H NMR (400 MHz, CDCl3) 
δ 7.48 (br s, 2H, H5' and N5-H), 7.33 – 7.19 (m, 4H, ArH), 7.09 (d, J = 8.0 Hz, 1H, ArH), 
7.05 – 6.92 (m, 3H, ArH), 6.26 (br s, 2H, -NH2 (guanidine)), 5.90 (br s, 1H, N
5'''-H), 5.11 (s, 
2H, -OCH2-C4'), 4.70 (br s, 1H, N
1-H), 4.49 – 4.32 (m, 3H, H5 and H6), 3.97 – 3.82 (m, 3H, 
H1'' and H2'''), 3.35 (br s, 1H, H5'''A or H5'''B), 3.06 (br s, 2H, H1), 2.95 (s, 2H, ArCH2-), 2.89 
(br s, 1H, H5'''B or H5'''A), 2.58 (s, 3H, ArCH3), 2.51 (s, 3H, ArCH3), 2.09 (s, 3H, ArCH3), 
1.63 – 1.19 (m, 28H, H2, H3, H4, H2'', H3'', H3''', H4''', -C(CH3)2, and -C(CH3)3), 0.80 (d, J 
= 6.5 Hz, 6H, H4'' and H5''); 13C NMR (101 MHz, CDCl3) δ 170.9 (C1'''), 159.0 (Pbf CAr), 
156.5 (C=N), 156.4 (CAr2'), 156.3 (C=O), 156.1 (CAr2), 144.6 (C4'), 138.4 (Pbf CAr), 132.7 
(Pbf CAr), 132.3 (Pbf CAr), 131.9 (CAr6 or CAr6'), 131.8 (CAr6' or CAr6), 128.9 (CAr4 and 
CAr4'), 128.4 (CAr1), 128.0 (CAr1'), 124.8 (Pbf CAr), 124.0 (C5'), 121.5 (CAr5), 120.5 
(CAr5'), 117.7 (Pbf CAr), 114.2 (CAr3), 112.8 (CAr3'), 86.6 (-C(CH3)2), 79.2 (-C(CH3)3), 
67.3 (C1''), 63.7 (-OCH2-C4'), 61.0 (C2'''), 53.7 (C6), 49.4 (C5), 43.4 (ArCH2-), 40.3 (C1), 
38.5 (C5'''), 38.0 (C2''), 31.6 (C4), 29.6 (C3'''), 28.7 (-C(CH3)2), 28.5 (-C(CH3)3), 27.6 (C2), 
25.6 (C4'''), 25.1 (C3''), 23.1 (C3), 22.6 (C4'' or C5''), 22.5 (C5'' or C4''), 19.5 (ArCH3), 18.1 
(ArCH3), 12.6 (ArCH3); IR (neat) ν̄max 3455, 3335, 2954, 2933, 2875, 2375, 2331, 2104, 
1689, 1653, 1559, 1540, 1512, 1457, 1437, 1368, 1243, 1162, 1107, 1091, 1053, 1031, 1003, 
903, 853, 807, 784, 751, 734, 663, 641, 617 cm-1; MS (ESI +ve) m/z 1009 ([M + Na]+, 100%), 
987 ([M + H]+, 17%); HRMS (ESI +ve TOF)  calcd for C50H72N11O8S 986.5286, found 






guanidinopentanamide dihydrochloride (68a) 
 
Following General Procedure A, azide 67a (50 mg, 0.05 mmol), 3-phenyl-1-propyne (18 
mg, 0.15 mmol), Cu(OAc)2∙H2O (2 mg, 0.01 mmol) and sodium ascorbate (4 mg, 0.02 mmol) 
were stirred in t-BuOH (1.0 mL) and H2O (0.25 mL) for 20 h to give the intermediate triazole 
as a light tan gum after flash chromatography over SiO2 gel (EtOAc/P.S. – 10:90  100:0). 
Following General Procedure C, the triazole was dissolved in CH2Cl2 (1.5 mL) and treated 
with H2O (18 mg, 1.00 mmol) and CF3CO2H (1.5 mL) followed by work-up with ethereal 
HCl to give the amine salt 68a (36 mg, 86% over two steps) as a light tan powder that rapidly 




 −44.2 (c 1.07, MeOH); 1H NMR (400 MHz, CD3OD) 
δ 7.86 (br s, 2H, H5' and Hα), 7.34 – 7.10 (m, 10H, ArH), 7.04 – 6.87 (m, 3H, ArH), 5.27 (br 
s, 1H, H2'''), 5.11 (s, 2H, -OCH2-C4'), 4.62 – 4.51 (m, 1H, H1A or H1B), 4.50 – 4.36 (m, 1H, 
H1B or H1A), 4.28 (br s, 1H, H2), 4.07 (s, 2H, -CH2Ph), 3.90 (t, J = 6.1 Hz, 2H, H1''), 3.07 
(br s, 2H, H5'''), 2.89 (br s, 2H, H6), 2.08 – 1.81 (m, 2H, H3'''), 1.74 – 1.17 (m, 11H, H3, H4, 
H5, H2'', H3'' and H4'''), 0.80 (d, J = 6.5 Hz, 6H, H4'' and H5''); 13C NMR (101 MHz, CD3OD) 
δ 169.8 (C1'''), 158.7 (C=N), 158.1 (CAr2'), 157.5 (CAr2), 148.4 (Cβ – observed by 
gHMBC), 145.7 (C4' – observed by gHMBC), 139.8 (Phenyl CAr), 133.1 (CAr6 or CAr6'), 
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132.6 (CAr6' or CAr6), 130.4 (CAr1), 130.0 (Phenyl CAr)*, 129.9 (Phenyl CAr* and CAr4 or 
CAr4'), 129.8 (CAr4' or CAr4), 129.7 (CAr1'), 128.0 (Phenyl CAr), 126.4 (C5' – observed by 
gHSQC/gHMBC), 124.5 (Cα – observed by gHSQC/gHMBC), 122.5 (CAr5), 121.5 (CAr5'), 
115.0 (CAr3), 113.9 (CAr3'), 68.3 (C1''), 65.1 (C2'''), 63.7 (-OCH2-C4'), 54.8 (C1), 51.4 (C2), 
41.6 (C5'''), 40.7 (C6), 39.4 (C2''), 32.4 (-CH2Ph), 32.3 (C3), 30.4 (C3'''), 28.2 (C5), 26.3 
(C3''), 26.1 (C4'''), 23.9 (C4), 23.1 (C4'' and C5''); IR (neat) ν̄max 3159, 3065, 2954, 2926, 
2868, 2379, 2314, 1734, 1700, 1684, 1653, 1636, 1559, 1540, 1521, 1507, 1473, 1457, 1437, 
1419, 1340, 1212, 1161, 1125, 1049, 1002, 853, 752, 731, 698, 668, 610 cm-1; MS (ESI +ve) 
m/2 376 ([M + 2H]2+, 100%), m/z 772 ([M + Na]+, 16%), 750 ([M + H]+, 14%); HRMS (ESI 





yl)pentanamide dihydrochloride (68b) 
 
Following General Procedure A, azide 67a (50 mg, 0.05 mmol), 4-phenyl-1-butyne (20 mg, 
0.15 mmol), Cu(OAc)2∙H2O (2 mg, 0.01 mmol) and sodium ascorbate (4 mg, 0.02 mmol) 
were stirred in t-BuOH (1.0 mL) and H2O (0.25 mL) for 20 h to give the intermediate triazole 
as a light tan gum after flash chromatography over SiO2 gel (MeOH/CH2Cl2. – 0:100  
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10:90). Following General Procedure C, the triazole was dissolved in CH2Cl2 (1.5 mL) and 
treated with H2O (18 mg, 1.00 mmol) and CF3CO2H (1.5 mL) followed by work-up with 
ethereal HCl to give the amine salt 68b (40 mg, 94% over two steps) as a light tan powder 




 −37.3 (c 1.03, MeOH); 1H NMR (400 MHz, 
CD3OD) δ 7.91 (s, 1H), 7.84 (s, 1H), 7.36 – 7.08 (m, 10H), 7.06 – 6.88 (m, 3H), 5.36 – 5.24 
(m, 1H), 5.12 (s, 2H), 4.62 – 4.54 (m, 1H), 4.44 (dd, J = 13.6, 8.9 Hz, 1H), 4.28 (br s, 1H), 
3.91 (t, J = 6.4 Hz, 2H), 3.15 – 2.93 (m, 6H), 2.89 (t, J = 7.1 Hz, 2H), 2.10 – 1.86 (m, 2H), 
1.73 – 1.19 (m, 11H), 0.80 (d, J = 6.6 Hz, 6H); 13C NMR (101 MHz, CD3OD) δ 169.5, 158.7, 
158.1, 157.5, 147.2 (observed by gHMBC), 145.6 (observed by gHMBC), 141.9, 133.1, 
132.6, 130.5, 129.9, 129.8, 129.74, 129.72**, 127.6, 126.3, 125.0, 122.5, 121.5, 115.0, 113.9, 
68.3, 65.4, 63.7, 54.7, 51.4, 41.6, 40.7, 39.4, 36.3, 32.2, 30.4, 28.2, 27.9, 26.3, 26.0, 23.9, 
23.1*; IR (neat) ν̄max 3159, 3065, 2954, 2928, 2868, 2379, 2350, 2314, 1734, 1718, 1700, 
1684, 1653, 1636, 1559, 1540, 1521, 1507, 1473, 1457, 1437, 1419, 1363, 1340, 1260, 1212, 
1161, 1124, 1109, 1049, 1002, 854, 751, 732, 700, 669, 609 cm-1; MS (ESI +ve) m/2 383 ([M 
+ 2H]2+, 100%), m/z 764 ([M + H]+, 12%), 786 ([M + Na]+, 9%); HRMS (ESI +ve TOF)  











yl)pentanamide dihydrochloride (68c) 
 
Following General Procedure A, azide 67a (50 mg, 0.05 mmol), cyclohexylacetylene (18 
mg, 0.15 mmol), Cu(OAc)2∙H2O (2 mg, 0.01 mmol) and sodium ascorbate (4 mg, 0.02 mmol) 
were stirred in t-BuOH (1.0 mL) and H2O (0.25 mL) for 20 h to give the intermediate triazole 
as a light tan gum after flash chromatography over SiO2 gel (MeOH/CH2Cl2. – 0:100  
10:90). Following General Procedure C, the triazole was dissolved in CH2Cl2 (1.5 mL) and 
treated with H2O (18 mg, 1.00 mmol) and CF3CO2H (1.5 mL) followed by work-up with 
ethereal HCl to give the amine salt 68c (38 mg, 92% over two steps) as a light tan powder 




 −27.2 (c 1.03, MeOH); 1H NMR (400 MHz, 
CD3OD) δ 8.11 (s, 1H), 7.85 (s, 1H), 7.37 – 7.23 (m, 2H), 7.23 – 7.12 (m, 3H), 7.07 – 6.88 
(m, 3H), 5.36 (t, J = 7.2 Hz, 1H), 5.13 (s, 2H), 4.59 (dd, J = 13.7, 3.3 Hz, 1H), 4.45 (dd, J = 
13.6, 8.8 Hz, 1H), 4.28 (br s, 1H), 3.92 (t, J = 6.3 Hz, 2H), 3.12 (t, J = 6.5 Hz, 2H), 2.90 (t, J 
= 6.8 Hz, 2H), 2.85 – 2.76 (m, 1H), 2.14 – 1.93 (m, 4H), 1.90 – 1.23 (m, 19H), 0.81 (d, J = 
6.6 Hz, 6H); 13C NMR (101 MHz, CD3OD) δ 169.3, 158.7, 158.2, 157.5, 153.0 (observed by 
gHMBC), 145.6 (observed by gHMBC), 133.1, 132.7, 130.5, 129.9, 129.8, 129.7, 126.3, 
124.1, 122.5, 121.5, 115.0, 113.9, 68.3, 65.8, 63.7, 54.7, 51.5, 41.7, 40.7, 39.4, 35.9, 33.70, 
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33.67, 32.2, 30.3, 28.2, 27.1*, 27.0, 26.3, 26.1, 23.9, 23.1*; IR (neat) ν̄max 3158, 3065, 2950, 
2928, 2870, 2380, 2349, 2312, 1734, 1718, 1700, 1684, 1653, 1636, 1559, 1540, 1521, 1507, 
1473, 1457, 1437, 1419, 1363, 1340, 1260, 1212, 1162, 1123, 1109, 1040, 1003, 855, 750, 
735, 701, 669, 608 cm-1; MS (ESI +ve) m/2 372 ([M + 2H]2+, 100%), m/z 742 ([M + H]+, 
11%), 764 ([M + Na]+, 8%); HRMS (ESI +ve TOF)  calcd for C40H60N11O3 742.4881, found 




yl)pentanamide dihydrochloride (68d) 
 
Following General Procedure A, azide 67a (50 mg, 0.05 mmol), 3-cyclohexyl-1-propyne 
(19 mg, 0.15 mmol), Cu(OAc)2∙H2O (2 mg, 0.01 mmol) and sodium ascorbate (4 mg, 0.02 
mmol) were stirred in t-BuOH (1.0 mL) and H2O (0.25 mL) for 20 h to give the intermediate 
triazole as a light tan gum after flash chromatography over SiO2 gel (MeOH/CH2Cl2. – 0:100 
 10:90). Following General Procedure C, the triazole was dissolved in CH2Cl2 (1.5 mL) 
and treated with H2O (18 mg, 1.00 mmol) and CF3CO2H (1.5 mL) followed by work-up with 
ethereal HCl to give the amine salt 68d (33 mg, 79% over two steps) as a light tan powder 




 −23.4 (c 0.80, MeOH); 1H NMR (400 MHz, 
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CD3OD) δ 7.93 (s, 1H), 7.84 (s, 1H), 7.36 – 7.24 (m, 2H), 7.23 – 7.13 (m, 3H), 7.06 – 6.91 
(m, 3H), 5.34 – 5.26 (m, 1H), 5.13 (s, 2H), 4.59 (dd, J = 13.9, 3.8 Hz, 1H), 4.44 (dd, J = 13.9, 
8.9 Hz, 1H), 4.27 (br s, 1H), 3.92 (t, J = 6.2 Hz, 2H), 3.10 (t, J = 6.8 Hz, 2H), 2.89 (t, J = 7.1 
Hz, 2H), 2.61 (d, J = 6.8 Hz, 2H), 2.11 – 1.89 (m, 2H), 1.77 – 1.13 (m, 20H), 1.04 – 0.91 (m, 
2H), 0.81 (d, J = 6.2 Hz, 6H); 13C NMR (101 MHz, CD3OD) δ 169.7, 158.7, 158.2, 157.5, 
147.0 (observed by gHMBC), 145.5 (observed by gHMBC), 133.1, 132.7, 130.5, 129.9, 
129.82, 129.76, 126.2, 124.8, 122.5, 121.5, 115.0, 113.9, 68.3, 65.2, 63.7, 54.7, 51.4, 41.7, 
40.7, 39.44, 39.41, 34.2*, 33.7, 32.3, 30.4, 28.2, 27.6, 27.4*, 26.3, 26.1, 23.9, 23.1*; IR (neat) 
ν̄max 3158, 3065, 2950, 2926, 2869, 2380, 2350, 2312, 1734, 1718, 1700, 1684, 1653, 1636, 
1559, 1540, 1521, 1507, 1473, 1457, 1437, 1419, 1363, 1340, 1260, 1213, 1161, 1125, 1109, 
1040, 1003, 855, 750, 735, 701, 669, 608 cm-1; MS (ESI +ve) m/2 379 ([M + 2H]2+, 100%), 
m/z 756 ([M + H]+, 19%), 778 ([M + Na]+, 16%); HRMS (ESI +ve TOF)  calcd for 

















Following General Procedure B, amine 63b 
(200 mg, 0.27 mmol), acid 24 (82 mg, 0.30 
mmol), EDCI (63 mg, 0.33 mmol) and HOBt (44 
mg, 0.30 mmol) were stirred in acetonitrile (2.7 
mL) for 18 h to give the product amide 67b (207 
mg, 77%) as a translucent tan gum after flash 
chromatography over SiO2 gel (MeOH/EtOAc – 
0.5:99.5). TLC (MeOH/EtOAc. – 0.5:99.5): Rf  = 





(c 0.70, MeOH); 1H NMR (400 MHz, CDCl3) δ 7.34 – 7.19 (m, 5H, H5' and ArH), 7.11 – 
6.97 (m, 3H, N2-H and ArH ), 6.98 – 6.90 (m, 2H, ArH), 6.20 (br s, 2H, -NH2), 5.94 (br s, 
1H, N5-H), 5.13 (s, 2H, -CH2-C4'), 4.72 (br s, 1H, N
1'''-H), 4.44 – 4.25 (m, 3H, H1 and H2), 
3.88 (t, J = 6.6 Hz, 2H, H1''), 3.83 (br s, 1H, H5'''), 3.27 – 2.99 (m, 4H, H5 and H1'''), 2.94 
(s, 2H, ArCH2-), 2.58 (s, 3H, ArCH3), 2.50 (s, 3H, ArCH3), 2.09 (s, 3H, ArCH3), 1.83 – 1.67 
(m, 2H, H4'''), 1.61 – 1.20 (m, 26H, H3, H4, H2'', H3'', H2''', H3''', -C(CH3)3 and -C(CH3)2), 
0.79 (d, J = 6.6 Hz, 6H, H4'' and H5''); 13C NMR (101 MHz, CDCl3) δ 170.0 (C6'''), 158.9 
(Pbf CAr), 156.7 (CAr2'), 156.5 (C=O), 156.3 (C=N), 155.9 (CAr2), 145.1 (C4'), 138.5 (Pbf 
CAr), 133.1 (Pbf CAr), 132.4 (Pbf CAr), 131.9 (CAr6 or CAr6'), 131.7 (CAr6' or CAr6), 128.8 
(CAr1), 128.7 (CAr4 or CAr4'), 128.6 (CAr4' or CAr4), 128.2 (CAr1'), 124.8 (Pbf CAr), 124.0 
205 
 
(C5'), 121.3 (CAr5), 120.3 (CAr5'), 117.7 (Pbf CAr), 113.5 (CAr3), 112.6 (CAr3'), 86.5 
(-C(CH3)2), 79.6 (-C(CH3)3), 67.2 (C1''), 63.4 (C5'''), 63.3 (-OCH2-C4'), 53.2 (C1), 49.0 (C2), 
43.4 (ArCH2-), 40.6 (C5), 40.4 (C1'''), 38.1 (C2''), 31.3 (C4'''), 29.8 (C3), 29.0 (C2'''), 28.7 
(-C(CH3)2), 28.6 (-C(CH3)3), 25.8 (C4), 25.1 (C3''), 22.6 (C4'' and C5''), 22.4 (C3'''), 19.4 
(ArCH3), 18.1 (ArCH3), 12.6 (ArCH3); IR (neat) ν̄max 3328, 2955, 2931, 2876, 2375, 2323, 
2104, 1700, 1684, 1653, 1559, 1540, 1507, 1457, 1437, 1419, 1340, 1241, 1164, 1106, 1091, 
1052, 1002, 854, 810, 782, 752, 734, 668, 640, 621 cm-1; MS (ESI +ve) m/z 1008 ([M + Na]+, 
100%), 986 ([M + H]+, 21%); HRMS (ESI +ve TOF) calcd for C50H72N11O8S 986.5286, 




yl)hexanamide dihydrochloride (69a) 
 
Following General Procedure A, azide 67b (45 mg, 0.05 mmol), 3-phenyl-1-propyne (18 
mg, 0.15 mmol), Cu(OAc)2∙H2O (2 mg, 0.01 mmol) and sodium ascorbate (4 mg, 0.02 mmol) 
were stirred in t-BuOH (1.0 mL) and H2O (0.25 mL) for 18 h to give the intermediate triazole 
as a light tan gum after flash chromatography over SiO2 gel (EtOAc/P.S. – 10:90  100:0). 
Following General Procedure C, the triazole was dissolved in CH2Cl2 (1.5 mL) and treated 
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with H2O (18 mg, 1.00 mmol) and CF3CO2H (1.5 mL) followed by work-up with ethereal 
HCl to give the amine salt 69a (37 mg, 97% over two steps) as a light tan powder that rapidly 




 +18.1 (c 1.00, MeOH); 1H NMR (400 MHz, CD3OD) δ 
7.82 (s, 1H, H5'), 7.80 (s, 1H, Hα), 7.34 – 7.11 (m, 10H, ArH), 7.03 – 6.89 (m, 3H, ArH), 
5.21 (br s, 1H, H2'''), 5.10 (s, 2H, -OCH2-C4'), 4.61 – 4.51 (m, 1H, H1A or H1B), 4.49 – 4.39 
(m, 1H, H1B or H1A), 4.30 (br s, 1H, H2), 4.05 (s, 2H, -CH2Ph), 3.90 (t, J = 6.0 Hz, 2H, H1''), 
3.14 (s, 2H, H5), 2.85 (s, 2H, H6'''), 2.02 – 1.77 (m, 2H, H3'''), 1.76 – 1.26 (m, 9H, H3, H4, 
H2'', H3'' and H5'''), 1.07 (s, 2H, H4'''), 0.80 (d, J = 6.5 Hz, 6H, H4'' and H5''); 13C NMR (101 
MHz, CD3OD) δ 170.1 (C1'''), 158.7 (C=N), 158.1 (CAr2'), 157.5 (CAr2), 148.4 (Cβ – 
observed by gHMBC), 145.7 (C4' – observed by gHMBC), 140.1 (Phenyl CAr), 133.1 (CAr6 
or CAr6'), 132.7 (CAr6' or CAr6), 130.4 (CAr1), 129.92 (Phenyl CAr)*, 129.89 (CAr4 or 
CAr4'), 129.86 (Phenyl CAr)*, 129.8 (CAr4' or CAr4), 129.7 (CAr1'), 127.9 (Phenyl CAr), 
126.2 (C5'), 124.0 (Cα), 122.4 (CAr5), 121.5 (CAr5'), 114.7 (CAr3), 113.9 (CAr3'), 68.2 
(C1''), 65.0 (C2'''), 63.6 (-CH2-C4'), 54.7 (C1), 51.1 (C2), 42.1 (C6'''), 40.5 (C5), 39.4 (C2''), 
32.61 (C3'''), 32.57 (-CH2Ph), 30.1 (C3), 27.8 (C5'''), 26.3 (C4), 26.2 (C3''), 23.5 (C4'''), 23.1 
(C4'' and C5''); IR (neat) ν̄max 3064, 2954, 2928, 2874, 2376, 2350, 2321, 1734, 1700, 1684, 
1653, 1623, 1559, 1540, 1507, 1490, 1457, 1437, 1419, 1340, 1218, 1164, 1109, 1087, 1049, 
1003, 855, 752, 729, 669, 621 cm-1; MS (ESI +ve) m/2 376 ([M + 2H]2+, 100%), m/z 750 ([M 
+ H]+, 32%), 772 ([M + Na]+, 8%); HRMS (ESI +ve TOF) calcd for C41H56N11O3 750.4568, 








yl)hexanamide dihydrochloride (69b) 
 
Following General Procedure A, azide 67b (45 mg, 0.05 mmol), 4-phenyl-1-butyne (20 
mg, 0.15 mmol), Cu(OAc)2∙H2O (2 mg, 0.01 mmol) and sodium ascorbate (4 mg, 0.02 mmol) 
were stirred in t-BuOH (1.0 mL) and H2O (0.25 mL) for 18 h to give the intermediate triazole 
as a light tan gum after flash chromatography over SiO2 gel (EtOAc/P.S. – 10:90  100:0). 
Following General Procedure C, the triazole was dissolved in CH2Cl2 (1.5 mL) and treated 
with H2O (18 mg, 1.00 mmol) and CF3CO2H (1.5 mL) followed by work-up with ethereal 
HCl to give the amine salt 69b (36 mg, 95% over two steps) as a light tan powder that rapidly 




 +19.4 (c 0.40, MeOH); 1H NMR (400 MHz, CD3OD) δ 
7.80 (s, 1H), 7.67 (s, 1H), 7.36 – 7.10 (m, 10H), 7.05 – 6.98 (m, 2H), 6.95 (t, J = 7.4 Hz, 1H), 
5.17 (t, J = 7.4 Hz, 1H), 5.12 (s, 2H), 4.57 (dd, J = 13.9, 3.7 Hz, 1H), 4.49 – 4.39 (m, 1H), 
4.30 (br s, 1H), 3.92 (t, J = 6.3 Hz, 2H), 3.23 – 3.07 (m, 2H), 3.04 – 2.91 (m, 4H), 2.90 – 
2.76 (m, 2H), 2.00 – 1.88 (m, 1H), 1.85 – 1.75 (m, 1H), 1.73 – 1.40 (m, 9H), 1.11 – 0.95 (m, 
2H), 0.81 (d, J = 6.6 Hz, 6H); 13C NMR (101 MHz, CD3OD) δ 170.2, 158.8, 158.2, 157.5, 
148.5 (observed by gHMBC), 145.9 (observed by gHMBC), 142.3, 133.1, 132.7, 130.4, 
129.9, 129.81, 129.76, 129.7*, 129.6*, 127.4, 126.1, 123.4, 122.4, 121.5, 114.8, 113.9, 68.2, 
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64.8, 63.6, 54.7, 51.1, 42.1, 40.5, 39.4, 36.6, 32.7, 30.1, 28.4, 27.8, 26.4, 26.3, 23.5, 23.1*; 
IR (neat) ν̄max 3164, 3065, 2953, 2927, 2874, 2375, 2322, 1734, 1700, 1684, 1653, 1623, 
1559, 1540, 1507, 1490, 1457, 1437, 1419, 1340, 1218, 1161, 1110, 1085, 1050, 1002, 855, 
750, 700, 668, 621 cm-1; MS (ESI +ve) m/2 383 ([M + 2H]2+, 100%), m/z 764 ([M + H]+, 
28%), 786 ([M + Na]+, 13%); HRMS (ESI +ve TOF) calcd for C42H58N11O3 764.4724, found 




yl)hexanamide dihydrochloride (69c) 
 
Following General Procedure A, azide 67b (45 mg, 0.05 mmol), cyclohexylacetylene (18 
mg, 0.15 mmol), Cu(OAc)2∙H2O (2 mg, 0.01 mmol) and sodium ascorbate (4 mg, 0.02 mmol) 
were stirred in t-BuOH (1.0 mL) and H2O (0.25 mL) for 18 h to give the intermediate triazole 
as a light tan gum after flash chromatography over SiO2 gel (EtOAc/P.S. – 10:90  100:0). 
Following General Procedure C, the triazole was dissolved in CH2Cl2 (1.5 mL) and treated 
with H2O (18 mg, 1.00 mmol) and CF3CO2H (1.5 mL) followed by work-up with ethereal 
HCl to give the amine salt 69c (31 mg, 84% over two steps) as a light tan powder that rapidly 




 +19.3 (c 0.60, MeOH); 1H NMR (400 MHz, CD3OD) 
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δ 7.94 (s, 1H), 7.82 (s, 1H), 7.36 – 7.24 (m, 2H), 7.24 – 7.12 (m, 3H), 7.07 – 6.91 (m, 3H), 
5.25 (t, J = 7.3 Hz, 1H), 5.12 (s, 2H), 4.63 – 4.52 (m, 1H), 4.51 – 4.40 (m, 1H), 4.31 (br s, 
1H), 3.99 – 3.84 (m, 2H), 3.24 – 3.07 (m, 2H), 2.87 (br s, 2H), 2.73 (br s, 1H), 2.09 – 1.21 
(m, 23H), 1.11 (br s, 2H), 0.81 (d, J = 6.6 Hz, 6H); 13C NMR (101 MHz, CD3OD) δ 169.9, 
158.8, 158.2, 157.5, 153.6 (observed by gHMBC), 145.7 (observed by gHMBC), 133.1, 
132.7, 130.4, 129.9, 129.8, 129.7, 126.2, 122.8, 122.4, 121.5, 114.8, 113.9, 68.2, 65.4, 63.6, 
54.7, 51.2, 42.1, 40.5, 39.4, 36.3, 33.94*, 33.91, 32.5, 30.1, 27.8, 27.3, 27.1, 26.4, 26.3, 23.6, 
23.1*; IR (neat) ν̄max 3329, 3164, 3065, 2954, 2928, 2874, 2375, 2322, 1734, 1700, 1684, 
1653, 1623, 1559, 1540, 1507, 1490, 1457, 1437, 1419, 1340, 1212, 1162, 1109, 1087, 1050, 
1003, 854, 750, 668, 622 cm-1; MS (ESI +ve) m/2 372 ([M + 2H]2+, 100%), m/z 742 ([M + 
H]+, 37%), 764 ([M + Na]+, 11%); HRMS (ESI +ve TOF) calcd for C40H59N11O3Na 
764.4700, found 764.4723 ([M + Na]+). 
 
(R)-6-Amino-2-azido-N-((R)-5-guanidino-1-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2-
yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)pentan-2-yl)hexanamide dihydrochloride (69d) 
 
Following General Procedure C, azide 67b (45 mg, 0.05 mmol) was dissolved in CH2Cl2 
(1.5 mL) and treated with H2O (18 mg, 1.00 mmol) and CF3CO2H (1.5 mL) followed by 
work-up with ethereal HCl to give the amine salt 69d (30 mg, 97%) as a light tan powder 
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 +43.4 (c 0.50, MeOH); 1H NMR (400 MHz, 
CDCl3) δ 7.75 (s, 1H), 7.34 – 7.23 (m, 2H), 7.22 – 7.12 (m, 3H), 7.05 – 6.90 (m, 3H), 5.10 
(s, 2H), 4.55 – 4.41 (m, 2H), 4.31 (br s, 1H), 3.91 (t, J = 6.4 Hz, 2H), 3.81 (t, J = 6.5 Hz, 1H), 
3.28 – 3.07 (m, 2H), 2.89 (br s, 2H), 1.77 – 1.50 (m, 9H), 1.50 – 1.41 (m, 2H), 1.27 (br s, 
2H), 0.80 (d, J = 6.6 Hz, 6H); 13C NMR (101 MHz, CD3OD) δ 172.9, 158.9, 158.2, 157.5, 
145.8 (observed by gHMBC), 133.0, 132.6, 130.5, 129.9, 129.8, 129.8, 126.0, 122.3, 121.5, 
114.8, 113.9, 68.2, 63.7, 63.4, 54.7, 51.1, 42.2, 40.5, 39.4, 31.9, 29.9, 27.7, 26.3, 26.3, 23.3, 
23.1*; IR (neat) ν̄max 3165, 3065, 2955, 2928, 2874, 2368, 2322, 2106, 1734, 1700, 1684, 
1653, 1623, 1559, 1540, 1507, 1490, 1457, 1437, 1419, 1340, 1216, 1161, 1106, 1088, 1051, 
1003, 855, 750, 668, 611 cm-1; MS (ESI +ve) m/2 318 ([M + 2H]2+, 100%), m/z 634 ([M + 
H]+, 64%), 656 ([M + Na]+, 23%); HRMS (ESI +ve TOF) calcd for C32H48N11O3 634.3942, 





Following General Procedure B, amine 
63c (65 mg, 0.10 mmol), acid 28 (54 mg, 
0.12 mmol), EDCI (23 mg, 0.12 mmol) and 
HOBt (18 mg, 0.11 mmol) were stirred in 
acetonitrile (1.0 mL) for 24 h to give the 
amide 67c (105 mg, 96%) as a translucent 







 −18.0 (c 0.40, MeOH); 1H NMR (400 MHz, CDCl3) δ 7.99 – 7.92 (m, 2H, ArH), 
7.90 – 7.84 (m, 2H, ArH), 7.53 (d, J = 9.0 Hz, 1H, HAr3), 7.45 (d, J = 9.0 Hz, 1H, HAr3'), 
7.38 – 7.29 (m, 2H, ArH), 7.25 – 7.16 (m, 3H, N5-H and ArH), 7.15 – 7.09 (m, 2H, ArH), 
7.06 (br s, 1H, H5'), 5.99 (br s, 2H, -NH2 (guanidine)), 5.08 (s, 2H, -OCH2-C4'), 4.63 (br s, 1H, 
N1-H), 4.37 – 4.23 (m, 3H, H5 and H6), 4.06 – 3.96 (m, 1H, H1''A or H1''B), 3.92 – 3.82 (m, 
1H, H1''B or H1''A), 3.81 – 3.74 (m, 1H, H2'''), 3.32 (br s, 1H, H5'''A or H5'''B), 3.09 (br s, 2H, 
H1), 2.95 (s, 2H, ArCH2-), 2.72 (br s, 1H, H5'''B or H5'''A), 2.55 (s, 3H, ArCH3), 2.49 (s, 3H, 
ArCH3), 2.08 (s, 3H, ArCH3), 1.57 – 1.03 (m, 28H, H2, H3, H4, H2'', H3'', H3''', 
H4''', -C(CH3)2 and -C(CH3)3), 0.58 (d, J = 6.4 Hz, 3H, H4'' or H5''), 0.51 (d, J = 6.3 Hz, 3H, 
H5'' or H4''); 13C NMR (101 MHz, CDCl3) δ 170.9 (C1'''), 159.0 (Pbf CAr), 156.2 (C=N), 
155.0 (Cα), 154.7 (CAr2'), 154.5 (CAr2), 144.5 (C4'), 138.4 (Pbf CAr), 134.1 (CAr8a or 
CAr8a'), 134.0 (CAr8a' or CAr8a), 132.8 (Pbf CAr), 132.4 (Pbf CAr), 130.2 (CAr4a), 130.0 
(CAr4), 129.7 (CAr4'), 129.3 (CAr4a'), 128.2 (CAr5), 128.1 (CAr5'), 126.7 (CAr7), 126.6 
(CAr7'), 125.7 (CAr8), 125.4 (CAr8'), 124.8 (Pbf CAr), 124.4 (CAr6), 124.0 (CAr6'), 123.8 
(C5' – observed by gHSQC), 121.5 (CAr1), 120.6 (CAr1'), 117.7 (Pbf CAr), 117.6 (CAr3), 
116.3 (CAr3'), 86.6 (-C(CH3)2), 79.0 (-C(CH3)3 – observed by gHMBC), 68.8 (C1''), 65.3 
(-OCH2-C4'), 60.8 (C2'''), 53.5 (C6), 49.3 (C5), 43.4 (C1), 40.3 (C5'''), 38.2 (C2''), 31.7 (C4), 
29.6 (C3'''), 28.7 (-C(CH3)2), 28.6 (-C(CH3)3), 27.3 (C2), 25.3 (C4'''), 24.7 (C3''), 23.1 (C3), 
22.5 (C4'' or C5''), 22.2 (C5'' or C4''), 19.5 (ArCH3), 18.1 (ArCH3), 12.6 (ArCH3); IR (neat) 
ν̄max 3320, 2955, 2927, 2868, 2108, 1688, 1617, 1559, 1540, 1507, 1458, 1366, 1244, 1164, 
1147, 1105, 1089, 1051, 1013, 903, 854, 808, 783, 748, 663, 640, 614 cm-1; MS (ESI +ve) 
m/z 413 (100%), 1108 ([M + Na]+, 20%), 1086 ([M + H]+, 13%); HRMS (ESI +ve TOF) 






guanidinopentanamide dihydrochloride (70a) 
 
Following General Procedure A, azide 67c (50 mg, 0.05 mmol), 4-phenyl-1-butyne (18 mg, 
0.14 mmol), Cu(OAc)2∙H2O (2 mg, 0.01 mmol) and sodium ascorbate (4 mg, 0.02 mmol) 
were stirred in t-BuOH (1.0 mL) and H2O (0.25 mL) for 18 h to give the intermediate triazole 
as a light tan gum after flash chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100  
10:90). Following General Procedure C, the triazole was dissolved in CH2Cl2 (1.5 mL) and 
treated with H2O (18 mg, 1.00 mmol) and CF3CO2H (1.5 mL) followed by work-up with 
ethereal HCl to give the amine salt 70a (25 mg, 58% over two steps) as a light tan powder 




 −65.4 (c 0.37, MeOH); 1H NMR (400 MHz, 
CD3OD) δ 8.05 – 7.96 (m, 2H, ArH), 7.93 – 7.86 (m, 2H, ArH), 7.66 – 7.60 (m, 2H, HAr3 
and Hα), 7.53 (d, J = 9.0 Hz, 1H, HAr3'), 7.39 (s, 1H, H5'), 7.37 – 7.27 (m, 2H, ArH), 7.27 
– 7.10 (m, 7H, ArH), 7.07 – 6.97 (m, 2H, ArH), 5.18 – 5.08 (m, 3H, H2''' and -OCH2-C4'), 
4.48 – 4.40 (m, 1H, H1A or H1B), 4.35 – 4.26 (m, 1H, H1B or H1A), 4.25 – 4.16 (m, 1H, H2), 
4.09 – 4.00 (m, 1H, H1''A or H1''B), 3.96 – 3.87 (m, 1H, H1''B or H1''A), 3.00 – 2.90 (m, 6H, 
H5''', Hγ and -CH2Ph ), 2.85 (t, J = 7.0 Hz, 2H, H6), 1.97 – 1.87 (m, 1H, H3A or H3B), 1.85 
– 1.03 (m, 12H, H3B or H3A, H4, H5, H3''', H4''', H2'' and H3''), 0.58 (d, J = 6.4 Hz, 3H, H4'' 
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or H5''), 0.52 (d, J = 6.4 Hz, 3H, H5'' or H4''); 13C NMR (101 MHz, CD3OD) δ 170.1 (C=O), 
158.7 (C=N), 156.2 (CAr2'), 155.7 (CAr2), 148.5 (Cβ), 145.9 (C4' - observed by gHMBC), 
142.4 (Phenyl CAr), 135.62 (CAr8a or CAr8a'), 135.57 (CAr8a' or CAr8a), 131.7 (CAr4a), 
131.0 (CAr4a'), 130.8 (CAr4 and CAr4'), 129.7 (Phenyl CAr)*, 129.6 (Phenyl CAr)*, 129.4 
(CAr5 or CAr5'), 129.2 (CAr5' or CAr5), 127.50 (CAr7), 127.46 (Phenyl CAr), 127.4 (CAr7'), 
126.7 (CAr8), 126.4 (CAr8'), 125.9 (Cα), 125.3 (CAr6), 124.8 (CAr6'), 123.2 (CAr1), 123.0 
(C5'), 121.5 (CAr1'), 118.3 (CAr3), 117.1 (CAr3'), 69.3 (C1''), 65.2 (-OCH2-C4'), 64.4 (C2'''), 
54.6 (C1), 51.1 (C2), 41.6 (C5'''), 40.6 (C6), 39.6 (C2''), 36.7 (Cγ), 32.2 (C3), 30.5 (C3'''), 
28.6 (-CH2Ph), 28.2 (C5), 26.0 (C4'''), 25.9 (C3''), 23.8 (C4), 23.0 (C4'' or C5''), 22.7 (C5'' or 
C4''); IR (neat) ν̄max 3318, 3155, 3061, 2952, 2928, 2868, 1669, 1653, 1617, 1591, 1559, 
1540, 1507, 1458, 1328, 1242, 1215, 1147, 1133, 1106, 1084, 1040, 1006, 905, 861, 808, 
748, 701, 680, 614 cm-1; MS (ESI +ve) m/2 433 ([M + 2H]2+, 100%), m/z 864 ([M + H]+, 














guanidinopentanamide dihydrochloride (70b) 
 
Following General Procedure A, azide 67c (50 mg, 0.05 mmol), 3-cyclohexyl-1-propyne 
(17 mg, 0.14 mmol), Cu(OAc)2∙H2O (2 mg, 0.01 mmol) and sodium ascorbate (4 mg, 0.02 
mmol) were stirred in t-BuOH (1.0 mL) and H2O (0.25 mL) for 18 h to give the intermediate 
triazole as a light tan gum after flash chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100 
 10:90). Following General Procedure C, the triazole was dissolved in CH2Cl2 (1.5 mL) 
and treated with H2O (18 mg, 1.00 mmol) and CF3CO2H (1.5 mL) followed by work-up with 
ethereal HCl to give the amine salt 70b (32 mg, 74% over two steps) as a light tan powder 
that rapidly transitioned to a sticky gum. [α]2D
3 −42.1 (c 0.37, MeOH); 1H NMR (400 MHz, 
CD3OD) δ 8.05 – 7.98 (m, 2H), 7.93 – 7.86 (m, 3H), 7.64 (d, J = 9.0 Hz, 1H), 7.53 (d, J = 
9.0 Hz, 1H), 7.44 (s, 1H), 7.38 – 7.27 (m, 2H), 7.24 – 7.12 (m, 2H), 7.04 (d, J = 8.5 Hz, 1H), 
7.00 (d, J = 8.5 Hz, 1H), 5.27 – 5.19 (m, 1H), 5.19 – 5.07 (m, 2H), 4.46 (dd, J = 13.8, 3.9 Hz, 
1H), 4.33 (dd, J = 13.6, 8.8 Hz, 1H), 4.28 – 4.17 (m, 1H), 4.11 – 4.00 (m, 1H), 3.97 – 3.85 
(m, 1H), 2.98 (t, J = 6.7 Hz, 2H), 2.87 (t, J = 6.8 Hz, 2H), 2.56 (d, J = 6.9 Hz, 2H), 2.03 – 
1.83 (m, 2H), 1.77 – 1.09 (m, 20H), 1.03 – 0.86 (m, 2H), 0.58 (d, J = 6.4 Hz, 3H), 0.52 (d, J 
= 6.4 Hz, 3H); 13C NMR (101 MHz, CD3OD) δ 169.7, 158.6, 156.2, 155.7, 147.1 (observed 
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by gHMBC), 145.9 (observed by gHMBC), 135.6, 135.6, 131.7, 130.9, 130.8*, 129.4, 129.2, 
127.5, 127.4, 126.7, 126.4, 126.1, 125.4, 124.8, 124.6, 123.2, 121.5, 118.4, 117.1, 69.3, 65.2, 
65.1, 54.6, 51.2, 41.6, 40.6, 39.6, 39.4, 34.2*, 33.7, 32.2, 30.5, 28.2, 27.6, 27.4*, 26.0, 25.9, 
23.8, 23.0, 22.7; IR (neat) ν̄max 3319, 3158, 3059, 2950, 2926, 2855, 1669, 1653, 1623, 1591, 
1559, 1540, 1507, 1458, 1328, 1242, 1213, 1147, 1133, 1106, 1084, 1040, 1007, 903, 861, 
808, 746, 613 cm-1; MS (ESI +ve) m/2 429 ([M + 2H]2+, 100%), m/z 856 ([M + H]+, 31%); 







Following General Procedure B, amine 63a (400 mg, 0.73 mmol), Fmoc-(D)-Arg(Pbf)-OH 
(61) (564 mg, 0.87 mmol), EDCI (166 mg, 0.87 mmol) and HOBt (118 mg, 0.79 mmol) were 
stirred in acetonitrile (7.2 mL) for 24 h to give the intermediate amide 72 (665 mg, 78%) as 
a translucent tan gum after flash chromatography over SiO2 gel (MeOH/EtOAc/P.S. – 
0:40:60  0.5:80:19.5). To a solution of the amide (250 mg, 0.21 mmol) in acetonitrile (2.1 
mL) was added tris-(2-aminoethyl)amine (155 mg, 1.06 mmol) and the reaction was stirred 
vigorously at rt for 90 min. The reaction mixture was diluted with CH2Cl2 (100 mL) and 
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washed successively with phosphate buffer (pH = 5.5) – (3 × 50 mL) and brine (1 × 50 mL). 
The organic phase was dried (Na2SO4), filtered, concentrated and the residue was subjected 
to flash chromatography over SiO2 gel (MeOH/CH2Cl2 – 5:95  10:90) to afford the 
intermediate amine 71 (151 mg, 74%). Following General Procedure B, the intermediate 
amine (53 mg, 0.06 mmol), phenylacetic acid (9 mg, 0.07 mmol), EDCI (13 mg, 0.07 mmol) 
and HOBt (9 mg, 0.06 mmol) were stirred in acetonitrile (0.6 mL) for 18 h to give the 
intermediate amide as a translucent tan gum. Following General Procedure C, the amide 
was dissolved in CH2Cl2 (1.7 mL) and treated with H2O (20 mg, 1.10 mmol) and CF3CO2H 
(1.7 mL) followed by work-up with ethereal HCl to give the amine salt 73 (27 mg, 61% over 




 −6.2 (c 0.57, 
MeOH); 1H NMR (400 MHz, CD3OD) δ 7.69 (s, 1H, H5'), 7.35 – 7.08 (m, 10H, ArH), 7.02 
– 6.86 (m, 3H, ArH), 5.05 (s, 2H, -OCH2-C4'), 4.48 – 4.30 (m, 2H, H1), 4.23 (s, 1H, H2), 
4.15 (br s, 1H, H2'''), 3.93 – 3.84 (m, 2H, H1''), 3.66 – 3.51 (m, 2H, -CH2Ph), 3.11 (br s, 2H, 
H6), 2.85 (br s, 2H, H5'''), 1.75 – 1.27 (m, 13H, H3, H4, H5, H2'', H3'', H3''' and H4'''), 0.79 
(d, J = 6.6 Hz, 6H, H4'' and H5''); 13C NMR (101 MHz, CD3OD) δ 174.9 (C1'''), 174.6 (Cα), 
158.8 (C=N), 158.1 (CAr2'), 157.5 (CAr2), 145.4 (C4'), 137.3 (Phenyl CAr), 133.0 (CAr6 or 
CAr6'), 132.7 (CAr6' or CAr6), 130.6 (Phenyl CAr)*, 130.4 (CAr1 and CAr1'), 129.83 (CAr4 
or CAr4'), 129.78 (Phenyl CAr)*, 129.7 (CAr4' or CAr4), 128.1 (Phenyl CAr), 126.3 (C5'), 
122.3 (CAr5), 121.5 (CAr5'), 114.8 (CAr3), 113.8 (CAr3'), 68.2 (C1''), 63.6 (-OCH2-C4'), 
55.2 (C2'''), 54.7 (C1), 51.1 (C2), 43.7 (-CH2Ph), 41.7 (C6), 40.5 (C5'''), 39.4 (C2''), 31.9 
(C3), 29.9 (C3'''), 28.1 (C5), 26.3 (C3''), 26.2 (C4'''), 23.6 (C4), 23.1 (C4'' and C5''); IR (neat) 
ν̄max 3069, 2955, 2931, 2869, 1663, 1540, 1506, 1473, 1438, 1386, 1260, 1203, 1089, 1053, 
1022, 800, 751, 721, 696, 616 cm-1; MS (ESI +ve) m/z 726 ([M + H]+, 100%), 748 ([M + 
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yl)carbamate dihydrochloride (74) 
 
Following General Procedure C, the intermediate amide 72 (50 mg, 0.04 mmol) was 
dissolved in CH2Cl2 (1.3 mL) and treated with H2O (15 mg, 0.85 mmol) and CF3CO2H (1.3 
mL) followed by work-up with ethereal HCl to give the amine salt 74 (36 mg, 95%) as a light 




 −4.4 (c 1.03, MeOH); 1H NMR 
(400 MHz, CD3OD) δ 7.82 – 7.51 (m, 5H), 7.42 – 7.08 (m, 9H), 7.04 – 6.83 (m, 3H), 5.05 
(s, 2H), 4.53 – 4.22 (m, 6H), 4.00 – 3.83 (m, 3H), 3.15 – 3.04 (m, 2H), 2.98 – 2.84 (m, 2H), 
1.75 – 1.25 (m, 13H), 0.79 (d, J = 6.6 Hz, 6H); 13C NMR (101 MHz, CDCl3) δ 175.0, 158.8, 
158.4, 158.1, 157.5, 147.7, 145.4, 141.3, 136.5*, 133.0, 132.7, 130.6, 130.5, 130.4, 129.84, 
129.76, 129.7, 126.0, 125.2*, 122.3, 122.0, 121.5*, 114.8, 113.8, 71.0, 68.2, 63.7, 56.2, 54.7, 
50.9, 48.5, 41.9, 40.7, 39.4, 32.1, 30.2, 28.1, 26.3, 26.2, 23.7, 23.1*; IR (neat) ν̄max 3168, 
3067, 2956, 2932, 2871, 1714, 1664, 1526, 1506, 1473, 1438, 1386, 1227, 1150, 1091, 1052, 
976, 917, 859, 737, 615 cm-1; MS (ESI +ve) m/2 416 ([M + 2H]2+, 100%), m/z 852 ([M + 
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Na]+, 8%); HRMS (ESI +ve TOF)  calcd for C47H60N9O5 830.4717, found 830.4747 ([M + 
H]+). 
 
6.3.4 – Series B1 
 (R)-6-((Tert-butoxycarbonyl)amino)-2-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2-
yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)hexanoic acid (75a) 
Following General Procedure A, azide 24 (400 mg, 1.47 
mmol), alkyne 21 (865 mg, 2.94 mmol), Cu(OAc)2∙H2O (59 
mg, 0.29 mmol) and sodium ascorbate (116 mg, 0.59 mmol) 
were stirred in t-BuOH (29.4 mL) and H2O (7.4 mL) for 26 
h to give the product triazole 75a (703 mg, 85%) as a 
translucent tan gum after flash chromatography over SiO2 
gel (EtOAc/P.S. – 10:90  MeOH/CH2Cl2 – 10:90). TLC 




 +5.0 (c 1.27, MeOH); 1H NMR (400 MHz, DMSO) 
δ 7.89 (s, 1H, H5'), 7.35 – 7.20 (m, 3H, ArH), 7.20 – 7.11 (m, 2H, ArH), 7.05 – 6.88 (m, 3H, 
ArH), 6.73 (br s, 1H, N6-H), 5.19 (br s, 1H, H2), 5.09 (s, 2H, -OCH2-C4'), 3.94 – 3.83 (m, 
2H, H1''), 2.89 – 2.77 (m, 2H, H6), 2.19 – 1.92 (m, 2H, H3), 1.61 – 1.50 (m, 1H, H3''), 1.47 
– 1.26 (m, 13H, H5, H2'' and -C(CH3)3), 1.19 – 1.07 (m, 1H, H4A or H4B), 1.01 – 0.88 (m, 
1H, H4B or H4A), 0.78 (d, J = 6.6 Hz, 6H, H4'' and H5''); 
13C NMR (101 MHz, DMSO) 
δ 156.1 (CAr2'), 155.7 (CAr2), 155.6 (C1), 155.5 (Cα), 142.9 (C4'), 131.13 (CAr6 or CAr6'), 
131.07 (CAr6' or CAr6), 128.4 (CAr4 or CAr4'), 128.3 (CAr4' or CAr4), 127.9 (CAr1), 127.4 
(CAr1'), 123.3 (C5'), 120.4 (CAr5), 119.8 (CAr5'), 113.0 (CAr3), 112.2 (CAr3'), 77.3 
(-C(CH3)3), 66.2 (C1''), 63.0 (C2 – observed by gHSQC), 62.2 (-OCH2-C4'), 39.4 (C6 – 
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observed by gHSQC), 37.4 (C2''), 31.4 (C3), 28.8 (C5), 28.2 (-C(CH3)3), 24.4 (C3''), 22.8 
(C4), 22.3 (C4'' and C5''); IR (neat) ν̄max 3345, 2956, 2932, 2869, 2362, 2341, 1734, 1718, 
1700, 1684, 1653, 1636, 1594, 1577, 1559, 1540, 1507, 1473, 1457, 1437, 1395, 1367, 1340, 
1260, 1238, 1165, 1124, 1109, 1052, 1003, 982, 931, 855, 810, 751, 734 cm-1; MS (ESI −ve) 
m/z 565 ([M − H]−, 100%); HRMS (ESI +ve TOF) calcd for C31H42N4O6Na 589.3002, found 
589.2993 ([M + Na]+). 
 
(R)-6-Amino-N-benzyl-2-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2-yl)oxy)methyl)-1H-
1,2,3-triazol-1-yl)hexanamide hydrochloride (76a) 
Following General Procedure B, acid 75a (50 mg, 0.09 
mmol), benzylamine (11 mg, 0.11 mmol), EDCI (20 mg, 
0.11 mmol) and HOBt (14 mg, 0.11 mmol) were stirred 
in acetonitrile (0.9 mL) for 24 h to give the intermediate 
amide as a translucent tan gum. Following General 
Procedure D, the amide was dissolved in CH2Cl2 (2.7 mL) and treated with CF3CO2H (2.7 
mL) followed by work-up with ethereal HCl to give the amine salt 76a (56 mg, 95% over 




 +7.0 (c 1.33, 
MeOH); 1H NMR (400 MHz, CD3OD) δ 7.75 (s, 1H, H5'), 7.34 – 7.10 (m, 10H, ArH), 7.05 
– 6.97 (m, 2H, ArH), 6.94 (t, J = 7.1 Hz, 1H, ArH), 5.29 (t, J = 7.6 Hz, 1H, H2), 5.15 – 5.04 
(m, 2H, -OCH2-C4'), 4.37 (s, 2H, -CH2Ph), 3.95 – 3.83 (m, 2H, H1''), 2.83 (t, J = 6.8 Hz, 2H, 
H6), 2.23 – 2.01 (m, 2H, H3), 1.72 – 1.50 (m, 3H, H5 and H3''), 1.46 – 1.38 (m, 2H, H2''), 
1.34 – 1.11 (m, 2H, H4), 0.77 (d, J = 6.6 Hz, 6H, H4'' and H5''); 13C NMR (101 MHz, CD3OD) 
δ 169.8 (C1), 158.2 (CAr2'), 157.6 (CAr2), 146.3 (C4'), 139.5 (Phenyl CAr), 132.8 (CAr6 or 
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CAr6'), 132.5 (CAr6' or CAr6), 130.7 (CAr1 and CAr1'), 129.9 (CAr4 or CAr4'), 129.84 
(Phenyl CAr)*, 129.76 (CAr4' or CAr4), 128.8 (Phenyl CAr)*, 128.7 (Phenyl CAr), 124.1 (C5'), 
122.5 (CAr5), 121.5 (CAr5'), 114.7 (CAr3), 113.7 (CAr3'), 68.2 (C1''), 64.9 (C2), 64.1 
(-OCH2-C4'), 44.6 (-CH2Ph), 40.5 (C6), 39.4 (C2''), 33.3 (C3), 28.0 (C5), 26.2 (C3''), 23.8 
(C4), 23.10 (C4'' or C5''), 23.07 (C5'' or C4''); IR (neat) ν̄max 3276, 3065, 2954, 2934, 2870, 
2364, 2318, 1718, 1684, 1669, 1653, 1636, 1594, 1576, 1559, 1540, 1507, 1473, 1457, 1437, 
1395, 1340, 1260, 1202, 1180, 1130, 1110, 1052, 1003, 982, 932, 836, 799, 751, 721, 698, 
615 cm-1; MS (ESI +ve) m/z 578 ([M + Na]+, 100%), 556 ([M + H]
+, 91%); HRMS (ESI +ve 




triazol-1-yl)-N-phenethylhexanamide hydrochloride (76b) 
Following General Procedure B, acid 75a (50 mg, 
0.09 mmol), β-phenylethylamine (13 mg, 0.11 mmol), 
EDCI (20 mg, 0.11 mmol) and HOBt (14 mg, 0.11 
mmol) were stirred in acetonitrile (0.9 mL) for 24 h to 
give the intermediate amide as a translucent tan gum. 
Following General Procedure D, the amide was dissolved in CH2Cl2 (2.7 mL) and treated 
with CF3CO2H (2.7 mL) followed by work-up with ethereal HCl to give the amine salt 76b 





 +7.9 (c 1.20, MeOH); 1H NMR (400 MHz, CD3OD) δ 7.72 (s, 1H), 7.35 – 7.08 (m, 
10H), 7.01 (t, J = 7.5 Hz, 2H), 6.94 (t, J = 7.4 Hz, 1H), 5.21 (t, J = 7.6 Hz, 1H), 5.14 – 5.06 
(m, 2H), 3.95 – 3.84 (m, 2H), 3.45 (t, J = 7.0 Hz, 2H), 2.83 (t, J = 7.2 Hz, 2H), 2.78 (t, J = 
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7.1 Hz, 2H), 2.15 – 1.94 (m, 2H), 1.70 – 1.50 (m, 3H), 1.47 – 1.38 (m, 2H), 1.29 – 1.10 (m, 
2H), 0.78 (d, J = 6.6 Hz, 6H); 13C NMR (101 MHz, CD3OD) δ 169.7, 158.2, 157.5, 146.1, 
140.3, 132.8, 132.6, 130.6, 130.0*, 129.9, 129.82, 129.76, 129.7*, 127.6, 124.2, 122.5, 121.5, 
114.7, 113.7, 68.2, 65.0, 64.0, 42.2, 40.5, 39.4, 36.3, 33.2, 28.0, 26.2, 23.7, 23.11, 23.09; IR 
(neat) ν̄max 3242, 3065, 2954, 2934, 2869, 2363, 1684, 1670, 1594, 1555, 1502, 1474, 1438, 
1385, 1367, 1261, 1219, 1161, 1123, 1110, 1052, 1002, 933, 852, 799, 749, 700, 616 cm-1; 
MS (ESI +ve) m/z 570 ([M + H]+, 100%), 592 ([M + Na]+, 82%); HRMS (ESI +ve TOF) 




1H-1,2,3-triazol-1-yl)hexanamide hydrochloride (76c) 
Following General Procedure B, acid 75a (50 mg, 0.09 
mmol), cyclohexylamine (11 mg, 0.11 mmol), EDCI (20 
mg, 0.11 mmol) and HOBt (14 mg, 0.11 mmol) were stirred 
in acetonitrile (0.9 mL) for 24 h to give the intermediate 
amide as a translucent tan gum. Following General 
Procedure D, the amide was dissolved in CH2Cl2 (2.7 mL) and treated with CF3CO2H (2.7 
mL) followed by work-up with ethereal HCl to give the amine salt 76c (48 mg, 94% over 




 +5.7 (c 1.37, 
MeOH); 1H NMR (400 MHz, CD3OD) δ 7.75 (s, 1H), 7.34 – 7.25 (m, 2H), 7.21 – 7.10 (m, 
3H), 7.06 – 6.98 (m, 2H), 6.95 (t, J = 7.4 Hz, 1H), 5.26 (t, J = 7.6 Hz, 1H), 5.14 – 5.04 (m, 
2H), 3.98 – 3.84 (m, 2H), 3.68 – 3.56 (m, 1H), 2.87 (t, J = 6.6 Hz, 2H), 2.19 – 1.98 (m, 2H), 
1.92 – 1.50 (m, 7H), 1.47 – 1.11 (m, 10H), 0.78 (d, J = 6.6 Hz, 6H); 13C NMR (101 MHz, 
222 
 
CD3OD) δ 168.9, 158.2, 157.5, 146.2, 132.7, 132.5, 130.6*, 129.8, 129.7, 123.9, 122.4, 
121.5, 114.7, 113.7, 68.2, 64.9, 64.1, 50.4, 40.5, 39.4, 33.8, 33.6, 33.5, 28.1, 26.7, 26.24, 
26.20, 26.17, 23.8, 23.11, 23.08; IR (neat) ν̄max 3265, 3065, 2934, 2855, 2371, 1680, 1665, 
1545, 1507, 1472, 1441, 1339, 1261, 1219, 1160, 1023, 892, 854, 805, 750, 616 cm-1; MS 
(ESI +ve) m/z 548 ([M + H]+, 100%), 570 ([M + Na]+, 73%); HRMS (ESI +ve TOF) calcd 




yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)hexanamide hydrochloride (76d) 
Following General Procedure B, acid 75a (50 mg, 0.09 
mmol), cyclohexylmethylamine (12 mg, 0.11 mmol), 
EDCI (20 mg, 0.11 mmol) and HOBt (14 mg, 0.11 
mmol) were stirred in acetonitrile (0.9 mL) for 24 h to 
give the intermediate amide as a translucent tan gum. 
Following General Procedure D, the amide was dissolved in CH2Cl2 (2.7 mL) and treated 
with CF3CO2H (2.7 mL) followed by work-up with ethereal HCl to give the amine salt 76d 





 +4.5 (c 1.00, MeOH); 1H NMR (400 MHz, CD3OD) δ 7.75 (s, 1H), 7.35 – 7.25 (m, 2H), 
7.22 – 7.10 (m, 3H), 7.01 (t, J = 7.0 Hz, 2H), 6.95 (t, J = 7.4 Hz, 1H), 5.29 (t, J = 7.6 Hz, 
1H), 5.15 – 5.05 (m, 2H), 3.97 – 3.85 (m, 2H), 3.04 (dd, J = 6.7, 2.6 Hz, 2H), 2.93 – 2.79 (m, 
2H), 2.21 – 2.00 (m, 2H), 1.76 – 1.40 (m, 10H), 1.35 – 1.10 (m, 6H), 0.97 – 0.83 (m, 2H), 
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0.78 (d, J = 6.6 Hz, 6H); 13C NMR (101 MHz, CD3OD) δ 170.1
‡, 158.2, 157.6, 146.2, 132.7, 
132.6, 130.7*, 129.9, 129.8, 124.0, 122.5, 121.5, 114.7, 113.7, 68.2, 65.0‡, 64.1, 47.2‡, 40.5, 
39.4, 39.2, 33.3, 32.08, 32.05, 28.1, 27.7, 27.1*, 26.3, 23.9, 23.12, 23.08; IR (neat) ν̄max 3241, 
3068, 2954, 2925, 2868, 2856, 2362, 1684, 1669, 1594, 1555, 1503, 1474, 1441, 1386, 1368, 
1261, 1223, 1161, 1123, 1109, 1052, 1019, 982, 932, 851, 799, 750, 615 cm-1; MS (ESI +ve) 
m/z 584 ([M + Na]+, 100%), 562 ([M + H]+, 81%); HRMS (ESI +ve TOF) calcd for 




triazol-1-yl)-N-(4-(trifluoromethyl)benzyl)hexanamide hydrochloride (76e) 
Following General Procedure B, acid 75a (50 mg, 
0.09 mmol), 4-(trifluoromethyl)benzylamine (19 
mg, 0.11 mmol), EDCI (20 mg, 0.11 mmol) and 
HOBt (14 mg, 0.11 mmol) were stirred in 
acetonitrile (0.9 mL) for 24 h to give the 
intermediate amide as a translucent tan gum. Following General Procedure D, the amide 
was dissolved in CH2Cl2 (2.7 mL) and treated with CF3CO2H (2.7 mL) followed by work-up 
with ethereal HCl to give the amine salt 76e (56 mg, 97% over two steps) as a light tan 




 +14.2 (c 1.50, MeOH); 1H NMR (400 
                                                 
‡ Indicates that the 13C NMR resonance was split into two resonances due to the presence of both amide 
rotamers (i.e. the syn- and anti-amide conformations); only the major resonance from each resonance pair is 




MHz, CD3OD) δ 7.79 (s, 1H), 7.59 (d, J = 8.0 Hz, 2H), 7.42 (d, J = 8.0 Hz, 2H), 7.34 – 7.22 
(m, 2H), 7.21 – 7.10 (m, 3H), 7.04 – 6.97 (m, 2H), 6.93 (t, J = 7.3 Hz, 1H), 5.37 (t, J = 7.4 
Hz, 1H), 5.16 – 5.04 (m, 2H), 4.52 – 4.40 (m, 2H), 3.95 – 3.82 (m, 2H), 2.86 (br s, 2H), 2.28 
– 2.04 (m, 2H), 1.75 – 1.61 (m, 2H), 1.61 – 1.48 (m, 1H), 1.46 – 1.37 (m, 2H), 1.36 – 1.11 
(m, 2H), 0.76 (d, J = 6.6 Hz, 6H); 13C NMR (101 MHz, CD3OD) δ 170.1, 158.2, 157.5, 146.3, 
144.2, 132.8, 132.5, 130.9 (q, 2JCF = 32.2 Hz)
†, 130.6, 129.9, 129.82, 129.75, 129.3*, 126.7 
(q, 3JCF = 3.8 Hz)*, 126.6, 124.5 (q, 
1JCF = 270.5 Hz)
†, 124.3, 122.5, 121.5, 114.7, 113.7, 
68.2, 64.9, 64.0, 44.0, 40.5, 39.4, 33.2, 28.0, 26.2, 23.8, 23.08, 23.05; IR (neat) ν̄max 3242, 
3067, 2955, 2928, 2869, 2361, 1684, 1620, 1594, 1555, 1504, 1474, 1441, 1420, 1387, 1324, 
1261, 1223, 1164, 1122, 1112, 1067, 1018, 849, 819, 751, 615 cm-1; MS (ESI +ve) m/z 624 
([M + H]+, 100%), 646 ([M + Na]+, 98%); HRMS (ESI +ve TOF) calcd for C34H41N5O3F3 






                                                 
† Incomplete multiplet resonance: the two 13C NMR quartet resonances (assigned to the carbons closest to the 
fluorine atoms (i.e. -CF3 and C-CF3)) were each missing one of their outer quartet peaks due to the strong JCF 
coupling that spread the weak quaternary signals over multiple lines (as quartets) – thus, the signals became 
even weaker and buried amongst the background noise. Furthermore, quaternary carbons do not experience 
the large Overhauser enhancement by proton decoupling that is experienced by protonated carbons, hence the 





yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)hexanamide hydrochloride (76f) 
Following General Procedure B, acid 75a (50 mg, 
0.09 mmol), 2-(4-fluorophenyl)ethylamine (15 mg, 
0.11 mmol), EDCI (20 mg, 0.11 mmol) and HOBt 
(14 mg, 0.11 mmol) were stirred in acetonitrile (0.9 
mL) for 24 h to give the intermediate amide as a 
translucent tan gum. Following General Procedure D, the amide was dissolved in CH2Cl2 
(2.7 mL) and treated with CF3CO2H (2.7 mL) followed by work-up with ethereal HCl to give 
the amine salt 76f (51 mg, 93% over two steps) as a light tan powder that rapidly transitioned 




 +10.8 (c 1.23, MeOH); 1H NMR (400 MHz, CD3OD) δ 7.70 (s, 1H), 
7.34 – 7.23 (m, 2H), 7.21 – 7.06 (m, 5H), 7.05 – 6.88 (m, 5H), 5.20 (t, J = 7.6 Hz, 1H), 5.14 
– 5.05 (m, 2H), 3.95 – 3.84 (m, 2H), 3.50 – 3.33 (m, 2H), 2.84 (t, J = 6.6 Hz, 2H), 2.76 (t, J 
= 6.9 Hz, 2H), 2.14 – 1.94 (m, 2H), 1.71 – 1.50 (m, 3H), 1.47 – 1.39 (m, 2H), 1.28 – 1.09 
(m, 2H), 0.78 (d, J = 6.6 Hz, 6H); 13C NMR (101 MHz, CD3OD) δ 169.8, 163.2 (d, 
1JCF = 
242.8 Hz), 158.2, 157.5, 146.2, 136.2 (d, 4JCF = 3.2 Hz), 132.8, 132.6, 131.7 (d, 
3JCF = 7.9 
Hz), 130.6*, 129.9, 129.8, 124.0, 122.4, 121.5, 116.2 (d, 2JCF = 21.4 Hz), 114.7, 113.7, 68.2, 
64.9, 64.0, 42.1, 40.5, 39.4, 35.4, 33.2, 28.0, 26.2, 23.8, 23.10, 23.08; IR (neat) ν̄max 3241, 
3068, 2954, 2925, 2868, 2362, 1684, 1594, 1555, 1503, 1474, 1441, 1386, 1368, 1261, 1223, 
1161, 1123, 1109, 1052, 1019, 982, 932, 851, 805, 750, 615 cm-1; MS (ESI +ve) m/z 610 ([M 
+ Na]+, 100%), 588 ([M + H]+, 86%); HRMS (ESI +ve TOF) calcd for C34H43N5O3F 







Following General Procedure A, azide 28 (1.20 g, 2.65 
mmol), alkyne 21 (1.56 g, 5.30 mmol), Cu(OAc)2∙H2O (106 
mg, 0.53 mmol) and sodium ascorbate (210 mg, 1.06 mmol) 
were stirred in t-BuOH (53 mL) and H2O (13.3 mL) for 18 h 
to give the product triazole 75b (1.63 g, 82%) as a translucent 
tan gum after flash chromatography over SiO2 gel 
(EtOAc/P.S. – 10:90  MeOH/CH2Cl2 – 10:90). TLC (MeOH/CH2Cl2 – 10:90): Rf  = 0.40, 




 −28.1 (c 1.03, MeOH); 1H NMR (400 MHz, DMSO) 
δ 7.84 (s, 1H, H5'), 7.60 (br s, 1H, N5-H), 7.33 – 7.18 (m, 3H, ArH), 7.18 – 7.10 (m, 2H, 
ArH), 7.01 – 6.94 (m, 2H, ArH), 6.88 (t, J = 7.3 Hz, 1H, ArH), 6.80 (br s, 2H, -NH2), 5.06 
(s, 2H, -OCH2-C4'), 4.91 (br s, 1H, H2), 3.93 – 3.81 (m, 2H, H1''), 3.07 – 2.96 (m, 2H, H5), 
2.94 (s, 2H, ArCH2-), 2.47 (s, 3H, ArCH3), 2.41 (s, 3H, ArCH3), 2.22 – 2.07 (m, 1H, H3A or 
H3B), 1.99 (s, 3H, ArCH3), 1.91 – 1.77 (m, 1H, H3B or H3A), 1.54 (td, J = 13.2, 6.6 Hz, 1H, 
H3''), 1.45 – 1.33 (m, 8H, H2'' and -C(CH3)2), 1.23 (br s, 1H, H4A or H4B), 1.07 (br s, 1H, 
H4B or H4A), 0.76 (d, J = 6.6 Hz, 6H, H4'' and H5''); 
13C NMR (101 MHz, DMSO) δ 157.4 
(Pbf CAr), 156.32 (C=N), 156.27 (C1), 156.1 (CAr2'), 155.7 (CAr2), 142.6 (C4'), 137.2 (Pbf 
CAr), 134.3 (Pbf CAr), 131.4 (Pbf CAr), 131.2 (CAr6 or CAr6'), 131.1 (CAr6' or CAr6), 128.5 
(CAr4 or CAr4'), 128.4 (CAr4' or CAr4), 127.9 (CAr1), 127.4 (CAr1'), 124.3 (Pbf CAr), 123.1 
(C5'), 120.4 (CAr5), 119.9 (CAr5'), 116.2 (Pbf CAr), 113.0 (CAr3), 112.2 (CAr3'), 86.2 
(-C(CH3)2), 66.2 (C1''), 64.9 (C2), 62.2 (-OCH2-C4'), 42.5 (ArCH2-), 39.5 (C5 – observed by 
227 
 
gHSQC), 37.5 (C2''), 30.2 (C3), 28.3 (-C(CH3)2), 25.9 (C4), 24.5 (C3''), 22.4 (C4'' and C5''), 
18.9 (ArCH3), 17.6 (ArCH3), 12.3 (ArCH3); IR (neat) ν̄max 3327, 2946, 2873, 2831, 2363, 
2167, 2027, 1617, 1559, 1506, 1442, 1405, 1238, 1108, 1023, 804, 751, 668 cm-1; MS (ESI 
+ve) m/z 747 ([M + H]+, 100%), MS (ESI −ve) m/z 745 ([M − H]−, 100%); HRMS (ESI +ve 




1H-1,2,3-triazol-1-yl)pentanamide hydrochloride (77a) 
Following General Procedure B, acid 75b (50 mg, 0.07 
mmol), benzylamine (9 mg, 0.08 mmol), EDCI (15 mg, 
0.08 mmol) and HOBt (11 mg, 0.07 mmol) were stirred 
in acetonitrile (0.7 mL) for 22 h to give the intermediate 
amide as a translucent tan gum. Following General 
Procedure C, the amide was dissolved in CH2Cl2 (2.0 mL) and treated with H2O (24 mg, 
1.34 mmol) and CF3CO2H (2.0 mL) followed by work-up with ethereal HCl to give the amine 





 +17.8 (c 0.93, MeOH); 1H NMR (400 MHz, CD3OD) δ 7.77 (s, 1H, H5'), 7.33 – 
7.11 (m, 10H, ArH), 7.05 – 6.91 (m, 3H, ArH), 5.34 – 5.27 (m, 1H, H2), 5.13 – 5.06 (m, 
2H, -OCH2-C4'), 4.44 – 4.32 (m, 2H, -CH2Ph), 3.95 – 3.82 (m, 2H, H1''), 3.20 – 3.12 (m, 2H, 
H5), 2.27 – 2.03 (m, 2H, H3), 1.60 – 1.33 (m, 5H, H4, H2'' and H3''), 0.77 (d, J = 6.9 Hz, 6H, 
H4'' and H5''); 13C NMR (101 MHz, CD3OD) δ 169.7 (C1), 158.7 (C=N), 158.2 (CAr2'), 
157.6 (CAr2), 146.3 (C4'), 139.5 (Phenyl CAr), 132.8 (CAr6 or CAr6'), 132.5 (CAr6' or 
CAr6), 130.7 (CAr1), 129.9 (CAr4 or CAr4'), 129.84 (Phenyl CAr)*, 129.82 (CAr1'), 129.76 
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(CAr4' or CAr4), 128.8 (Phenyl CAr)*, 128.6 (Phenyl CAr), 124.2 (C5'), 122.5 (CAr5), 121.5 
(CAr5'), 114.8 (CAr3), 113.7 (CAr3'), 68.2 (C1''), 64.8 (C2), 64.1 (-OCH2-C4'), 44.6 (-
CH2Ph), 41.8 (C5), 39.4 (C2''), 31.0 (C3), 26.4 (C4), 26.2 (C3''), 23.09 (C4'' or C5''), 23.07 
(C5'' or C4''); IR (neat) ν̄max 3328, 3183, 3065, 2955, 2932, 2871, 2364, 2323, 1669, 1653, 
1617, 1559, 1540, 1507, 1473, 1457, 1437, 1387, 1363, 1340, 1213, 1123, 1107, 1082, 1040, 
1003, 855, 801, 749, 698, 669 cm-1; MS (ESI +ve) m/z 584 ([M + H]+, 100%), 606 ([M + 




triazol-1-yl)-N-phenethylpentanamide hydrochloride (77b) 
Following General Procedure B, acid 75b (50 mg, 
0.07 mmol), β-phenylethylamine (10 mg, 0.08 mmol), 
EDCI (15 mg, 0.08 mmol) and HOBt (11 mg, 0.07 
mmol) were stirred in acetonitrile (0.7 mL) for 22 h to 
give the intermediate amide as a translucent tan gum. 
Following General Procedure C, the amide was dissolved in CH2Cl2 (2.0 mL) and treated 
with H2O (24 mg, 1.34 mmol) and CF3CO2H (2.0 mL) followed by work-up with ethereal 
HCl to give the amine salt 77b (37 mg, 87% over two steps) as a light tan powder that rapidly 




 +33.8 (c 0.97, MeOH); 1H NMR (400 MHz, CD3OD) 
δ 7.71 (s, 1H), 7.34 – 7.08 (m, 10H), 7.04 – 6.91 (m, 3H), 5.21 (t, J = 7.7 Hz, 1H), 5.12 – 
5.06 (m, 2H), 3.95 – 3.83 (m, 2H), 3.48 – 3.41 (m, 2H), 3.14 (t, J = 7.0 Hz, 2H), 2.78 (t, J = 
7.1 Hz, 2H), 2.18 – 1.95 (m, 2H), 1.61 – 1.50 (m, 1H), 1.48 – 1.29 (m, 4H), 0.77 (d, J = 6.6 
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Hz, 6H); 13C NMR (101 MHz, CD3OD) δ 169.6, 158.7, 158.2, 157.5, 146.1, 140.2, 132.8, 
132.6, 130.6, 130.0*, 129.9, 129.81, 129.77, 129.7*, 127.6, 124.2, 122.5, 121.5, 114.7, 113.8, 
68.2, 64.9, 64.0, 42.2, 41.9, 39.4, 36.3, 30.8, 26.2, 26.2, 23.09, 23.08; IR (neat) ν̄max 3330, 
3185, 3065, 2953, 2930, 2870, 2364, 2322, 1684, 1669, 1653, 1617, 1559, 1540, 1507, 1473, 
1457, 1437, 1387, 1363, 1340, 1212, 1123, 1109, 1087, 1040, 1003, 936, 855, 801, 748, 700, 
668 cm-1; MS (ESI +ve) m/z 598 ([M + H]+, 100%), 620 ([M + Na]+, 22%); HRMS (ESI +ve 




yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)pentanamide hydrochloride (77c) 
Following General Procedure B, acid 75b (50 mg, 0.07 
mmol), cyclohexylamine (8 mg, 0.08 mmol), EDCI (15 
mg, 0.08 mmol) and HOBt (11 mg, 0.07 mmol) were 
stirred in acetonitrile (0.7 mL) for 21 h to give the 
intermediate amide as a translucent tan gum. Following 
General Procedure C, the amide was dissolved in CH2Cl2 (2.0 mL) and treated with H2O 
(24 mg, 1.34 mmol) and CF3CO2H (2.0 mL) followed by work-up with ethereal HCl to give 
the amine salt 77c (39 mg, 95% over two steps) as a light tan powder that rapidly transitioned 




 +15.9 (c 0.83, MeOH); 1H NMR (400 MHz, CD3OD) δ 7.77 (s, 1H), 
7.34 – 7.24 (m, 2H), 7.23 – 7.09 (m, 3H), 7.05 – 6.98 (m, 2H), 6.95 (t, J = 7.4 Hz, 1H), 5.24 
(t, J = 7.7 Hz, 1H), 5.14 – 5.05 (m, 2H), 3.96 – 3.85 (m, 2H), 3.68 – 3.57 (m, 1H), 3.18 (t, J 
= 7.0 Hz, 2H), 2.22 – 2.00 (m, 2H), 1.92 – 1.12 (m, 15H), 0.77 (d, J = 6.6 Hz, 6H); 13C NMR 
(101 MHz, CD3OD) δ 168.7, 158.8, 158.2, 157.5, 146.2, 132.7, 132.5, 130.7*, 129.9, 129.7, 
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124.0, 122.5, 121.5, 114.7, 113.8, 68.2, 64.8, 64.1, 50.4, 41.9, 39.4, 33.7, 33.6, 31.1, 26.7, 
26.4, 26.3, 26.20, 26.16, 23.1*; IR (neat) ν̄max 3329, 3185, 3067, 2953, 2929, 2868, 2364, 
2323, 1684, 1669, 1653, 1617, 1559, 1540, 1507, 1473, 1457, 1437, 1387, 1363, 1340, 1213, 
1123, 1108, 1088, 1040, 1003, 941, 855, 802, 749, 668 cm-1; MS (ESI +ve) m/z 576 ([M + 
H]+, 100%), 598 ([M + Na]+, 19%); HRMS (ESI +ve TOF) calcd for C32H46N7O3 576.3662, 
found 576.3688 ([M + H]+). 
 
(R)-N-(Cyclohexylmethyl)-5-guanidino-2-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2-
yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)pentanamide hydrochloride (77d) 
Following General Procedure B, acid 75b (50 mg, 0.07 
mmol), cyclohexylmethylamine (9 mg, 0.08 mmol), 
EDCI (15 mg, 0.08 mmol) and HOBt (11 mg, 0.07 mmol) 
were stirred in acetonitrile (0.7 mL) for 24 h to give the 
intermediate amide as a translucent tan gum. Following 
General Procedure C, the amide was dissolved in CH2Cl2 (2.0 mL) and treated with H2O 
(24 mg, 1.34 mmol) and CF3CO2H (2.0 mL) followed by work-up with ethereal HCl to give 
the amine salt 77d (25 mg, 60% over two steps) as a light tan powder that rapidly transitioned 




 −5.6 (c 0.63, MeOH); 1H NMR (400 MHz, CD3OD) δ 7.76 (s, 1H), 
7.34 – 7.24 (m, 2H), 7.22 – 7.10 (m, 3H), 7.05 – 6.98 (m, 2H), 6.95 (t, J = 7.4 Hz, 1H), 5.31 
(t, J = 7.6 Hz, 1H), 5.13 – 5.04 (m, 2H), 3.96 – 3.85 (m, 2H), 3.17 (t, J = 6.7 Hz, 2H), 3.07 – 
2.99 (m, 2H), 2.26 – 2.01 (m, 2H), 1.77 – 1.36 (m, 11H), 1.33 – 1.12 (m, 3H), 0.96 – 0.82 
(m, 2H), 0.78 (d, J = 6.6 Hz, 6H); 13C NMR (101 MHz, CD3OD) δ 169.9, 158.8, 158.2, 157.6, 
146.4, 132.8, 132.6, 130.7, 129.9, 129.84, 129.76, 124.2, 122.5, 121.5, 114.8, 113.8, 68.2, 
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64.8, 64.1, 47.2, 41.8, 39.4, 39.2, 32.08, 32.06, 31.0, 27.7, 27.1*, 26.31, 26.25, 23.11, 23.08; 
IR (neat) ν̄max 3330, 3185, 2954, 2926, 2869, 2364, 2322, 1684, 1669, 1653, 1617, 1559, 
1540, 1507, 1473, 1457, 1437, 1387, 1363, 1340, 1213, 1123, 1108, 1088, 1049, 854, 801, 
749, 668 cm-1; MS (ESI +ve) m/z 590 ([M + H]+, 100%), 612 ([M + Na]+, 28%); HRMS (ESI 




triazol-1-yl)-N-(4-(trifluoromethyl)benzyl)pentanamide hydrochloride (77e) 
Following General Procedure B, acid 75b (50 mg, 
0.07 mmol), 4-(trifluoromethyl)benzylamine (14 
mg, 0.08 mmol), EDCI (15 mg, 0.08 mmol) and 
HOBt (11 mg, 0.07 mmol) were stirred in 
acetonitrile (0.7 mL) for 24 h to give the 
intermediate amide as a translucent tan gum. Following General Procedure C, the amide 
was dissolved in CH2Cl2 (2.0 mL) and treated with H2O (24 mg, 1.34 mmol) and CF3CO2H 
(2.0 mL) followed by work-up with ethereal HCl to give the amine salt 77e (30 mg, 65% 




 +17.8 (c 
1.23, MeOH); 1H NMR (400 MHz, CD3OD) δ 7.77 (s, 1H), 7.62 – 7.52 (m, 2H), 7.45 – 7.36 
(m, 2H), 7.33 – 7.07 (m, 5H), 7.05 – 6.84 (m, 3H), 5.40 – 5.30 (m, 1H), 5.14 – 5.04 (m, 2H), 
4.49 – 4.40 (m, 2H), 3.93 – 3.79 (m, 2H), 3.23 – 3.08 (m, 2H), 2.25 – 1.97 (m, 2H), 1.62 – 
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1.18 (m, 5H), 0.77 – 0.71 (m, 6H); 13C NMR (101 MHz, CD3OD)
† δ 169.9, 158.8, 158.2, 
157.6, 149.6, 144.2, 132.8, 132.5, 130.6, 129.9, 129.83, 129.76, 129.3*, 126.7 (q, 3JCF = 3.6 
Hz)*, 124.3, 122.5, 121.5, 114.7, 113.7, 68.2, 64.8, 64.1, 44.0, 41.9, 39.4, 30.9, 26.4, 26.2, 
23.09, 23.07; IR (neat) ν̄max 2954, 2926, 2869, 2371, 2349, 2322, 1700, 1684, 1669, 1653, 
1617, 1559, 1540, 1507, 1473, 1457, 1437, 1387, 1363, 1340, 1324, 1260, 1223, 1164, 1110, 
1067, 1052, 1017, 917, 818, 751, 669 cm-1; MS (ESI +ve) m/z 652 ([M + H]+, 100%), 674 
([M + Na]+, 18%); HRMS (ESI +ve TOF) calcd for C34H41N7O3F3 652.3223, found 652.3243 
([M + H]+). 
 
(R)-N-(4-Fluorophenethyl)-5-guanidino-2-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2-
yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)pentanamide hydrochloride (77f) 
Following General Procedure B, acid 75b (50 mg, 
0.07 mmol), 2-(4-fluorophenyl)ethylamine (11 mg, 
0.08 mmol), EDCI (15 mg, 0.08 mmol) and HOBt 
(11 mg, 0.07 mmol) were stirred in acetonitrile (0.7 
mL) for 24 h to give the intermediate amide as a 
translucent tan gum. Following General Procedure C, the amide was dissolved in CH2Cl2 
                                                 
† Missing resonances: the two carbons closest to the fluorine atoms (i.e. -CF3 and C-CF3) could not be 
assigned to resonances in the 13C NMR spectrum due to the strong JCF coupling that spread the weak 
quaternary resonances over multiple lines (as quartets) – thus, the resonances became even weaker and buried 
amongst the background noise. Furthermore, quaternary carbons do not experience the large Overhauser 
enhancement by proton decoupling that is experienced by protonated carbons, thus making the resonances 




(2.0 mL) and treated with H2O (24 mg, 1.34 mmol) and CF3CO2H (2.0 mL) followed by 
work-up with ethereal HCl to give the amine salt 77f (37 mg, 84% over two steps) as a light 




 +12.6 (c 1.00, MeOH); 1H NMR 
(400 MHz, CD3OD) δ 7.72 (s, 1H), 7.34 – 7.05 (m, 7H), 7.04 – 6.85 (m, 5H), 5.20 (t, J = 7.6 
Hz, 1H), 5.10 (s, 2H), 3.94 – 3.81 (m, 2H), 3.50 – 3.34 (m, 2H), 3.15 (t, J = 6.9 Hz, 2H), 2.79 
– 2.68 (m, 2H), 2.18 – 1.96 (m, 2H), 1.60 – 1.26 (m, 5H), 0.77 (d, J = 6.5 Hz, 6H); 13C NMR 
(101 MHz, CD3OD) δ 169.6, 163.2 (d, 
1JCF = 242.8 Hz), 158.7, 158.2, 157.5, 146.0 (observed 
by gHMBC), 136.2 (d, 4JCF = 3.2 Hz), 132.8, 132.6, 131.7 (d, 
3JCF = 7.9 Hz)*, 130.6, 129.9, 
129.80, 129.76, 124.1, 122.5, 121.5, 116.2 (d, 2JCF = 21.4 Hz)*, 114.7, 113.7, 68.2, 64.8, 
64.0, 42.2, 41.9, 39.4, 35.5, 30.8, 26.3, 26.2, 23.09, 23.08; IR (neat) ν̄max 3330, 3194, 3072, 
2954, 2931, 2869, 2370, 2323, 1671, 1669, 1625, 1603, 1573, 1551, 1509, 1473, 1441, 1385, 
1364, 1220, 1158, 1108, 1040, 1005, 914, 823, 750, 668 cm-1; MS (ESI +ve) m/z 616 ([M + 
H]+, 100%), 638 ([M + Na]+, 25%); HRMS (ESI +ve TOF) calcd for C34H43N7O3F 616.3411, 




Following General Procedure B, acid 75b (50 mg, 
0.07 mmol), 3,5-difluorobenzylamine (12 mg, 0.08 
mmol), EDCI (15 mg, 0.08 mmol) and HOBt (11 mg, 
0.07 mmol) were stirred in acetonitrile (0.7 mL) for 24 
h to give the intermediate amide as a translucent tan 
gum. Following General Procedure C, the amide was dissolved in CH2Cl2 (2.0 mL) and 
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treated with H2O (24 mg, 1.34 mmol) and CF3CO2H (2.0 mL) followed by work-up with 
ethereal HCl to give the amine salt 77g (23 mg, 53% over two steps) as a light tan powder 




 −13.9 (c 0.50, MeOH); 1H NMR (400 MHz, 
CD3OD) δ 7.76 (s, 1H), 7.33 – 7.09 (m, 5H), 7.05 – 6.77 (m, 6H), 5.33 (dd, J = 8.6, 6.6 Hz, 
1H), 5.13 – 5.06 (m, 2H), 4.37 (m, 2H), 3.93 – 3.81 (m, 2H), 3.17 (t, J = 7.1 Hz, 2H), 2.21 – 
1.98 (m, 2H), 1.59 – 1.25 (m, 5H), 0.79 – 0.71 (m, 6H); 13C NMR (101 MHz, CD3OD) 
δ 169.9, 164.8 (dd, 1,3JCF = 248.6, 12.0 Hz)*, 158.8, 158.2, 157.6, 146.4, 144.3 (t, 
3JCF = 9.1 
Hz), 132.8, 132.5, 130.7*, 129.9, 129.8, 124.2, 122.5, 121.5, 114.8, 113.7, 111.5 (d, 2JCF = 
25.7 Hz)*, 103.7 (t, 2JCF = 25.8 Hz), 68.2, 64.8, 64.2, 43.7, 41.9, 39.4, 30.9, 26.4, 26.2, 23.1, 
23.0; IR (neat) ̄νmax 3329, 3196, 3070, 2955, 2931, 2869, 2369, 2323, 1671, 1625, 1597, 1573, 
1550, 1503, 1462, 1441, 1384, 1364, 1317, 1222, 1163, 1117, 1041, 1004, 914, 847, 750, 
733, 668 cm-1; MS (ESI +ve) m/z 620 ([M + H]+, 100%), 642 ([M + Na]+, 34%); HRMS (ESI 




yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)pentanamide hydrochloride (77h) 
Following General Procedure B, acid 75b (50 mg, 0.07 
mmol), 3-fluoroaniline (9 mg, 0.08 mmol), EDCI (15 
mg, 0.08 mmol) and HOBt (11 mg, 0.07 mmol) were 
stirred in acetonitrile (0.7 mL) for 24 h to give the 
intermediate amide as a translucent tan gum. Following 
General Procedure C, the amide was dissolved in CH2Cl2 (2.0 mL) and treated with H2O 
(24 mg, 1.34 mmol) and CF3CO2H (2.0 mL) followed by work-up with ethereal HCl to give 
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the amine salt 77h (33 mg, 79% over two steps) as a light tan powder that rapidly transitioned 




 +3.5 (c 0.93, MeOH); 1H NMR (400 MHz, CD3OD) δ 7.70 (s, 1H), 
7.65 (d, J = 11.3 Hz, 1H), 7.43 – 7.39 (m, 1H), 7.35 – 7.08 (m, 6H), 7.06 – 6.88 (m, 3H), 
6.88 – 6.79 (m, 1H), 5.34 (dd, J = 9.6, 5.0 Hz, 1H), 5.14 – 5.05 (m, 2H), 3.94 – 3.82 (m, 2H), 
3.15 (t, J = 7.3 Hz, 2H), 2.41 – 2.24 (m, 1H), 2.21 – 2.06 (m, 1H), 1.65 – 1.24 (m, 5H), 0.80 
– 0.72 (m, 6H); 13C NMR (101 MHz, CD3OD) δ 168.4, 164.4 (d, 
1JCF = 242.6 Hz), 158.8, 
158.2, 157.6, 146.5, 141.4 (d, 3JCF = 10.8 Hz), 132.8, 132.6, 131.5 (d, 
3JCF = 9.4 Hz), 130.7, 
129.9, 129.81, 129.76, 124.9, 122.5, 121.5, 117.1 (d, 4JCF = 2.9 Hz), 114.8, 113.7, 112.2 (d, 
2JCF = 21.8 Hz), 108.6 (d, 
2JCF = 26.7 Hz), 68.1, 65.1, 64.1, 41.7, 39.4, 30.5, 26.6, 26.2, 23.10, 
23.08; IR (neat) ν̄max 3329, 3171, 2955, 2931, 2871, 2369, 2323, 2107, 1672, 1626, 1555, 
1503, 1474, 1443, 1387, 1368, 1260, 1223, 1160, 1087, 1049, 1024, 875, 799, 750, 669, 611 
cm-1; MS (ESI +ve) m/z 588 ([M + H]+, 100%), 610 ([M + Na]+, 9%); HRMS (ESI +ve TOF) 




triazol-1-yl)-N-phenylpentanamide hydrochloride (77i) 
Following General Procedure B, acid 75b (50 mg, 0.07 
mmol), aniline (8 mg, 0.08 mmol), EDCI (15 mg, 0.08 
mmol) and HOBt (11 mg, 0.07 mmol) were stirred in 
acetonitrile (0.7 mL) for 24 h to give the intermediate 
amide as a translucent tan gum. Following General 
Procedure C, the amide was dissolved in CH2Cl2 (2.0 mL) and treated with H2O (24 mg, 
1.34 mmol) and CF3CO2H (2.0 mL) followed by work-up with ethereal HCl to give the amine 
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 +18.3 (c 0.83, MeOH); 1H NMR (400 MHz, CD3OD) δ 7.79 (s, 1H), 7.62 (d, J = 
7.7 Hz, 2H), 7.38 – 7.09 (m, 8H), 7.04 – 6.89 (m, 3H), 5.48 (dd, J = 8.4, 6.8 Hz, 1H), 5.15 – 
5.06 (m, 2H), 3.93 – 3.77 (m, 2H), 3.20 (t, J = 7.0 Hz, 2H), 2.37 – 2.10 (m, 2H), 1.64 – 1.29 
(m, 5H), 0.73 (d, J = 6.6 Hz, 6H); 13C NMR (101 MHz, CD3OD) δ 167.9, 158.8, 158.2, 157.6, 
146.5, 139.3, 132.7, 132.5, 130.7, 130.2*, 129.9, 129.82, 129.77, 126.1, 124.0, 122.5, 
121.5**, 114.7, 113.7, 68.1, 65.3, 64.2, 41.9, 39.4, 31.1, 26.4, 26.2, 23.1, 23.0; IR (neat) ν̄max 
3346, 3277, 3201, 2954, 2931, 2871, 2370, 2323, 1671, 1625, 1602, 1555, 1501, 1474, 1445, 
1386, 1368, 1254, 1215, 1163, 1123, 1109, 1048, 1019, 873, 810, 750, 692 cm-1; MS (ESI 
+ve) m/z 570 ([M + H]+, 100%), 592 ([M + Na]+, 20%); HRMS (ESI +ve TOF) calcd for 




yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)pentanamide hydrochloride (77j) 
Following General Procedure B, acid 75b (50 mg, 
0.07 mmol), 3,5-dimethoxyaniline (12 mg, 0.08 
mmol), EDCI (15 mg, 0.08 mmol) and HOBt (11 mg, 
0.07 mmol) were stirred in acetonitrile (0.7 mL) for 
22 h to give the intermediate amide as a translucent 
tan gum. Following General Procedure C, the amide was dissolved in CH2Cl2 (2.0 mL) and 
treated with H2O (24 mg, 1.34 mmol) and CF3CO2H (2.0 mL) followed by work-up with 
ethereal HCl to give the amine salt 77j (36 mg, 81% over two steps) as a light tan powder 




 +10.5 (c 0.90, MeOH); 1H NMR (400 MHz, 
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CD3OD) δ 7.77 (s, 1H), 7.34 – 7.09 (m, 5H), 7.05 – 6.86 (m, 5H), 6.27 (s, 1H), 5.53 – 5.45 
(m, 1H), 5.14 – 5.05 (m, 2H), 3.92 – 3.80 (m, 2H), 3.75 (s, 6H), 3.19 (t, J = 6.9 Hz, 2H), 2.37 
– 2.24 (m, 1H), 2.22 – 2.09 (m, 1H), 1.62 – 1.29 (m, 5H), 0.73 (d, J = 6.6 Hz, 6H); 13C NMR 
(101 MHz, CD3OD) δ 168.0, 162.7*, 158.8, 158.2, 157.6, 146.4, 141.0, 132.6, 132.5, 130.7, 
129.9, 129.79, 129.77, 124.1, 122.5, 121.5, 114.7, 113.7, 99.8*, 98.0, 68.1, 65.3, 64.2, 56.0, 
41.8, 39.4, 31.0, 26.3, 26.2, 23.1, 23.0; IR (neat) ν̄max 3345, 3278, 3199, 2955, 2931, 2870, 
2370, 2323, 1672, 1619, 1595, 1555, 1502, 1446, 1386, 1260, 1205, 1154, 1110, 1049, 1019, 
844, 750, 669 cm-1; MS (ESI +ve) m/z 630 ([M + H]+, 100%), 652 ([M + Na]+, 34%); HRMS 




yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)pentanamide hydrochloride (77k) 
Following General Procedure B, acid 75b (50 mg, 0.07 
mmol), cyclopropylamine (5 mg, 0.08 mmol), EDCI (15 
mg, 0.08 mmol) and HOBt (11 mg, 0.07 mmol) were 
stirred in acetonitrile (0.7 mL) for 23 h to give the 
intermediate amide as a translucent tan gum. Following 
General Procedure C, the amide was dissolved in CH2Cl2 (2.0 mL) and treated with H2O 
(24 mg, 1.34 mmol) and CF3CO2H (2.0 mL) followed by work-up with ethereal HCl to give 
the amine salt 77k (34 mg, 89% over two steps) as a light tan powder that rapidly transitioned 




 +5.1 (c 0.80, MeOH); 1H NMR (400 MHz, CD3OD) δ 7.77 (s, 1H), 
7.36 – 7.25 (m, 2H), 7.23 – 7.10 (m, 3H), 7.04 – 6.99 (m, 2H), 6.96 (td, J = 7.4, 0.9 Hz, 1H), 
5.20 (dd, J = 8.5, 6.9 Hz, 1H), 5.14 – 5.05 (m, 2H), 3.96 – 3.84 (m, 2H), 3.17 (t, J = 7.0 Hz, 
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2H), 2.73 – 2.65 (m, 1H), 2.22 – 2.01 (m, 2H), 1.61 – 1.31 (m, 5H), 0.82 – 0.65 (m, 8H), 0.57 
– 0.45 (m, 2H); 13C NMR (101 MHz, CD3OD) δ 171.1, 158.8, 158.2, 157.5, 146.2, 132.8, 
132.5, 130.7, 129.9, 129.83, 129.76, 124.0, 122.5, 121.5, 114.7, 113.7, 68.2, 64.6, 64.0, 41.8, 
39.4, 31.0, 26.3, 26.2, 23.8, 23.09, 23.07, 6.7, 6.6; IR (neat) ν̄max 3344, 3278, 3200, 2955, 
2931, 2871, 2369, 2323, 1666, 1626, 1594, 1555, 1503, 1474, 1440, 1387, 1367, 1253, 1212, 
1163, 1123, 1109, 1049, 1004, 854, 750, 668 cm-1; MS (ESI +ve) m/z 534 ([M + H]+, 100%), 
556 ([M + Na]+, 41%); HRMS (ESI +ve TOF) calcd for C29H40N7O3 534.3193, found 
534.3204 ([M + H]+). 
 
(R)-N-(Cyclopropylmethyl)-5-guanidino-2-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2-
yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)-N-propylpentanamide hydrochloride (77l) 
Following General Procedure B, acid 75b (50 mg, 0.07 
mmol), N-propyl-cyclopropylmethylamine (9 mg, 0.08 
mmol), EDCI (15 mg, 0.08 mmol) and HOBt (11 mg, 0.07 
mmol) were stirred in acetonitrile (0.7 mL) for 24 h to give 
the intermediate amide as a translucent tan gum. 
Following General Procedure C, the amide was dissolved in CH2Cl2 (2.0 mL) and treated 
with H2O (24 mg, 1.34 mmol) and CF3CO2H (2.0 mL) followed by work-up with ethereal 
HCl to give the amine salt 77l (36 mg, 86% over two steps) as a light tan powder that rapidly 




 +5.2 (c 0.70, MeOH); 1H NMR (400 MHz, CD3OD) : 
(mixture of rotamers) ‡ δ 7.74 (s, 1H), 7.34 – 7.25 (m, 2H), 7.21 – 7.10 (m, 3H), 7.05 – 6.91 
                                                 
‡ All rotamer resonances are reported. 
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(m, 3H), 5.86 – 5.73 (m, 1H), 5.18 – 5.02 (m, 2H), 3.98 – 3.83 (m, 2H), 3.54 – 3.24 (m, 4H), 
3.23 – 3.11 (m, 2H), 2.22 – 1.99 (m, 2H), 1.66 – 1.28 (m, 7H), 1.06 – 0.93 (m, 1H), 0.92 – 
0.80 (m, 3H), 0.78 (d, J = 6.6 Hz, 6H), 0.59 – 0.39 (m, 2H), 0.35 – 0.13 (m, 2H); 13C NMR 
(101 MHz, CD3OD) : (mixture of rotamers)
‡ δ 169.2, 168.8, 158.8, 158.2, 157.49, 157.45, 
146.6, 146.5, 132.8, 132.5, 130.6, 129.88, 129.86, 129.7, 123.74, 123.66, 122.5, 121.5, 114.6, 
113.7, 68.2, 64.0, 63.9, 60.9, 53.7, 51.9, 51.0, 49.9, 42.0, 39.4, 31.6, 31.5, 26.3, 26.1, 23.6, 
23.10, 23.07, 21.7, 11.8, 11.6, 11.5, 10.6, 5.1, 4.4, 4.2, 4.0; IR (neat) ν̄max 3345, 3189, 2955, 
2931, 2871, 2370, 2323, 1650, 1594, 1503, 1474, 1438, 1385, 1367, 1254, 1214, 1162, 1122, 
1109, 1047, 1020, 934, 855, 801, 749, 669 cm-1; MS (ESI +ve) m/z 590 ([M + H]+, 100%), 
612 ([M + Na]+, 16%); HRMS (ESI +ve TOF) calcd for C33H48N7O3 590.3819, found 
590.3834 ([M + H]+). 
 
(R)-6-((Tert-butoxycarbonyl)amino)-2-(4-((((S)-2'-(isopentyloxy)-[1,1'-binaphthalen]-
2-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)hexanoic acid  (75c) 
Following General Procedure A, azide 24 (253 
mg, 0.93 mmol), alkyne 20 (733 mg, 1.86 mmol), 
Cu(OAc)2∙H2O (37 mg, 0.19 mmol) and sodium 
ascorbate (74 mg, 0.37 mmol) were stirred in 
t-BuOH (18.6 mL) and H2O (4.7 mL) at 40 °C for 
72 h to give the product triazole 75c (386 mg, 64%) 
as a translucent tan gum after flash chromatography over SiO2 gel (EtOAc/P.S. – 10:90  
                                                 
‡ All rotamer resonances are reported. 
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 −11.3 (c 0.76, MeOH); 1H NMR (400 
MHz, DMSO) δ 8.04 (app. t, J = 8.6 Hz, 2H, ArH), 7.93 (app. t, J = 8.0 Hz, 2H, ArH), 7.74 
(d, J = 9.0 Hz, 1H, ArH), 7.57 (d, J = 9.0 Hz, 1H, ArH), 7.47 – 7.37 (br s, 1H, H5'), 7.37 – 
7.26 (m, 2H, ArH), 7.26 – 7.13 (m, 2H, ArH), 7.00 – 6.89 (m, 2H, ArH), 6.74 (br s, 1H, 
N6-H), 5.22 – 5.06 (m, 3H, H2 and -OCH2-C4'), 4.05 – 3.90 (m, 2H, H1''), 2.87 – 2.74 (m, 
2H, H6), 2.04 (br s, 1H, H3A or H3B), 1.91 (br s, 1H, H3B or H3A), 1.39 – 1.13 (m, 14H, H5, 
H2'', H3'' and -C(CH3)3), 1.08 (br s, 1H, H4A or H4B), 0.86 (br s, 1H, H4B or H4A), 0.57 (d, J 
= 6.3 Hz, 3H, H4'' or H5''), 0.55 (d, J = 6.2 Hz, 3H, H5'' or H4''); 13C NMR (101 MHz, 
DMSO)† δ 155.5 (Cα), 154.1 (CAr2'), 153.7 (CAr2), 143.5 (C4' – observed by gHMBC), 
133.4 (CAr8a or CAr8a'), 133.3 (CAr8a' or CAr8a), 129.2 (CAr4), 129.1 (CAr4'), 129.0 
(CAr4a), 128.7 (CAr4a'), 127.9 (CAr5 and CAr5'), 126.2 (CAr7), 126.1 (CAr7'), 124.7 
(CAr8), 124.5 (CAr8'), 123.5 (CAr6), 123.3 (CAr6'), 123.0 (C5'), 119.8 (CAr1), 119.1 
(CAr1'), 116.2 (CAr3), 115.6 (CAr3'), 77.3 (-C(CH3)3), 67.2 (C1''), 63.0 (-OCH2-C4'), 39.4 
(C6), 37.6 (C2''), 31.0 (C3), 28.7 (C5), 28.2 (-C(CH3)3), 24.1 (C3''), 22.6 (C4), 22.2 (C4'' or 
C5''), 22.1 (C5'' or C4''); IR (neat) ν̄max 3342, 3061, 2954, 2932, 2869, 2366, 2345, 1734, 
1718, 1700, 1684, 1653, 1623, 1591, 1559, 1540, 1507, 1458, 1430, 1395, 1366, 1329, 1263, 
1243, 1165, 1147, 1083, 1046, 1015, 915, 862, 809, 747, 668, 610 cm-1; MS (ESI −ve) m/z 
665 ([M − H]−, 100%); HRMS (ESI −ve TOF) calcd for C39H45N4O6 665.3339, found 
665.3353 ([M − H]−). 
                                                 
† Missing resonances: two carbons (the carboxyl carbon (C1) and the adjacent methine carbon (C2)) could not 
be assigned to resonances in the 13C NMR spectrum; the corresponding methine proton (H2) was assigned to a 
very broad signal in the 1H NMR spectrum (by gCOSY correlation with H3). This 1H NMR signal showed no 





yl)sulfonyl)guanidino)pentanoic acid (75d) 
Following General Procedure A, azide 28 (152 mg, 
0.34 mmol), alkyne 20 (265 mg, 0.67 mmol), 
Cu(OAc)2∙H2O (13 mg, 0.07 mmol) and sodium 
ascorbate (27 mg, 0.13 mmol) were stirred in 
t-BuOH (6.7 mL) and H2O (1.7 mL) for 24 h to give 
the product triazole 75d (236 mg, 83%) as a 
translucent tan gum after flash chromatography over 





 −25.8 (c 0.43, MeOH); 1H NMR (400 MHz, DMSO) δ 8.03 (d, J = 9.0 Hz, 1H, 
ArH), 7.98 – 7.88 (m, 2H, ArH), 7.84 (d, J = 8.0 Hz, 1H, ArH), 7.73 (d, J = 9.1 Hz, 1H, ArH), 
7.54 (br s, 1H, N5-H), 7.52 (d, J = 9.0 Hz, 1H, ArH), 7.39 (br s, 1H, H5'), 7.32 (t, J = 7.0 Hz, 
1H, ArH), 7.28 – 7.18 (m, 2H, ArH), 7.14 (t, J = 7.4 Hz, 1H, ArH), 6.94 (d, J = 8.5 Hz, 1H, 
ArH), 6.90 (d, J = 8.4 Hz, 1H, ArH), 6.82 (br s, 2H, -NH2), 5.13 and 5.06 (ABq, J = 12.4 Hz, 
2H, -OCH2-C4'), 4.81 (br s, 1H, H2), 4.05 – 3.88 (m, 2H, H1''), 2.96 (br s, 2H, H5), 2.92 (s, 
2H, ArCH2-), 2.48 (s, 3H, ArCH3), 2.42 (s, 3H, ArCH3), 2.08 (br s, 1H, H3A or H3B), 1.98 
(s, 3H, ArCH3), 1.73 (br s, 1H, H3B or H3A), 1.36 (s, 6H, -C(CH3)2), 1.29 – 0.87 (m, 5H, H4, 
H2'', H3''), 0.56 (d, J = 6.2 Hz, 3H, H4'' or H5''), 0.54 (d, J = 6.2 Hz, 3H, H5'' or H4''); 13C 
NMR (101 MHz, DMSO)† δ 157.4 (Pbf CAr), 156.3 (C=N), 154.1 (CAr2'), 153.8 (CAr2), 
                                                 
† Missing resonances: two carbons (the carboxyl carbon (C1) and the adjacent methine carbon (C2)) could not 
be assigned to resonances in the 13C NMR spectrum; the corresponding methine proton (H2) was assigned to a 
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142.7 (C4'), 137.2 (Pbf CAr), 134.3 (Pbf CAr), 133.4 (CAr8a or CAr8a'), 133.3 (CAr8a' or 
CAr8a), 131.3 (Pbf CAr), 129.2 (CAr4), 129.1 (CAr4'), 129.0 (CAr4a), 128.6 (CAr4a'), 127.9 
(CAr5 and CAr5'), 126.1 (CAr7), 126.0 (CAr7'), 124.7 (CAr8), 124.5 (CAr8'), 124.3 (Pbf 
CAr), 123.4 (CAr6), 123.2 (CAr6'), 122.7 (C5'), 119.8 (CAr1), 119.1 (CAr1'), 116.23 (Pbf 
CAr), 116.20 (CAr3), 115.5 (CAr3'), 86.2 (-C(CH3)2), 67.2 (C1''), 63.2 (-OCH2-C4'), 42.4 
(ArCH2-), 39.6 (C5 – observed by gHSQC), 37.6 (C2''), 30.0 (C3), 28.2 (-C(CH3)2), 25.8 
(C4), 24.1 (C3''), 22.2 (C4'' or C5''), 22.1 (C5'' or C4''), 18.9 (ArCH3), 17.6 (ArCH3), 12.2 
(ArCH3); IR (neat) ν̄max 2961, 2932, 2873, 2362, 2342, 1734, 1700, 1684, 1653, 1623, 1559, 
1540, 1507, 1473, 1457, 1437, 1419, 1399, 1260, 1243, 1147, 1109, 1087, 1059, 1016, 907, 
852, 808, 784, 746, 734, 668, 641 cm-1; MS (ESI −ve) m/z 845 ([M − H]−, 100%); HRMS 




yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)pentanamide hydrochloride (78a) 
Following General Procedure B, acid 75d (50 
mg, 0.06 mmol), benzylamine (8 mg, 0.07 mmol), 
EDCI (14 mg, 0.07 mmol) and HOBt (10 mg, 
0.06 mmol) were stirred in acetonitrile (0.6 mL) 
for 21 h to give the intermediate amide as a 
translucent tan gum. Following General Procedure C, the amide was dissolved in CH2Cl2 
(1.8 mL) and treated with H2O (21 mg, 1.18 mmol) and CF3CO2H (1.8 mL) followed by 
                                                 
very broad signal in the 1H NMR spectrum (by gCOSY correlation with H3). This 1H NMR signal showed no 
heterocorrelations in 2-D NMR (i.e. gHSQC and gHMBC). 
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work-up with ethereal HCl to give the amine salt 78a (37 mg, 87% over two steps) as a light 




 −15.0 (c 0.90, MeOH); 1H NMR 
(400 MHz, CD3OD) δ 8.02 – 7.96 (m, 2H, ArH), 7.91 – 7.85 (m, 2H, ArH), 7.58 (d, J = 9.0 
Hz, 1H, ArH), 7.51 (d, J = 9.0 Hz, 1H, ArH), 7.36 – 7.11 (m, 10H, ArH and H5'), 7.08 (d, J 
= 8.6 Hz, 1H, ArH), 7.02 (d, J = 8.6 Hz, 1H, ArH), 5.20 (dd, J = 8.7, 6.7 Hz, 1H, H2), 5.14 
and 5.09 (ABq, J = 12.4 Hz, 2H, -OCH2-C4'), 4.35 (s, 2H, -CH2Ph), 4.02 (dt, J = 9.6, 6.0 Hz, 
1H, H1''A or H1''B), 3.91 (dt, J = 9.6, 6.3 Hz, 1H, H1''B or H1''A), 3.17 – 3.04 (m, 2H, H5), 
2.18 – 2.05 (m, 1H, H3A or H3B), 2.02 – 1.84 (m, 1H, H3B or H3A), 1.49 – 1.11 (m, 5H, H4, 
H2'', H3''), 0.55 (d, J = 6.4 Hz, 3H, H4'' or H5''), 0.52 (d, J = 6.3 Hz, 3H, H5'' or H4''); 13C 
NMR (101 MHz, CD3OD) δ 169.6 (C1), 158.7 (C=N), 156.1 (CAr2'), 155.5 (CAr2), 146.3 
(C4' – observed by gHMBC), 139.5 (Phenyl CAr), 135.6 (CAr8a or CAr8a'), 135.5 (CAr8a' 
or CAr8a), 131.6 (CAr4a), 130.9 (CAr4a'), 130.8 (CAr4), 130.7 (CAr4'), 129.8 (Phenyl 
CAr)*, 129.3 (CAr5 or CAr5'), 129.2 (CAr5' or CAr5), 128.8 (Phenyl CAr)*, 128.6 (Phenyl 
CAr), 127.5 (CAr7 or CAr7'), 127.4 (CAr7' or CAr7), 126.7 (CAr8), 126.4 (CAr8'), 125.2 
(CAr6), 124.8 (CAr6'), 124.0 (C5'), 122.9 (CAr1), 121.4 (CAr1'), 117.7 (CAr3), 117.0 
(CAr3'), 69.2 (C1''), 65.1 (-OCH2-C4'), 64.7 (C2), 44.5 (-CH2Ph), 41.8 (C5), 39.5 (C2''), 30.8 
(C3), 26.2 (C4), 25.8 (C3''), 23.0 (C4'' or C5''), 22.8 (C5'' or C4''); IR (neat) ν̄max 3335, 3190, 
3059, 2959, 2931, 2875, 2364, 2325, 1734, 1700, 1684, 1669, 1653, 1636, 1623, 1590, 1559, 
1540, 1507, 1473, 1457, 1437, 1419, 1399, 1340, 1261, 1241, 1212, 1147, 1083, 1040, 1007, 
908, 861, 808, 775, 745, 699, 668, 601 cm-1; MS (ESI +ve) m/z 684 ([M + H]+, 100%), 706 
([M + Na]+, 8%); HRMS (ESI +ve TOF) calcd for C41H46N7O3 684.3662, found 684.3669 





1H-1,2,3-triazol-1-yl)-N-phenethylpentanamide hydrochloride (78b) 
Following General Procedure B, acid 75d (50 
mg, 0.06 mmol), β-phenylethylamine (9 mg, 0.07 
mmol), EDCI (14 mg, 0.07 mmol) and HOBt (10 
mg, 0.06 mmol) were stirred in acetonitrile (0.6 
mL) for 21 h to give the intermediate amide as a 
translucent tan gum. Following General Procedure C, the amide was dissolved in CH2Cl2 
(1.8 mL) and treated with H2O (21 mg, 1.18 mmol) and CF3CO2H (1.8 mL) followed by 
work-up with ethereal HCl to give the amine salt 78b (21 mg, 49% over two steps) as a light 




 −20.3 (c 0.33, MeOH); 1H NMR 
(400 MHz, CD3OD) δ 8.01 (s, 1H), 7.99 (s, 1H), 7.92 – 7.85 (m, 2H), 7.60 (d, J = 9.0 Hz, 
1H), 7.52 (d, J = 9.1 Hz, 1H), 7.37 – 7.00 (m, 12H), 5.16 – 5.06 (m, 3H), 4.07 – 3.98 (m, 
1H), 3.96 – 3.88 (m, 1H), 3.49 – 3.34 (m, 2H), 3.08 (t, J = 7.1 Hz, 2H), 2.75 (t, J = 7.1 Hz, 
2H), 2.09 – 1.98 (m, 1H), 1.91 – 1.79 (m, 1H), 1.36 – 1.12 (m, 5H), 0.56 (d, J = 6.4 Hz, 3H), 
0.52 (d, J = 6.3 Hz, 3H); 13C NMR (101 MHz, CD3OD) δ 169.6, 158.8, 156.2, 155.5, 146.4 
(observed by gHMBC), 140.3, 135.61, 135.57, 131.6, 130.9, 130.8, 130.7, 130.0*, 129.7*, 
129.3, 129.2, 127.6, 127.5, 127.4, 126.7, 126.4, 125.2, 124.8, 123.9, 122.9, 121.5, 117.7, 
117.0, 69.2, 65.2, 64.6, 42.2, 41.8, 39.5, 36.3, 30.7, 26.1, 25.9, 23.0, 22.8; IR (neat) ̄νmax 3335, 
3189, 3061, 2960, 2932, 2874, 2364, 2325, 1734, 1700, 1684, 1669, 1653, 1636, 1623, 1591, 
1559, 1540, 1507, 1473, 1457, 1437, 1419, 1363, 1340, 1261, 1241, 1213, 1147, 1132, 1083, 
1045, 1016, 908, 878, 864, 808, 775, 747, 699, 668, 601 cm-1; MS (ESI +ve) m/z 698 ([M + 
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H]+, 100%), 720 ([M + Na]+, 7%); HRMS (ESI +ve TOF) calcd for C42H48N7O3 698.3819, 
found 698.3837 ([M + H]+). 
 




Following General Procedure B, acid 75a (176 mg, 
0.31 mmol), amine 25 (143 mg, 0.33 mmol), EDCI (72 
mg, 0.37 mmol) and HOBt (50 mg, 0.33 mmol) were 
stirred in acetonitrile (3.1 mL) for 48 h to give the 
product amide 79a (251 mg, 82%) as a translucent tan 
gum after flash chromatography over SiO2 gel 
(EtOAc/P.S. – 60:40  80:20). TLC (EtOAc/P.S. – 




 −8.0 (c 1.23, MeOH); 1H NMR 
(400 MHz, CDCl3) δ 7.54 (br s, 2H, H5′ and N
2′′′-H), 7.32 – 7.17 (m, 4H, ArH), 7.09 – 6.99 
(m, 2H, ArH), 6.99 – 6.90 (m, 2H, ArH), 6.11 (br s, 3H, N5′′′-H and -NH2), 5.34 – 5.25 (m, 
1H, H5), 5.09 (s, 2H, -OCH2-C4′), 4.71 (br s, 1H, N
1-H), 3.96 (br s, 1H, H2′′′), 3.90 (t, J = 
6.1 Hz, 2H, H1′′), 3.30 (br s, 2H, H1′′′), 3.08 – 2.95 (m, 4H, H1 and H5′′′), 2.94 (s, 2H, 
ArCH2-), 2.54 (s, 3H, ArCH3), 2.49 (s, 3H, ArCH3), 2.21 – 2.12 (m, 1H, H4A or H4B), 2.08 
(s, 3H, ArCH3), 2.02 – 1.88 (m, 1H, H4B or H4A), 1.64 – 1.09 (m, 26H, H2, H3, H2′′, H3′′, 
H3′′′, H4′′′, -C(CH3)2 and -C(CH3)3), 0.78 (d, J = 6.3 Hz, 6H, H4′′ and H5′′); 
13C NMR (101 
MHz, CDCl3) δ 168.5 (C6), 158.9 (Pbf CAr), 156.6 (CAr2′), 156.3 (CAr2 and C=N), 155.9 
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(Cα), 145.0 (C4′), 138.4 (Pbf CAr), 132.9 (Pbf CAr), 132.3 (Pbf CAr), 131.8 (CAr6 or CAr6′), 
131.6 (CAr6′ or CAr6), 128.9 (CAr1), 128.8 (CAr4), 128.7 (CAr4′), 128.1 (CAr1′), 124.8 
(Pbf CAr), 122.6 (C5′), 121.5 (CAr5), 120.4 (CAr5′), 117.7 (Pbf CAr), 113.7 (CAr3), 112.6 
(CAr3′), 86.6 (-C(CH3)2), 79.4 (-C(CH3)3), 67.2 (C1′′), 63.8 (C5), 63.5 (-OCH2-C4′), 54.6 
(C1′′′), 49.6 (C2′′′), 43.4 (ArCH2-), 40.8 (C1 or C5′′′), 40.1 (C5′′′ or C1), 38.1 (C2′′), 32.3 
(C4), 29.3 (C3′′′), 29.0 (C2), 28.7 (-C(CH3)2), 28.5 (-C(CH3)3), 25.6 (C4′′′), 25.1 (C3′′), 22.8 
(C3), 22.63 (C4′′ or C5′′), 22.61 (C5′′ or C4′′), 19.4 (ArCH3), 18.1 (ArCH3), 12.6 (ArCH3); 
IR (neat) ν̄max 3443, 3339, 2958, 2926, 2870, 2101, 1700, 1684, 1617, 1559, 1545, 1507, 
1457, 1442, 1395, 1368, 1241, 1163, 1106, 1091, 1052, 1028, 905, 853, 808, 784, 751, 734, 
668, 659, 640, 620, 615 cm-1; MS (ESI +ve) m/z 1009 ([M + Na]+, 100%), 987 ([M + H]+, 







Following General Procedure A, azide 79a (50 mg, 0.05 mmol), 3-phenyl-1-propyne (18 
mg, 0.15 mmol), Cu(OAc)2∙H2O (2 mg, 0.01 mmol) and sodium ascorbate (4 mg, 0.02 mmol) 
were stirred in t-BuOH (1.0 mL) and H2O (0.25 mL) for 24 h to give the intermediate triazole 
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as a light tan gum after flash chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100  
10:90). Following General Procedure C, the triazole was dissolved in CH2Cl2 (1.5 mL) and 
treated with H2O (18 mg, 1.00 mmol) and CF3CO2H (1.5 mL) followed by work-up with 
ethereal HCl to give the amine salt 80a (40 mg, 95% over two steps) as a light tan powder 




 +6.2 (c 1.07, MeOH); 1H NMR (400 MHz, 
CD3OD) δ 7.92 (s, 1H, Hα), 7.69 (s, 1H, H5′), 7.36 – 7.09 (m, 10H, ArH), 7.05 – 6.97 (m, 
2H, ArH), 6.94 (t, J = 7.3 Hz, 1H, ArH), 5.25 (t, J = 7.0 Hz, 1H, H2), 5.09 (s, 2H, -OCH2-C4′), 
4.66 – 4.56 (m, 1H, H1′′′A or H1′′′B), 4.51 – 4.40 (m, 1H, H1′′′B or H1′′′A), 4.32 (br s, 1H, 
H2′′′), 4.14 – 4.02 (m, 2H, -CH2Ph), 3.95 – 3.86 (m, 2H, H1′′), 3.12 (br s, 2H, H5′′′), 2.83 (br 
s, 2H, H6), 1.98 – 1.25 (m, 11H, H3, H5, H2′′, H3′′, H3′′′ and H4′′′), 1.16 – 0.99 (m, 2H, H4), 
0.78 (d, J = 6.6 Hz, 6H, H4′′ and H5′′); 13C NMR (101 MHz, CD3OD) δ 170.2 (C1), 158.7 
(C=N), 158.2 (CAr2′), 157.5 (CAr2), 148.3 (Cβ – observed by gHMBC), 145.9 (C4′ – 
observed by gHMBC), 140.2 (Phenyl CAr), 132.9 (CAr6 or CAr6′), 132.6 (CAr6′ or CAr6), 
130.5 (CAr1), 129.97 (Phenyl CAr)*, 129.95 (Phenyl CAr)*, 129.9 (CAr4), 129.79 (CAr4′), 
129.76 (CAr1′), 127.9 (Phenyl CAr), 125.7 (Cα), 124.5 (C5′), 122.5 (CAr5), 121.5 (CAr5′), 
114.8 (CAr3), 113.8 (CAr3′), 68.2 (C1′′), 64.6 (C2), 64.0 (-OCH2-C4′), 55.2 (C1′′′), 51.2 
(C2′′′), 42.0 (C5′′′), 40.5 (C6), 39.4 (C2′′), 32.9 (C3), 32.4 (-CH2Ph), 30.0 (C3′′′), 27.7 (C5), 
26.3 (C4′′′), 26.2 (C3′′), 23.6 (C4), 23.11 (C4′′ or C5′′), 23.10 (C5′′ or C4′′); IR (neat) ν̄max 
3333, 3166, 3061, 2958, 2934, 2872, 2377, 2324, 1684, 1669, 1653, 1559, 1540, 1507, 1473, 
1457, 1437, 1395, 1363, 1340, 1260, 1219, 1162, 1124, 1109, 1049, 1002, 855, 808, 751, 
726, 698, 697, 668, 616 cm-1; MS (ESI +ve) m/2 376 ([M + 2H]2+, 100%), m/z 750 ([M + 
H]+, 27%), 772 ([M + Na]+, 8%); HRMS (ESI +ve TOF) calcd for C41H56N11O3 750.4568, 





yl)hexanamide dihydrochloride (80b) 
 
Following General Procedure A, azide 79a (50 mg, 0.05 mmol), 4-phenyl-1-butyne (20 mg, 
0.15 mmol), Cu(OAc)2∙H2O (2 mg, 0.01 mmol) and sodium ascorbate (4 mg, 0.02 mmol) 
were stirred in t-BuOH (1.0 mL) and H2O (0.25 mL) for 20 h to give the intermediate triazole 
as a light tan gum after flash chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100  
10:90). Following General Procedure C, the triazole was dissolved in CH2Cl2 (1.5 mL) and 
treated with H2O (18 mg, 1.00 mmol) and CF3CO2H (1.5 mL) followed by work-up with 
ethereal HCl to give the amine salt 80b (36 mg, 85% over two steps) as a light tan powder 




 +3.1 (c 0.97, MeOH); 1H NMR (400 MHz, 
CD3OD) δ 8.07 (s, 1H), 7.79 (s, 1H), 7.35 – 7.07 (m, 10H), 7.05 – 6.96 (m, 2H), 6.93 (t, J = 
7.4 Hz, 1H), 5.38 – 5.28 (m, 1H), 5.13 – 5.03 (m, 2H), 4.76 – 4.64 (m, 1H), 4.61 – 4.49 (m, 
1H), 4.28 (br s, 1H), 3.96 – 3.81 (m, 2H), 3.21 – 3.06 (m, 4H), 3.06 – 2.95 (m, 2H), 2.95 – 
2.81 (m, 2H), 2.15 – 1.89 (m, 2H), 1.81 – 1.09 (m, 11H), 0.77 (d, J = 6.6 Hz, 6H); 13C NMR 
(101 MHz, CD3OD) δ 170.3, 158.7, 158.2, 157.5, 146.1 (observed by gHMBC), 144.2 
(observed by gHMBC), 141.7, 132.8, 132.6, 130.5*, 129.9**, 129.8, 129.7*, 127.7, 127.0, 
124.7, 122.5, 121.5, 114.8, 113.8, 68.2, 64.7, 64.0, 56.0, 51.3, 42.0, 40.5, 39.4, 36.1, 32.9, 
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29.7, 27.8, 27.5, 26.4, 26.2, 23.7, 23.1*; IR (neat) ν̄max 3334, 3165, 3059, 2959, 2934, 2872, 
2378, 2324, 1684, 1669, 1653, 1559, 1540, 1507, 1473, 1457, 1437, 1395, 1363, 1340, 1260, 
1218, 1162, 1124, 1109, 1048, 1021, 856, 751, 702, 668, 616 cm-1; MS (ESI +ve) m/2 383 
([M + 2H]2+, 100%), m/z 764 ([M + H]+, 24%), 786 ([M + Na]+, 8%); HRMS (ESI +ve TOF) 





yl)hexanamide dihydrochloride (80c) 
 
Following General Procedure A, azide 79a (50 mg, 0.05 mmol), cyclohexylacetylene (18 
mg, 0.15 mmol), Cu(OAc)2∙H2O (2 mg, 0.01 mmol) and sodium ascorbate (4 mg, 0.02 mmol) 
were stirred in t-BuOH (1.0 mL) and H2O (0.25 mL) for 20 h to give the intermediate triazole 
as a light tan gum after flash chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100  
10:90). Following General Procedure C, the triazole was dissolved in CH2Cl2 (1.5 mL) and 
treated with H2O (18 mg, 1.00 mmol) and CF3CO2H (1.5 mL) followed by work-up with 
ethereal HCl to give the amine salt 80c (39 mg, 94% over two steps) as a light tan powder 




 +2.9 (c 0.97, MeOH); 1H NMR (400 MHz, 
CD3OD) δ 8.16 (br s, 1H), 7.78 (br s, 1H), 7.36 – 7.23 (m, 2H), 7.22 – 7.09 (m, 3H), 7.05 – 
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6.90 (m, 3H), 5.31 (br s, 1H), 5.09 (s, 2H), 4.77 – 4.62 (m, 1H), 4.62 – 4.45 (m, 1H), 4.32 (br 
s, 1H), 3.98 – 3.84 (m, 2H), 3.14 (br s, 2H), 2.90 (br s, 3H), 2.14 – 1.05 (m, 23H), 0.78 (d, J 
= 6.4 Hz, 6H); 13C NMR (101 MHz, CD3OD) δ 170.3, 158.7, 158.2, 157.5, 152.9 (observed 
by gHMBC), 146.5 (observed by gHMBC), 132.8, 132.6, 130.5, 129.9, 129.82, 129.77, 
126.4, 124.9, 122.5, 121.5, 114.8, 113.8, 68.2, 64.7, 64.0, 56.2, 51.3, 42.1, 40.6, 39.4, 35.8, 
33.8*, 33.0, 29.9, 27.9, 27.1*, 27.0, 26.4, 26.2, 23.7, 23.1*; IR (neat) ν̄max 3338, 3168, 3059, 
2953, 2931, 2870, 2371, 2323, 1684, 1669, 1653, 1559, 1540, 1507, 1473, 1457, 1437, 1395, 
1363, 1340, 1260, 1218, 1164, 1123, 1108, 1048, 1017, 853, 818, 750, 668, 616 cm-1; MS 
(ESI +ve) m/2 372 ([M + 2H]2+, 100%), m/z 742 ([M + H]+, 52%), 764 ([M + Na]+, 38%); 





1,2,3-triazol-1-yl)hexanamide dihydrochloride (80d) 
 
Following General Procedure A, azide 79a (50 mg, 0.05 mmol), 3-cyclohexyl-1-propyne 
(19 mg, 0.15 mmol), Cu(OAc)2∙H2O (2 mg, 0.01 mmol) and sodium ascorbate (4 mg, 0.02 
mmol) were stirred in t-BuOH (1.0 mL) and H2O (0.25 mL) for 20 h to give the intermediate 
triazole as a light tan gum after flash chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100 
251 
 
 10:90). Following General Procedure C, the triazole was dissolved in CH2Cl2 (1.5 mL) 
and treated with H2O (18 mg, 1.00 mmol) and CF3CO2H (1.5 mL) followed by work-up with 
ethereal HCl to give the amine salt 80d (38 mg, 90% over two steps) as a light tan powder 




 +5.2 (c 1.00, MeOH); 1H NMR (400 MHz, 
CD3OD) δ 8.21 (s, 1H), 7.76 (s, 1H), 7.35 – 7.23 (m, 2H), 7.22 – 7.10 (m, 3H), 7.05 – 6.97 
(m, 2H), 6.94 (t, J = 7.3 Hz, 1H), 5.37 – 5.27 (m, 1H), 5.11 (s, 2H), 4.79 – 4.68 (m, 1H), 4.61 
– 4.50 (m, 1H), 4.29 (br s, 1H), 3.95 – 3.85 (m, 2H), 3.21 – 3.07 (m, 2H), 2.98 – 2.83 (m, 
2H), 2.70 (d, J = 5.4 Hz, 2H), 2.13 – 1.90 (m, 2H), 1.85 – 0.94 (m, 22H), 0.79 (d, J = 6.6 Hz, 
6H); 13C NMR (101 MHz, CD3OD) δ 170.3, 158.7, 158.2, 157.5, 146.2 (observed by 
gHMBC), 146.0 (observed by gHMBC), 132.9, 132.6, 130.5, 129.9, 129.82, 129.77, 127.5, 
124.5, 122.5, 121.5, 114.8, 113.8, 68.2, 64.7, 64.0, 56.5, 51.3, 42.0, 40.6, 39.4, 39.3, 34.02, 
33.97, 32.90, 32.87, 29.7, 27.8, 27.5, 27.34, 27.32, 26.4, 26.3, 23.7, 23.1*; IR (neat) ν̄max 
3338, 3169, 3060, 2953, 2925, 2867, 2370, 2323, 1684, 1669, 1653, 1559, 1540, 1507, 1473, 
1457, 1437, 1387, 1363, 1340, 1261, 1217, 1162, 1136, 1124, 1109, 1049, 1002, 936, 853, 
749, 668, 616 cm-1; MS (ESI +ve) m/2 379 ([M + 2H]2+, 100%), m/z 756 ([M + H]+, 41%), 
778 ([M + Na]+, 17%); HRMS (ESI +ve TOF) calcd for C41H62N11O3 756.5037, found 










Following General Procedure B, acid 75b (200 
mg, 0.27 mmol), amine 22 (69 mg, 0.27 mmol), 
EDCI (62 mg, 0.32 mmol) and HOBt (43 mg, 0.32 
mmol) were stirred in acetonitrile (2.7 mL) for 48 h 
to give the product amide 79b (241 mg, 91%) as a 
translucent tan gum. TLC (EtOAc/P.S. – 60:40): Rf  





−9.1 (c 1.03, MeOH); 1H NMR (400 MHz, CDCl3) δ 7.89 (br s, 1H, N
5′′′-H), 7.69 (s, 1H, 
H5′), 7.32 – 7.17 (m, 4H, ArH), 7.10 – 6.97 (m, 2H, ArH), 6.97 – 6.87 (m, 2H, ArH), 6.31 
(br s, 2H, -NH2), 6.03 (br s, 1H, N
5-H), 5.65 (br s, 1H, H2), 5.12 and 5.08 (ABq, J = 12.3 Hz, 
2H), 4.66 (br s, 1H, N1′′′-H), 4.04 – 3.93 (m, 1H, H5′′′), 3.93 – 3.84 (m, 2H, H1′′), 3.46 – 3.27 
(m, 3H, H5A or H5B and H6′′′), 3.03 – 2.90 (m, 5H, H5B or H5A, H1′′′ and ArCH2-), 2.60 (s, 
3H, ArCH3), 2.52 (s, 3H, ArCH3), 2.21 – 1.98 (m, 5H, H3 and ArCH3), 1.63 – 1.02 (m, 26H, 
H4, H2′′, H3′′, H2′′′, H3′′′, H4′′′, -C(CH3)2 and –C(CH3)3), 0.78 (d, J = 6.6 Hz, 6H, H4′′ and 
H5′′); 13C NMR (101 MHz, CDCl3) δ 168.7 (C1), 159.0 (Pbf CAr), 156.7 (C=N), 156.6 
(CAr2′), 156.2 (Cα), 156.0 (CAr2), 145.0 (C4′), 138.5 (Pbf CAr), 132.7 (Pbf CAr), 132.4 (Pbf 
CAr), 131.8 (CAr6 or CAr6′), 131.6 (CAr6′ or CAr6), 128.9 (CAr1), 128.7 (CAr4), 128.6 
(CAr4′), 128.0 (CAr1′), 124.9 (Pbf CAr), 122.7 (C5′), 121.4 (CAr5), 120.2 (CAr5′), 117.8 
(Pbf CAr), 113.8 (CAr3), 112.5 (CAr3′), 86.6 (-C(CH3)2), 79.2 (-C(CH3)3), 67.1 (C1′′), 63.6 
(-OCH2-C4′), 62.7 (C2), 54.4 (C6′′′), 50.0 (C5′′′), 43.4 (ArCH2-), 40.3 (C1′′′), 38.8 (C5), 38.0 
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(C2′′), 31.4 (C4′′′), 29.8 (C3), 29.7 (C2′′′), 28.7 (-C(CH3)2), 28.5 (-C(CH3)3), 25.6 (C4), 25.1 
(C3′′), 23.1 (C3′′′), 22.63 (C4′′ or C5′′), 22.61 (C5′′ or C4′′), 19.5 (ArCH3), 18.2 (ArCH3), 
12.6 (ArCH3); IR (neat) ν̄max 3338, 2956, 2932, 2873, 2356, 2323, 2100, 1718, 1700, 1684, 
1653, 1636, 1617, 1559, 1540, 1507, 1457, 1441, 1419, 1395, 1363, 1340, 1250, 1163, 1107, 
1091, 1051, 1005, 933, 853, 806, 782, 752, 733, 668, 642, 621 cm-1; MS (ESI +ve) m/z 1009 
([M + Na]+, 100%), 987 ([M + H]+, 8%); HRMS (ESI +ve TOF) calcd for C50H72N11O8S 




yl)pentanamide dihydrochloride (81a) 
 
Following General Procedure A, azide 79b (50 mg, 0.05 mmol), 3-phenyl-1-propyne (18 
mg, 0.15 mmol), Cu(OAc)2∙H2O (2 mg, 0.01 mmol) and sodium ascorbate (4 mg, 0.02 mmol) 
were stirred in t-BuOH (1.0 mL) and H2O (0.25 mL) for 24 h to give the intermediate triazole 
as a light tan gum after flash chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100  
10:90). Following General Procedure C, the triazole was dissolved in CH2Cl2 (1.5 mL) and 
treated with H2O (18 mg, 1.00 mmol) and CF3CO2H (1.5 mL) followed by work-up with 
ethereal HCl to give the amine salt 81a (35 mg, 84% over two steps) as a light tan powder 
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 +5.1 (c 1.00, MeOH); 1H NMR (400 MHz, 
CD3OD) δ 7.94 (s, 1H, Hα), 7.70 (s, 1H, H5′), 7.36 – 7.10 (m, 10H, ArH), 7.05 – 6.98 (m, 
2H, ArH), 6.95 (t, J = 7.1 Hz, 1H, ArH), 5.26 (dd, J = 8.9, 6.2 Hz, 1H, H2), 5.09 (s, 
2H, -OCH2-C4′), 4.62 (dd, J = 13.8, 3.6 Hz, 1H, H1′′′A or H1′′′B), 4.45 (dd, J = 13.7, 9.5 Hz, 
1H, H1′′′B or H1′′′A), 4.35 – 4.23 (m, 1H, H2′′′), 4.14 – 4.02 (m, 2H, -CH2Ph), 3.96 – 3.85 
(m, 2H, H1′′), 3.06 (t, J = 6.8 Hz, 2H, H5), 2.83 (t, J = 7.0 Hz, 2H, H6′′′), 2.04 – 1.91 (m, 
1H, H3A or H3B), 1.84 – 1.14 (m, 12H, H3B or H3A, H4, H2′′, H3′′, H3′′′, H4′′′, H5′′′), 0.78 
(d, J = 6.6 Hz, 6H, H4′′ and H5′′); 13C NMR (101 MHz, CD3OD) δ 170.0 (C1), 158.7 (C=N), 
158.2 (CAr2′), 157.6 (CAr2), 148.2 (Cβ – observed by gHMBC), 146.0 (C4′ – observed by 
gHMBC), 140.0 (Phenyl CAr), 132.9 (CAr6 or CAr6′), 132.6 (CAr6′ or CAr6), 130.5 (CAr1), 
129.98 (Phenyl CAr)*, 129.96 (Phenyl CAr)*, 129.9 (CAr4), 129.8 (CAr1′), 129.8 (CAr4′), 
128.0 (Phenyl CAr), 125.8 (Cα), 124.4 (C5′), 122.5 (CAr5), 121.5 (CAr5′), 114.8 (CAr3), 
113.8 (CAr3′), 68.2 (C1′′), 64.4 (C2), 64.0 (-OCH2-C4′), 55.2 (C1′′′), 51.4 (C2′′′), 41.6 (C5), 
40.6 (C6′′′), 39.4 (C2′′), 32.3 (-CH2Ph), 32.2 (C3′′′), 30.6 (C3), 28.2 (C5′′′), 26.3 (C3′′), 26.0 
(C4), 23.8 (C4′′′), 23.1 (C4′′ and C5′′); IR (neat) ν̄max 3338, 3186, 3064, 2953, 2935, 2870, 
2358, 2323, 1734, 1718, 1700, 1684, 1653, 1636, 1617, 1595, 1559, 1540, 1507, 1473, 1457, 
1437, 1419, 1395, 1363, 1340, 1219, 1162, 1108, 1091, 1050, 1021, 937, 853, 751, 721, 697, 
669, 620 cm-1;  MS (ESI +ve) m/2 376 ([M + 2H]2+, 100%), m/z 750 ([M + H]+, 18%), 772 
([M + Na]+, 7%); HRMS (ESI +ve TOF) calcd for C41H56N11O3 750.4568, found 750.4572 






yl)pentanamide dihydrochloride (81b) 
 
Following General Procedure A, azide 79b (50 mg, 0.05 mmol), 4-phenyl-1-butyne (20 
mg, 0.15 mmol), Cu(OAc)2∙H2O (2 mg, 0.01 mmol) and sodium ascorbate (4 mg, 0.02 mmol) 
were stirred in t-BuOH (1.0 mL) and H2O (0.25 mL) for 24 h to give the intermediate triazole 
as a light tan gum after flash chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100  
10:90). Following General Procedure C, the triazole was dissolved in CH2Cl2 (1.5 mL) and 
treated with H2O (18 mg, 1.00 mmol) and CF3CO2H (1.5 mL) followed by work-up with 
ethereal HCl to give the amine salt 81b (40 mg, 94% over two steps) as a light tan powder 




 +9.5 (c 0.83, MeOH); 1H NMR (400 MHz, 
CD3OD) δ 7.96 (s, 1H), 7.78 (s, 1H), 7.34 – 7.09 (m, 10H), 7.06 – 6.96 (m, 2H), 6.93 (t, J = 
7.4 Hz, 1H), 5.32 (dd, J = 9.1, 6.0 Hz, 1H), 5.11 (s, 2H), 4.65 (dd, J = 13.8, 3.6 Hz, 1H), 4.49 
(dd, J = 13.8, 8.9 Hz, 1H), 4.31 – 4.20 (m, 1H), 3.94 – 3.85 (m, 2H), 3.19 (t, J = 6.9 Hz, 2H), 
3.11 – 2.96 (m, 4H), 2.84 (t, J = 7.2 Hz, 2H), 2.20 – 1.92 (m, 2H), 1.75 – 1.23 (m, 11H), 0.78 
(d, J = 6.6 Hz, 6H); 13C NMR (101 MHz, CD3OD) δ 170.0, 158.8, 158.2, 157.5, 147.9 
(observed by gHMBC), 146.1 (observed by gHMBC), 141.9, 132.9, 132.6, 130.5*, 129.9, 
129.82*, 129.79, 129.7*, 127.6, 126.3, 124.5, 122.5, 121.5, 114.8, 113.8, 68.2, 64.5, 64.0, 
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55.6, 51.5, 41.8, 40.6, 39.4, 36.3, 32.0, 30.6, 28.2, 27.8, 26.2, 26.1, 23.8, 23.1*; IR (neat) ̄νmax 
3338, 3140, 3065, 2953, 2925, 2871, 2378, 2324, 1734, 1718, 1700, 1684, 1669, 1653, 1636, 
1617, 1559, 1540, 1507, 1473, 1457, 1437, 1419, 1395, 1363, 1340, 1213, 1160, 1136, 1109, 
1049, 1003, 937, 853, 751, 699, 669, 620 cm-1; MS (ESI +ve) m/2 383 ([M + 2H]2+, 100%), 
m/z 786 ([M + Na]+, 28%), 764 ([M + H]+, 22%); HRMS (ESI +ve TOF) calcd for 





yl)pentanamide dihydrochloride (81c) 
 
Following General Procedure A, azide 79b (50 mg, 0.05 mmol), cyclohexylacetylene (18 
mg, 0.15 mmol), Cu(OAc)2∙H2O (2 mg, 0.01 mmol) and sodium ascorbate (4 mg, 0.02 mmol) 
were stirred in t-BuOH (1.0 mL) and H2O (0.25 mL) for 24 h to give the intermediate triazole 
as a light tan gum after flash chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100  
10:90). Following General Procedure C, the triazole was dissolved in CH2Cl2 (1.5 mL) and 
treated with H2O (18 mg, 1.00 mmol) and CF3CO2H (1.5 mL) followed by work-up with 
ethereal HCl to give the amine salt 81c (40 mg, 97% over two steps) as a light tan powder 




 +2.6 (c 0.97, MeOH); 1H NMR (400 MHz, 
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CD3OD) δ 7.82 (s, 1H), 7.73 (s, 1H), 7.34 – 7.24 (m, 2H), 7.17 (mp, 3H), 7.05 – 6.97 (m, 
2H), 6.94 (t, J = 7.2 Hz, 1H), 5.37 – 5.29 (m, 1H), 5.10 (s, 2H), 4.60 – 4.41 (m, 2H), 4.30 (br 
s, 1H), 3.97 – 3.84 (m, 2H), 3.18 (t, J = 6.2 Hz, 2H), 2.89 – 2.79 (m, 2H), 2.79 – 2.67 (m, 
1H), 2.13 – 1.21 (m, 23H), 0.78 (d, J = 6.6 Hz, 6H); 13C NMR (101 MHz, CD3OD) δ 170.0, 
158.8, 158.2, 157.6, 154.6 (observed by gHMBC), 146.1 (observed by gHMBC), 132.8, 
132.6, 130.6*, 129.9, 129.8, 124.4, 123.3, 122.5, 121.5, 114.8, 113.8, 68.2, 64.3, 64.1, 54.5, 
51.5, 41.5, 40.6, 39.4, 36.7, 34.40, 34.35, 32.3, 30.8, 28.2, 27.4*, 27.3, 26.3, 25.9, 23.8, 
23.1*; IR (neat) ν̄max 3337, 3139, 3064, 2954, 2927, 2864, 2378, 2324, 1734, 1718, 1700, 
1684, 1669, 1653, 1636, 1617, 1559, 1540, 1507, 1473, 1457, 1437, 1419, 1395, 1363, 1340, 
1261, 1213, 1159, 1123, 1109, 1049, 1002, 937, 853, 800, 750, 668, 619 cm-1; MS (ESI +ve) 
m/2 372 ([M + 2H]2+, 100%), m/z 742 ([M + H]+, 58%), 764 ([M + Na]+, 52%); HRMS (ESI 





1-yl)pentanamide dihydrochloride (81d) 
 
Following General Procedure A, azide 79b (50 mg, 0.05 mmol), 3-cyclohexyl-1-propyne 
(19 mg, 0.15 mmol), Cu(OAc)2∙H2O (2 mg, 0.01 mmol) and sodium ascorbate (4 mg, 0.02 
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mmol) were stirred in t-BuOH (1.0 mL) and H2O (0.25 mL) for 24 h to give the intermediate 
triazole as a light tan gum after flash chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100 
 10:90). Following General Procedure C, the triazole was dissolved in CH2Cl2 (1.5 mL) 
and treated with H2O (18 mg, 1.00 mmol) and CF3CO2H (1.5 mL) followed by work-up with 
ethereal HCl to give the amine salt 81d (38 mg, 90% over two steps) as a light tan powder 




 +3.0 (c 0.70, MeOH); 1H NMR (400 MHz, 
CD3OD) δ 7.98 (s, 1H), 7.75 (s, 1H), 7.35 – 7.24 (m, 2H), 7.23 – 7.09 (m, 3H), 7.05 – 6.98 
(m, 2H), 6.94 (t, J = 7.4 Hz, 1H), 5.30 (dd, J = 8.9, 6.2 Hz, 1H), 5.09 (s, 2H), 4.64 (dd, J = 
13.8, 3.5 Hz, 1H), 4.47 (dd, J = 13.8, 9.3 Hz, 1H), 4.28 (br s, 1H), 3.97 – 3.84 (m, 2H), 3.19 
(t, J = 6.8 Hz, 2H), 2.83 (t, J = 7.1 Hz, 2H), 2.63 (d, J = 6.8 Hz, 2H), 2.15 – 1.88 (m, 2H), 
1.78 – 1.12 (m, 20H), 1.06 – 0.93 (m, 2H), 0.79 (d, J = 6.6 Hz, 6H); 13C NMR (101 MHz, 
CD3OD) δ 170.0, 158.8, 158.2, 157.6, 147.1 (observed by gHMBC), 146.2 (observed by 
gHMBC), 132.9, 132.6, 130.6, 129.88, 129.85, 129.8, 126.2, 124.4, 122.5, 121.5, 114.8, 
113.8, 68.2, 64.5, 64.0, 55.4, 51.5, 41.8, 40.6, 39.5, 39.4, 34.2, 34.1, 33.6, 32.2, 30.7, 28.2, 
27.6, 27.4*, 26.3, 26.1, 23.8, 23.1*; IR (neat) ̄νmax 3337, 3140, 3064, 2953, 2926, 2866, 2376, 
2323, 1734, 1718, 1700, 1684, 1669, 1653, 1636, 1617, 1559, 1540, 1507, 1473, 1457, 1437, 
1419, 1395, 1363, 1340, 1260, 1214, 1159, 1123, 1109, 1049, 1003, 937, 870, 852, 750, 669, 
620 cm-1; MS (ESI +ve) m/2 379 ([M + 2H]2+, 100%), m/z 778 ([M + Na]+, 38%), 756 ([M + 










Following General Procedure B, acid 75c 
(182 mg, 0.27 mmol), amine 25 (131 mg, 0.30 
mmol), EDCI (63 mg, 0.33 mmol) and HOBt 
(44 mg, 0.30 mmol) were stirred in acetonitrile 
(2.7 mL) for 18 h to give the product amide 79c 
(252 mg, 86%) as a translucent tan gum after 
flash chromatography over SiO2 gel 
(EtOAc/P.S. – 80:20). TLC (EtOAc/P.S. – 




 −18.3 (c 0.43, MeOH); 
1H NMR (400 MHz, CDCl3) δ 7.99 – 7.90 (m, 2H, ArH), 7.90 – 7.82 (m, 2H, ArH), 7.45 (d, 
J = 9.0 Hz, 1H, ArH), 7.41 (d, J = 9.0 Hz, 1H, ArH), 7.38 – 7.09 (m, 6H, ArH), 6.72 (s, 1H, 
H5′), 6.04 (br s, 3H, N5′′′-H and -NH2), 5.17 – 5.02 (m, 3H, H5 and -OCH2-C4′), 4.66 (br s, 
1H, N1-H), 4.02 – 3.80 (m, 3H, H5 and H1′′), 3.32 – 3.20 (m, 2H, H1′′′), 3.07 – 2.85 (m, 6H, 
H1, H5′′′ and ArCH2-), 2.56 (s, 3H, ArCH3), 2.50 (s, 3H, ArCH3), 2.12 – 1.99 (m, 4H, ArCH3 
and H4A or H4B), 1.83 – 1.72 (m, 1H, H4B or H4A), 1.50 – 0.98 (m, 26H, H2, H3, H2′′, H3′′, 
H3′′′, H4′′′, -C(CH3)3 and -C(CH3)2), 0.55 (d, J = 6.3 Hz, 3H, H4′′ or H5′′), 0.51 (d, J = 6.2 
Hz, 3H, H5′′ or H4′′); 13C NMR (101 MHz, CD3OD) δ 168.3 (C6), 158.9 (Pbf CAr), 156.2 
(Cα), 156.1 (C=N), 154.6 (CAr2′), 153.8 (CAr2), 145.1 (C4′), 138.4 (Pbf CAr), 134.13 
(CAr8a or CAr8a′), 134.10 (CAr8a′ or CAr8a), 133.0 (Pbf CAr), 132.4 (Pbf CAr), 130.0 
(CAr4a), 129.71 (CAr4), 129.67 (CAr4′), 129.3 (CAr4a′), 128.2 (CAr5), 128.1 (CAr5′), 
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126.6 (CAr7), 126.5 (CAr7′), 125.7 (CAr8), 125.3 (CAr8′), 124.8 (Pbf CAr), 124.3 (CAr6), 
123.8 (CAr6′), 122.4 (C5′), 121.6 (CAr1), 120.2 (CAr1′), 117.7 (Pbf CAr), 116.4 (CAr3), 
115.9 (CAr3′), 86.5 (-C(CH3)2), 79.3 (-C(CH3)3 – observed by gHMBC), 68.3 (C1′′′), 64.6 
(-OCH2-C4′), 63.8 (C5), 54.7 (C1′′′), 49.4 (C2′′′), 43.4 (ArCH2-), 40.8 (C5′′′), 40.1 (C1), 38.1 
(C2′′), 31.8 (C4), 29.3 (C3′′′), 29.0 (C2), 28.7 (-C(CH3)2), 28.6 (-C(CH3)3), 25.5 (C4′′′), 24.7 
(C3′′), 22.8 (C3), 22.5 (C4′′ or C5′′), 22.2 (C5′′ or C4′′), 19.5 (ArCH3), 18.1 (ArCH3), 12.6 
(ArCH3); IR (neat) ν̄max 3320, 2954, 2928, 2870, 2102, 1718, 1700, 1684, 1653, 1617, 1559, 
1540, 1507, 1457, 1363, 1243, 1163, 1147, 1089, 1045, 1014, 908, 852, 807, 782, 749, 734, 
661, 641, 621 cm-1; MS (ESI +ve) m/z 1109 ([M + Na]+, 100%), 1087 ([M + H]+, 17%); 





yl)hexanamide dihydrochloride (82a) 
 
Following General Procedure A, azide 79c (50 mg, 0.05 mmol), 4-phenyl-1-butyne (18 mg, 
0.14 mmol), Cu(OAc)2∙H2O (2 mg, 0.01 mmol) and sodium ascorbate (4 mg, 0.02 mmol) 
were stirred in t-BuOH (1.0 mL) and H2O (0.25 mL) for 24 h to give the intermediate triazole 
as a light tan gum after flash chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100  
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10:90). Following General Procedure C, the triazole was dissolved in CH2Cl2 (1.4 mL) and 
treated with H2O (18 mg, 1.00 mmol) and CF3CO2H (1.4 mL) followed by work-up with 
ethereal HCl to give the amine salt 82a (24 mg, 56% over two steps) as a light tan powder 




 −27.9 (c 0.47, MeOH); 1H NMR (400 MHz, 
CD3OD) δ 8.05 – 7.94 (m, 2H, ArH), 7.93 – 7.81 (m, 2H, ArH), 7.73 (s, 1H, H5′), 7.58 (d, J 
= 8.9 Hz, 1H, ArH), 7.49 (d, J = 8.9 Hz, 1H, ArH), 7.39 – 7.11 (m, 10H, ArH), 7.09 – 6.99 
(m, 2H, ArH), 5.11 (m, 3H, H2 and -OCH2-C4′), 4.61 – 4.50 (m, 1H, H1′′′A or H1′′′B), 4.47 
– 4.34 (m, 1H, H1′′′B or H1′′′A), 4.25 (br s, 1H, H2′′′), 4.08 – 3.96 (m, 1H, H1′′A or H1′′B), 
3.96 – 3.86 (m, 1H, H1′′B or H1′′A), 3.19 – 2.94 (m, 6H, H5′′′, Hγ and -CH2Ph), 2.86 (br s, 
2H, H6), 1.96 – 1.84 (m, 1H, H3A or H3B), 1.76 – 0.79 (m, 12H, H3B or H3A, H4, H5, H2′′, 
H3′′, H3′′′ and H4′′′), 0.55 (d, J = 6.4 Hz, 3H, H4′′ or H5′′), 0.51 (d, J = 6.3 Hz, 3H, H5′′ or 
H4′′); 13C NMR (101 MHz, CD3OD) δ 170.1 (C1), 158.7 (C=N), 156.1 (CAr2′), 155.4 
(CAr2), 148.4 (Cβ – observed by gHMBC), 145.7 (C4′ – observed by gHMBC), 142.4 
(Phenyl CAr), 135.6 (CAr8a or CAr8a′), 135.5 (CAr8a′ or CAr8a), 131.6 (CAr4a), 130.9 
(CAr4a′), 130.8 (CAr4), 130.7 (CAr4′), 129.76 (Phenyl CAr)*, 129.75 (Phenyl CAr)*, 129.3 
(CAr5), 129.2 (CAr5′), 127.49 (Phenyl CAr), 127.48 (CAr7 and CAr7′), 126.6 (CAr8), 126.4 
(CAr8′), 125.3 (CAr6), 124.8 (CAr6′ and Cα), 124.0 (C5′), 122.9 (CAr1), 121.4 (CAr1′), 
117.7 (CAr3), 117.0 (CAr3′), 69.2 (C1′′), 65.2 (-OCH2-C4′), 64.6 (C2), 54.7 (C1′′′), 51.2 
(C2′′′), 42.1 (C5′′′), 40.6 (C6), 39.5 (C2′′), 36.8 (Cγ), 32.8 (C3), 30.1 (C3′′′), 28.5 (-CH2Ph), 
27.9 (C5), 26.3 (C4′′′), 25.8 (C3′′), 23.6 (C4), 23.0 (C4′′ or C5′′), 22.7 (C5′′ or C4′′); IR (neat) 
ν̄max 3320, 3178, 2954, 2926, 2869, 2375, 2352, 2322, 1734, 1718, 1700, 1684, 1669, 1653, 
1617, 1559, 1540, 1507, 1457, 1437, 1363, 1243, 1212, 1147, 1085, 1055, 1040, 1005, 912, 
865, 809, 776, 746, 701, 669, 611 cm-1; MS (ESI +ve) m/2 433 ([M + 2H]2+, 100%), m/z 865 
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([M + H]+, 21%); HRMS (ESI +ve TOF) calcd for C50H62N11O3 864.5037, found 864.5078 




yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)hexanamide dihydrochloride (82b) 
 
Following General Procedure A, azide 79c (50 mg, 0.05 mmol), 3-cyclohexyl-1-propyne 
(17 mg, 0.15 mmol), Cu(OAc)2∙H2O (2 mg, 0.01 mmol) and sodium ascorbate (4 mg, 0.02 
mmol) were stirred in t-BuOH (1.0 mL) and H2O (0.25 mL) for 24 h to give the intermediate 
triazole as a light tan gum after flash chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100 
 10:90). Following General Procedure C, the triazole was dissolved in CH2Cl2 (1.4 mL) 
and treated with H2O (18 mg, 1.00 mmol) and CF3CO2H (1.4 mL) followed by work-up with 
ethereal HCl to give the amine salt 82b (32 mg, 75% over two steps) as a light tan powder 




 −10.2 (c 0.80, MeOH); 1H NMR (400 MHz, 
CD3OD) δ 8.04 – 7.96 (m, 2H), 7.94 (s, 1H), 7.92 – 7.86 (m, 2H), 7.59 (d, J = 9.0 Hz, 1H), 
7.51 (d, J = 9.0 Hz, 1H), 7.37 – 7.27 (m, 2H), 7.25 – 7.14 (m, 3H), 7.06 (d, J = 8.4 Hz, 1H), 
7.02 (d, J = 8.5 Hz, 1H), 5.21 – 5.04 (m, 3H), 4.66 – 4.56 (m, 1H), 4.51 – 4.41 (m, 1H), 4.29 
(br s, 1H), 4.08 – 3.99 (m, 1H), 3.97 – 3.87 (m, 1H), 3.16 – 3.03 (m, 2H), 2.95 – 2.81 (m, 
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2H), 2.63 (d, J = 6.5 Hz, 2H), 1.97 – 1.86 (m, 1H), 1.80 – 0.79 (m, 23H), 0.56 (d, J = 6.4 Hz, 
3H), 0.52 (d, J = 6.3 Hz, 3H); 13C NMR (101 MHz, CD3OD) δ 170.1, 158.7, 156.2, 155.4, 
147.5 (observed by gHMBC), 146.0 (observed by gHMBC), 135.6, 135.5, 131.6, 130.9, 
130.8, 130.7, 129.3, 129.2, 127.48, 127.46, 126.6, 126.4, 125.8, 125.2, 124.8, 124.2, 122.9, 
121.4, 117.8, 117.0, 69.2, 65.1, 64.6, 55.2, 51.2, 42.0, 40.6, 39.6, 39.5, 34.2, 34.2, 33.9, 32.8, 
30.0, 27.9, 27.6, 27.5, 27.4, 26.3, 25.8, 23.6, 23.0, 22.8; IR (neat) ν̄max 3320, 3178, 2953, 
2923, 2854, 2376, 2351, 2321, 1734, 1718, 1700, 1684, 1669, 1653, 1617, 1559, 1540, 1507, 
1457, 1437, 1374, 1363, 1340, 1261, 1244, 1212, 1147, 1083, 1055, 1040, 1006, 915, 864, 
809, 774, 744, 669, 614 cm-1; MS (ESI +ve) m/2 429 ([M + 2H]2+, 100%), m/z 857 ([M + 






Following General Procedure B, acid 75d 
(120 mg, 0.14 mmol), amine 22 (37 mg, 0.14 
mmol), EDCI (33 mg, 0.17 mmol) and HOBt 
(23 mg, 0.17 mmol) were stirred in 
acetonitrile (1.4 mL) for 48 h to give the 
product amide 79d (143 mg, 93%) as a 
translucent tan gum. TLC (EtOAc/P.S. – 




 −8.7 (c 1.27, MeOH); 
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1H NMR (400 MHz, CDCl3) δ 7.90 (app. t, J = 9.0 Hz, 2H, ArH), 7.85 (d, J = 8.2 Hz, 1H, 
ArH), 7.77 (m, 2H, N5′′′-H and ArH), 7.48 (d, J = 9.0 Hz, 1H, ArH), 7.42 (d, J = 9.0 Hz, 1H, 
ArH), 7.33 (t, J = 7.3 Hz, 1H, ArH), 7.24 – 7.04 (m, 6H, H5′ and ArH), 6.27 (br s, 2H, -NH2), 
5.93 (br s, 1H, N5-H), 5.49 (br s, 1H, H2), 5.11 and 5.07 (ABq, J = 12.3 Hz, 2H, -OCH2-C4′), 
4.64 (br s, 1H, N1′′′-H), 4.05 – 3.84 (m, 3H, H1′′ and H5′′′), 3.40 – 3.22 (m, 3H, H5A or H5B 
and H6′′′), 2.93 (br s, 5H, H5B or H5A, H1′′′ and ArCH2-), 2.61 (s, 3H, ArCH3), 2.52 (s, 3H, 
ArCH3), 2.13 – 2.01 (m, 4H, H3A or H3B and ArCH3), 1.96 – 1.82 (m, 1H, H3B or H3A), 1.53 
– 1.07 (m, 25H, H4A or H4B, H2′′, H3′′, H2′′′, H3′′′, H4′′′, -C(CH3)2 and -C(CH3)3), 0.93 – 
0.77 (m, 1H, H4B or H4A), 0.57 (d, J = 6.3 Hz, 3H, H4′′ or H5′′), 0.53 (d, J = 6.3 Hz, 3H, H5′′ 
or H4′′); 13C NMR (101 MHz, CD3OD) δ 168.5 (C1), 159.0 (Pbf CAr), 156.6 (C=N), 156.2 
(Cα), 154.7 (CAr2′), 154.1 (CAr2), 145.0 (C4′), 138.5 (Pbf CAr), 134.14 (CAr8a or CAr8a′), 
134.10 (CAr8a′ or CAr8a), 132.8 (Pbf CAr), 132.4 (Pbf CAr), 130.0 (CAr4a), 129.52 (CAr4), 
129.51 (CAr4′), 129.2 (CAr4a′), 128.04 (CAr5), 127.99 (CAr5′), 126.4 (CAr7), 126.3 
(CAr7′), 125.7 (CAr8), 125.4 (CAr8′), 124.9 (Pbf CAr), 124.1 (CAr6), 123.6 (CAr6′), 122.7 
(C5′), 121.7 (CAr1), 120.1 (CAr1′), 117.8 (Pbf CAr), 116.9 (CAr3), 115.9 (CAr3′), 86.6 
(-C(CH3)2), 79.2 (-C(CH3)3, 68.3 (C1′′), 64.7 (-OCH2-C4′), 62.7 (C2), 54.3 (C6′′′), 50.0 
(C5′′′), 43.4 (ArCH2-), 40.3 (C1′′′), 38.9 (C5), 38.2 (C2′′), 31.4 (C4′′′), 29.8 (C3), 29.6 (C5′′′), 
28.7 (-C(CH3)2), 28.5 (-C(CH3)3), 25.5 (C4), 24.7 (C3′′), 23.1 (C3′′′), 22.5 (C4′′ or C5′′), 22.3 
(C5′′ or C4′′), 19.6 (ArCH3), 18.2 (ArCH3), 12.6 (ArCH3); IR (neat) ν̄max 3334, 2958, 2933, 
2878, 2377, 2323, 2099, 1751, 1734, 1718, 1700, 1684, 1653, 1636, 1617, 1559, 1540, 1507, 
1490, 1473, 1457, 1437, 1419, 1395, 1363, 1340, 1244, 1166, 1154, 1106, 1090, 1048, 1015, 
904, 853, 808, 779, 748, 668, 641, 620, 609 cm-1; MS (ESI +ve) m/z 1109 ([M + Na]+, 100%), 
265 
 
1087 ([M + H]+, 9%); HRMS (ESI +ve TOF) calcd for C58H75N11O8SNa 1108.5419, found 




yl)pentanamide dihydrochloride (83a) 
 
Following General Procedure A, azide 79d (45 mg, 0.04 mmol), 4-phenyl-1-butyne (16 
mg, 0.12 mmol), Cu(OAc)2∙H2O (2 mg, 0.01 mmol) and sodium ascorbate (4 mg, 0.02 mmol) 
were stirred in t-BuOH (0.8 mL) and H2O (0.2 mL) for 24 h to give the intermediate triazole 
as a light tan gum after flash chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100  
10:90). Following General Procedure C, the triazole was dissolved in CH2Cl2 (1.2 mL) and 
treated with H2O (15 mg, 0.83 mmol) and CF3CO2H (1.2 mL) followed by work-up with 
ethereal HCl to give the amine salt 83a (37 mg, 95% over two steps) as a light tan powder 




 −10.3 (c 0.90, MeOH); 1H NMR (400 MHz, 
CD3OD) δ 8.19 (s, 1H, Hα), 8.03 – 7.94 (m, 2H, ArH), 7.92 – 7.84 (m, 2H, ArH), 7.60 (d, J 
= 9.0 Hz, 1H, ArH), 7.49 (d, J = 9.0 Hz, 1H, ArH), 7.37 – 7.13 (m, 10H, H5′ and ArH), 7.08 
– 6.99 (m, 2H, ArH), 5.24 (dd, J = 9.3, 5.6 Hz, 1H, H2), 5.14 and 5.10 (ABq, J = 12.4 Hz, 
2H, -OCH2-C4′), 4.77 – 4.69 (m, 1H, H1′′′A or H1′′′B), 4.59 – 4.49 (m, 1H, H1′′′B or H1′′′A), 
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4.22 (br s, 1H, H2′′′), 4.07 – 3.97 (m, 1H, H1′′A or H1′′B), 3.94 – 3.85 (m, 1H, H1′′B or H1′′A), 
3.22 – 3.10 (m, 4H, H5 and Hγ), 3.08 – 2.98 (m, 2H, -CH2Ph), 2.84 (t, J = 7.2 Hz, 2H, H6′′′), 
2.16 – 2.01 (m, 1H, H3A or H3B), 1.93 – 1.81 (m, 1H, H3B or H3A), 1.78 – 1.07 (m, 11H, H4, 
H2′′, H3′′, H3′′′, H4′′′ and H5′′′), 0.55 (d, J = 6.4 Hz, 3H, H4′′ or H5′′), 0.51 (d, J = 6.3 Hz, 
3H, H5′′ or H4′′); 13C NMR (101 MHz, CD3OD) δ 170.0 (C1), 158.8 (C=N), 156.1 (CAr2′), 
155.5 (CAr2), 146.4 (Cβ – observed by gHMBC), 146.2 (C4′ – observed by gHMBC), 141.3 
(Phenyl CAr), 135.6 (CAr8a or CAr8a′), 135.5 (CAr8a′ or CAr8a), 131.6 (CAr4a), 130.9 
(CAr4a′), 130.80 (CAr4), 130.77 (CAr4′), 129.9 (Phenyl CAr)*, 129.8 (Phenyl CAr)*, 129.3 
(CAr5), 129.2 (CAr5′), 128.3 (Cα – observed by gHMBC), 127.9 (Phenyl CAr), 127.51 
(CAr7), 127.46 (CAr7′), 126.6 (CAr8), 126.4 (CAr8′), 125.3 (CAr6), 124.8 (CAr6′), 124.5 
(C5′ – observed by gHMBC), 122.9 (CAr1), 121.4 (CAr1′), 117.8 (CAr3), 117.0 (CAr3′), 
69.2 (C1′′), 65.0 (-OCH2-C4′), 64.5 (C2), 56.6 (C1′′′), 51.5 (C2′′′), 41.7 (C5), 40.6 (C6′′′), 
39.5 (C2′′), 35.9 (-CH2Ph), 31.8 (C3′′′), 30.4 (C3), 28.1 (C5′′′), 27.1 (Cγ), 26.0 (C4), 25.8 
(C3′′), 23.8 (C4′′′), 23.0 (C4′′ or C5′′), 22.7 (C5′′ or C4′′); IR (neat) ν̄max 3334, 3147, 3060, 
2953, 2933, 2874, 2377, 2324, 1751, 1734, 1718, 1700, 1684, 1653, 1636, 1617, 1559, 1540, 
1507, 1490, 1473, 1457, 1437, 1419, 1395, 1363, 1340, 1319, 1243, 1215, 1164, 1147, 1108, 
1083, 1047, 1009, 903, 861, 810, 747, 702, 668, 620, 608 cm-1; MS (ESI +ve) m/2 433 ([M 
+ 2H]2+, 100%), m/z 887 ([M + Na]+, 18%), 865 ([M + H]+, 8%); HRMS (ESI +ve TOF) 










triazol-1-yl)pentanamide dihydrochloride (83b) 
 
Following General Procedure A, azide 79d (45 mg, 0.04 mmol), 3-cyclohexyl-1-propyne 
(15 mg, 0.12 mmol), Cu(OAc)2∙H2O (2 mg, 0.01 mmol) and sodium ascorbate (4 mg, 0.02 
mmol) were stirred in t-BuOH (0.8 mL) and H2O (0.2 mL) for 24 h to give the intermediate 
triazole as a light tan gum after flash chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100 
 10:90). Following General Procedure C, the triazole was dissolved in CH2Cl2 (1.2 mL) 
and treated with H2O (15 mg, 0.83 mmol) and CF3CO2H (1.2 mL) followed by work-up with 
ethereal HCl to give the amine salt 83b (26 mg, 68% over two steps) as a light tan powder 




 −25.9 (c 0.30, MeOH); 1H NMR (400 MHz, 
CD3OD) δ 8.03 – 7.96 (m, 2H), 7.93 – 7.82 (m, 3H), 7.57 (d, J = 9.0 Hz, 1H), 7.51 (d, J = 
9.0 Hz, 1H), 7.38 – 7.25 (m, 2H), 7.25 – 7.13 (m, 3H), 7.07 (d, J = 8.4 Hz, 1H), 7.02 (d, J = 
8.4 Hz, 1H), 5.33 – 5.25 (m, 1H), 5.11 and 5.09 (ABq, J = 12.3 Hz, 2H), 4.57 – 4.47 (m, 2H), 
4.32 – 4.23 (m, 1H), 4.08 – 4.00 (m, 1H), 3.97 – 3.88 (m, 1H), 3.13 (br s, 2H), 2.84 (br s, 
2H), 2.63 – 2.51 (m, 2H), 2.00 (s, 1H), 1.78 – 0.84 (m, 23H), 0.57 (d, J = 6.4 Hz, 3H), 0.53 
(d, J = 6.3 Hz, 3H); 13C NMR (101 MHz, CD3OD) δ 170.1, 158.9, 156.2, 147.5 (observed by 
gHMBC), 146.3 (observed by gHMBC), 155.5, 135.60, 135.56, 131.6, 130.9, 130.8, 130.7, 
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129.3, 129.2, 127.5*, 126.7, 126.4, 125.3, 125.2, 124.8, 124.2, 123.0, 121.5, 117.8, 117.0, 
69.2, 65.2, 64.1, 54.4, 51.6, 41.2, 40.5, 39.7, 39.5, 34.4, 34.34, 34.28, 32.2, 30.6, 28.2, 27.7, 
27.5*, 25.9, 25.7, 23.5, 23.0, 22.8; IR (neat) ν̄max 3337, 3146, 3059, 2952, 2923, 2853, 2378, 
2323, 1751, 1734, 1718, 1700, 1684, 1653, 1636, 1623, 1559, 1540, 1507, 1490, 1473, 1457, 
1437, 1419, 1395, 1363, 1340, 1319, 1261, 1244, 1202, 1177, 1131, 1083, 1056, 1017, 916, 
862, 808, 775, 748, 721, 669, 620, 609 cm-1; MS (ESI +ve) m/2 429 ([M + 2H]2+, 100%), m/z 
857 ([M + H]+, 34%), 879 ([M + Na]+, 16%); HRMS (ESI +ve TOF) calcd for C49H66N11O3 






Following General Procedure B, acid 75c 
(150 mg, 0.23 mmol), amine 29 (109 mg, 0.25 
mmol), EDCI (52 mg, 0.27 mmol) and HOBt 
(37 mg, 0.25 mmol) were stirred in acetonitrile 
(2.3 mL) for 18 h to give the intermediate ester 
as a translucent tan gum after flash 
chromatography over SiO2 gel (EtOAc). The 
ester was dissolved in THF (3.0 mL) with 
stirring, H2O (2.0 mL) and LiOH∙H2O (84 mg, 
2.00 mmol) were added and the reaction was stirred vigorously at rt for 24 h. The mixture 
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was diluted with 1.0 M aqueous HCl (25 mL), extracted with EtOAc (2 × 50 mL) and the 
combined organic extracts were washed with H2O (1 × 50 mL), brine (1 × 50 mL), dried 
(MgSO4), filtered and concentrated to give the acid 84 (205 mg, 86% over two steps) as a 




 −4.6 (c 1.53, MeOH);  1H NMR 
(400 MHz, CD3OD) : (mixture of rotamers) δ 8.00 – 7.90 (m, 2H, ArH), 7.90 – 7.81 (m, 2H, 
ArH), 7.58 – 7.42 (m, 2H, ArH)‡, 7.34 – 7.22 (m, 2H, ArH), 7.22 – 6.98 (m, 5H, H5′ and 
ArH), 5.21 (t, J = 7.0 Hz, 1H, H2), 5.15 – 5.03 (m, 2H, -OCH2-C4′), 4.36 – 4.26 (m, 1H, 
H2′′′), 4.05 – 3.85 (m, 2H, H1′′), 3.17 (br s, 1H, H5′′′A or H5′′′B), 3.08 (br s, 1H, H5′′′B or 
H5′′′A), 3.01 – 2.86 (m, 4H, H6 and ArCH2-), 2.60 – 2.52 (m, 3H, ArCH3)
‡, 2.52 – 2.44 (m, 
3H, ArCH3)
‡, 2.08 – 2.00 (m, 4H, H3A or H3B and ArCH3)
‡, 1.93 – 1.75 (m, 2H, H3B or H3A 
and H3′′′A or H3′′′B), 1.73 – 0.80 (m, 25H, H4, H5, H2′′, H3′′, H3′′′B or H3′′′A, H4′′′, -C(CH3)2 
and -C(CH3)3), 0.59 – 0.46 (m, 6H, H4′′ and H5′′)
‡; 13C NMR (101 MHz, CD3OD) : (mixture 
of rotamers)† δ 174.8 (C1′′′), 170.2 (C1), 160.0 (Pbf CAr), 158.6 (Cα), 158.2 (C=N), 156.1 
(CAr2′), 155.4 (CAr2), 146.1 (C4′), 139.5 (Pbf CAr), 135.6 (CAr8a or CAr8a′), 135.5 (CAr8a′ 
or CAr8a), 134.5 (Pbf CAr), 133.7 (Pbf CAr)
Δ, 131.5 (CAr4a), 130.8 (CAr4a′)Δ, 130.7 (CAr4), 
130.6 (CAr4′), 129.3 (CAr5), 129.2 (CAr5′), 127.5 (CAr7), 127.4 (CAr7′), 126.7 (CAr8)∆, 
126.3 (CAr8′), 126.2 (Pbf CAr), 125.1 (CAr6), 124.8 (CAr6′), 123.8 (C5′), 122.8 (CAr1), 
                                                 
‡ Indicates that the 1H NMR resonance was split into two or more signals due to the presence of amide and 
carbamate rotamers (e.g. the syn- and anti-amide conformations). 
† All 13C NMR resonances (except those denoted with a Δ symbol) were split into two resonances due to the 
presence of amide and/or carbamate rotamers (e.g. the syn- and anti-amide conformations); only the major 
resonance from each resonance pair is reported for clarity. 
∆ Indicates that the 13C NMR resonance was not split into multiple resonances due to rotamers. 
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121.3 (CAr1′), 118.6 (Pbf CAr), 117.6 (CAr3), 116.9 (CAr3′), 87.8 (-C(CH3)2), 80.1 
(-C(CH3)3), 69.1 (C1′′)
Δ, 65.1 (-OCH2-C4′), 64.7 (C2), 53.7 (C2′′′)
Δ, 44.1 (ArCH2-), 41.6 
(C5′′′), 41.1 (C6)Δ, 39.5 (C2′′)Δ, 33.8 (C3), 30.4 (C3′′′), 30.0 (C5), 29.0 (-C(CH3)2 
or -C(CH3)3), 28.9 (-C(CH3)3 or -C(CH3)2)
Δ, 27.2 (C4′′′), 25.8 (C3′′), 23.9 (C4), 23.0 (C4′′ or 
C5′′), 22.8 (C5′′ or C4′′), 19.8 (ArCH3), 18.6 (ArCH3), 12.7 (ArCH3); IR (neat) ν̄max 3336, 
2967, 2931, 2870, 2369, 2322, 1700, 1684, 1653, 1559, 1540, 1507, 1473, 1457, 1419, 1363, 
1340, 1244, 1163, 1147, 1088, 1049, 1016, 906, 852, 808, 783, 747, 669, 614 cm-1; MS (ESI 
−ve) m/z 1074 ([M − H]−, 100%); HRMS (ESI −ve TOF) calcd for C58H73N8O10S 1073.5170, 






Following General Procedure B, acid 84 (50 mg, 0.05 mmol), benzylamine (6 mg, 0.06 
mmol), EDCI (11 mg, 0.06 mmol) and HOBt (8 mg, 0.05 mmol) were stirred in acetonitrile 
(0.5 mL) for 24 h to give the intermediate amide as a translucent tan gum. Following General 
Procedure C, the amide was dissolved in CH2Cl2 (1.4 mL) and treated with H2O (17 mg, 
0.94 mmol) and CF3CO2H (1.4 mL) followed by work-up with ethereal HCl to give the amine 
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 −8.7 (c 0.87, MeOH); 1H NMR (400 MHz, CD3OD) : (mixture of rotamers) δ 8.02 
– 7.92 (m, 2H, ArH), 7.91 – 7.81 (m, 2H, ArH), 7.62 – 7.41 (m, 2H, ArH)‡, 7.37 – 6.97 (m, 
12H, H5′ and ArH), 5.48 – 5.25 (m, 1H, H2)‡, 5.16 – 5.03 (m, 2H, -OCH2-C4′)
‡, 4.40 – 4.19 
(m, 3H, H2′′′ and -CH2Ph)
‡, 4.07 – 3.85 (m, 2H, H1′′), 3.24 – 3.05 (m, 2H, H5′′′)‡, 2.93 – 
2.76 (m, 2H, H6)‡, 2.22 – 2.01 (m, 2H, H3A or H3B), 1.97 – 1.06 (m, 12H, H3B or H3A, H4, 
H5, H2′′, H3′′, H3′′′ and H4′′′), 0.60 – 0.46 (m, 6H, H4′′ and H5′′)‡; 13C NMR (101 MHz, 
CD3OD) : (mixture of rotamers)
† δ 174.2 (C1′′′), 170.6 (C1), 158.9 (C=N), 156.1 (CAr2′), 
155.5 (CAr2), 145.8 (C4′ – observed by gHMBC), 139.8 (Phenyl CAr), 135.6 (CAr8a), 135.5 
(CAr8a′), 131.5 (CAr4a), 130.9 (CAr4a′)∆, 130.8 (CAr4), 130.7 (CAr4′), 129.8 (Phenyl 
CAr)*, 129.3 (CAr5)
Δ, 129.2 (CAr5′)Δ, 128.8 (Phenyl CAr)*, 128.4 (Phenyl CAr), 127.6 
(CAr7), 127.4 (CAr7′), 126.7 (CAr8)Δ, 126.4 (CAr8′), 125.2 (CAr6), 124.8 (CAr6′), 124.2 
(C5′ – observed by gHMBC), 122.9 (CAr1), 121.4 (CAr1′), 117.7 (CAr3), 116.9 (CAr3′), 
69.2 (C1′′), 65.1 (-OCH2-C4′), 64.0 (C2), 55.0 (C2′′′), 44.2 (-CH2Ph), 42.1 (C5′′′), 40.5 (C6), 
39.5 (C2′′)Δ, 32.7 (C3), 30.1 (C3′′′), 27.5 (C5), 26.4 (C4′′′), 25.8 (C3′′)Δ, 23.2 (C4), 23.0 (C4′′ 
or C5′′), 22.8 (C5′′ or C4′′); IR (neat) ν̄max 3060, 2954, 2932, 2869, 2367, 2319, 1734, 1718, 
1700, 1684, 1669, 1653, 1623, 1590, 1559, 1540, 1507, 1490, 1457, 1437, 1419, 1395, 1363, 
                                                 
‡ Indicates that the 1H NMR resonance was split into two or more signals due to the presence of amide and 
carbamate rotamers (e.g. the syn- and anti-amide conformations).  
† All 13C NMR resonances (except those denoted with a Δ symbol) were split into two resonances due to the 
presence of amide and/or carbamate rotamers (e.g. the syn- and anti-amide conformations); only the major 
resonance from each resonance pair is reported for clarity. 
∆ Indicates that the 13C NMR resonance was not split into multiple resonances due to rotamers. 
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1340, 1261, 1242, 1223, 1146, 1109, 1084, 1049, 1014, 914, 861, 809, 746, 668, 608 cm-1; 
MS (ESI +ve) m/2 407 ([M + 2H]2+, 100%), m/z 812 ([M + H]+, 24%); HRMS (ESI +ve TOF)  







Following General Procedure B, acid 84 (50 mg, 0.05 mmol), β-phenylethylamine (7 mg, 
0.06 mmol), EDCI (11 mg, 0.06 mmol) and HOBt (8 mg, 0.05 mmol) were stirred in 
acetonitrile (0.5 mL) for 24 h to give the intermediate amide as a translucent tan gum. 
Following General Procedure C, the amide was dissolved in CH2Cl2 (1.4 mL) and treated 
with H2O (17 mg, 0.94 mmol) and CF3CO2H (1.4 mL) followed by work-up with ethereal 
HCl to give the amine salt 85b (39 mg, 92% over two steps) as a light tan powder that rapidly 




 −19.4 (c 0.40, MeOH); 1H NMR (400 MHz, CD3OD) : 
(mixture of rotamers) δ 8.04 – 7.91 (m, 2H), 7.91 – 7.80 (m, 2H), 7.60 – 7.41 (m, 2H)‡, 7.36 
                                                 
‡ Indicates that the 1H NMR resonance was split into two or more signals due to the presence of amide and 
carbamate rotamers (e.g. the syn- and anti-amide conformations).  
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– 6.97 (m, 12H), 5.50 – 5.24 (m, 1H)‡, 5.16 – 5.03 (m, 2H)‡, 4.26 – 4.10 (m, 1H)‡, 4.07 – 
3.83 (m, 2H), 3.57 – 3.31 (m, 2H)‡, 3.24 – 3.02 (m, 2H)‡, 2.97 – 2.74 (m, 4H)‡, 2.22 – 2.02 
(m, 1H), 1.97 – 1.02 (m, 12H), 0.55 (d, J = 6.3 Hz, 3H)‡, 0.51 (d, J = 6.3 Hz, 3H)‡; 13C NMR 
(101 MHz, CD3OD) : (mixture of rotamers)
† δ 174.1, 170.3, 158.8, 156.1, 155.5, 145.8, 
140.5, 135.6∆, 135.5Δ, 131.6, 130.9Δ, 130.8, 130.7, 130.1*, 129.6*, 129.3, 129.2, 127.6, 
127.5, 127.4, 126.7Δ, 126.4, 125.2, 124.8, 124.2, 122.9, 121.4Δ, 117.7, 117.0, 69.2, 65.1, 64.1, 
55.5, 42.2, 42.1, 40.4, 39.5Δ, 36.7, 32.7, 30.3, 27.5, 26.3, 25.8Δ, 23.3, 23.0, 22.8; IR (neat) 
ν̄max 2953, 2926, 2869, 2366, 2322, 1734, 1718, 1700, 1684, 1669, 1653, 1623, 1591, 1559, 
1540, 1507, 1490, 1457, 1437, 1419, 1395, 1363, 1340, 1261, 1242, 1223, 1085, 1048, 1016, 
915, 861, 809, 748, 698, 668, 613 cm-1; MS (ESI +ve) m/2 414 ([M + 2H]2+, 100%), m/z 826 
([M + H]+, 28%); HRMS (ESI +ve TOF)  calcd for C48H60N9O4 826.4768, found 826.4800 







                                                 
† All 13C NMR resonances (except those denoted with a Δ symbol) were split into two resonances due to the 
presence of amide and/or carbamate rotamers (e.g. the syn- and anti-amide conformations); only the major 
resonance from each resonance pair is reported for clarity. 








Following General Procedure B, acid 84 (50 mg, 0.05 mmol), piperidine (5 mg, 0.06 mmol), 
EDCI (11 mg, 0.06 mmol) and HOBt (8 mg, 0.05 mmol) were stirred in acetonitrile (0.5 mL) 
for 24 h to give the intermediate amide as a translucent tan gum. Following General 
Procedure C, the amide was dissolved in CH2Cl2 (1.4 mL) and treated with H2O (17 mg, 
0.94 mmol) and CF3CO2H (1.4 mL) followed by work-up with ethereal HCl to give the amine 





 −18.5 (c 0.60, MeOH); 1H NMR (400 MHz, CD3OD) : (mixture of rotamers) δ 
8.05 – 7.93 (m, 2H, ArH), 7.92 – 7.83 (m, 2H, ArH), 7.62 – 7.43 (m, 2H, ArH)‡, 7.37 – 7.11 
(m, 5H), 7.10 – 6.98 (m, 2H), 5.45 – 5.26 (m, 1H)‡, 5.18 – 5.03 (m, 2H)‡, 4.75 – 4.66 (m, 
1H)‡, 4.08 – 3.87 (m, 2H), 3.67 – 3.36 (m, 2H)‡, 3.28 – 3.06 (m, 4H)‡, 2.89 (m, 2H)‡, 2.22 – 
2.05 (m, 1H), 1.99 – 1.08 (m, 18H), 0.56 (d, J = 6.4 Hz, 3H)‡, 0.53 (d, J = 5.9 Hz, 3H)‡; 13C 
                                                 
‡ Indicates that the 1H NMR resonance was split into two or more signals due to the presence of amide and 
carbamate rotamers (e.g. the syn- and anti-amide conformations). 
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NMR (101 MHz, CD3OD) : (mixture of rotamers)
† δ 170.9, 170.1, 158.9, 156.2, 155.4, 146.0, 
135.6∆, 135.5Δ, 131.6, 130.9, 130.74, 130.71, 129.3, 129.2, 127.5, 127.4, 126.6Δ, 126.4, 
125.2, 124.8, 124.2, 122.6, 121.5, 117.7, 117.0, 69.2Δ, 65.1, 64.4, 50.7, 48.1, 44.7, 42.2, 40.6, 
39.5, 33.2, 30.2, 27.8, 27.7, 26.8, 26.5, 25.8Δ, 25.6, 23.6, 23.0, 22.8; IR (neat) ν̄max 2950, 
2924, 2869, 2367, 2322, 1734, 1718, 1700, 1684, 1669, 1653, 1636, 1623, 1591, 1559, 1540, 
1507, 1490, 1457, 1437, 1419, 1395, 1363, 1340, 1261, 1243, 1222, 1107, 1082, 1048, 1015, 
912, 865, 808, 747, 669, 613 cm-1; MS (ESI +ve) m/2 396 ([M + 2H]2+, 100%), m/z 790 ([M 












                                                 
†  All 13C NMR resonances (except those denoted with a Δ symbol) were split into two resonances due to the 
presence of amide and/or carbamate rotamers (e.g. the syn- and anti-amide conformations); only the major 
resonance from each resonance pair is reported for clarity. 
∆ Indicates that the 13C NMR resonance was not split into multiple resonances due to rotamers. 
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Following General Procedure B, acid 42 (246 mg, 
0.59 mmol), amine 29 (261 mg, 0.59 mmol), EDCI (136 
mg, 0.71 mmol) and HOBt (107 mg, 0.64 mmol) were 
stirred in acetonitrile (6.0 mL) for 21 h to give the 
intermediate amide as a translucent tan gum after flash 
chromatography over SiO2 gel (EtOAc). To a solution 
of the amide in THF (5.0 mL) was added LiOH·H2O 
(210 mg, 5.00 mmol) and H2O (5.0 mL) followed by vigorous stirring at rt for 18 h. The 
reaction mixture was diluted with 1.0 M aqueous HCl (50 mL), extracted with EtOAc (3 x 
40 mL) and the combined extracts were dried (MgSO4), filtered and concentrated to afford 
the acid 86 (398 mg, 82% over two steps) as a translucent tan gum after flash chromatography 





(c 1.87, MeOH); 1H NMR (400 MHz, CD3OD) δ 8.03 – 7.94 (m, 2H, ArH), 7.92 – 7.81 (m, 
2H, ArH), 7.75 (br s, 1H, N2-H), 7.50 – 7.39 (m, 2H, ArH), 7.36 – 7.27 (m, 1H, ArH), 7.23 
– 7.14 (m, 2H, ArH), 7.12 – 6.95 (m, 3H, ArH), 4.54 and 4.42 (ABq, J = 14.6 Hz, 
2H, -OCH2-Cα), 4.16 (br s, 1H, H2), 4.12 – 4.04 (m, 1H, H1′′A or H1′′B), 3.99 – 3.88 (m, 1H, 
H1′′B or H1′′A), 3.08 – 2.84 (m, 4H, H5 and ArCH2-), 2.60 (s, 3H, ArCH3), 2.53 (s, 3H, 
ArCH3), 2.11 (s, 3H, ArCH3), 1.56 – 1.44 (m, 1H, H3A or H3B), 1.41 – 1.12 (m, 11H, H4, 
H2′′, H3′′ and -C(CH3)2), 1.09 – 0.96 (m, 1H, H3B or H3A), 0.58 (d, J = 6.4 Hz, 3H, H4′′ or 
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H5′′), 0.52 (d, J = 6.4 Hz, 3H, H5′′ or H4′′); 13C NMR (101 MHz, CD3OD)
† δ 173.8 (C1), 
170.6 (Cα), 160.4 (Pbf CAr – observed by gHMBC), 156.1 (CAr2′), 154.0 (CAr2), 139.8 (Pbf 
CAr – observed by gHMBC), 135.4 (CAr8a or CAr8a′), 135.1 (CAr8a′ or CAr8a), 134.5 (Pbf 
CAr – observed by gHMBC), 133.7 (Pbf CAr – observed by gHMBC), 131.5 (CAr4a), 131.10 
(CAr4), 131.06 (CAr4′), 130.8 (CAr4a′), 129.5 (CAr5), 129.3 (CAr5′), 127.74 (CAr7), 
127.70 (CAr7′), 126.6 (CAr8), 126.4 (Pbf CAr – observed by gHMBC), 126.0 (CAr8′), 125.4 
(CAr6), 125.0 (CAr6′), 121.9 (CAr1), 120.6 (CAr1′), 118.7 (Pbf CAr – observed by gHMBC), 
117.1 (CAr3), 115.9 (CAr3′), 88.1 (-C(CH3)2 – observed by gHMBC), 69.2 (C1′′), 69.2 
(-OCH2-Cα), 52.4 (C2), 44.1 (ArCH2-), 41.6 (C5 – observed by gHSQC), 39.4 (C2′′), 30.9 
(C4), 30.1 (C3), 28.9 (-C(CH3)2), 25.8 (C3′′), 22.9 (C4′′ or C5′′), 22.8 (C5′′ or C4′′), 19.9 
(ArCH3), 18.6 (ArCH3), 12.8 (ArCH3); IR (neat) ν̄max 2953, 2926, 2372, 2324, 1734, 1718, 
1700, 1684, 1653, 1636, 1617, 1577, 1559, 1540, 1521, 1507, 1490, 1473, 1457, 1437, 1419, 
1395, 1363, 1340, 1271, 1243, 1147, 1092, 852, 808, 779, 748, 668, 619, 609 cm-1; MS (ESI 
−ve) m/z 821 ([M − H]−, 100%); HRMS (ESI +ve TOF) calcd for C46H54N4O8SNa 845.3560, 





                                                 
† The guanidine carbon (C=N) could not be assigned to a resonance in the 13C NMR spectrum. This carbon 
was easily observed and assigned to resonances in the 13C NMR spectra of the corresponding amide derivatives 





yl)oxy)acetamido)pentanamide hydrochloride (87a) 
Following General Procedure B, acid 86 (50 mg, 
0.06 mmol), benzylamine (8 mg, 0.07 mmol), 
EDCI (14 mg, 0.07 mmol) and HOBt (10 mg, 0.07 
mmol) were stirred in acetonitrile (0.6 mL) for 22 
h to give the intermediate amide as a translucent 
tan gum. Following General Procedure C, the amide was dissolved in CH2Cl2 (1.8 mL) and 
treated with H2O (22 mg, 1.21 mmol) and CF3CO2H (1.8 mL) followed by work-up with 
ethereal HCl to give the amine salt 87a (41 mg, 97% over two steps) as a light tan powder 




 −7.5 (c 0.83, MeOH); 1H NMR (400 MHz, 
CD3OD) δ 8.06 – 7.97 (m, 2H, ArH), 7.95 – 7.86 (m, 2H, ArH), 7.52 (d, J = 9.0 Hz, 1H, 
ArH), 7.46 (d, J = 9.0 Hz, 1H, ArH), 7.39 – 7.15 (m, 9H, ArH), 7.10 – 7.02 (m, 2H, ArH), 
4.57 and 4.43 (ABq, J = 14.7 Hz, 2H, -OCH2-Cα), 4.37 – 4.25 (m, 2H, -CH2Ph), 4.23 (t, J = 
6.0 Hz, 1H, H2), 4.08 (dt, J = 9.7, 6.1 Hz, 1H, H1′′A or H1′′B), 3.93 (dt, J = 9.6, 6.4 Hz, 1H, 
H1′′B or H1′′A), 3.09 – 2.89 (m, 2H, H5), 1.62 – 1.49 (m, 1H, H3A or H3B), 1.31 – 1.02 (m, 
6H, H3B or H3A, H4, H2′′ and H3′′), 0.56 (d, J = 6.5 Hz, 3H, H4′′ or H5′′), 0.50 (d, J = 6.4 
Hz, 3H, H5′′ or H4′′); 13C NMR (101 MHz, CD3OD) δ 172.9 (C1), 171.0 (Cα), 158.7 (C=N), 
156.1 (CAr2′), 154.2 (CAr2), 140.0 (Phenyl CAr), 135.4 (CAr8a or CAr8a′), 135.2 (CAr8a′ 
or CAr8a), 131.6 (CAr4a), 131.13 (CAr4), 131.09 (CAr4′), 130.9 (CAr4a′), 129.8 (Phenyl 
CAr)*, 129.5 (CAr5), 129.3 (CAr5′), 128.7 (Phenyl CAr)*, 128.5 (Phenyl CAr), 127.8 (CAr7), 
127.7 (CAr7′), 126.6 (CAr8), 126.1 (CAr8′), 125.4 (CAr6), 125.0 (CAr6′), 122.1 (CAr1), 
120.8 (CAr1′), 117.3 (CAr3), 116.3 (CAr3′), 69.6 (C1′′), 69.3 (-OCH2-Cα), 53.3 (C2), 44.2 
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(-CH2Ph), 41.9 (C5), 39.5 (C2′′), 30.5 (C3), 25.9 (C4), 25.8 (C3′′), 23.0 (C4′′ or C5′′), 22.8 
(C5′′ or C4′′); IR (neat) ν̄max 3334, 3188, 2954, 2926, 2376, 2323, 1734, 1718, 1700, 1684, 
1653, 1636, 1617, 1577, 1559, 1540, 1521, 1507, 1490, 1473, 1457, 1437, 1419, 1395, 1363, 
1340, 1329, 1271, 1242, 1215, 1147, 1094, 1073, 1047, 920, 862, 807, 775, 747, 696, 669, 
621, 608 cm-1; MS (ESI +ve) m/z 660 ([M + H]+, 100%), 682 ([M + Na]+, 16%); HRMS (ESI 




N-phenethylpentanamide hydrochloride (87b) 
Following General Procedure B, acid 86 (50 mg, 
0.06 mmol), β-phenylethylamine (9 mg, 0.07 
mmol), EDCI (14 mg, 0.07 mmol) and HOBt (10 
mg, 0.07 mmol) were stirred in acetonitrile (0.6 mL) 
for 22 h to give the intermediate amide as a translucent tan gum. Following General 
Procedure C, the amide was dissolved in CH2Cl2 (1.8 mL) and treated with H2O (22 mg, 
1.21 mmol) and CF3CO2H (1.8 mL) followed by work-up with ethereal HCl to give the amine 





 −3.7 (c 0.97, MeOH); 1H NMR (400 MHz, CD3OD) δ 8.05 – 7.98 (m, 2H), 7.94 
– 7.86 (m, 2H), 7.56 (d, J = 9.1 Hz, 1H), 7.46 (d, J = 9.0 Hz, 1H), 7.38 – 7.12 (m, 9H), 7.10 
– 7.02 (m, 2H), 4.52 and 4.44 (ABq, J = 14.8 Hz, 2H), 4.18 – 4.08 (m, 2H), 3.96 (dt, J = 9.5, 
6.5 Hz, 1H), 3.42 – 3.32 (m, 2H), 3.02 – 2.89 (m, 2H), 2.79 – 2.67 (m, 2H), 1.53 – 1.41 (m, 
1H), 1.34 – 0.96 (m, 6H), 0.57 (d, J = 6.5 Hz, 3H), 0.52 (d, J = 6.4 Hz, 3H); 13C NMR (101 
MHz, CD3OD) δ 172.8, 170.9, 158.7, 156.1, 154.3, 140.5, 135.4, 135.2, 131.7, 131.14, 
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131.08, 131.0, 130.1*, 129.7*, 129.5, 129.3, 127.8, 127.7, 127.6, 126.6, 126.1, 125.4, 125.0, 
122.2, 120.8, 117.2, 116.3, 69.6, 69.3, 53.2, 42.1, 41.9, 39.5, 36.6, 30.5, 25.9, 25.8, 23.0, 
22.8; IR (neat) ̄νmax 3335, 3185, 2953, 2926, 2874, 2376, 2323, 1734, 1718, 1700, 1684, 1653, 
1636, 1617, 1577, 1559, 1540, 1521, 1507, 1490, 1473, 1457, 1437, 1419, 1395, 1363, 1340, 
1319, 1271, 1244, 1215, 1147, 1094, 1072, 1048, 920, 861, 808, 775, 747, 698, 668, 620, 
609 cm-1; MS (ESI +ve) m/z 674 ([M + H]+, 100%), 696 ([M + Na]+, 14%); HRMS (ESI +ve 




binaphthalen]-2-yl)oxy)acetamido)pentanamide hydrochloride (87c) 
Following General Procedure B, acid 86 (40 
mg, 0.05 mmol), 2-(4-fluorophenyl)ethylamine 
(8 mg, 0.06 mmol), EDCI (11 mg, 0.06 mmol) 
and HOBt (8 mg, 0.06 mmol) were stirred in 
acetonitrile (0.5 mL) for 22 h to give the intermediate amide as a translucent tan gum. 
Following General Procedure C, the amide was dissolved in CH2Cl2 (1.5 mL) and treated 
with H2O (18 mg, 1.00 mmol) and CF3CO2H (1.5 mL) followed by work-up with ethereal 
HCl to give the amine salt 87c (26 mg, 74% over two steps) as a light tan powder that rapidly 




 −9.2 (c 0.50, MeOH); 1H NMR (400 MHz, CD3OD) δ 8.06 
– 8.00 (m, 2H), 7.93 – 7.88 (m, 2H), 7.56 (d, J = 9.1 Hz, 1H), 7.48 (d, J = 9.0 Hz, 1H), 7.39 
– 7.29 (m, 2H), 7.26 – 7.14 (m, 4H), 7.10 – 7.03 (m, 2H), 6.98 (app. t, J = 8.8 Hz, 2H), 4.49 
(ABq, J = 14.8 Hz, 2H), 4.18 – 4.08 (m, 2H), 3.97 (dt, J = 9.5, 6.6 Hz, 1H), 3.40 – 3.32 (m, 
2H), 3.03 – 2.91 (m, 2H), 2.73 (t, J = 7.2 Hz, 2H), 1.50 – 1.40 (m, 1H), 1.33 – 0.97 (m, 6H), 
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0.58 (d, J = 6.5 Hz, 3H), 0.52 (d, J = 6.5 Hz, 3H); 13C NMR (101 MHz, CD3OD) δ 172.8, 
170.9, 163.2 (d, 1JCF = 242.7 Hz), 158.7, 156.1, 154.3, 136.5 (d, 
4JCF = 3.2 Hz), 135.5, 135.3, 
131.8 (d, 3JCF = 7.9 Hz), 131.7, 131.14, 131.10, 131.0, 129.5, 129.3, 127.8, 127.7, 126.6, 
126.1, 125.5, 125.0, 122.2, 120.8, 117.2, 116.3, 116.2 (d, 2JCF = 21.3 Hz), 69.6, 69.3, 53.1, 
42.1, 41.9, 39.5, 35.7, 30.5, 25.9, 25.8, 23.0, 22.7; IR (neat) ν̄max 3335, 3184, 2954, 2927, 
2873, 2375, 2323, 1734, 1718, 1700, 1684, 1653, 1636, 1623, 1577, 1559, 1540, 1521, 1507, 
1490, 1473, 1457, 1437, 1419, 1395, 1363, 1340, 1319, 1272, 1243, 1219, 1147, 1096, 1074, 
1048, 1016, 920, 860, 807, 775, 748, 669, 620, 609 cm-1; MS (ESI +ve) m/z 692 ([M + H]+, 
100%), 714 ([M + Na]+, 6%); HRMS (ESI +ve TOF) calcd for C41H47N5O4F 692.3612, found 




Following General Procedure B, acid 42 (207 mg, 
0.50 mmol), amine 22 (142 mg, 0.55 mmol), EDCI 
(115 mg, 0.60 mmol) and HOBt (81 mg, 0.54 mmol) 
were stirred in acetonitrile (5.0 mL) for 24 h to give 
the product amide 88 (309 mg, 94%) as a translucent 
tan gum after flash chromatography over SiO2 gel 





−28.7c 0.73, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 8.01 (d, J = 9.1 Hz, 1H, ArH), 7.99 (d, 
J = 8.9 Hz, 1H, ArH), 7.89 (app. t, J = 6.7 Hz, 2H, ArH), 7.48 (d, J = 9.1 Hz, 1H, ArH), 7.39 
– 7.29 (m, 3H, ArH), 7.28 – 7.22 (m, 2H, ArH), 7.18 (app. t, J = 9.2 Hz, 2H, ArH), 5.60 (d, 
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J = 9.1 Hz, 1H, N5-H), 4.48 (s, 2H, -OCH2-Cβ), 4.42 (br s, 1H, N
1-H), 4.01 (dt, J = 9.4, 6.3 
Hz, 1H, H1′′A or H1′′B), 3.94 (dt, J = 9.5, 6.4 Hz, 1H, H1′′B or H1′′A), 3.79 – 3.72 (m, 1H, 
H5), 3.06 (dd, J = 12.3, 4.7 Hz, 1H, H6A or H6B), 2.99 – 2.88 (m, 3H, H1 and H6B or H6A), 
1.44 (s, 9H, -C(CH3)3), 1.33 – 1.15 (m, 6H, H2, H4A or H4B, H2′′ and H3′′), 1.11 – 1.02 (m, 
1H, H4B or H4A), 0.86 – 0.76 (m, 2H, H3), 0.60 (d, J = 6.5 Hz, 3H, H4′′ or H5′′), 0.56 (d, J 
= 6.4 Hz, 3H, H5′′ or H4′′); 13C NMR (125 MHz, CDCl3) δ 167.9 (Cβ), 155.8 (Cα), 154.5 
(CAr2′), 151.9 (CAr2), 133.8 (CAr8a or CAr8a′), 133.6 (CAr8a′ or CAr8a), 129.7 (CAr4a), 
129.6 (CAr4), 129.4 (CAr4′), 129.1 (CAr4a′), 127.86 (CAr5), 127.92 (CAr5′), 126.6 (CAr7), 
126.5 (CAr7′), 125.3 (CAr8), 124.9 (CAr8′), 124.0 (CAr6), 123.8 (CAr6′), 120.1 (CAr1), 
119.5 (CAr1′), 115.7 (CAr3), 113.8 (CAr3′), 78.9 (-C(CH3)3), 68.1 (C1′′), 67.7 (-OCH2-Cβ), 
54.2 (C6), 47.6 (C5), 40.1 (C1), 37.9 (C2′′), 31.0 (C4), 29.3 (C2), 28.3 (-C(CH3)3), 24.5 
(C3′′), 22.6 (C3), 22.1 (C4′′ or C5′′), 22.0 (C5′′ or C4′′);IR (neat) ν̄max 3385, 2930, 2101, 
1683, 1506, 1457, 1363, 1243, 1168, 1094, 807, 747 cm-1; MS (ESI +ve) m/z 676 ([M + Na]+, 




(isopentyloxy)-[1,1'-binaphthalen]-2-yl)oxy)acetamide hydrochloride (89a) 
Following General Procedure A, azide 88 (50 
mg, 0.08 mmol), 3-phenyl-1-propyne (27 mg, 
0.23 mmol), Cu(OAc)2∙H2O (3 mg, 0.02 mmol) 
and sodium ascorbate (6 mg, 0.03 mmol) were 
stirred in t-BuOH (1.6 mL) and H2O (0.4 mL) for 20 h to give the intermediate triazole as a 
light tan gum after flash chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100  10:90). 
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Following General Procedure C, the triazole was dissolved in CH2Cl2 (2.3 mL) and treated 
with H2O (27 mg, 1.52 mmol) and CF3CO2H (2.3 mL) followed by work-up with ethereal 
HCl to give the amine salt 89a (27 mg, 50% over two steps) as a light tan powder that rapidly 




 −14.5 (c 0.58, MeOH); 1H NMR (500 MHz, CD3OD) 
δ 8.08 (d, J = 9.1 Hz, 1H, ArH), 8.04 (d, J = 9.1 Hz, 1H, ArH), 7.98 (d, J = 8.2 Hz, 1H, ArH), 
7.93 (d, J = 8.2 Hz, 1H, ArH), 7.59 (d, J = 9.0 Hz, 1H, ArH), 7.44 – 7.34 (m, 3H, ArH), 7.31 
– 7.22 (m, 2H, ArH), 7.22 – 7.08 (m, 8H, Hα and ArH), 4.38 and 4.11 (ABq, J = 14.6 Hz, 
2H, -CHAHB-C=O), 4.31 (dd, J = 14.0, 4.3 Hz, 1H, H1A or H1B), 4.10 – 3.98 (m, 2H, H2 and 
H1′′A or H1′′B ), 3.99 – 3.87 (m, 3H, H1′′B or H1′′A and -CH2Ph), 3.67 (dd, J = 14.0, 9.2 Hz, 
1H, H1B or H1A), 2.81 – 2.66 (m, 2H, H6), 1.53 – 1.40 (m, 2H, H5), 1.36 – 1.25 (m, 1H, H3A 
or H3B), 1.27 – 1.11 (m, 2H, H2′′), 1.14 – 1.02 (m, 1H, H3′′), 1.03 – 0.93 (m, 2H, H4), 0.88 
– 0.76 (m, 1H, H3B or H3A), 0.52 (d, J = 6.6 Hz, 3H, H4′′ or H5′′), 0.48 (d, J = 6.6 Hz, 3H, 
H5′′ or H4′′); 13C NMR (125 MHz, CD3OD) δ 170.7 (C=O), 156.1 (CAr2′), 153.7 (CAr2), 
148.2 (Cβ), 140.4 (Phenyl CAr), 135.2 (CAr8a or CAr8a′), 135.1 (CAr8a′ or CAr8a), 131.5 
(CAr4a), 131.1 (CAr4 and CAr4′), 130.8 (CAr4a′), 129.7 (Phenyl CAr)*, 129.5 (CAr5 and 
Phenyl CAr)*, 129.2 (CAr5′), 128.0 (Phenyl CAr), 127.7 (CAr7), 127.5 (CAr7′), 126.3 (CAr8), 
126.1 (CAr8′), 125.3 (CAr6), 125.2 (CAr6′), 124.3 (Cα), 121.5 (CAr1), 121.1 (CAr1′), 117.3 
(CAr3), 115.7 (CAr3′), 69.4 (C1′′), 68.9 (-OCH2-C=O), 54.3 (C1), 50.0 (C2), 40.5 (C6), 39.3 
(C2′′), 32.5 (C3), 32.0 (-CH2Ph), 27.8 (C5), 25.5 (C3′′), 23.4 (C4), 22.8 (C4′′ or C5′′), 22.4 
(C5′′ or C4′′); IR (neat) ν̄max 3650, 2957, 1734, 1683, 1653, 1558, 1506, 1457, 1244, 1073, 
809, 750 cm-1; MS (ESI +ve) m/z 670 ([M + H]+, 100%), 692 ([M + Na]+, 10%); HRMS (ESI 





(isopentyloxy)-[1,1'-binaphthalen]-2-yl)oxy)acetamide hydrochloride (89b) 
Following General Procedure A, azide 88 (50 mg, 
0.08 mmol), phenylacetylene (24 mg, 0.23 mmol), 
Cu(OAc)2∙H2O (3 mg, 0.02 mmol) and sodium 
ascorbate (6 mg, 0.03 mmol) were stirred in 
t-BuOH (1.6 mL) and H2O (0.4 mL) for 20 h to give the intermediate triazole as a light tan 
gum after flash chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100  10:90). Following 
General Procedure C, the triazole was dissolved in CH2Cl2 (2.3 mL) and treated with H2O 
(27 mg, 1.52 mmol) and CF3CO2H (2.3 mL) followed by work-up with ethereal HCl to give 
the amine salt 89b (37 mg, 70% over two steps) as a light tan powder that rapidly transitioned 




 −19.7 (c 1.22, MeOH); 1H NMR (500 MHz, CD3OD) δ 8.10 – 7.82 (m, 
6H), 7.74 (d, J = 7.5 Hz, 2H), 7.51 (d, J = 9.0 Hz, 1H), 7.46 – 7.18 (m, 7H), 7.13 (d, J = 8.6 
Hz, 1H), 7.09 (d, J = 8.6 Hz, 1H), 4.54 – 4.29 (m, 3H), 4.12 (br s, 1H), 4.00 – 3.80 (m, 3H), 
2.86 – 2.64 (m, 2H), 1.59 – 1.39 (m, 2H), 1.35 – 1.22 (m, 1H), 1.22 – 1.08 (m, 2H), 1.08 – 
0.93 (m, 3H), 0.93 – 0.74 (m, 1H), 0.50 (d, J = 6.6 Hz, 3H), 0.46 (d, J = 6.7 Hz, 3H); 13C 
NMR (125 MHz, CD3OD) δ 171.0, 156.1, 153.8, 150.3, 135.2, 135.0, 131.6, 131.4, 131.1, 
131.0, 130.0*, 129.44, 129.42, 129.2, 127.9, 127.6, 126.7*, 126.3, 126.1, 125.3, 125.2, 122.7, 
121.5, 121.0, 117.3, 115.6, 69.4, 69.0, 54.2, 50.0, 40.5, 39.2, 31.9, 27.9, 25.5, 23.5, 22.7, 
22.4; IR (neat) ̄νmax 3373, 2954, 1683, 1653, 1558, 1506, 1244, 1147, 809, 765 cm
-1; MS (ESI 
+ve) m/z 656 ([M + H]+, 100%); HRMS (ESI +ve TOF) calcd for C41H45N5O3Na 678.3420, 





(isopentyloxy)-[1,1'-binaphthalen]-2-yl)oxy)acetamide hydrochloride (89c) 
Following General Procedure A, azide 88 (50 
mg, 0.08 mmol), 5-methyl-1-hexyne (22 mg, 0.23 
mmol), Cu(OAc)2∙H2O (3 mg, 0.02 mmol) and 
sodium ascorbate (6 mg, 0.03 mmol) were stirred 
in t-BuOH (1.6 mL) and H2O (0.4 mL) for 20 h to give the intermediate triazole as a light tan 
gum after flash chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100  10:90). Following 
General Procedure C, the triazole was dissolved in CH2Cl2 (2.3 mL) and treated with H2O 
(27 mg, 1.52 mmol) and CF3CO2H (2.3 mL) followed by work-up with ethereal HCl to give 
the amine salt 89c (37 mg, 70% over two steps) as a light tan powder that rapidly transitioned 
to a sticky gum. 1H NMR (500 MHz, CD3OD) δ 8.10 (d, J = 8.9 Hz, 1H), 8.04 (d, J = 9.0 Hz, 
1H), 7.98 (d, J = 8.3 Hz, 1H), 7.92 (d, J = 8.1 Hz, 1H), 7.62 (d, J = 9.0 Hz, 1H), 7.44 – 7.33 
(m, 3H), 7.27 (m, 2H), 7.20 (s, 1H), 7.15 (d, J = 8.6 Hz, 1H), 7.11 (d, J = 8.5 Hz, 1H), 4.45 
and 4.34 (ABq, J = 14.6 Hz, 2H), 4.27 (dd, J = 13.9, 4.5 Hz, 1H), 4.13 – 4.01 (m, 2H), 4.01 
– 3.90 (m, 1H), 3.74 (dd, J = 13.9, 8.7 Hz, 1H), 2.80 – 2.66 (m, 2H), 2.65 – 2.53 (m, 2H), 
1.54 – 1.37 (m, 4H), 1.37 – 1.06 (m, 6H), 1.02 – 0.76 (m, 8H), 0.56 (d, J = 6.5 Hz, 3H), 0.51 
(d, J = 6.6 Hz, 3H); 13C NMR (125 MHz, CD3OD) δ 170.8, 156.1, 153.8, 149.2, 135.2, 135.1, 
131.5, 131.09, 131.05, 130.8, 129.5, 129.2, 127.9, 127.7, 126.3, 126.1, 125.3, 125.2, 123.4, 
121.6, 121.1, 117.3, 115.8, 69.4, 69.1, 54.2, 49.9, 40.4, 39.7, 39.3, 32.0, 28.6, 27.8, 25.6, 
24.2, 23.4, 22.8, 22.7*, 22.5; IR (neat) ν̄max 3363, 2956, 2361, 1680, 1653, 1507, 1272, 1203, 
1136, 810 cm-1; MS (ESI +ve) m/z 650 ([M + H]+, 100%); HRMS (ESI +ve TOF) calcd for 




6.4 – Microbiology and pharmacology 
6.4.1 – Minimum inhibitory concentration (MIC) and cytotoxicity assays  
Primary screening (University of Western Australia) 
The following experiments were performed by Dr. Katherine Hammer and/or Dr. 
Daniel Knight. MIC assays were performed on Staphylococcus aureus (ATCC 29213), 
methicillin-resistant Staphylococcus aureus (NCTC 10442), Enterococcus faecalis (ATCC 
29212) and Escherichia coli (ATCC 25922) in Mueller Hinton broth and incubation was 
performed in ambient air at 35 °C for 24 h. Streptococcus pneumoniae (ATCC 49619) was 
cultivated in Mueller Hinton broth with 2.5% lysed horse blood and incubated with 5% CO2 
at 35 °C for 24 h. MIC studies for Clostridium difficile (ATCC 700057) and Clostridium 
difficile (NSW132 - RT027) were conducted in Brucella broth supplemented with haemin 
and vitamin K and incubation was performed anaerobically at 35 °C for 48 h. Each compound 
was dissolved in DMSO at 5 mg/mL and then diluted to 512 μg/mL with sterile, distilled 
water. The compounds were then serially diluted in 100 μL volumes of sterile, distilled water 
in a 96-well microtitre tray. Each test organism in double strength broth (100 μL) was then 
added to each well and incubated as described above. Testing concentrations of the 
compounds ranged from 0.25 μg/mL to 128 μg/mL. Vancomycin and a control well (i.e. no 
antibacterial compound present) were included in the assays. A DMSO control (5% v/v) was 
also tested to ensure that the solvent did not inhibit bacterial growth. The assay was 
performed in triplicate for each organism/compound combination and the modal MIC values 
were recorded. The MIC was recorded as the lowest concentration that inhibited bacterial 
growth. The minimum bactericidal concentration (MBC) was also recorded as the lowest 
concentration that caused cellular death.  
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Secondary screening (Community for Open Antimicrobial Drug Discovery (CO-ADD)) 
 Samples were provided to CO-ADD for antimicrobial screening by whole cell growth 
inhibition assays. The inhibition of growth was measured against five bacteria: Escherichia 
coli (ATCC 25922), Klebsiella pneumoniae (ATCC 700603), Acinetobacter baumannii 
(ATCC 19606), Pseudomonas aeruginosa (ATCC 27853) and Staphylococcus aureus 
(ATCC 43300), and two fungi: Candida albicans (ATCC 90028) and Cryptococcus 
neoformans (ATCC 208821). In addition to MIC, compounds were screened for cytotoxicity 
against a human embryonic kidney cell line (HEK293) by determining their CC50 value. 
Samples were prepared in DMSO to a final testing concentration of 32 μg/mL and serially 
diluted 1:2 fold for 8 times. Each sample concentration was prepared in 384-well plates, non-
binding surface (NBS) plate (Corning 3640) for each bacterial/fungal strain and tissue-culture 
treated (Corning 3712/3764) black for mammalian cell types, all in duplicate (n = 2) and 
keeping the final DMSO concentration to a maximum of 0.5%. All the sample preparation 
was done using liquid handling robots.  
Bacterial Inhibition 
All bacteria were cultured in Cation-adjusted Mueller Hinton broth at 37 °C 
overnight. A sample of each culture was then diluted 40-fold in fresh broth and incubated at 
37 °C for 1 – 3.5 h. The resultant mid-log phase cultures were diluted (CFU/mL measured 
by OD600), then added to each well of the compound-containing plates, giving a cell density 
of 5 × 105 CFU/mL and a total volume of 50 μL. All plates were covered and incubated at 37 
°C for 18 h without shaking. Inhibition of bacterial growth was determined by measuring 
absorbance at 600 nm (OD600), using a Tecan M1000 Pro monochromator plate reader. The 
percentage of growth inhibition was calculated for each well, using the negative control 
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(media only) and positive control (bacteria without inhibitors) on the same plate as 
references. The MIC was determined as the lowest concentration at which growth was fully 
inhibited, defined by an inhibition ≥ 80%. Colistin and vancomycin were used as positive 
bacterial inhibitor standards for Gram-negative and Gram-positive bacteria, respectively. 
Each antibiotic standard was provided in four concentrations, with two above and two below 
its MIC value, and plated into the first eight wells of column 23 of the 384-well NBS plates. 
Fungal Inhibition 
Fungi strains were cultured for three days on Yeast Extract-Peptone Dextrose agar at 
30 °C. A yeast suspension of 1 × 106 to 5 × 106 CFU/mL (as determined by OD530) was 
prepared from five colonies. The suspension was subsequently diluted and added to each well 
of the compound-containing plates giving a final cell density of fungi suspension of 2.5 × 
103 CFU/mL and a total volume of 50 μL. All plates were covered and incubated at 35 °C for 
36 h without shaking. Growth inhibition for C. albicans was determined by measuring 
absorbance at 630 nm (OD630), while the growth inhibition of C. neoformans was determined 
measuring the difference in absorbance between 600 and 570 nm (OD600-570), after the 
addition of resazurin (0.001 % final concentration) and incubation at 35 °C for 2 h. The 
absorbance was measured using a Biotek Multiflo Synergy HTX plate reader. In both cases, 
the percentage of growth inhibition was calculated for each well, using the negative control 
(media only) and positive control (fungi without inhibitors) on the same plate. The MIC was 
determined as the lowest concentration at which the growth was fully inhibited, definied as 
an inhibition ≥ 80% for C. albicans and an inhibition ≥ 70% for C. neoformans. Due to the 
higher variance in growth and inhibition, a lower threshold was applied to the data for C. 
neoformans. Fluconazole was used a positive fungal inhibitor standard for C. albicans and 
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C. neoformans using the same control methodology as the bacterial inhibition assays. The 
antifungal standard was provided in four concentrations, with two above and two below its 
MIC value, and plated into the first eight wells of column 23 of the 384-well NBS plates. 
Cytotoxicity Assay 
 HEK293 cells were counted manually in a Neubauer haemocytometer and then plated 
in the 384-well plates containing the compounds to give a density of 5000 cells/well in a final 
volume of 50 μL. Dulbecco’s modified eagle medium (DMEM) supplemented with 10% fetal 
bovine serum (FBS) was used as a growth media and the cells were incubated together with 
the compounds for 20 h at 37 °C in 5% CO2. Cytotoxicity (cell viability) was measured by 
fluorescence, ex: 560/10 nm, em: 590/10 nm (F560/590), after addition of 5 μL of 25 μg/mL 
resazurin (2.3 μg/mL final concentration) and after incubation for further 3 h at 37 °C in 5% 
CO2. The fluorescence intensity was measured using a Tecan M1000 Pro monochromator 
plate reader, using automatic gain calculation. CC50 (concentration at 50% cytotoxicity) 
values were calculated by curve-fitting the inhibition values vs. log(concentration) using a 
sigmoidal dose-response function, with variable fitting values for bottom, top and slope. 
Tamoxifen was utilized as a positive cytotoxicity standard; it was used in eight concentrations 
in two-fold serial dilutions with 50 μg/mL as the highest concentration tested. 
6.4.2 – In vivo CDI mouse model (Monash University) 
Study design 
 The foillowing in vivo study was performed by Prof. Dena Lyras, Dr. Melanie Hutton 
and Dr. Amy King. Mice were pre-treated with an antibiotic cocktail containing kanamycin 
(0.4 mg/ml; Amresco), gentamicin (0.035 mg/ml; Sigma), colistin (850 U/ml; Sigma), 
metronidazole (0.215 mg/ml; Sigma), vancomycin (0.045 mg/ml; Sigma) and cefaclor (0.3 
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mg/ml; Sigma) in the drinking water for seven days, followed by three days of cefaclor alone 
to disrupt the commensal microbiota and induce susceptibility to infection with C. difficile. 
The mice were switched to plain drinking water and given clean cages on the day of infection. 
Groups of five mice were infected with 105 C. difficile spores of the RT027 strain M7404. 
Six hours post-infection, mice were given 2.5 mg of the selected compounds (in 10% aqueous 
DMSO) by oral gavage. The mice were then administered fresh compound every 12 hours 
after the initial dose. The mice were monitored twice daily for weight loss and other 
physiological signs of infection. Blood was also collected at euthanasia and left to clot at 
room temperature prior to centrifugation. The serum was collected and frozen at −80 °C. 
Faeces collected at euthanasia was also frozen −80 °C for subsequent pharmacokinetic 
analysis. Note that mice were euthanised according to animal ethics guidelines: i.e. if the 
mice lose ≥ 10 % of their total body weight in the first 24 h or ≥ 15 % at any point after 24 h. 
Sample preparation 
Each compound was suspended in 100% DMSO to obtain a stock concentration of 
250 mg/mL. Twenty minutes prior to administration, the compounds were diluted (1:10) by 
adding warm water (37 °C) to the compound stock solution to achieve a final concentration 
of 25 mg/mL. The compounds were vortexed and carried to the animal house floating in 
warm water in an attempt to maintain a homogeneous solution. They were then vortexed 
again immediately prior to gavaging the mice. Each mouse received 100 μL of solution 
containing 2.5 mg of compound – this equates to a dose of 100 mg/kg (based on an average 





6.4.3 – Pharmacokinetics assay 
Mouse blood analysis: procedure 
 A 200 μL aliquot of the mouse blood was placed into a glass vial and diluted with 
phosphate buffered saline (PBS) solution (3.3 mL). The solution was vortexed for 20 s and 
then CH2Cl2 (3.5 mL) was added and the mixture was manually swirled to ensure adequate 
mixing with minimal emulsion formation. The layers were allowed to separate and the 
CH2Cl2 was removed by syringe. The aqueous blood layer was extracted again with another 
aliquot of CH2Cl2 (3.5 mL). The two extracts were combined and evaporated under reduced 
pressure to obtain an opaque residue. The residue was dissolved in MeOH (2.0 mL) with the 
aid of ultrasonication (30 s); the solution was filtered through a PTFE membrane (0.45 μm). 
The obtained solution was then subjected to LRMS analysis.   
Mouse blood analysis: procedure verification 
To ensure the mouse blood analysis procedure was sufficiently sensitive to detect 
small amounts of drug absorption, unadulterated mouse blood (i.e. blood from an untreated 
cohort) was doped with a small quantity of lead compound 2 and then subjected to the 
analysis procedure. The volume of mouse blood was accounted for to ensure that an accurate 
concentration representative of a 1% systemic bioavailability was achieved. To dope the 
blood with the correct concentration, 50 μL of a 0.05 mg/mL solution of compound 2 in 0.1% 
DMSO in H2O was added to the PBS diluent prior to extraction with CH2Cl2. The 
corresponding doubly-protonated molecular ion (m/2 = 421 = [M + 2H]2+) was found in the 






Mouse faeces analysis: procedure 
The obtained sample of mouse faeces (from the treated cohort) was added to a glass 
vial with CH2Cl2 (2.0 mL) and the mixture was stirred vigorously for 30 min. The solution 
was then filtered through a cotton plug and the solvent was removed under reduced pressure. 
The residue was taken up in MeOH (1.0 mL), sonicated for 30 s and then filtered through a 
PTFE membrane filter (0.45 μm). The obtained solution was then subjected to LRMS 
analysis.   
6.4.4 – Comparative solubility assay 
Procedure 
 Five milligrams of the target compound was fully dissolved in 50 μL DMSO. Small 
aliquots (5 μL) of H2O were added to the DMSO solution with manual agitation in between 
each addition; additions were continued until a visible turbidity/cloudiness was apparent that 
did not fade after mixing. The quantity of H2O required for precipitation of the compound 
was recorded; this value was then divided by the standard value (i.e. 15 μL = quantity of H2O 
required to precipitate lead compound 1) to obtain a comparative solubility ratio. This ratio 
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Appendix A – Supplementary figures and schemes 
A1 – Additional reaction mechanisms  
Mechanism for alkynes 20 and 21 
 
Scheme A1.1 – Mechanism of base-promoted ether 
synthesis (i.e. Williamson ether synthesis).78 
 
Mechanisms for N-Cbz and N-Boc protecting group installation 
 
 














Mechanism for the mixed-anhydride reduction reaction  
 
Scheme A1.4 – Mechanism showing formation of the mixed anhydride 
intermediate followed by borohydride reduction78 to give the alcohol product. PG 
= Protecting Group = Cbz or Fmoc. 
 
Mechanism for mesylation and SN2 azidation  
 
Scheme A1.5 – Mechanism showing the formation of the mesylate 
followed by SN2-type displacement of the mesylate leaving group by the 






Mechanism for iodination and oxazolidinone by-product formation 
 
 
Scheme A1.6 – Mechanism for the formation of azide 25 from the alcohol precursor: 
iodination followed by azidation/N-Fmoc deprotection.59, 78 The potential oxazolidinone 







Mechanism for base-promoted N-Fmoc deprotection 
 
Scheme A1.7 – Mechanism of base-promoted Fmoc cleavage by piperidine 
with the dibenzofulvene scavenging pathway (red) shown. In DMSO at 
50 °C, an azide anion can also function as the catalytic base required for N-
Fmoc cleavage.84 
 
Mechanism for copper-catalysed diazotransfer reaction 
 




A2 – Additional figures and schemes 
 
 
Figure A2.1 – Structure for compound 90 (made by a current PhD 




Figure A2.2 – HPLC trace for compound 2 synthesized by N-Boc/N-Pbf deprotection 




Figure A2.3 – HPLC trace for compound 2 synthesized by N-Boc/N-Pbf deprotection 
with H2O present; minimal impurities were observed (~95% pure). 
 
Figure A2.4 – Recrystallization of compound 68b by passive evaporation of MeOH/CH2Cl2. 
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Appendix B – Biological testing data and supplementary information  
This appendix contains a complete set of the in vitro antimicrobial testing data 
acquired for all final compounds – see Tables B1.1 – B2.9 in Sections B1 and B2. The 
solubility assay data (Tables B3.1 – B3.6 in Section B3) and HPLC purity traces (Figures 
B4.1 – B4.4 in Section B4) are also included. 
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B1 – Primary MIC screening data (UWA) 
 






























64a Biphenyl Lys Bn 8 8 8 8 32 32 32 
64b Biphenyl Lys PhEt 8 4 8 8 16 8 16 
64c Biphenyl Lys OBn 16 16 16 32 32 8 32 
65a Biphenyl Arg Bn 16 16 16 16 64 64 16 
65b Biphenyl Arg PhEt 16 16 16 32 64 128 16 
65c Biphenyl Arg OBn 4 4 8 16 32 32 32 
66a Binaphthyl Arg Bn 4 4 8 8 32 64 64 
66b Binaphthyl Arg PhEt 4 4 8 8 >128 16 16 
66c Binaphthyl Arg OBn 4 4 8 8 >128 32 32 




Table B1.2 – Antibacterial activities of Series A2 derivatives reported as MIC values (μg/mL). † No terminal triazole – compound 69d contains 






























68a Biphenyl Lys Arg Bn 8 8 16 4 64 16 16 
68b Biphenyl Lys Arg PhEt 4 4 8 8 64 8 8 
68c Biphenyl Lys Arg Cy 8 4 8 4 64 4 8 
68d Biphenyl Lys Arg CH2Cy 4 4 4 4 32 4 4 
69a Biphenyl Arg Lys Bn 4 4 8 4 32 64 64 
69b Biphenyl Arg Lys PhEt 4 4 8 4 32 16 16 
69c Biphenyl Arg Lys Cy 4 4 8 4 32 32 32 
69d Biphenyl Arg Lys N/A† 16 16 16 8 64 64 32 
70a Binaphthyl Lys Arg PhEt 4 4 4 4 16 16 16 
70b Binaphthyl Lys Arg CH2Cy 4 4 4 4 16 8 16 
















































73 Biphenyl Lys Arg Bn 8 8 8 8 32 16 16 
74 Biphenyl Lys Arg Fmo† 4 4 4 4 64 32 32 

































76a Biphenyl Lys Bn 8 16 16 8 32 32 32 
76b Biphenyl Lys PhEt 8 8 8 8 16 32 32 
76c Biphenyl Lys Cy 8 16 16 8 32 16 32 
76d Biphenyl Lys CH2Cy 8 8 8 8 16 16 32 
76e Biphenyl Lys 4-CF3-Bn 4 4 4 8 16 32 32 
76f Biphenyl Lys 4-F-PhEt 4 8 8 8 16 32 64 
77a Biphenyl Arg Bn 4 8 8 4 32 32 64 
77b Biphenyl Arg PhEt 2 2 4 4 16 8 32 
77c Biphenyl Arg Cy 4 4 4 4 16 8 16 
77d Biphenyl Arg CH2Cy 4 4 8 8 32 32 64 


































77e Biphenyl Arg 4-CF3-Bn 16 16 16 32 64 128 128 
77f Biphenyl Arg 4-F-PhEt 4 4 4 4 32 64 64 
77g Biphenyl Arg 3,5-diF-Bn 8 8 8 16 32 32 32 
77h Biphenyl Arg 3-F-Ph 4 8 8 8 32 32 64 
77i Biphenyl Arg Ph 2 2 2 2 16 16 32 
77j Biphenyl Arg 3,5-diMeO-Bn 4 4 4 4 32 32 32 
77k Biphenyl Arg Cyclopropyl 16 32 32 8 64 64 128 
77l Biphenyl Arg 
Ethyl and 
Cyclopropylmethyl 
4 4 4 2 32 16 16 
78a Binaphthyl Arg Bn 4 8 2 8 >128 16 16 
78b Binaphthyl Arg PhEt 8 8 4 16 >128 16 64 

































80a Biphenyl Lys Arg Bn 4 4 8 4 32 8 16 
80b Biphenyl Lys Arg PhEt 4 4 8 8 16 16 16 
80c Biphenyl Lys Arg Cy 16 16 16 32 64 64 128 
80d Biphenyl Lys Arg CH2Cy 4 4 4 8 32 16 16 
81a Biphenyl Arg Lys Bn 8 8 8 4 32 32 16 
81b Biphenyl Arg Lys PhEt 4 8 8 2 16 16 16 
81c Biphenyl Arg Lys Cy 8 8 8 2 16 8 16 
81d Biphenyl Arg Lys CH2Cy 4 4 4 2 16 8 16 










































82a Binaphthyl Lys Arg PhEt 4 4 4 4 16 16 16 
82b Binaphthyl Lys Arg CH2Cy 4 4 4 4 16 16 16 
83a Binaphthyl Arg Lys PhEt 4 4 4 2 8 16 16 
83b Binaphthyl Arg Lys CH2Cy 4 4 4 2 8 8 8 













































85a Binaphthyl Lys Arg Bn 8 8 8 8 32 16 16 
85b Binaphthyl Lys Arg PhEt 8 8 4 8 32 16 32 
85c Binaphthyl Arg Lys Piperidinyl† 8 8 8 8 16 16 32 





























87a Bn 2 2 2 2 >128 8† 8† 
87b PhEt 2 2 4 2 >128 32 32 
87c 4-F-PhEt >128 >128 >128 >128 >128 >128 64 
Vancomycin  1 1 4 1 >16 0.5 0.5 
Table B1.9 – Antibacterial activities of Series C derivatives reported as MIC values (μg/mL). Compound 87a 







































89a Ph 4 8 4 32 >128 16 16 
89b Bn 4 4 4 32 >128 8 8 
89c Isopentyl 8 8 4 32 128 16 16 
Vancomycin  1 1 4 1 >16 0.5 0.5 





























































Vancomycin 1 >32 >32 >32 >32 - - - 
Colistin >32 0.25 0.25 0.25 0.125 - - - 
Fluconazole - - - - - 0.125 8 - 




Table B2.2 – Antibacterial activities of Series A1 derivatives reported as MIC values (μg/mL). The cytotoxicity of each compound is also reported as the 











































64a Biphenyl Lys Bn 16 32 >32 32 >32 32 32 14.2 
64b Biphenyl Lys PhEt 16 32 32 >32 32 >32 16 4.8 
64c Biphenyl Lys OBn 16 32 >32 32 32 16 32 4.7 
65a Biphenyl Arg Bn 16 >32 >32 >32 >32 >32 32 29.0 
65b Biphenyl Arg PhEt 16 >32 >32 >32 >32 >32 32 >32 
65c Biphenyl Arg OBn 8 >32 >32 >32 >32 8 16 >32 
66a Binaphthyl Arg Bn 4 >32 >32 >32 >32 32 8 16.5 
66b Binaphthyl Arg PhEt 4 >32 >32 >32 >32 32 8 15.9 





Table B2.3 – Antibacterial activities of Series A2 derivatives reported as MIC values (μg/mL). The cytotoxicity of each compound is also 


























68a Biphenyl Lys Arg Bn 4 16 16 8 16 32 32 21.9 
68b Biphenyl Lys Arg PhEt 2 8 16 16 8 32 4 >32 
68c Biphenyl Lys Arg Cy 4 8 16 16 8 32 4 14.2 
68d Biphenyl Lys Arg CH2Cy 2 16 16 8 4 >32 4 >32 
69a Biphenyl Arg Lys Bn 4 16 32 16 8 32 4 17.8 
69b Biphenyl Arg Lys PhEt 2 8 16 16 4 32 2 17.4 
69c Biphenyl Arg Lys Cy 4 8 32 8 8 32 2 15.3 
69d Biphenyl Arg Lys N/A† 8 32 32 16 16 >32 4 >32 
70a Binaphthyl Lys Arg PhEt 4 32 >32 32 >32 8 2 >32 













Table B2.4 – Antibacterial activities of Series A2 derivatives reported as MIC values (μg/mL). The cytotoxicity of each compound is also 
































73 Biphenyl Lys Arg Fmo† 4 32 32 32 16 32 2 28.7 
74 Biphenyl Lys Arg Bn 4 >32 >32 >32 >32 >32 8 16.5 
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Table B2.5 – Antibacterial activities of Series B1 derivatives reported as MIC values (μg/mL). The cytotoxicity of each compound is also reported as 










































76a Biphenyl Lys Bn 16 32 >32 32 >32 >32 >32* >32 
76b Biphenyl Lys PhEt 8 >32 >32 32 >32 >32 >32* >32 
76c Biphenyl Lys Cy 8 32 >32 32 >32 32 32* >32 
76d Biphenyl Lys CH2Cy 8 >32 >32 32 >32 32 16* 5.6 
76e Biphenyl Lys 4-CF3-Bn 8 >32 >32 32 >32 >32 32* >32 
76f Biphenyl Lys 4-F-PhEt 8 >32 >32 16 >32 >32 12* 5.5 
77a Biphenyl Arg Bn 8 >32 >32 32 >32 16 16 16.8 
77b Biphenyl Arg PhEt 8 >32 >32 32 >32 16 32 17.9 
77c Biphenyl Arg Cy 4 >32 >32 32 >32 16 16 19.7 
77d Biphenyl Arg CH2Cy 4 >32 >32 >32 >32 32 32 16.9 
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Table B2.6 – Antibacterial activities of Series B1 derivatives reported as MIC values (μg/mL). The cytotoxicity of each compound is also reported as 
the CC50 (μg/mL). 
 
 








































77e Biphenyl Arg 4-CF3-Bn 16 >32 >32 >32 >32 >32 32 >32 
77f Biphenyl Arg 4-F-PhEt 16 >32 >32 >32 >32 >32 32 19.1 
77g Biphenyl Arg 3,5-diF-Bn 16 >32 >32 >32 >32 >32 >32 22.9 
77h Biphenyl Arg 3-F-Ph 4 >32 >32 >32 >32 >32 4 >32 




8 >32 >32 >32 >32 >32 >32 12.2 
77k Biphenyl Arg Cyclopropyl 32 >32 >32 >32 >32 >32 >32 20.0 




8 >32 >32 >32 >32 32 32 19.7 
78a Binaphthyl Arg Bn 8 >32 >32 >32 >32 16 8 16.5 




Table B2.7 – Antibacterial activities of Series B2 derivatives reported as MIC values (μg/mL). The cytotoxicity of each compound is also 




























80a Biphenyl Lys Arg Bn 4 16 32 16 8 32 4 17.1 
80b Biphenyl Lys Arg PhEt 2 8 16 8 8 32 4 16.4 
80c Biphenyl Lys Arg Cy 4 16 16 8 8 32 4 19.8 
80d Biphenyl Lys Arg CH2Cy 2 32 16 8 8 16 4 19.1 
81a Biphenyl Arg Lys Bn 8 16 32 32 >32 32 4* >32 
81b Biphenyl Arg Lys PhEt 4 16 16 32 16 32 2* >32 
81c Biphenyl Arg Lys Cy 4 8 16 16 16 32 2* >32 
81d Biphenyl Arg Lys CH2Cy 8 16 16 16 16 32 2* >32 
82a Binaphthyl Lys Arg PhEt 2 16 >32 8 >32 4 2 >32 
82b Binaphthyl Lys Arg CH2Cy 2 32 >32 8 >32 4 1 16.6 
83a Binaphthyl Arg Lys PhEt 4 32 >32 32 >32 32 1* >32 





























85a Binaphthyl Lys Arg Bn 4 32 32 32 >32 16 4 17.4 
85b Binaphthyl Lys Arg PhEt 2 32 16 8 >32 16 2 15.2 
85c Binaphthyl Lys Arg 
Piperid-
inyl† 
2 16 16 8 32 16 4 16.8 
Table B2.8 – Antibacterial activities of Series B2 derivatives reported as MIC values (μg/mL). The cytotoxicity of each compound is also 




















Table B2.9 – Antibacterial activities of Series C derivatives reported as MIC values (μg/mL). The cytotoxicity of each compound is 










































87a Bn 4 >32 >32 >32 >32 >32 16* >32 
87b PhEt 4 >32 >32 >32 >32 32 16* >32 
87c 4-F-PhEt 4 >32 >32 >32 >32 >32 16* >32 
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1 Binaphthyl - - 15 1 7.47 
66c Binaphthyl Arg OBenzyl 20 1.33 6.61 
65c Biphenyl Arg OBenzyl 65 4.33 4.26 
64a Biphenyl Lys Benzyl >300 (NP) >20 (NP) 4.97 
























1 Binaphthyl - - - 15 1 7.47 
2 Binaphthyl Lys Arg PhEt 45 3 5.76 
73 Biphenyl Lys Arg Benzyl 15 1 3.02 























1 Binaphthyl - - - 15 1 7.47 
70a Binaphthyl Lys Arg PhEt 30 2 6.24 
68b Biphenyl Lys Arg PhEt 35 2.33 3.89 
68c Biphenyl Lys Arg Cy 60 4 4.07 
68d Biphenyl Lys Arg CH2Cy 45 3 4.60 
69c Biphenyl Arg Lys Cy 30 2 4.07 





















1 Binaphthyl - - 15 1 7.47 
77c Biphenyl Arg Cy 30 2 3.77 
76d Biphenyl Lys CH2Cy >200 (NP) >13.3 (NP) 5.81 























1 Binaphthyl - - - 15 1 7.47 
83b Binaphthyl Arg Lys CH2Cy 15 1 6.94 
81d Biphenyl Arg Lys CH2Cy 55 3.67 4.60 
80c Biphenyl Lys Arg Cy 30 2 4.07 























1 Binaphthyl - 15 1 7.47 
87a Binaphthyl Benzyl 15 1 5.82 



















Figure B4.2 – HPLC trace and peak integration table for compound 87a. 
 
 


















Figure C1.1 – 1H NMR spectrum of compound 62a (recorded in CDCl3). The new triazole proton is 





Figure C1.2 – 13C NMR spectrum of compound 62a (recorded in CDCl3). The new triazole carbons 
are marked with a red asterisk (*). 
 
Figure C1.3 – Selected expansion of the gHMBC spectrum of compound 63a (recorded in CDCl3). 
The expansion shows the relevant correlations (circled in red and blue) that prove the 1,4-




Figure C1.4 – 1H NMR spectrum of compound 64c (recorded in CD3OD). Visible rotameric shoulder 
peaks are marked with a red asterisk (*).  
 
Figure C1.5 – Selected expansion of the 13C NMR spectrum of compound 64c (recorded in CD3OD). 




Figure C1.6– Selected expansion of the 13C NMR spectrum of compound 64c recorded in CD3OD at 
rt (blue), DMSO-d6 at rt (green) and DMSO-d6 at 90 °C (red). Visible rotameric shoulder peaks are 
marked with a red asterisk (*). Note the reduced 13C NMR resonance splitting in the sample recorded 
in DMSO-d6 at 90 °C.  
 
 
Figure C1.7 – 1H NMR spectrum of compound 76d recorded in CD3OD. Visible rotameric shoulder 




Figure C1.8 – Selected expansions of the 13C NMR spectrum of compound 76d recorded in CD3OD. 
Visible rotameric splitting of 13C NMR resonances is marked with a red asterisk (*).  
 
Figure C1.9 – Selected expansion of the 1H NMR spectrum of scaffold acid 84 recorded in DMSO-
d6. The rotameric splitting of 1H NMR resonances assigned to the amide (NH) and triazole (CH) 




Figure C1.10 – 1H NMR spectrum of scaffold acid 84 recorded in DMSO-d6. Primary rotameric 
splitting of 1H NMR resonances is marked with a red asterisk (*). Secondary rotameric splitting of 
1H NMR resonances is marked with a green asterisk (*). 
 
Figure C1.11 –  Selected expansions of the alkyl region of the 13C NMR spectrum of scaffold acid 
84 recorded in CD3OD. Primary rotameric splitting of 13C NMR resonances is marked with a red 





Figure C1.12 –  Selected expansions of the aromatic region of the 13C NMR spectrum of scaffold 
acid 84 recorded in CD3OD. Rotameric splitting of 13C NMR resonances is marked with a red asterisk 
(*).  
 
Figure C1.13 – Selected expansion of the 13C NMR spectrum of compound 84 recorded in CD3OD 
at rt (blue), DMSO-d6 at rt (green) and DMSO-d6 at 90 °C (red). Primary rotameric splitting of 13C 
NMR resonances is marked with a red asterisk (*). Secondary rotameric splitting of 13C NMR 
resonances is marked with a green asterisk (*). Note the reduced amount of primary and secondary 




Figure C1.14 – Selected expansion of the 13C NMR spectrum of compound 84 recorded in CD3OD 
at rt (blue), DMSO-d6 at rt (green) and DMSO-d6 at 90 °C (red). Visible rotameric splitting of 13C 
NMR resonances is marked with a red asterisk (*). Note the reduced number of split 13C NMR 
resonances in the sample recorded in DMSO-d6 at 90 °C. 
 
Figure C1.15– Selected expansion of the 1H NMR spectrum of compound 84 recorded in CD3OD at 
rt (blue), DMSO-d6 at rt (green) and DMSO-d6 at 90 °C (red). Visible rotameric splitting of the 
resonance assigned to the triazole methine proton is marked on the two 1H NMR spectra that were 





Figure C1.16 – Selected expansion of the 1H NMR spectra compound 63b (top spectra in blue - 
recorded in CDCl3) and compound 62b (bottom spectra in red – recorded in CDCl3). The expansion 




Figure C1.17 – 13C NMR spectrum of bis-triazole compound 68a recorded in CD3OD. The locations 
of the missing 13C NMR resonances (as determined by gHSQC and gHMBC) are marked with a red 




Figure C1.18 – Selected expansion of the gHSQC NMR spectrum of bis-triazole compound 68a 
recorded in CD3OD. The relevant correlations that allowed for assignment of the triazole methine 
carbons are marked. 
 
Figure C1.19 – Selected expansion of the gHMBC NMR spectrum of bis-triazole compound 68a 
recorded in CD3OD. The relevant correlations that allowed for assignment of the both the methine 




Figure C1.20 – Selected expansion of the gHMBC NMR spectrum of bis-triazole compound 68b 
recorded in CD3OD. The relevant correlations that allowed for assignment of the quaternary triazole 
carbons are marked.  
 
Figure C1.21 – Selected expansion of the gHSQC NMR spectrum of bis-triazole compound 68b 
recorded in CD3OD. The relevant correlations that allowed for assignment of the triazole methine 




Figure C1.22 – Selected expansion of the 13C NMR spectra of compound 64c recorded in CD3OD 
(blue) and DMSO-d6 (red). Note the new 13C NMR resonances that are observed with the use of 
DMSO-d6 (marked with red arrows  ).  
 
Figure C1.23 – Selected expansion of the 13C NMR spectra of compound 75a recorded in CD3OD 
(blue) and DMSO-d6 (red). Note the new 13C NMR resonances that are observed with the use of 
DMSO-d6 (marked with red arrows  ). Missing resonances are marked with a red asterisk (*); note 




Figure C1.24 – Selected expansion of the 1H NMR spectrum of compound 75a recorded in CD3OD 
(blue) and DMSO-d6 (red). Note the broadening of the labelled resonances (assigned to the triazole 
and methine protons) in the spectrum acquired in CD3OD; reduced broadening was observed for the 
resonance assigned to the triazole proton (H5′) in the spectrum acquired in DMSO-d6 (red arrow ). 
 
 
Figure C1.25 – Selected expansion of the gHSQC NMR spectrum of alkyne 21 recorded in CDCl3. 
The anomalous correlation is circled in red; note the reversed polarity of the DEPT Q 13C resonances 
assigned to the alkyne carbons.  
